**RULE 17, EXHIBIT 9**

**Chronic Pain Disorder**

**Medical Treatment Guidelines**

**Revised: December 27, 2011**

**Effective: February 14, 2012**

|  |  |
| --- | --- |
| **Adopted: January 8, 1998** | **Effective: March 15, 1998** |
| **Revised: May 27, 2003** | **Effective: July 30, 2003** |
| **Revised: September 29, 2005** | **Effective: January 1, 2006** |
| **Revised: April 26, 2007** | **Effective: July 1, 2007** |

Presented by:

**State of Colorado**

**Department of Labor and Employment**

DIVISION OF WORKERS’ COMPENSATION

TABLE OF CONTENTS

|  |  |  |
| --- | --- | --- |
| Section | description | page |

[a. INTRODUCTION 1](#_Toc394576880)

[b. GENERAL GUIDELINE PRINCIPLES 2](#_Toc394576881)

[1. APPLICATION OF THE GUIDELINES 2](#_Toc394576882)

[2. EDUCATION 2](#_Toc394576883)

[3. TREATMENT PARAMETER DURATION 2](#_Toc394576884)

[4. ACTIVE INTERVENTIONS 2](#_Toc394576885)

[5. ACTIVE THERAPEUTIC EXERCISE PROGRAM 2](#_Toc394576886)

[6. POSITIVE PATIENT RESPONSE 2](#_Toc394576887)

[7. RE-EVALUATION OF TREATMENT EVERY 3 TO 4 WEEKS 2](#_Toc394576888)

[8. SURGICAL INTERVENTIONS 3](#_Toc394576889)

[9. SIX-MONTH TIME FRAME 3](#_Toc394576890)

[10. RETURN-TO-WORK 3](#_Toc394576891)

[11. DELAYED RECOVERY 3](#_Toc394576892)

[12. GUIDELINE RECOMMENDATIONS AND INCLUSION OF MEDICAL EVIDENCE 3](#_Toc394576893)

[13. TREATMENT OF PRE-EXISTING CONDITIONS 4](#_Toc394576894)

[c. INTRODUCTION TO CHRONIC PAIN 5](#_Toc394576895)

[d. DEFINITIONS 7](#_Toc394576896)

[e. INITIAL EVALUATION & DIAGNOSTIC PROCEDURES 10](#_Toc394576897)

[1. HISTORY TAKING AND PHYSICAL EXAMINATION (Hx & PE) 10](#_Toc394576898)

[a. Medical History 10](#_Toc394576899)

[b. Pain History 11](#_Toc394576900)

[c. Medical Management History: 11](#_Toc394576901)

[d. Substance Use/Abuse 12](#_Toc394576902)

[e. Other Factors Affecting Treatment Outcome 12](#_Toc394576903)

[f. Physical Examination 12](#_Toc394576904)

[2. PERSONALITY/ PSYCHOLOGICAL/PSYCHOSOCIAL EVALUATION FOR PAIN MANAGEMENT 14](#_Toc394576905)

[a. Qualifications 15](#_Toc394576906)

[b. Clinical Evaluation 15](#_Toc394576907)

[c. Tests of Psychological Functioning 17](#_Toc394576908)

[3. DIAGNOSTIC STUDIES 24](#_Toc394576909)

[4. LABORATORY TESTING 24](#_Toc394576910)

[5. INJECTIONS–DIAGNOSTIC 25](#_Toc394576911)

[a. Spinal Diagnostic Injections 25](#_Toc394576912)

[b. Other Diagnostic Injections 27](#_Toc394576913)

[i. Sympathetic Injections 28](#_Toc394576914)

[ii. Peripheral Nerve Blocks 28](#_Toc394576915)

[6. SPECIAL TESTS 28](#_Toc394576916)

[a. Computer-Enhanced Evaluations 28](#_Toc394576917)

[b. Functional Capacity Evaluation (FCE) 29](#_Toc394576918)

[c. Jobsite Evaluation and Alterations 29](#_Toc394576919)

[d. Vocational Assessment 30](#_Toc394576920)

[e. Work Tolerance Screening (Fitness for Duty) 30](#_Toc394576921)

[f. THERAPEUTIC PROCEDURES – NON-OPERATIVE 31](#_Toc394576922)

[1. ACUPUNCTURE 31](#_Toc394576923)

[a. Acupuncture 33](#_Toc394576924)

[b. Acupuncture with Electrical Stimulation 33](#_Toc394576925)

[c. Other Acupuncture Modalities 33](#_Toc394576926)

[d. Total Time Frames For Acupuncture and Acupuncture with Electrical Stimulation 33](#_Toc394576927)

[2. BIOFEEDBACK 34](#_Toc394576928)

[a. EMG/Electromyogram (EMG) 34](#_Toc394576929)

[b. Skin Temperature 34](#_Toc394576930)

[c. Respiration Feedback (RFB) 34](#_Toc394576931)

[d. Respiratory Sinus Arrhythmia (RSA) 34](#_Toc394576932)

[e. Heart Rate Variability (HRV) 34](#_Toc394576933)

[f. Electrodermal Response (EDR) 34](#_Toc394576934)

[g. Electroencephalograph (EEG, QEEG) 34](#_Toc394576935)

[3. COMPLEMENTARY ALTERNATIVE MEDICINE (CAM) 35](#_Toc394576936)

[a. Alternative Medical Systems 35](#_Toc394576937)

[b. Mind-body Interventions 35](#_Toc394576938)

[c. Biological-based Practices 35](#_Toc394576939)

[d. Body-based Therapy 36](#_Toc394576940)

[e. Energy-based Practices 36](#_Toc394576941)

[4. DISTURBANCES OF SLEEP 36](#_Toc394576942)

[5. INJECTIONS—THERAPEUTIC 37](#_Toc394576943)

[a. Therapeutic Spinal Injections: 38](#_Toc394576944)

[i. Epidural Steroid Spinal Injections (ESI) 39](#_Toc394576945)

[ii. Zygapophyseal (Facet) Injections 41](#_Toc394576946)

[iii. Sacroiliac Joint Injections 41](#_Toc394576947)

[iv. Intradiscal Steroid Therapy 42](#_Toc394576948)

[b. Radio Frequency Medial Branch Neurotomy/Facet Rhizotomy: 42](#_Toc394576949)

[c. Dorsal Nerve Root Ganglion Radiofrequency Ablation 44](#_Toc394576950)

[d. Trigger Point Injections and Dry Needling Treatment 44](#_Toc394576951)

[e. Prolotherapy 45](#_Toc394576952)

[f. Epiduroscopy and Epidural Lysis of Adhesions 45](#_Toc394576953)

[g. Botulinum Toxin Injections 46](#_Toc394576954)

[6. INTERDISCIPLINARY REHABILITATION PROGRAMS 47](#_Toc394576955)

[a. Formal Interdisciplinary Rehabilitation Programs: 49](#_Toc394576956)

[b. Informal Interdisciplinary Rehabilitation Program: 51](#_Toc394576957)

[c. Opioid/Chemical Treatment Programs: 52](#_Toc394576958)

[7. MEDICATIONS and Medical Management 53](#_Toc394576959)

[a. Alpha-Acting Agents 55](#_Toc394576960)

[b. Anticonvulsants 56](#_Toc394576961)

[c. Antidepressants 58](#_Toc394576962)

[d. Hypnotics and Sedatives 61](#_Toc394576963)

[e. Marijuana 62](#_Toc394576964)

[f. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 64](#_Toc394576965)

[g. Opioids 65](#_Toc394576966)

[h. Skeletal Muscle Relaxants 76](#_Toc394576967)

[i. Topical Drug Delivery 78](#_Toc394576968)

[j. Tramadol (Ultram) 80](#_Toc394576969)

[k. Other Agents 81](#_Toc394576970)

[8. ORTHOTICS/PROSTHETICS/EQUIPMENT 81](#_Toc394576971)

[9. PATIENT EDUCATION 82](#_Toc394576972)

[10. PERSONALITY/PSYCHOLOGICAL/PSYCHOSOCIAL INTERVENTION 83](#_Toc394576973)

[i. Cognitive Behavioral Therapy (CBT) or similar treatment 85](#_Toc394576974)

[ii. Other psychological/psychiatric interventions 85](#_Toc394576975)

[11. RESTRICTION OF ACTIVITIES 86](#_Toc394576976)

[12. RETURN-TO-WORK 86](#_Toc394576977)

[a. Job History Interview 86](#_Toc394576978)

[b. Coordination of Care 87](#_Toc394576979)

[c. Communication 87](#_Toc394576980)

[d. Establishment of Return-To-Work Status 87](#_Toc394576981)

[e. Establishment of Activity Level Restrictions 87](#_Toc394576982)

[f. Rehabilitation and Return-To-Work 87](#_Toc394576983)

[g. Vocational Assistance 87](#_Toc394576984)

[13. THERAPY—ACTIVE 88](#_Toc394576985)

[a. Activities of Daily Living (ADL) 89](#_Toc394576986)

[b. Aquatic Therapy 89](#_Toc394576987)

[c. Functional Activities 90](#_Toc394576988)

[d. Functional Electrical Stimulation 90](#_Toc394576989)

[e. Spinal Stabilization 90](#_Toc394576990)

[f. Neuromuscular Re-education 90](#_Toc394576991)

[g. Therapeutic Exercise 91](#_Toc394576992)

[h. Work Conditioning 91](#_Toc394576993)

[i. Work Simulation 92](#_Toc394576994)

[14. THERAPY—PASSIVE 92](#_Toc394576995)

[a. Electrical Stimulation (Unattended) 93](#_Toc394576996)

[b. Iontophoresis 93](#_Toc394576997)

[c. Manipulation 93](#_Toc394576998)

[d. Manipulation under General Anesthesia (MUA) 94](#_Toc394576999)

[e. Manipulation Under Joint Anesthesia (MUJA) 95](#_Toc394577000)

[f. Massage—Manual or Mechanical 95](#_Toc394577001)

[g. Mobilization (Joint) 95](#_Toc394577002)

[h. Mobilization (Soft Tissue) 95](#_Toc394577003)

[i. Percutaneous Electrical Nerve Stimulation (PENS) 96](#_Toc394577004)

[j. Superficial Heat and Cold Therapy (Including Infrared Therapy) 96](#_Toc394577005)

[k. Traction—Manual 97](#_Toc394577006)

[l. Traction—Mechanical 97](#_Toc394577007)

[m. Transcutaneous Electrical Nerve Stimulation (TENS) 97](#_Toc394577008)

[n. Ultrasound (Including Phonophoresis) 97](#_Toc394577009)

[o. Vertebral Axial Decompression (VAX-D)/DRX, 9000 98](#_Toc394577010)

[g. THERAPEUTIC PROCEDURES – OPERATIVE 99](#_Toc394577011)

[1. NEUROSTIMULATION 99](#_Toc394577012)

[2. PERIPHERAL NERVE STIMULATION 103](#_Toc394577013)

[3. INTRATHECAL DRUG DELIVERY 103](#_Toc394577014)

[4. NEUROABLATION WITH RHIZOTOMY AS THE EXCEPTION 104](#_Toc394577015)

[5. DORSAL NERVE ROOT RESECTION 105](#_Toc394577016)

[h. MAINTENANCE MANAGEMENT 106](#_Toc394577017)

[1. HOME EXERCISE PROGRAMS AND EXERCISE EQUIPMENT 106](#_Toc394577018)

[2. EXERCISE PROGRAMS REQUIRING SPECIAL FACILITIES 107](#_Toc394577019)

[3. PATIENT EDUCATION MANAGEMENT 107](#_Toc394577020)

[4. PSYCHOLOGICAL MANAGEMENT 107](#_Toc394577021)

[5. NON OPIOID MEDICATION MANAGEMENT 107](#_Toc394577022)

[6. OPIOID MEDICATION MANAGEMENT 107](#_Toc394577023)

[7. THERAPY MANAGEMENT 108](#_Toc394577024)

[8. INJECTION THERAPY 108](#_Toc394577025)

[9. PURCHASE OR RENTAL OF DURABLE MEDICAL EQUIPMENT 110](#_Toc394577026)

\*\*\**For ease of reference, we have included generic names as well as major trade names.   Trade names were noted as identified by the national center for biotechnology information, US. National Library of Medicine, PubMed Health. The Division of Workers’ Compensation is not endorsing any specific products, nor brand over generic equivalent*

 **DEPARTMENT OF LABOR AND EMPLOYMENT**

Division of Workers’ Compensation

CCR 1101-3

**RULE 17, EXHIBIT 9**

CHRONIC PAIN DISORDER MEDICAL TREATMENT GUIDELINES

1. INTRODUCTION

This document has been prepared by the Colorado Department of Labor and Employment, Division of Workers’ Compensation (Division) and should be interpreted within the context of guidelines for physicians/providers treating individuals qualifying under Colorado’s Workers’ Compensation Act as injured workers with chronic pain.

Although the primary purpose of this document is advisory and educational, these guidelines are enforceable under the Workers’ Compensation Rules of Procedure, 7 CCR 1101-3. The Division recognizes that acceptable medical practice may include deviations from these guidelines, as individual cases dictate. Therefore, these guidelines are not relevant as evidence of a provider’s legal standard of professional care.

To properly utilize this document, the reader should not skip nor overlook any sections.

1. GENERAL GUIDELINE PRINCIPLES

The principles summarized in this section are key to the intended implementation of all Division of Workers’ Compensation guidelines and critical to the reader’s application of the guidelines in this document.

* 1. APPLICATION OF THE GUIDELINES The Division provides procedures to implement medical treatment guidelines and to foster communication to resolve disputes among the provider, payer and patient through the Workers’ Compensation Rules of Procedure. In lieu of more costly litigation, parties may wish to seek administrative dispute resolution services through the Division or the office of administrative courts.
	2. EDUCATION of the patient and family, as well as the employer, insurer, policy makers and the community should be the primary emphasis in the treatment of chronic pain and disability. Currently, practitioners often think of education last, after medications, manual therapy, and surgery. Practitioners must develop and implement an effective strategy and skills to educate patients, employers, insurance systems, policy makers, and the community as a whole. An education-based paradigm should always start with inexpensive communication providing reassuring information to the patient. More in-depth education currently exists within a treatment regime employing functional restorative and innovative programs of prevention and rehabilitation. No treatment plan is complete without addressing issues of individual and/or group patient education as a means of facilitating self-management of symptoms and prevention.
	3. TREATMENT PARAMETER DURATION Timeframes for specific interventions commence once treatments have been initiated, not on the date of injury. Obviously, duration will be impacted by patient compliance, as well as availability of services. Clinical judgment may substantiate the need to accelerate or decelerate the timeframes discussed in this document.
	4. ACTIVE INTERVENTIONS emphasizing patient responsibility, such as therapeutic exercise and/or functional treatment, are generally emphasized over passive modalities, especially as treatment progresses. Generally, passive interventions are viewed as a means to facilitate progress in an active rehabilitation program with concomitant attainment of objective functional gains.
	5. ACTIVE THERAPEUTIC EXERCISE PROGRAM Exercise program goals should incorporate patient strength, endurance, flexibility, coordination, and education. This includes functional application in vocational or community settings.
	6. POSITIVE PATIENT RESPONSEPositive results are defined primarily as functional gains that can be objectively measured. Objective functional gains include, but are not limited to: positional tolerances, range-of-motion (ROM), strength, endurance, activities of daily living, ability to function at work, cognition, psychological behavior, and efficiency/velocity measures that can be quantified. Subjective reports of pain and function should be considered and given relative weight when the pain has anatomic and physiologic correlation. Anatomic correlation must be based on objective findings.
	7. RE-EVALUATION OF TREATMENT EVERY 3 TO 4 WEEKS If a given treatment or modality is not producing positive results within 3 to 4 weeks, the treatment should be either modified or discontinued. Reconsideration of diagnosis should also occur in the event of poor response to a seemingly rational intervention.
	8. SURGICAL INTERVENTIONSSurgery should be contemplated within the context of expected functional outcome and not purely for the purpose of pain relief. The concept of “cure” with respect to surgical treatment by itself is generally a misnomer. All operative interventions must be based upon positive correlation of clinical findings, clinical course, and diagnostic tests. A comprehensive assimilation of these factors must lead to a specific diagnosis with positive identification of pathologic conditions.
	9. SIX-MONTH TIME FRAMEThe prognosis drops precipitously for returning an injured worker to work once he/she has been temporarily totally disabled for more than six months. The emphasis within these guidelines is to move patients along a continuum of care and return to work within a six-month timeframe, whenever possible. It is important to note that timeframes may be less pertinent for injuries that do not involve work-time loss or are not occupationally related.
	10. RETURN-TO-WORKis therapeutic, assuming the work is not likely to aggravate the basic problem or increase long-term pain. The practitioner must provide specific written physical limitations and the patient should never be released to “sedentary” or “light duty.” The following physical limitations should be considered and modified as recommended: lifting, pushing, pulling, crouching, walking, using stairs, overhead work, bending at the waist, awkward and/or sustained postures, tolerance for sitting or standing, hot and cold environments, data entry and other repetitive motion tasks, sustained grip, tool usage and vibration factors. Even if there is residual chronic pain, return-to-work is not necessarily contraindicated.

	The practitioner should understand all of the physical demands of the patient’s job position before returning the patient to full duty and should request clarification of the patient’s job duties. Clarification should be obtained from the employer or if necessary, including, but not limited to: a healthcare professional with experience in ergonomics, an occupational health nurse, occupational therapist, vocational rehabilitation specialist, or an industrial hygienist.
	11. DELAYED RECOVERYBy definition, patients with chronic pain will fit into the category of delayed recovery. All of these patients should have a psychological or psychiatric evaluation, if not previously provided as well as interdisciplinary rehabilitation or vocational goal setting. It is essential to address all barriers to recovery which might include issues related to psychosocial, personality, employment, litigation, and compensation, The Division recognizes that 3 to 10% of all industrially injured patients will not recover within the timelines outlined in this document despite optimal care. Such individuals may require treatments beyond the limits discussed within this document, but such treatment will require clear documentation by the authorized treating practitioner focusing on objective functional gains afforded by further treatment and impact upon prognosis.
	12. GUIDELINE RECOMMENDATIONS AND INCLUSION OF MEDICAL EVIDENCEGuidelines are recommendations based on available evidence and/or consensus recommendations. When possible, guideline recommendations will note the level of evidence supporting the treatment recommendation. When interpreting medical evidence statements in the guideline, the following apply:

Consensus means the opinion of experienced professionals based on general medical principles. Consensus recommendations are designated in the guideline as “generally well accepted,” “generally accepted,” “acceptable,” or “well-established.”

“Some” means the recommendation considered at least one adequate scientific study, which reported that a treatment was effective.

“Good” means the recommendation considered the availability of multiple adequate scientific studies or at least one relevant high-quality scientific study, which reported that a treatment was effective.

“Strong” means the recommendation considered the availability of multiple relevant and high quality scientific studies, which arrived at similar conclusions about the effectiveness of a treatment.

All recommendations in the guideline are considered to represent reasonable care in appropriately selected cases, regardless of the level of evidence attached to it. Those procedures considered inappropriate, unreasonable, or unnecessary are designated in the guideline as “not recommended.”

* 1. TREATMENT OF PRE-EXISTING CONDITIONSThe conditions that preexisted the work injury/disease will need to be managed under two circumstances: (a) A pre-existing condition exacerbated by a work injury/disease should be treated until the patient has returned to their objectively verified prior level of functioning or MMI; and (b) A pre-existing condition not directly caused by a work injury/disease but which may prevent recovery from that injury should be treated until its objectively verified negative impact has been controlled. The focus of treatment should remain on the work injury/disease.

The remainder of this document should be interpreted within the parameters of these guideline principles that may lead to more optimal medical and functional outcomes for injured workers.

1. INTRODUCTION TO CHRONIC PAIN

The International Association for the Study of Pain (IASP) defines pain as "an unpleasant sensory and emotional experience with actual or potential tissue damage." Pain is a complex experience embracing physical, mental, social, and behavioral processes that often compromises the quality of life of many individuals. Pain is an unpleasant subjective perception usually in the context of tissue damage.

Pain is subjective and cannot be measured or indicated objectively. Pain evokes negative emotional reactions such as fear, anxiety, anger, and depression. People usually regard pain as an indicator of physical harm, despite the fact that pain can exist without tissue damage and tissue damage can exist without pain. Many people report pain in the absence of tissue damage or any likely pathophysiologic cause. There is no way to distinguish their experience from that due to actual tissue damage. If they regard their experience as pain and they report it the same way as pain caused by tissue damage, it should be accepted as pain.

Pain can generally be classified as:

* Nociceptive which includes pain from visceral origins or damage to other tissues. Myofascial pain is a nociceptive type of pain characterized by myofascial trigger points limited to a specific muscle or muscles.
* Neuropathic including that originating from brain, peripheral nerves or both; and
* Psychogenic that originates in mood, characterological, social, or psychophysiological processes.

Recent advances in the neurosciences reveal additional mechanisms involved in chronic pain. In the past, pain was seen as a sensation arising from the stimulation of pain receptors by damaged tissue, initiating a sequence of nerve signals ending in the brain and there recognized as pain. A consequence of this model was that ongoing pain following resolution of tissue damage was seen as less physiological and more psychological than acute pain with identifiable tissue injury. Current research indicates that chronic pain involves additional mechanisms that cause: 1) neural remodeling at the level of the spinal cord and higher levels of the central nervous system; 2) changes in membrane responsiveness and connectivity leading to activation of larger pain pathways; and 3) recruitment of distinct neurotransmitters.

Changes in gene function and expression may occur, with lasting functional consequences. These physiologic functional changes cause chronic pain to be experienced in body regions beyond the original injury and to be exacerbated by little or no stimulation. The chronic pain experience clearly represents both psychologic and complex physiologic mechanisms, many of which are just beginning to be understood.

Chronic painis defined as "pain that persists for at least 30 days beyond the usual course of an acute disease or a reasonable time for an injury to heal or that is associated with a chronic pathological process that causes continuous pain (e.g., reflex sympathetic dystrophy)." The very definition of chronic pain describes a delay or outright failure to increase function and relieve pain associated with some specific illness or accident.Delayed recovery should prompt a clinical review of the case and a psychological evaluation by the health care provider. Referral to a recognized pain specialist for further evaluation is recommended. Consideration may be given to new diagnostic testing or a change in treatment plan.

The term “chronic pain syndrome” has been used and defined in a variety of ways that generally indicate a belief on the part of the health care provider that the patient's pain is inappropriate or out of proportion to existing problems or illness.Use of the term “chronic pain syndrome” should be discontinued because the term ceases to have meaning due to the many different physical and psychosocial issues associated with it. Instead, practitioners should use the nationally accepted terminology indicated in the definition section and/or the psychiatric diagnosis of "pain disorder" and the subtypes according to established standards of the American Psychiatric Association (APA).

The IASP offers taxonomy of pain, which underscores the wide variety of pathological conditions associated with chronic pain. This classification system may not address the psychological and psychosocial issues that occur in the perception of pain, suffering, and disability and may require referral to psychiatric or psychological clinicians. These issues should be documented with preference to the diagnostic categories of the Diagnostic and Statistical Manual of Mental Disorders (DSM), published by the American Psychiatric Association including the subcategories of pain disorder and any other applicable diagnostic categories (i.e., depressive, anxiety, and adjustment disorders). Pain disorder associated with general medical condition may be used for treatment; however, it may not be used to establish impairment therefore, more specific DSM coding of the condition is required when appropriate.

Chronic pain is a phenomenon not specifically relegated to anatomical or physiologic parameters.The prevailing biomedical model (which focuses on identified disease pathology as the sole cause of pain) cannot capture all of the important variables in pain behavior. While diagnostic labels may pinpoint contributory physical and/or psychological factors and lead to specific treatment interventions that are helpful, a large number of patients defy precise taxonomic classification. Furthermore, such diagnostic labeling often overlooks important social contributions to the chronic pain experience. Failure to address these operational parameters of the chronic pain experience may lead to incomplete or faulty treatment plans. The term "pain disorder" is perhaps the most useful term in the medical literature today, in that it captures the multi-factorial nature of the chronic pain experience.

It is recognized that some health care practitioners, by virtue of their experience, additional training, and/or accreditation by pain specialty organizations, have much greater expertise in the area of chronic pain evaluation and treatment than others. Referrals for the treatment of chronic pain should be to such recognized specialists. Chronic pain treatment plans should be monitored and coordinated by physicians with expertise in pain management including specialty training and/or certification.

Most acute and some chronic pain problems are adequately addressed in other Division treatment guidelines, and are generally not within the scope of these guidelines. However, because chronic pain is more often than not multi-factorial, involving more than one pathophysiologic or mental disorder, some overlap with other guidelines is inevitable. These guidelines are meant to apply to any patient who fits the operational definition of chronic pain discussed at the beginning of this section.

1. DEFINITIONS
	1. **AFTER SENSATION** Refers to the abnormal persistence of a sensory perception, provoked by a stimulus even though the stimulus has ceased.
	2. **ALLODYNIA** Pain due to a non-noxious stimulus that does not normally provoke pain.

	Mechanical Allodynia – Refers to the abnormal perception of pain from usually non-painful mechanical stimulation.

	Static Mechanical Allodynia – Refers to pain obtained by applying a single stimulus such as light pressure to a defined area.

	Dynamic Mechanical Allodynia – Obtained by moving the stimulus such as a brush or cotton tip across the abnormal hypersensitive area.

	Thermal Allodynia – Refers to the abnormal sensation of pain from usually non-painful thermal stimulation such as cold or warmth.
	3. **ANALGESIA** Absence of pain in response to stimulation that would normally be painful.
	4. **BIOPSYCHOSOCIAL** A term that reflects the multiple facets of any clinical situation; namely, the biological, psychological, and social situation of the patient.
	5. **CENTRAL PAIN** Pain initiated or caused by a primary lesion or dysfunction in the central nervous system.
	6. **CENTRAL SENSITIZATION** The experience of pain evoked by the excitation of non-nociceptive neurons or of nerve fibers that normally relay non-painful sensations to the spinal cord. This results when non-nociceptive afferent neurons act on a sensitized central nervous system (CNS). Experimental data suggest that pathways normally carrying pain signals themselves become overstimulated and/or fail to respond to inhibitory influencescausing increased pain**.** An example is ‘wind-up’ which occurs when cells in the dorsal horn of the spinal cord increase their rate of action potential discharge in response to repeated stimulation by nociceptors ([Woolf CJ, 2006](#Woolf2006); [Zhou Y 2008](#Zhou2008)) .
	7. **DYSESTHESIA** An abnormal sensation described by the patient as unpleasant. As with paresthesia, dysesthesia may be spontaneous or evoked by maneuvers on physical examination.
	8. **HYPERALGESIA** Refers to an exaggerated pain response from a usually painful stimulation.
	9. **HYPERESTHESIA (POSITIVE SENSORY PHENOMENA)** Includes allodynia, hyperalgesia, and hyperpathia. Elicited by light touch, pin prick, cold, warm, vibration, joint position sensation or two-point discrimination, which is perceived as increased or more.
	10. **HYPERPATHIA** a condition of altered perception such that stimuli which would normally be innocuous, if repeated or prolonged, result in severe explosive persistent pain.
	11. **HYPOALGESIA** Diminished pain perception in response to a normally painful stimulus.
	12. **HYPOESTHESIA (NEGATIVE SENSORY PHENOMENA)** (also hypesthesia), diminished sensitivity to stimulation
	13. **MALINGERING** Intentional feigning of illness or disability in order to achieve external incentives such as recreational drugs or money.
	14. **MYOFASCIAL PAIN** A regional pain characterized by tender points in taut bands of muscle that produce pain in a characteristic reference zone.
	15. **MYOFASCIAL TRIGGER POINT** A physical sign in a muscle which includes a) exquisite tenderness in a taut muscle band; and b) referred pain elicited by mechanical stimulation of the trigger point. The following findings may be associated with myofascial trigger points: 1) Local twitch or contraction of the taut band when the trigger point is mechanically stimulated; 2) Reproduction of the patient’s spontaneous pain pattern when the trigger point is mechanically stimulated; 3) Weakness without muscle atrophy; 4) Restricted range of motion of the affected muscle; and 5) Autonomic dysfunction associated with the trigger point such as changes in skin or limb temperature.
	16. **NEURALGIA** Pain in the distribution of a nerve or nerves.
	17. **NEURITIS** Inflammation of a nerve or nerves.
	18. **NEUROGENIC PAIN** Pain initiated or caused by a primary lesion, dysfunction, or transitory perturbation in the peripheral or central nervous system.
	19. **NEUROPATHIC PAIN** Pain due to an injured or dysfunctional central or peripheral nervous system.
	20. **NEUROPATHY** A disturbance of function or pathological change in a nerve: in one nerve, (mononeuropathy) in several nerves, (mononeuropathy multiplex); **OR** diffuse and bilateral, (polyneuropathy). Neuropathy should be associated with objective findings such as consistent sensory abnormalities, consistent motor findings (e.g. weakness, atrophy, fasciculations, muscle cramping) and/or neuropathic abnormalities on EMG/nerve conduction testing.
	21. **NOCICEPTOR** A receptor preferentially sensitive to a noxious stimulus or to a stimulus which would become noxious if prolonged.
	22. **PAIN BEHAVIOR** The non-verbal actions (such as grimacing, groaning, limping, using visible pain relieving or support devices and requisition of pain medications, among others) that are outward manifestations of pain, and through which a person may communicate that pain is being experienced.
	23. **PAIN THRESHOLD** The smallest stimulus perceived by a subject as painful during laboratory testing. The term also loosely applies to the biological variation among human beings in sensing and coping with pain.
	24. **PARESTHESIA** An abnormal sensation that is not described as pain. It can be either a spontaneous sensation (such as pins and needles) or a sensation evoked from non-painful or painful stimulation, such as light touch, thermal, or pinprick stimulus on physical examination.
	25. **PERIPHERAL NEUROPATHIC PAIN** Pain initiated or caused by a primary lesion or dysfunction in the peripheral nervous system.
	26. **SOMATIC DYSFUNCTION** Somatic dysfunction is impaired or altered function of related components of the somatic (body framework) system which includes skeletal, arthrodial, and myofascial structures.
	27. **SUMMATION** Refers to abnormally painful sensation to a repeated stimulus although the actual stimulus remains constant. The patient describes the pain as growing and growing as the same intensity stimulus continues.
	28. **SYMPATHETICALLY MAINTAINED PAIN (SMP)** A pain that is maintained by sympathetic pathways and intensifiedby circulating catecholamines.
	29. **TENDER POINTS** Tenderness on palpation at a tendon insertion, muscle belly or over bone. Palpation should be done with the thumb or forefinger, applying pressure approximately equal to a force of 4 kilograms (blanching of the entire nail bed).
2. INITIAL EVALUATION & DIAGNOSTIC PROCEDURES

The Division recommends the following diagnostic procedures be considered, at least initially, the responsibility of the workers’ compensation carrier to ensure that an accurate diagnosis and treatment plan can be established. Standard procedures that should be utilized when initially diagnosing a work-related chronic pain complaint are listed below.

* 1. HISTORY TAKING AND PHYSICAL EXAMINATION (Hx & PE): are generally accepted, well-established and widely used procedures that establish the foundation/basis for and dictate subsequent stages of diagnostic and therapeutic procedures. When findings of clinical evaluations and those of other diagnostic procedures are not complementing each other, the objective clinical findings should have preference. The medical records should reasonably document the following:
		1. Medical History**:** As in other fields of medicine, a thorough patient history is an important part of the evaluation of chronic pain. In taking such a history, factors influencing a patient’s current status can be made clear and taken into account when planning diagnostic evaluation and treatment. One efficient manner in which to obtain historical information is by using a questionnaire. The questionnaire may be sent to the patient prior to the initial visit or administered at the time of the office visit. History should ascertain the following elements.
			1. General Information – General items requested are name, sex, age, birth date, etc.
			2. Level of Education – The level of patients’ education may influence response to treatment.
			3. Work History/Occupation – To include both impact of injury on job duties and impact on ability to perform job duties, work history, job description, mechanical requirements of the job, duration of employment, and job satisfaction.
			4. Current employment status.
			5. Marital status.
			6. Family Environment – Is the patient living in a nuclear family or with friends? Is there or were there, any family members with chronic illness or pain problems? Responses to such questions reveal the nature of the support system or the possibility of conditioning toward chronicity.
			7. Ethnic Origin – Ethnicity of the patient, including any existing language barriers, may influence the patient’s perception of and response to pain. Literature indicates that providers may under-treat patients of certain ethnic backgrounds due to underestimation of their pain ([Todd, 2000](#Todd2000)).
			8. Belief System – Patients should be asked about their value systems, including spiritual and cultural beliefs, in order to determine how these may influence the patient’s and family’s response to illness and treatment recommendations.
			9. Activities of Daily Living – Pain has a multidimensional effect on the patient that is reflected in changes in usual daily vocational, social, recreational, and sexual activities.
			10. Past and present psychological problems.
			11. History of abuse – Physical, emotional, sexual.
			12. History of disability in the family.
			13. Sleep disturbances.
			14. Causality: How did this injury occur? Was the problem initiated by a work-related injury or exposure?
		2. Pain History**:** Characterization of the patient’s pain and of the patient’s response to pain is one of the key elements in treatment.
			1. Site of Pain – Localization and distribution of the pain help determine the type of pain the patient has (i.e., central versus peripheral).
			2. Pain diagram drawings to document the distribution of pain.
			3. Visual Analog Scale (VAS). Including a discussion of the range of pain during the day and how activities, use of modalities, and other actions affect the intensity of pain.
			4. Duration.
			5. Place of onset. Circumstances during which the pain began (e.g. an accident, an illness, a stressful incident or spontaneous onset).
			6. Pain Characteristics – Such as burning, shooting, stabbing, and aching. Time of pain occurrence, as well as intensity, quality, and radiation, give clues to the diagnosis and potential treatment. Quality of pain can be helpful in identifying neuropathic pain which is normally present most of the day, at night and is described as burning.
			7. List of activities which aggravate or exacerbate, ameliorate, or have no effect on the level of pain.
			8. Associated Symptoms – Does the patient have numbness or paresthesia, dysesthesia, weakness, bowel or bladder dysfunction, decreased temperature, increased sweating, cyanosis or edema? Is there local tenderness, allodynia, hyperesthesia, or hyperalgesia?

c. Medical Management History:

i. Diagnostic Tests – All previous radiological and laboratory investigations should be reviewed.

ii. Prior Treatment – Chronological review of medical records including previous medical evaluations and response to treatment interventions. In other words, what has been tried and which treatments have helped?

iii. Prior Surgery – If the patient has had prior surgery specifically for the pain, he/she may be less likely to have a positive outcome.

iv. Medications – History of and current use of medications, including over the counter and herbal/dietary supplements to determine drug usage (or abuse) interactions and efficacy of treatment. Drug allergies and other side effects experienced with previous or current medication therapy and adherence to currently prescribed medications should be documented. Ideally, this includes dosing schedules as reported by the patient or patient representative. Information should be checked against the Colorado Prescription Drug Monitoring Program (PDMP), offered by the Colorado Pharmacy Board.

v. Review of Systems Check List – Determine if there is any interplay between the pain complaint and other medical conditions.

vi. Psychosocial Functioning – Determine if any of the following are present: current symptoms of depression or anxiety; evidence of stressors in the workplace or at home; and past history of psychological problems. Other confounding psychosocial issues may be present, including the presence of psychiatric disease. Due to the high incidence of co-morbid problems in populations that develop chronic pain, it is recommended that patients diagnosed with chronic pain should be referred for a full psychosocial evaluation.

vii. Pre-existing Conditions – Treatment of these conditions is appropriate when the pre-existing condition affects recovery from chronic pain.

viii. Family history pertaining to similar disorders.

d. Substance Use/Abuse:

i. Alcohol use.

ii. Smoking History and use of nicotine replacements.

iii. History of current and prior prescription and street drug use or abuse.

iv. The use of caffeine or caffeine containing beverages.

v. Substance abuse information may be only fully obtainable from multiple sources over time. Patient self reports may be unreliable. Patient self reports should always be checked against medical records.

e. Other Factors Affecting Treatment Outcome:

i. Compensation/Disability/Litigation.

ii. Treatment Expectations – What does the patient expect from treatment: complete relief of pain or reduction to a more tolerable level?

f. Physical Examination:

i. Neurologic Evaluation – Includes cranial nerves survey, muscle tone and strength, atrophy, detailed sensory examination (see ii-below), motor evaluation (station, gait, coordination) reflexes (normal tendon reflexes and presence or absence of abnormal reflexes such as frontal lobe release signs or upper motor neuron signs, cerebellar testing and provocative neurological maneuvers.

ii. Sensory Evaluation – A detailed sensory examination is crucial in evaluating a patient with chronic pain complaints. Quantitative sensory testing, such as Semmes-Weinstein, may be useful tools in determining sensory abnormalities. The examination should determine if the following sensory signs are present and consistent on repeated examination.

* + - * 1. Hyperalgesia.
				2. Hyperpathia.
				3. Paresthesia.
				4. Dysesthesia.
				5. Mechanical Allodynia – static versus dynamic.
				6. Thermal Allodynia.
				7. Hypoesthesia.
				8. Hyperesthesia.
				9. Summation.

iii.Musculoskeletal Evaluation – Range-of-motion, segmental mobility, musculoskeletal provocative maneuvers, palpation, observation, and functional activities. All joints, muscles, ligaments, and tendons should be examined for asymmetry, swelling, laxity, and tenderness. A portion of the musculoskeletal evaluation is the myofascial examination. The myofascial examination includes palpating soft tissues for evidence of tightness and trigger points.

iv. Evaluation of non-physiologic findings:

A) If applicable, Waddell Signs, which include 5 categories of clinical signs (1) tenderness- superficial and non-anatomic, (2) pain with simulation: axial loading and rotation, (3) regional findings: sensory and motor inconsistent with nerve root patterns (4) distraction /inconsistency in straight leg raising findings, and (5) over-reaction to physical examination maneuvers. Significance may be attached to positive findings in 3 out of 5 of these categories, but not to isolated findings. Waddell advocates considering Waddell’s signs prior to recommending a surgical procedure. These signs should be measured routinely to identify patients requiring further assessment (i.e., biopsychosocial) prior to undergoing back surgery.

It is generally agreed that Waddell signs are associated with decreased functional performance and greater subjective pain levels, though they provide no information on the etiology of pain. Waddell Signs cannot be used to predict or diagnose malingering. Their presence of 3 out of 5 signs may most appropriately be viewed as a “yellow flag”, or screening test, alerting clinicians to those patients who require a more comprehensive approach to their assessment and care plan. Therefore, for chronic back pain, a psychosocial evaluation should be part of the total evaluation of the patient. Refer to Section E. 2, Personality/Psychological/Psychosocial Evaluation.

B) Variability on formal exam including variable sensory exam, inconsistent tenderness, and/or swelling secondary to extrinsic sources.

C) Inconsistencies between formal exam and observed abilities of range-of-motion, motor strength, gait and cognitive/emotional state should be noted in the assessment.

* 1. PERSONALITY/ PSYCHOLOGICAL/PSYCHOSOCIAL EVALUATION FOR PAIN MANAGEMENT are generally accepted, well-established, and widely used diagnostic procedures not only with selected use in acute pain problems, but also with more widespread use in subacute and chronic pain populations. Diagnostic evaluations should distinguish between conditions that are pre-existing, aggravated by the current injury or work related.

	Psychosocial evaluations should determine if further psychosocial or behavioral interventions are indicated for patients diagnosed with chronic pain. The interpretations of the evaluation should provide clinicians with a better understanding of the patient in his or her social environment, thus allowing for more effective rehabilitation. Psychosocial assessment requires consideration of variations in pain experience and expression resulting from affective, cognitive, motivational and coping processes, and other influences such as gender, age, race, ethnicity, national origin, religion, sexual orientation, disability, language, or socioeconomic status.

	While there is some agreement about which psychological factors need to be assessed in patients with chronic pain, a comprehensive psychological evaluation should attempt to identify both primary psychiatric risk factors or “red flags” (e.g. psychosis, active suicidality), as well as secondary risk factors or “yellow flags” (e.g. moderate depression, job dissatisfaction) ([Bruns D and Disorbio J 2009](#BrunsandDisorbio2009)). Significant personality disorders must be taken into account when considering a patient for spinal cord stimulation and other major procedures.

	Psychometric Testing is a valuable component of a consultation to assist the physician in making a more effective treatment plan. There is good evidence that psychometric testing can have significant ability to predict medical treatment outcome ([Sinikallio S, Aalto, T, Airaksinen, O, 2009;](#Sinikallio2009) [Sinikallio S, Aalto, T, Airaksinen, O, Lehto, SM, 2010](#sinikallio2010); [Block A 2001).](#BlockA2001) For example, one study found that psychometric testing exceeded the ability of discography to predict disability in patients with low back pain ([Carragee, 2005](#Carragee2005)). Pre-procedure psychiatric/psychological evaluation must be done prior to diagnostic confirmatory testing for the procedure. Examples include discography for fusion, spinal cord stimulation, or intrathecal drug delivery systems and should not be done by a psychologist employed by the physician planning to perform the procedure.

	In many instances, psychological testing has validity comparable to that of commonly used medical tests; for example, the correlation between high trait anger and blood pressure is equal to the correlation between reduced blood flow and the failure of a synthetic hemodialysis graft ([Meyer G 2001).](#MeyerG2001) Thus, psychometric testing may be of comparable validity to medical tests and may provide unique and useful diagnostic information ([Meyer G 2001](#MeyerG2001)).

	All patients who are diagnosed as having chronic pain should be referred for a psychosocial evaluation, as well as concomitant interdisciplinary rehabilitation treatment. This referral should be performed in a way so as to not imply that the patient’s claims are invalid, or that the patient is malingering or mentally ill. Even in cases where no diagnosable mental condition is present, these evaluations can identify social, cultural, coping and other variables that may be influencing the patient’s recovery process and may be amenable to various treatments including behavioral therapy. As pain is understood to be a biopsychosocial phenomenon, these evaluations should be regarded as an integral part of the assessment of chronic pain conditions.
		1. Qualifications:
			1. A psychologist with a PhD, PsyD, EdD credentials, or a physician with Psychiatric MD/DO credentials may perform the initial comprehensive evaluations. It is preferable that these professionals have experience in diagnosing and treating chronic pain disorders in injured workers.
			2. Psychometric tests should be administered by psychologists with a PhD, PsyD, or EdD, or health professionals working under the supervision of a doctorate level psychologist. Physicians with appropriate training may also administer such testing but interpretation of the tests should be done by properly credentialed mental health professionals.
		2. Clinical Evaluation:

		Special note to health care providers: most providers are required to adhere to the federal regulations under the Health Insurance Portability and Accountability Act (HIPAA). Unlike general health insurers, workers compensation insurers are not required to adhere to HIPAA standards thus, providers should assume that sensitive information included in a report sent to the insurer could be forwarded to the employer. The Colorado statute provides a limited waiver of medical information regarding the work-related injury or disease to the extent necessary to resolve the claim. it is recommended that the health care provider either 1) obtain a full release from the patient regarding information that may go to the employer or 2) not include sensitive health information not directly related to the work related conditions in reports sent to the insurer.

		All chronic pain patients should have a clinical evaluation that addresses the following areas:

A**.** History of Injury – The history of the injury should be reported in the patient’s words or using similar terminology. Caution must be exercised when using translators.

* + - * Nature of injury.
			* Psychosocial circumstances of the injury.
			* Current symptomatic complaints.
			* Extent of medical corroboration.
			* Treatment received and results.
			* Compliance with treatment.
			* Coping strategies used, including perceived locus of control, catastrophizing, and risk aversion.
			* Perception of medical system and employer.
			* History of response to prescription medications.

B.Health History.

* + - * Nature of injury.
			* Medical history.
			* Psychiatric history.
			* History of alcohol or substance abuse.
			* Activities of daily living.
			* Previous injuries, including disability, impairment, and compensation.

C.Psychosocial History.

* + - * Childhood history, including abuse/neglect.
			* Educational history.
			* Family history, including disability.
			* Marital history and other significant adulthood activities and events.
			* Legal history, including criminal and civil litigation.
			* Employment history.
			* Military duty- because post-traumatic stress disorder (PTSD) might be an unacceptable condition for many military personnel to acknowledge, it may be prudent to screen initially for signs of depression or anxiety – both ofwhich may be present in PTSD.
			* Signs of pre-injury psychological dysfunction.
			* Current and past interpersonal relations, support, living situation.
			* Financial history.

D.Mental status exam including cognition, affect, mood, orientation, thinking, and perception. May include mini mental status exam or frontal assessment battery if appropriate.

E.Assessment of any danger posed to self or others.

F.Psychological test results, if performed.

G.Current psychiatric diagnosis consistent with the standards of the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders.

H.Pre-existing psychiatric conditions. Treatment of these conditions is appropriate when the pre-existing condition affects recovery from chronic pain.

I.Causality (to address medically probable cause and effect, distinguishing pre-existing psychological symptoms, traits and vulnerabilities from current symptoms).

J.Treatment recommendations with respect to specific goals, frequency, timeframes, and expected outcomes.

* + 1. Tests of Psychological Functioning**:** Psychometric testing is a valuable component of a consultation to assist the physician in making a more effective treatment plan. Psychometric testing is useful in the assessment of mental conditions, pain conditions, cognitive functioning, treatment planning, vocational planning, and evaluation of treatment effectiveness. While there is no general agreement as to which psychometric tests should be specifically recommended for psychological evaluations of chronic pain conditions, standardized tests are preferred over those which are not for assessing diagnosis.

		In contrast, non-standardized tests can be useful for “ipsative” outcome assessment, where a test is administered more than once, and a patient’s current reports are compared with his or her own reports in the past.

		It is appropriate for the mental health provider to use their discretion and administer selective psychometric tests within their expertise and within standards of care in the community. Use of screening psychometrics by non-mental health providers is encouraged but mental health provider consultation should always be utilized for chronic pain patients in which invasive palliative pain procedures or chronic opiate treatment is being contemplated. Some of these tests are available in Spanish and other languages, and many are written at a 6th grade reading level. Examples of frequently used psychometric tests performed include, but not limited to the following:
			1. Comprehensive Inventories for Medical Patients:

a)Battery for Health Improvement, 2nd Edition (BHI-2tm).

What it measures – Depression, anxiety and hostility; violent and suicidal ideation; borderline, dependency, chronic maladjustment, substance abuse, conflicts with work, family and physician, pain preoccupation, somatization, perception of functioning and others.

Benefits – When used as a part of a comprehensive evaluation, can contribute substantially to the understanding of psychosocial factors underlying pain reports, perceived disability and somatic preoccupation; as well as to design interventions. Serial administrations can track changes in a broad range of variables during the course of treatment, and assess outcome.

Characteristics – Standardized test normalized on patients with chronic pain or injury and on community members, with reference groups for six other subcategories of injured patients.

b) Millon tm Behavioral Medical Diagnostic (MBMD tm):

What it measures – Updated version of the Millon Behavioral Health Inventory (MBHI). Provides information on coping styles (introversive, inhibited, dejected, cooperative, sociable, etc.), health habits (smoking, drinking, eating, etc.), psychiatric indications (anxiety, depression, etc.), stress moderators (illness apprehension vs. illness tolerance, etc.), treatment prognostics (interventional fragility vs. interventional resilience, medication abuse vs. medication competence, etc.) and other factors.

Benefits – When used as a part of a comprehensive evaluation, can contribute substantially to the understanding of psychosocial factors affecting medical patients. Understanding risk factors and patient personality type can help to optimize treatment protocols for a particular patient.

Characteristics – Standardized test normalized on medical patients with various diseases, on obesity, and on chronic pain groups.

* + - 1. Comprehensive Psychological Inventories:

			These tests are designed for detecting various psychiatric syndromes, but in general are more prone to false positive findings when administered to medical patients.

a) Millon tm Clinical Multiaxial Inventorytm, 3rd Edition (MCMI-III tm).

What it measures – Has scales based on DSM diagnostic criteria for affective, personality and psychotic disorders and somatization.

Benefits – When used as a part of a comprehensive evaluation, can screen for a broad range of DSM diagnoses.

Characteristics – Standardized test normalized on psychiatric patients.

b) Minnesota Multiphasic Personality Inventory®, 2nd Edition (MMPI-2®).

What it measures – Original scale constructs, such as hysteria and psychasthenia are archaic but continue to be useful. Newer content scales include depression, anxiety, health concerns, bizarre mentation, social discomfort, low self-esteem, and almost 100 others.

Benefits – When used as a part of a comprehensive evaluation, measure a number of factors that have been associated with poor treatment outcome.

Characteristics – Standardized test normalized on community members

c) Minnesota Multiphasic Personality Inventory®, 2nd Edition Revised Form (MMPI-2®).

What it measures – 50 scales assess a wide range of psychiatric disorders and personality traits, plus 8 validity scales, critical items.

Benefits – new version of MMPI-2 has undergone extensive revision to correct perceived MMPI-2 deficiencies. Has advantages over the original MMPI-2 in psychiatric assessment, but may be less capable when assessing patients with chronic pain.

Characteristics – Standardized test normalized on community members, with multiple other reference groups.

d) Personality Assessment Inventory tm (PAI).

What it measures – A measure of general psychopathology that assesses depression, anxiety, somatic complaints, stress, alcohol and drug use reports, mania, paranoia, schizophrenia, borderline, antisocial, and suicidal ideation and more than 30 others.

Benefits – When used as a part of a comprehensive evaluation, can contribute substantially to the identification of a wide variety of risk factors that could potentially affect the medical patient.

Characteristics – Standardized test normalized on community members.

* + - 1. Brief Multidimensional Screens for Medical Patients:

			Treating providers, to assess a variety of psychological and medical conditions, including depression, pain, disability and others, may use brief instruments. These instruments may also be employed as repeated measures to track progress in treatment, or as one test in a more comprehensive evaluation. Brief instruments are valuable in that the test may be administered in the office setting and hand scored by the physician. Results of these tests should help providers distinguish which patients should be referred for a specific type of comprehensive evaluation.

a) Brief Battery for Health Improvement, 2nd Edition (BBHI-2 tm).

What it measures – Depression, anxiety, somatization, pain, function, and defensiveness.

Benefits – Can identify patients needing treatment for depression and anxiety, and identify patients prone to somatization, pain magnification and self-perception of disability. Can compare the level of factors above to other pain patients and community members. Serial administrations can track changes in measured variables during the course of treatment, and assess outcome.

Characteristics – Standardized test normalized on patients with chronic pain or injury and on community members, with reference groups for six subcategories of injured patients.

b) Pain Patient Profile (P3®).

What it measures – Assesses depression, anxiety, and somatization.

Benefits – Can identify patients needing treatment for depression and anxiety, as well as identify patients prone to somatization. Can compare the level of depression, anxiety and somatization to other pain patients and community members. Serial administrations can track changes in measured variables during the course of treatment, and assess outcome.

Characteristics – Standardized test normalized on patients with chronic pain, and on community members.

c) Multidimensional Pain Inventory (MPI).

What it measures – Interference, support, pain severity, life-control, affective distress, response of significant other to pain, and self-perception of disability at home and work, and in social and other activities of daily living.

Benefits – Can identify patients with high levels of disability perceptions, affective distress, or those prone to pain magnification. Serial administrations can track changes in measured variables during the course of treatment, and assess outcome.

Characteristics – Partially standardized test, initially developed primarily with male military personnel, and later normalized on patients with chronic pain in the United States and Sweden.

d) SF-36®.

What it measures – A survey of general health well-being and functional states.

Benefits – Assesses a broad spectrum of patient disability reports. Serial administrations could be used to track patient perceived functional changes during the course of treatment, and assess outcome.

Characteristics – Non-standardized test without norms.

e) Sickness Impact Profile© (SIP).

What it measures – Perceived disability in the areas of sleep, eating, home management, recreation, mobility, body care, social interaction, emotional behavior, and communication.

Benefits – Assesses a broad spectrum of patient disability reports. Serial administrations could be used to track patient perceived functional changes during the course of treatment, and assess outcome.

Characteristics – Non-standardized test without norms.

f) McGill Pain Questionnaire (MPQ).

What it measures – Cognitive, emotional and sensory aspects of pain.

Benefits – Can identify patients prone to pain magnification. Repeated administrations can track progress in treatment for pain.

Characteristics – Non-standardized test without norms.

g) McGill Pain Questionnaire – Short Form (MPQ-SF).

What it measures – Emotional and sensory aspects of pain.

Benefits – Can identify patients prone to pain magnification. Repeated administrations can track progress in treatment for pain.

Characteristics – Non-standardized test without norms.

h) Oswestry Disability Questionnaire (ODQ).

What it measures – Disability secondary to low back pain.

Benefits – Can measure patients’ self-perceptions of disability. Serial administrations could be used to track changes in self-perceptions of functional ability during the course of treatment, and assess outcome.

Characteristics – Non-standardized test without norms.

i) Visual Analog Scales (VAS).

What it measures – Graphical measure of patient’s pain report, where the patient makes a mark on a line to represent pain level.

Benefits – Quantifies the patients’ pain report, most-commonly using a 10 centimeter horizontal line. Serial administrations could be used to track changes in pain reports during the course of treatment and assess outcome.

Characteristics – Non-standardized test without norms. Some patients may have difficulty with this conceptual test format, depending on perceptual, visuomotor, cultural orientation or other factors.

j) Numerical Rating Scales (NRS).

What it measures – Numerical report of patients’ pain.

Benefits – Quantifies the patients’ pain report, typically on a 0-10 scale. Serial administrations could be used to track changes in pain reports during the course of treatment and assess outcome.

Characteristics – Recommended by JCAHO. Non-standardized test without norms. May be more easily understood than the VAS.

* + - 1. Brief Multidimensional Screens for Psychiatric Patients:

			These tests are designed for detecting various psychiatric syndromes, but in general are more prone to false positive findings when administered to medical patients.

a) Brief Symptom Inventory (BSI®).

What it measures: Somatization, obsessive-compulsive, depression, anxiety, phobic anxiety, hostility, paranoia, psychoticism, and interpersonal sensitivity.

Benefits: Can identify patients needing treatment for depression and anxiety, as well as identify patients prone to somatization. Can compare the level of depression, anxiety, and somatization to community members. Serial administrations could be used to track changes in measured variables during the course of treatment, and assess outcome.

Characteristics – standardized test normalized on community members

b) Brief Symptom Inventory – 18 (BSI-18®).

What it Measures: Depression, anxiety, somatization.

Benefits: Can identify patients needing treatment for depression and anxiety, as well as identify patients prone to somatization. Can compare the level of depression, anxiety, and somatization to community members. Serial administrations could be used to track patient perceived functional changes during the course of treatment, and assess outcome.

Characteristics – standardized test normalized on patients with chronic pain associated with cancer

c) Symptom Check List 90 (SCL 90).

What it measures: Somatization, obsessive-compulsive, depression, anxiety, phobic anxiety, hostility, paranoia, psychoticism, and interpersonal sensitivity.

Benefits: Can identify patients needing treatment for depression and anxiety, as well as identify patients prone to somatization. Can compare the level of depression, anxiety and somatization to community members. Serial administrations could be used to track changes in measured variables during the course of treatment, and assess outcome.

Characteristics – standardized test normalized on community members

* + - 1. Brief Specialized Psychiatric Screening Measures:

a) Beck Depression Inventory® (BDI).

What it measures: Depression.

Benefits: Can identify patients needing referral for further assessment and treatment for depression and anxiety, as well as identify patients prone to somatization. Repeated administrations can track progress in treatment for depression, anxiety, and somatic preoccupation. Requires a professional evaluation to verify diagnosis.

Characteristics – standardized test without norms, uses cutoff scores.

b) Post Traumatic Stress Diagnostic Scale (PDS®).

What it Measures: Post Traumatic Stress Disorder (PTSD).

Benefits: Helps confirm suspected PTSD diagnosis. Repeated administrations can track treatment progress of PTSD patients.

Characteristics – standardized test normalized on community members.

c) Center of Epidemiologic Studies – Depression Questionnaire.

What it measures: Depression.

Benefits: Brief self-administered screening test. Requires a professional evaluation to verify diagnosis.

Characteristics – nonstandardized test without norms

d) Brief Patient Health Questionnaire tm from PRIME - MD®

What it measures: Depression, panic disorder.

Benefits: Brief self-administered screening test. Requires a professional evaluation to verify diagnosis.

Characteristics – nonstandardized test without norms, keyed to diagnostic criteria, uses cutoff scores.

e) Zung Questionnaire.

What it measures: Depression.

Benefits: Brief self-administered screening test. Requires a professional evaluation to verify diagnosis.

Characteristics – Non-standardized test without norms.

* 1. DIAGNOSTIC STUDIESImaging of the spine and/or extremities is a generally accepted, well-established, and widely used diagnostic procedure when specific indications, based on history and physical examination, are present. Physicians should refer to specific acute care Division guidelines for detailed information about specific testing procedures. Tests should be performed to rule in or out specific diagnoses.
		1. Radiographic Imaging, MRI, CT, bone scan, radiography, and other special imaging studies may provide useful information for many musculoskeletal disorders causing chronic pain. Most imaging is likely to demonstrate aging changes which are usually not pathologic. Refer to specific guidelines for details. Patients should be informed before the test is performed the purpose of the exam, e.g. to rule out unsuspected cancer, and the likelihood that non pathologic aging changes will be found.
		2. Electrodiagnostic studies may be useful in the evaluation of patients with suspected myopathic or neuropathic disease and may include Nerve Conduction Studies (NCS), Standard Needle Electromyography, or Somatosensory Evoked Potential (SSEP). The evaluation of electrical studies is complex and should be performed by specialists who are well trained in the use of this diagnostic procedure.
		3. Special testing procedures may be considered when attempting to confirm the current diagnosis or reveal alternative diagnosis. In doing so, other special tests may be performed at the discretion of the physician.
		4. Testing for Complex Regional Pain Syndrome (CRPS-I) or Sympathetically Maintained Pain (SMP) is described in the Division’s Complex Regional Pain Syndrome/Reflex Sympathetic Dystrophy Medical Treatment Guidelines.
	2. LABORATORY TESTING is generally accepted, well-established, and widely used procedures and can provide useful diagnostic and monitoring information. They may be used when there is suspicion of systemic illness; infection; neoplasia; underlying rheumatologic disorder or connective tissue disorder; or based on history and/or physical examination. Tests include, but are not limited to the following:
		1. Complete Blood Count (CBC) with differential can detect infection, blood dyscrasias, and medication side effects;
		2. Erythrocyte sedimentation rate, rheumatoid factor, Antinuclear Antigen (ANA), Human Leukocyte Antigen (HLA), and C-reactive protein can be used to detect evidence of a rheumatologic, infection, or connective tissue disorder;
		3. Thyroid, glucose and other tests to detect endocrine disorders; (e.g. catecholamines, free and total testosterone levels, both of which may be deficient in chronic pain patients secondary to prolonged stress and/or chronic use of opioid analgesics);
		4. Serum calcium, phosphorous, uric acid, alkaline phosphatase, and acid phosphatase can detect metabolic bone disease;
		5. Urinalysis can detect bacteria (usually with culture and sensitivity), calcium, phosphorus, hydroxyproline, or hematuria;
		6. Liver and kidney function may be performed for baseline testing and monitoring of medications; and
		7. Toxicology screen. Serum and/or urine may be performed as appropriate. Ablood alcohol level may also be appropriate if alcohol abuse is suspected.
	3. INJECTIONS–DIAGNOSTIC
		1. Spinal Diagnostic Injections**:** Diagnostic injections should not be done merely to identify all possible pain generators. The indications for the diagnostic injections must be met and a specific therapeutic goal clarified to justify the need for further diagnostic injections.

		Description — generally accepted, well-established procedures. These injections may be useful for localizing the source of pain, and may have added therapeutic value when combined with injection of therapeutic medication(s). Each diagnostic injection has inherent risks, and risk versus benefit should always be evaluated when considering injection therapy. Since these procedures are invasive, less invasive or non-invasive procedures should be considered first. Selection of patients, choice of procedure, and localization of the level for injection should be determined by clinical information indicating strong suspicion for pathologic condition(s) and the source of pain symptoms.

		Because injections are invasive with an inherent risk, the number of diagnostic procedures should be limited in any individual patient to those most likely to be primary pain generators. Patients should not receive all of the diagnostic blocks listed merely in an attempt to identify 100% of the pain generators.

		The interpretation of the test results are primarily based on functional change, symptom report, and pain response (via a recognized pain scale before, and at an appropriate time after the injection). The diagnostic significance of the test result should be evaluated in conjunction with clinical information and the results of other diagnostic procedures. Injections with local anesthetics of differing duration may be used to support a diagnosis. In some cases, injections at multiple levels may be required to accurately diagnose cervical conditions. Refer to Section F. 5., Therapeutic Procedures, Non-Operative, Injections – Therapeutic, for information on specific injections.

		It is obligatory that sufficient data be accumulated by the examiner performing this procedure such that the diagnostic value of the procedure is evident to other reviewers. This entails, at a minimum, documentation of patient response immediately following the procedure including details of any symptoms with a response and the degree of response. Additionally, a log must be recorded as part of the medical record which documents response, if any, on an hourly basis for, at a minimum, the expected duration of the local anesthetic phase of the procedure. Responses must be identified as to specific body part (e.g., low back, neck, leg, or arm pain). The physician must identify the local anesthetic used and the expected duration of response for diagnostic purposes.

		Multiple injections provided at the same session without staging may seriously dilute the diagnostic value of these procedures. Physicians must carefully weigh the diagnostic value of the procedure against the possible therapeutic value.

		Special Requirements for Diagnostic Injections ⎯ Since multi-planar, fluoroscopy during most procedures is required to document technique and needle placement, an experienced physician should perform the procedure. Permanent images are required to verify needle placement for all spinal procedures. The subspecialty disciplines of the physicians performing injections may be varied, including, but not limited to: anesthesiology, radiology, surgery, or physiatry. The physician who performs spinal injections for low back pain should document hands-on training through workshops of the type offered by organizations such as the International Spine Intervention Society (ISIS) and/or completed fellowship training with interventional training. The physician who performs spinal injections for cervical pain should have completed fellowship training in pain medicine with interventional training, or its equivalent. Physicians performing spinal injections for low back and cervical pain should obtain fluoroscopy training and must also have the appropriate training in radiation safety, usually overseen by a radiation safety officer.

		Complications ⎯ General complications of diagnostic injections may include transient neurapraxia, nerve injury, infection, headache, vasovagal effects, as well as epidural hematoma, permanent neurologic damage, dural perforation and CSF leakage, and spinal meningeal abscess. Severe complications of cervical injections are remote but can include spinal cord damage, quadriplegia, and/or death. Injections at a C2-C3 level frequently cause temporary neuritis with ataxia.

		Contraindications ⎯ Absolute contraindications to diagnostic injections include: (a) bacterial infection – systemic or localized to region of injection, (b) bleeding diatheses, (c) hematological conditions, and (d) possible pregnancy.

		Relative Contraindications –

		Relative contraindications to diagnostic injections may include: (a) allergy to contrast or shellfish, (b) poorly controlled Diabetes Mellitus and/or hypertension.

		Drugs affecting coagulation, such as aspirin, NSAIDs and other anti-platelet or anti-coagulants require restriction from use. Decisions regarding the number of restricted days should be made in consultation with the prescribing physician and other knowledgeable experts.

		Specific Diagnostic Injections ⎯ In general, relief should last for at least the duration of the local anesthetic used and should significantly relieve pain and result in functional improvement. Refer to Section F.5, Therapeutic Injections for information on other specific therapeutic injections. The following injections are used primarily for diagnosis:

i. Medial Branch Blocks: (Refer to Low Back and Cervical Spine Medical Treatment Guidelines).

ii. Transforaminal Injections: (Refer to Low Back and Cervical Spine Medical Treatment Guidelines)

iii. Zygapophyseal (Facet) Blocks: (Refer to Low Back and Cervical Spine Medical Treatment Guidelines)

iv. Atlanto-Axial and Atlanto-Occipital Injections: (Refer to Cervical Spine Medical Treatment Guidelines).

v. Sacroiliac Joint Injection: (Refer to Low Back and Cervical Spine Medical Treatment Guidelines).

* + 1. Other Diagnostic Injections:

		These injections are frequently employed in assessing the type of pain a patient may be having. They also aid in ascertaining possible mechanisms and origins of the pain as well as the site of the pain source. Some diagnostic injections have therapeutic properties that may be used to both diagnose and treat chronic pain. In those cases, refer to Section F.5, Non-operative Treatment – Injections - Therapeutic for specific information regarding these injections.

		Description — generally accepted, well-established procedures. These injections may be useful for localizing the source of pain, and may have added therapeutic value when combined with injection of therapeutic medication(s). Each diagnostic injection has inherent risks, and risk versus benefit should always be evaluated when considering injection therapy. Since these procedures are invasive, less invasive or non-invasive procedures should be considered first. Selection of patients, choice of procedure, and localization of the level for injection should be determined by clinical information indicating strong suspicion for pathologic condition(s) and the source of pain symptoms.

		The interpretation of the test result is primarily based upon pain response; the diagnostic significance of the test result should be evaluated in conjunction with clinical information and the results of other diagnostic procedures. Injections with local anesthetics of differing duration are required to confirm a diagnosis. In some cases, injections at multiple levels may be required to accurately diagnose pain. Refer to Section F.5, Therapeutic Injections for information on specific injections.

		Special Requirements for Diagnostic Injections ⎯ Since fluoroscopic, arthrographic and/or CT guidance during procedures is required to document technique and needle placementan experienced physician should perform the procedure. The subspecialty disciplines of the physicians may be varied, including, but not limited to: anesthesiology, radiology, surgery, or physiatry. The physician should have experience in ongoing injection training workshops provided by organizations such as the International Spine Intervention Society (ISIS). In addition, physicians should obtain fluoroscopy training and must have the appropriate training radiation safety, usually overseen by a radiation safety officer.

		Complications ⎯ General complications of diagnostic injections may include transient neurapraxia, nerve injury, infection, headache, vasovagal effects, as well as epidural hematoma, permanent neurologic damage, dural perforation and CSF leakage, and spinal meningeal abscess. Severe complications of cervical injections are remote but can include spinal cord damage, quadriplegia, and/or death.

		Contraindications ⎯ Absolute contraindications of diagnostic injections include: (a) bacterial infection – systemic or localized to region of injection, (b) bleeding diatheses, (c) hematological conditions, and (d) possible pregnancy.

		Relative Contraindications: Relative contraindications of these injections may include: (a) allergy to contrast or shellfish, (b) poorly controlled diabetes mellitus and/or hypertension.

		Drugs affecting coagulation, such as aspirin, NSAIDs and other anti-platelets or anti-coagulants require restriction from use. Decisions regarding the number of restricted days should be made in consultation with the prescribing physician and other knowledgeable experts.

		Specific Diagnostic Injections ⎯ In general, relief should last for at least the duration of the local anesthetic used and give significant relief of pain. Refer to Section F.5, Therapeutic Injections for information on other specific therapeutic injections. The following injections are used primarily for diagnosis:

i.Sympathetic Injections: are diagnostic injections that may be used in suspected cases of CRPS-I. Refer to the Division’s Complex Regional Pain Syndrome/Reflex Sympathetic Dystrophy Medical Treatment Guidelines for specific information regarding the use of these injections.

ii.Peripheral Nerve Blocks: are diagnostic injections that may be used for specific nerve injury or entrapment syndromes. Not all peripheral nerve blocks require fluoroscopy. On occasion they are used for treatment in chronic pain or CRPS. Repeat injection for treatment should be based on functional changes. These injections are usually limited to 3 injections per site per year.

* 1. SPECIAL TESTS are generally well-accepted tests and are performed as part of a skilled assessment of the patients’ capacity to return to work, his/her strength capacities, and/or physical work demand classifications and tolerance. The procedures in this subsection are listed in alphabetical order.
		1. Computer-Enhanced Evaluations**:** may include isotonic, isometric, isokinetic and/or isoinertial measurement of movement, range-of-motion, endurance, or strength. Values obtained can include degrees of motion, torque forces, pressures, or resistance. Indications include determining validity of effort, effectiveness of treatment and demonstrated motivation. These evaluations should not be used alone to determine return to work restrictions.
* Frequency: One time for evaluation. Can monitor improvements in strength every 3 to 4 weeks up to a total of 6 evaluations.
	+ 1. Functional Capacity Evaluation (FCE)**:** is a comprehensive or modified evaluation of the various aspects of function as they relate to the worker’s ability to return-to-work. Areas such as endurance, lifting (dynamic and static), postural tolerance, specific range-of-motion, coordination and strength, worker habits, employability and financial status, as well as psychosocial aspects of competitive employment may be evaluated. Components of this evaluation may include: (a) musculoskeletal screen; (b) cardiovascular profile/aerobic capacity; (c) coordination; (d) lift/carrying analysis; (e) job-specific activity tolerance; (f) maximum voluntary effort; (g) pain assessment/psychological screening; and (h) non-material and material handling activities. Standardized national guidelines (such as National Institute for Occupational Safety and Health (NIOSH)) should be used as the basis for FCE recommendations.

		When an FCE is being used to determine return to a specific jobsite, the provider is responsible for fully understanding the job duties. A jobsite evaluation is frequently necessary. FCEs cannot be used in isolation to determine work restrictions. The authorized treating physician must interpret the FCE in light of the individual patient's presentation and medical and personal perceptions. FCEs should not be used as the sole criteria to diagnose malingering.

		Full FCEs are rarely necessary. In many cases, a work tolerance screening will identify the ability to perform the necessary job tasks.
* Frequency: Can be used: 1) initially to determine baseline status; and 2) for case closure when patient is unable to return to the pre-injury position and further information is desired to determine permanent work restrictions. Prior authorization is required for FCEs performed during treatment.
	+ 1. Jobsite Evaluation and Alterations**:** is a comprehensive analysis of the physical, mental, and sensory components of a specific job. The goal of the jobsite evaluation is to identify any job modification needed to ensure the safety of the employee upon return to work. These components may include, but are not limited to: (a) postural tolerance (static and dynamic); (b) aerobic requirements; (c) range-of-motion; (d) torque/force; (e) lifting/carrying; (f) cognitive demands; (g) social interactions; (h) visual perceptual; (i) environmental requirements of a job; (j) repetitiveness; and (k) essential functions of a job; and (l) ergonomic set up. Job descriptions provided by the employer are helpful but should not be used as a substitute for direct observation.

		Jobsite evaluation and alteration should include input from a health care professional with experience in ergonomics or a certified ergonomist; the employee, and the employer. The employee must be observed performing all job functions in order for the jobsite evaluation to be a valid representation of a typical workday.

		A jobsite evaluation may include observation and instruction of how work is done, what material changes (desk, chair) should be made, and determination of readiness to return to work.

		Requests for a jobsite evaluation should describe the expected goals for the evaluation. Goals may include, but are not limited to the following:
			1. To determine if there are potential contributing factors to the person’s condition and/or for the physician to assess causality;
			2. To make recommendations for, and to assess the potential for ergonomic changes;
			3. To provide a detailed description of the physical and cognitive job requirements;
			4. To assist the patient in their return to work by educating them on how they may be able to do their job more safely in a bio-mechanically appropriate manner;
			5. To give detailed work/activity restrictions.
* Frequency: One time with additional visits as needed for follow-up per jobsite.
	+ 1. Vocational Assessment**:** Once an authorized practitioner has reasonably determined and objectively documented that a patient will not be able to return to his/her former employment and can reasonably prognosticate final restrictions, implementation of a timely vocational assessment can be performed. The vocational assessment should provide valuable guidance in the determination of future rehabilitation program goals. It should clarify rehabilitation goals, which optimize both patient motivation and utilization of rehabilitation resources. If prognosis for return to former occupation is determined to be poor, except in the most extenuating circumstances, vocational assessment should be implemented within 3 to 12 months post-injury. Declaration of Maximum Medical Improvement(MMI) should not be delayed solely due to lack of attainment of a vocational assessment.
* Frequency: One time with additional visits as needed for follow-up.
	+ 1. Work Tolerance Screening (Fitness for Duty)**:** is a determination of an individual's tolerance for performing a specific job based on a job activity or task. It may include a test or procedure to specifically identify and quantify work-relevant cardiovascular, physical fitness and postural tolerance. It may also address ergonomic issues affecting the patient’s return-to-work potential. May be used when a full FCE is not indicated.
* Frequency: One time for initial screen. May monitor improvements in strength every 3 to 4 weeks up to a total of 6 visits.
1. THERAPEUTIC PROCEDURES – NON-OPERATIVE

Non-operative therapeutic rehabilitation is applied to patients with chronic and complex problems of de-conditioning and functional disability. Treatment modalities may be utilized sequentially or concomitantly depending on chronicity and complexity of the problem, and treatment plans should always be based on a diagnosis utilizing appropriate diagnostic procedures.

Before initiation of any therapeutic procedure, the authorized treating physician, employer and insurer must consider these important issues in the care of the injured worker:

a.Patients undergoing therapeutic procedure(s) should be released or returned to modified or restricted duty during their rehabilitation at the earliest appropriate time. Refer to F.12, Return-to-Work in this section for detailed information.

b.Reassessment of the patient’s status in terms of functional improvement should be documented after each treatment. If patients are not responding within the recommended time periods, alternative treatment interventions, further diagnostic studies or consultations should be pursued. Continued treatment should be monitored using objective measures such as:

* Return-to-work or maintaining work status;
* Fewer restrictions at work or performing activities of daily living (ADL);
* Decrease in usage of medications related to the work injury; and
* Measurable functional gains, such as increased range-of-motion or documented increase in strength.

c.Clinicians should provide and document education to the patient. No treatment plan is complete without addressing issues of individual and/or group patient education as a means of facilitating self-management of symptoms.

d.Psychological or psychosocial screening should be performed on all chronic pain patients.

The following procedures are listed in alphabetical order.

* 1. ACUPUNCTURE When acupuncture has been studied in randomized clinical trials, it is often compared with sham acupuncture and/or with no acupuncture (usual care). The differences between true acupuncture and usual care have been moderate, but clinically important. These differences can be partitioned into two components: nonspecific effects and specific effects. Nonspecific effects, such as patient beliefs and expectations, attention from the acupuncturist, administration of acupuncture in a relaxing setting, and other components of what is often called the placebo effect. Specific effects refer to any additional effects which occur in the same setting of expectations and attention, but are attributable to the penetration of the skin in the specific, classic acupuncture points on the surface of the body by the needles themselves.

	In most controlled studies the differences between the sham and the classic acupuncture, specific effects of classic acupuncture, have been small in relation to the nonspecific effects. However, the sham controlled studies have shown consistent advantages of both true and sham acupuncture over no acupuncture, when the studies have included a third comparison group which was randomized to usual medical care. Having this third comparison group has been advantageous in the interpretation of the nonspecific effects of acupuncture, since the third comparison group controls for some influences on study outcome including more frequent contact with providers, the natural history of the condition, regression to the mean, the effect of being observed in a clinical trial, and, if the follow-up observations are done consistently in all three treatment groups, for biased reporting of outcomes. Controlling for these factors enables researchers to more closely estimate the contextual and personal interactive effects of acupuncture as it is generally practiced.

	Because the sham acupuncture interventions in the clinical trials are generally done by trained acupuncturists, and not by totally untrained personnel, the sham acupuncture interventions may include some of the effects of true acupuncture ([Dincer F 2003),](#DincerF2003) much as a partial agonist of a drug may produce some of the effects of the actual drug. For example, a sham procedure involving toothpicks rather than acupuncture needles may stimulate cutaneous afferents in spite of not penetrating the skin, much as a neurological sensory examination may test nociceptor function without skin penetration. To the extent that afferent stimulation is part of the mechanism of action of acupuncture, interpreting the sham results as purely a control group would lead to an underestimation of the analgesic effects of acupuncture. Thus we consider in our analysis that “sham” or non-classic acupuncture may have a positive clinical effect when compared to usual care.

	Clinical trials of acupuncture typically enroll participants who are interested in acupuncture, and may respond to some of the nonspecific aspects of the intervention more than would be expected of patients who have no interest in or desire for acupuncture. The nonspecific effects of acupuncture may not be produced in patients who have no wish to be referred for it.

	There is good evidence that both acupuncture and sham acupuncture are superior to usual care without acupuncture for moderate short-term and mild long-term alleviation of low back pain, neck pain, and the pain of joint osteoarthritis ([Ernst E 2011](#ErnestE2011); [Haake M 2007](#HaakeM2007); [Brinkhaus B 2006](#BrinkhausB2006)). In these studies 5-15 treatments were provided. Comparisons of acupuncture and sham acupuncture have been inconsistent, and the advantage of true over sham acupuncture has been small in relation to the advantage of sham over no acupuncture”

	Acupuncture is recommended for chronic pain patients who are trying to increase function and/or decrease medication usage and have an expressed interest in this modality. Acupuncture is not the same procedure as dry needling for coding purposes; however, some acupuncturists may use acupuncture treatment for myofascial trigger points. Dry needling is performed specifically on myofascial trigger points. Refer to Section F. 5. e. Therapeutic Procedures, Non-Operative, Trigger Point Injections and Dry Needling Treatment.

	Credentialed practitioners with experience in evaluation and treatment of chronic pain patients must perform acupuncture evaluations. The exact mode of action is only partially understood. Western medicine studies suggest that acupuncture stimulates the nervous system at the level of the brain, promotes deep relaxation, and affects the release of neurotransmitters. Acupuncture is commonly used as an alternative or in addition to traditional Western pharmaceuticals. It may be used when pain medication is reduced or not tolerated; as an adjunct to physical rehabilitation, surgical intervention; and/or as part of multidisciplinary treatment to hasten the return of functional activity. Acupuncture must be performed by practitioners with the appropriate credentials in accordance with state and other applicable regulations. Therefore, if not otherwise within their professional scope of practice and licensure, those performing acupuncture must have the appropriate credentials, such as L.A.c., R.A.c, or Dipl. Ac.
		1. Acupuncture**:** is the insertion and removal of filiform needles to stimulate acupoints (acupuncture points). Needles may be inserted, manipulated, and retained for a period of time.Acupuncture has a variety of possible physiologic actions, but their relevance to the clinical response is speculative, for example, one crossover trial measured increased nitric oxide synthase activity in arms which had had acupuncture, increasing palmar blood flow, but this observation may have no bearing on actual analgesic effects ([Tsuchiya M 2007](#TsuchiyaM2007)).

		Indications include joint pain, joint stiffness, soft tissue pain and inflammation, paresthesia, post-surgical pain relief, muscle spasm, and scar tissue pain.
		2. Acupuncture with Electrical Stimulation**:** is the use of electrical current (micro- amperage or mille-amperage) on the needles at the acupuncture site. It is used to increase effectiveness of the needles by continuous stimulation of the acupoint. Physiological effects (depending on location and settings) can include endorphin release for pain relief, reduction of inflammation, increased blood circulation, analgesia through interruption of pain stimulus, and muscle relaxation.

		It is indicated to treat chronic pain conditions, radiating pain along a nerve pathway, muscle spasm, inflammation, scar tissue pain, and pain located in multiple sites.

		There is some evidence that a combination of electrical acustimulation to the wrist combined with neck stretching and strengthening exercises for 30 minutes two times per week for a period of about 4 weeks demonstrates more improvement in chronic neck pain and patient self-confidence in performing functional activities than neck exercises alone for up to one month [(Chan DKC 2009).](#ChanDKC2009)
		3. Other Acupuncture Modalities**:** Acupuncture treatment is based on individual patient needs and therefore treatment may include a combination of procedures to enhance treatment effect. Other procedures may include the use of heat, soft tissue manipulation/massage, and exercise. Refer to Sections F.13 and 14, Active Therapy (Therapeutic Exercise) and Passive Therapy sections (Massage and Superficial Heat and Cold Therapy) for a description of these adjunctive acupuncture modalities and time frames.
		4. Total Time Frames For Acupuncture and Acupuncture with Electrical Stimulation: Time frames are not meant to be applied to each of the above sections separately. The time frames are to be applied to all acupuncture treatments regardless of the type or combination of therapies being provided.
* Time to Produce Effect: 3 to 6 treatments.
* Frequency: 1 to 3 times per week.
* Optimum Duration: 1 to 2 months.
* Maximum Duration: 15 treatments.

Any of the above acupuncture treatments may extend longer if objective functional gains can be documented or when symptomatic benefits facilitate progression in the patient’s treatment program. Treatment beyond 15 treatments must be documented with respect to need and ability to facilitate positive symptomatic and functional gains. Such care should be re-evaluated and documented with each series of treatments

* 1. BIOFEEDBACK is a form of behavioral medicine that helps patients learn self-awareness and self-regulation skills for the purpose of gaining greater control of their physiology, such as muscle activity, brain waves, and measures of autonomic nervous system activity. There is good evidence that biofeedback and cognitive behavioral therapy are equally effective in managing chronic pain ([Hoffman BM 2007).](#HoffmanBM2007) Stress-related psycho-physiological reactions may arise as a reaction to organic pain and in some cases may cause pain. Electronic instrumentation is used to monitor the targeted physiology and then displayed or fed back to the patient visually, auditorily, or tactilely with coaching by a biofeedback specialist.

	Indications for biofeedback include individuals who are suffering from musculoskeletal injury where muscle dysfunction or other physiological indicators of excessive or prolonged stress response affects and/or delays recovery. Other applications include training to improve self-management of pain, anxiety, panic, anger or emotional distress, opioid withdrawal, insomnia/sleep disturbance, and other central and autonomic nervous system imbalances. Biofeedback is often utilized for relaxation training. Mental health professionals may also utilize it as a component of psychotherapy, where biofeedback and other behavioral techniques are integrated with psychotherapeutic interventions. Biofeedback is often used in conjunction with physical therapy or medical treatment.

	Recognized types of biofeedback include the following:
		1. EMG/Electromyogram (EMG)**:** Used for self-management of pain and stress reactions involving muscle tension.
		2. Skin Temperature**:** Used for self-management of pain and stress reactions, especially vascular headaches.
		3. Respiration Feedback (RFB)**:** Used for self-management of pain and stress reactions via breathing control.
		4. Respiratory Sinus Arrhythmia (RSA)**:** Used for self-management of pain and stress reactions via synchronous control of heart rate and respiration. Respiratory sinus arrhythmia is a benign phenomenon which consists of a small rise in heart rate during inhalation, and a corresponding decrease during exhalation. This phenomenon has been observed in meditators and athletes, and is thought to be a psycho-physiological indicator of health.
		5. Heart Rate Variability (HRV)**:** Used for self-management of stress via managing cardiac reactivity.
		6. Electrodermal Response (EDR)**:** Used for self-management of stress involving palmar sweating or galvanic skin response.
		7. Electroencephalograph (EEG, QEEG)**:** Used for self-management of various psychological states by controlling brainwaves.

The goal in biofeedback treatment is normalizing the physiology to the pre-injury status to the extent possible and involves transfer of learned skills to the workplace and daily life. Candidates for biofeedback therapy or training should be motivated to learn and practice biofeedback and self-regulation techniques. In the course of biofeedback treatment, patient stressors are discussed and self-management strategies are devised. If the patient has not been previously evaluated, a psychological evaluation should be performed prior to beginning biofeedback treatment for chronic pain. The psychological evaluation may reveal cognitive difficulties, belief system conflicts, somatic delusions, secondary gain issues, hypochondriasis, and possible biases in patient self-reports, which can affect biofeedback. Home practice of skills is often helpful for mastery and may be facilitated by the use of home training tapes.

Psychologists or psychiatrists, who provide psycho-physiological therapy which integrates biofeedback with psychotherapy, should be either Biofeedback Certification International Alliance (BCIA) certified or practicing within the scope of their training. All non-licensed health care providers of biofeedback for chronic pain patients must be BCIA certified and shall have their biofeedback treatment plan approved by the authorized treating psychologist or psychiatrist. Biofeedback treatment must be done in conjunction with the patient’s psychosocial intervention. Biofeedback may also be provided by health care providers, who follow a set treatment and educational protocol. Such treatment may utilize standardized material or relaxation tapes.

* Time to Produce Effect: 3 to 4 sessions.
* Frequency: 1 to 2 times per week.
* Optimum Duration: 6 to 8 sessions.
* Maximum Duration: 10 to 12 sessions. Treatment beyond 12 sessions must be documented with respect need, expectation, and ability to facilitate positive symptomatic and functional gains.
	1. COMPLEMENTARY ALTERNATIVE MEDICINE (CAM)is a term used to describe a broad range of treatment modalities, a number of which are generally accepted and supported by some scientific literature, and others which still remain outside the generally accepted practice of conventional Western Medicine. In many of these approaches, there is attention given to the relationship between physical, emotional, and spiritual well-being. While CAM may be performed by a myriad of both licensed and non-licensed health practitioners with training in one or more forms of therapy, credentialed practitioners should be used when available or applicable.

	Although CAM practices are diverse and too numerous to list, they can be generally classified into five domains:
		1. Alternative Medical Systems**:** These are defined as medical practices that have developed their own systems of theory, diagnosis and treatment and have evolved independent of and usually prior to conventional Western Medicine. Some examples are Traditional Chinese Medicine, Ayurvedic Medicine, Homeopathy, and Naturopathy.
		2. Mind-body Interventions**:** These include practices such as hypnosis, meditation, bioenergetics, and prayer. Reflexology does not appear to relieve low back pain ([Poole H 2007](#PooleH2007)).
		3. Biological-based Practices**:** These include herbal and dietary therapy as well as the use of nutritional supplements. To avoid potential drug interactions, supplements should be used in consultation with the authorized treating physician.
		4. Body-based Therapy**:** Included in this category are the practices of Yoga and Rolfing bodywork.
		5. Energy-based Practices**:** Energy-based practices include a wide range of modalities that support physical as well as spiritual and/or emotional healing. Some of the more well-known energy practices include Qi Gong, Tai Chi, Healing Touch and Reiki. Practices such as Qi Gong and Tai Chi are taught to the patient and are based on exercises the patient can practice independently at home. Other energy-based practices such as Healing Touch and Reiki involve a practitioner/patient relationship and may provide some pain relief [(So PS [Cochrane] 2008](#SoPS2008)). Tai Chi may improve range of motion in those with rheumatoid arthritis ([Wang 2008;](#Wang2008) [Han A [Cochrane], 2004).](#HanA2004)

Methods used to evaluate chronic pain patients for participation in CAM will differ with various approaches and with the training and experience of individual practitioners. A patient may be referred for CAM therapy when the patient’s cultural background, religious beliefs, or personal concepts of health suggest that an unconventional medical approach might assist in the patient’s recovery or when the physician’s experience and clinical judgment support a CAM approach. The patient must demonstrate a high degree of motivation to return to work and improve their functional activity level while participating in therapy. Other more traditional conservative treatments should generally be attempted before referral to CAM. Treatment with CAM requires prior authorization.

* Time to Produce Effect: Functional treatment goals and number of treatments for time to produce effect should be set with the practitioner and the patient before the beginning of treatment.
* Frequency: Per CAM therapy selected.
* Optimum Duration: Should be based upon the physician’s clinical judgment and demonstration by the patient of positive symptomatic and functional gains. Practitioner provided CAM therapy is not recommended on a maintenance basis.
	1. DISTURBANCES OF SLEEP are common in chronic pain. Although primary insomnia may accompany pain as an independent co-morbid condition, it more commonly occurs secondary to the pain condition itself. Exacerbations of pain often are accompanied by exacerbations of insomnia; the reverse can also occur. Sleep laboratory studies have shown disturbances of sleep architecture in pain patients. Loss of deep slow-wave sleep and increase in light sleep occur and sleep efficiency, the proportion of time in bed spent asleep, is decreased. These changes are associated with patient reports of non-restorative sleep. Sleep apnea may also occur as a primary diagnosis or be caused or exacerbated opioid and hypnotic use. This should be investigated diagnostically (refer to Section F. 7. g., Medications and Medical Management, Opioids).

	Many chronic pain patients develop behavioral habits that exacerbate and maintain sleep disturbances. Excessive time in bed, irregular sleep routine, napping, low activity, and worrying in bed are all maladaptive responses that can arise in the absence of any psychopathology. Relaxation training such as progressive relaxation, biofeedback, mindfulness meditation, or imagery training and other forms of cognitive therapy can reduce dysfunctional beliefs and attitudes about sleep ([Silber MH 2005).](#SilberMH2005)

	There is some evidence that behavioral modification, such as patient education and group or individual counseling with cognitive behavioral therapy can be effective in reversing the effects of insomnia ([Currie SR 2000).](#CurrieSR2000) Cognitive and behavioral interventions should be undertaken before prescribing medication solely for insomnia. Behavioral modifications are easily implemented and can include:

**a.** Maintaining a regular sleep schedule, retiring and rising at approximately the same time on weekdays and weekends.

**b.** Limiting naps to 30 minutes twice per day or less

**c.** Avoiding caffeinated beverages after lunchtime.

**d.** Making the bedroom quiet and comfortable, eliminating disruptive lights, sounds, television sets, pets, and keeping a bedroom temperature of about 65 degrees Fahrenheit.

**e.** Avoiding alcohol or nicotine within two hours of bedtime.

**f.** Avoiding large meals within two hours of bedtime.

**g.** Exercising vigorously during the day, but not within two hours of bedtime, since this may raise core temperature and activate the nervous system.

**h.** Associating the bed with sleep and sexual activity only, using other parts of the home for television, reading and talking on the telephone.

**i.** Leaving the bedroom when unable to sleep for more than 20 minutes, returning to the bedroom when ready to sleep again.

**j.** Reducing time in bed to estimated typical sleeping time

**k.** Arising at a regular time each day, regardless of the number of hours slept

**l.** Engaging in relaxing activities until drowsy

Behavioral modifications should be trialed before the use of hypnotics. Reinforcing these behaviors may also decrease hypnotic use and overall medication costs. There is some evidence that group cognitive behavioral therapy reduces the severity and daytime consequences of insomnia for at least six months ([Morin CM 2006](#MorinCM2006)).Melatonin or ramelteon a longer acting melatonin agonist may be preferred by some patients and is a reasonable alternative to sedative hypnotics. There is some evidence that ramelteon, while producing a small amount of reduction in sleep latency, does not appreciably increase total sleep time or daytime function [(Mayer, 2009).](#Mayer2009)

* 1. INJECTIONS—THERAPEUTIC

	When considering the use of injections in chronic pain management, the treating physician must carefully consider the inherent risks and benefits. First, it is understood that these injections are seldom meant to be “curative” and when used for therapeutic purposes they are employed in conjunction with other treatment modalities for maximum benefit.

	Second, education of the patient should include the proposed goals of the injections, expected gains, risks or complications, and alternative treatment.

	Finally, reassessment of the patient’s status in terms of functional improvement should be documented after each injection. Any continued use of injections should be monitored using objective measures such as:

a. Return-to-work or maintaining work status.

b. Fewer restrictions at work or performing activities of daily living.

c. Decrease in usage of medications related to the work injury.

d. Measurable functional gains, such as increased range-of-motion or documented increase in strength.

Visual analog scales (VAS) provide important subjective data but cannot be used to measure function.

The physician must be aware of the possible placebo effect as well as the long-term effects of injections related to the patient’s physical and mental status. Strict adherence to contraindications, both absolute and relative, may prevent potential complications. Subjecting the patient to potential risks, i.e., needle trauma, infection, nerve injury, or systemic effects of local anesthetics and corticosteroids, must be considered before the patient consents to such procedures, especially for repeat procedures.

* + 1. Therapeutic Spinal Injections:

		Description –The following injections are considered to be reasonable treatment for patients with chronic pain. Other injections not listed may be beneficial. Therapeutic spinal injections may be used after initial conservative treatments, such as physical and occupational therapy, medication, manual therapy, exercise, acupuncture, etc., have been undertaken. Therapeutic injections should be used only after imaging studies and diagnostic injections have established pathology. Injections are invasive procedures that can cause serious complications; thus clinical indications and contraindications should be closely adhered to. The purpose of spinal injections is to facilitate active therapy by providing short-term relief through reduction of pain and inflammation. All patients should continue appropriate exercise with functionally directed rehabilitation. Active treatment, which patients should have had prior to injections is essential and will frequently require a repeat of the sessions previously ordered (Refer to section F. 13, Active Therapy). Injections by themselves are not likely to provide long-term relief. Rather, active rehabilitation with modified work achieves long-term relief by increasing active ROM, strength, and stability. If the first injection does not provide a diagnostic response with temporary and sustained pain relief substantiated by accepted pain scales, (i.e., 80% pain reduction), and improvement in function, similar injections should not be repeated. Cervical injections are invasive procedures that can cause catastrophic complications. Refer to the Cervical Spine Injury guidelines for more specific contraindications.

		Considerations – For all spinalinjections (excluding trigger point, botulinum toxin, and occipital or peripheralnerve blocks) multi-planar, during procedures is required to document technique and needle placement, and should be performed by a physician experienced in the procedure. Permanent images are required to verify needle placement. The subspecialty disciplines of the physicians may be varied, including, but not limited to: anesthesiology, radiology, surgery, or physiatry. The physician who performs injections for low back pain should document hands on training through workshops of the type offered by organizations such as theInternational Spine Intervention Society (ISIS) and**/**or completed fellowship training with interventional training.The physician who performs injections for cervical pain should have completed fellowship training in pain medicine with interventional training, or its equivalent.In addition, physicians who perform spinal injections should obtain fluoroscopy training and must also have appropriate training in radiation safety, usually overseen by a radiation safety officer.Complications – General complications of these spinal injections may include transient neurapraxia, local pain, nerve injury, infection, headache, urinary retention and vasovagal effects; epidural hematoma, permanent neurologic damage, dural perforation and cerebral spinal fluid (CSF) leakage, and/or spinal meningeal abscess may also occur. Permanent paresis, anaphylaxis and arachnoiditis have been rarely reported with the use of epidural steroids. With steroid injections, there may be a dose-dependent suppression of the hypothalamic-pituitary adrenal axis lasting between one and three months.For cervical injections, severe complications are remote but can include spinal cord damage, quadriplegia, and/or death.

		Contraindications – Absolute contraindications of therapeutic injections include: (a) bacterial infection – systemic or localized to region of injection, (b) bleeding diatheses, (c) hematological conditions, and (d) possible pregnancy.

		Relative Contraindications: Relative contraindications of these injections may include: (a) allergy to contrast or shellfish, (b) poorly controlled diabetes mellitus and/or hypertension.

		Drugs affecting coagulation, such as aspirin, NSAIDs and other anti-platelets or anti-coagulants require restriction from use. Decisions regarding the number of restricted days should be made in consultation with the prescribing physician and other knowledgeable experts.
			1. Epidural Steroid Spinal Injections (ESI):

			Description – Epidural steroid injections (ESI) deliver corticosteroid into the epidural space. The purpose of ESI is to reduce pain and inflammation, restoring range-of-motion and thereby facilitating progress in more active treatment programs. ESI uses three approaches: transforaminal, translaminar (midline), and caudal.

			Needle Placement – Multi-planar fluoroscopic imagingis required for all transforaminal epidural steroid injections. Injection of contrast dye is necessary to verify needle placement and flow of medication into the epidural space. Permanent images are required to verify needle placement.

			Indications for acute exacerbations – There is some evidence that epidural steroid injections are effective for patients with radicular pain or radiculopathy (sensory or motor loss in a specific dermatome or myotome). They are not recommended for chronic axial pain. There is some evidence that ESI injections in the low back are not effective for spinal stenosis without radicular findings.Additionally, there is some evidence in studies of the lumbar spine that patients who smoke or who have pain unaffected by rest or activity are less likely to have a successful outcome from ESIs [( Division of Workers’ Compensation [DOWC] Low Back Pain Medical Treatment Guidelines [MTG], 2007).](#DOWCLowBack2007)

			Indications for chronic radicular pain - Injections for chronic radiculopathy are rarely appropriate. Steroid injections are thought to act by decreasing the acute/subacute swelling and chemical reaction resulting form a disc herniation. Herniated discs in a chronic state would not benefit from this type of treatment. There is some evidence that about 50% of patients with chronic radicular pain will have a clinically meaningful decrease in pain and disability lasting at least 3 months from one injection of anesthetic or anesthetic with steroids ([Ng L 2005).](#NgL2005) Generally, epidural injections should be limited to acute exacerbations of radicular pain at the same location as the work-related injury. There may be a small sub-population of patients with chronic radiculopathy who receive benefit from an injection. Repeated injections are frequently unnecessary and should only be done when documented functional improvement occurs, which may include a return to baseline function or ability to continue working. A positive result would include a return to base line function, return to increased work duties, and a measurable improvement in physical activity goals including return to baseline after an exacerbation and achieved for at least 3 months.
* Time to Produce Effect: Local anesthetic, less than 30 minutes; corticosteroid, 48 to 72 hours for 80% of patients and 72 hours to 2 weeks for 20% of patients.
* Frequency: One or more divided levels can be injected in one session. Whether injections are repeated depends upon the patient’s response to the previous injection session. For acute documented recurrent disc herniation with new radicular intensity, subsequent injection sessions may occur after 1 to 2 weeks if patient response has been favorable. If the first injection does not provide a diagnostic response of temporary and sustained pain relief (at least 2 to 6 weeks) substantiated by accepted pain scales (i.e., 80% pain reduction as measured by tools such as VAS) and improvement in function, similar injections should not be repeated.
* For chronic radiculopathy, injections may be repeated only if when a functional documented response lasts for 3 months. Patients should be reassessed after each injection session for an 80% improvement in pain (as measured by accepted pain scales) and evidence of functional improvement. A positive result would include a return to base line function, return to increased work duties, and a measurable improvement in physical activity goals including return to baseline after an exacerbation.
* Optimum/Maximum Duration: No more than 4 in 1 year. Injections may only be repeated when the above functional and time goals are met. Repeated injections with steroids should be done with caution especially in patients who have received other steroid injections or oral steroid therapy as higher yearly total doses of steroids may be associated with an increase in osteoarthritis ([Felson D 1987).](#FelsonD1987)
	+ - 1. Zygapophyseal (Facet) Injections:

			Description – A generally accepted intra-articular or pericapsular injection of local anesthetic and corticosteroid. Medial branch nerve blocks may be diagnostic only. There is conflicting evidence to support a long-term therapeutic effect using facet injections. There is no justification for a combined facet and medial branch block.

			Zygapophyseal injections have almost no role in acute and subacute low back and thus are only permitted in chronic low back pain if there is indication in low back pain/cervical guideline that the patient meets the criteria for a diagnostic injection.

			Patients should be reassessed after each injection session for an 80% improvement in pain (as measured by accepted pain scales) and evidence of functional improvement for 6 months. A positive result would include a return to base line function, return to increased work duties, and measurable improvement in physical activity goals including return to baseline after an exacerbation.
* Time to Produce Effect: Low back pain: 48 to 72 hours for corticosteroid). Up to30 minutes for local anesthetic; corticosteroid up to 72 hours.
* Optimum/Maximum Duration: 2 for each applicable joint per year. Injections may only be repeated when the above functional and time goals are met.
	+ - 1. Sacroiliac Joint Injections:

			Description - A generally accepted injection of local anesthetic in an intra-articular fashion into the sacroiliac joint under radiographic guidance.May include the use of corticosteroids. Long-term therapeutic effect has not yet been established.

			SI joint injections have almost no role in acute and subacute low back and thus are only permitted in chronic low back pain if there is strong evidence per the indications in low back pain guideline that the patient meets the criteria for a diagnostic injection.

			A successful injection should document relief from previously painful maneuvers (e.g., Patrick’s test) on post-injection physical exam. Patients should be reassessed after each injection session for an 80% improvement in pain (as measured by accepted pain scales) and evidence of functional improvement for 6 months. A positive result would include a return to base line function, return to increased work duties, and a measurable improvement in physical activity goals including return to baseline after an exacerbation
* Time to Produce Effect: Approximately 30 minutes for local anesthetic; 48 to 72 hours for corticosteroid.
* Optimum/Maximum Duration: 2 per year. Injections may only be repeated when the above functional and time goals are met.
	+ - 1. Intradiscal Steroid Therapy: consists of injection of a steroid preparation into the intervertebral disc under fluoroscopic guidance at the time of discography. There is good evidence that it is not effective in the treatment of suspected discogenic back pain and its use is not recommended ([DOWC [Low Back Pain MTG], 2007](#DOWCLowBack2007)).
		1. Radio Frequency Medial Branch Neurotomy/Facet Rhizotomy:

i. Description ⎯ A procedure designed to denervate the facet joint by ablating the corresponding sensory medial branches. Continuous percutaneous radiofrequency is the method generally used.

There is good evidence to support Radio Frequency Medial Branch Neurotomy in the cervical spine but benefits beyond one year are not yet established ([DOWC [Low Back Pain MTG], 2007](#DOWCLowBack2007)). Evidence in the lumbar spine is conflicting; however, the procedure is generally accepted. In one study, 60% of patients maintained at least 90% pain relief at 12 months. Radio frequency Medial Branch Neurotomy is the procedure of choice over alcohol, phenol, or cryoablation. Precise positioning of the probe using fluoroscopic guidance is required since the maximum effective diameter of the device is a 5x8 millimeter oval. Permanent images should be recorded to verify placement of the device.

ii. Indications ⎯ Those patients with proven, significant, facetogenic pain. A minority of low back patients would be expected to qualify for this procedure. This procedure is not recommended for patients with multiple pain generators or involvement of more than 3 levels of medial branch nerves.

Individuals should have met all of the following indications: Pain of well-documented facet origin, typically with extension and/or rotation unresponsive to active and/or passive therapy, unresponsive to manual therapy, and in which a psychosocial screening has been performed (e.g., pain diagram, Waddell’s signs, thorough psychosocial history, screening questionnaire). It is generally recommended that this procedure not be performed until three months of active therapy and manual therapy have been completed. All patients should continue appropriate exercise with functionally directed rehabilitation. Active treatment, which patients will have had prior to the procedure, is essential and will frequently require a repeat of the sessions previously ordered (Refer to section E. 11, Active Therapy.)

All patients should have a successful response to a diagnostic medial nerve branch block and a separate comparative block. ISIS suggests controlled blocks using either placebo or anesthetics with varying lengths of activity (i.e., bupivacaine longer than lidocaine). To be a positive diagnostic block the patient should report a reduction of pain of 80% or greater from baseline for the length of time appropriate for the local anesthetic used. In almost all cases this will mean a reduction of pain to 1 or 2 on the VAS 10-point scale correlated with functional improvement. The patient should also identify activities of daily living (which may include measurements of range-of-motion) that are impeded by their pain and can be observed to document functional improvement in the clinical setting. Ideally, these activities should be assessed throughout the observation period for function. The observer should not be the physician who performed the procedure. It is suggested that this be recorded on a form similar to ISIS recommendations.

A separate comparative block on a different date should be performed to confirm the level of involvement. A comparative block uses anesthetics with varying lengths of activity.

iii. Complications ⎯ Bleeding, infection, or neural injury. The clinician must be aware of the risk of developing a localized neuritis, or rarely, a deafferentation centralized pain syndrome as a complication of this and other neuroablative procedures.

iv. Post-Procedure Therapy ⎯ Active therapy. Implementation of a gentle aerobic reconditioning program (e.g., walking) and back education within the first post-procedure week, barring complications. Instruction and participation in a long-term home-based program of ROM, core strengthening, postural or neuromuscular re-education, endurance, and stability exercises should be accomplished over a period of four to ten visits post-procedure.

v. Requirements for Repeat Radiofrequency Medial Branch Neurotomy (or additional-level RF Neurotomies): In some cases pain may recur. Successful RF Neurotomy usually provides from six to eighteen months of relief.

Before a repeat RF Neurotomy is done, a confirmatory medial branch injection should be performed if the patient’s pain pattern presents differently than the initial evaluation. The long-term effects of repeat rhizotomies, especially on younger patients are unknown. There is a possibility that repeated denervation could result in premature degenerative changes. In addition the patient should always reconsider all of the possible permanent complications before consenting to a repeat procedure. There are no studies addressing the total number of RF neurotomies that should be done for a patient. The patient should document 6 to 18 months minimum improvement.

In occasional patients, additional levels of RF neurotomy may be necessary. The initial indications including repeat blocks and limitations apply.

* Optimum/Maximum duration twice in the first year after the initial rhizotomy and once a year after, up to 12 total. They may only be repeated when the patient demonstrates functional improvement
	+ 1. Dorsal Nerve Root Ganglion Radiofrequency Ablation**:** Percutaneous radiofrequency partial lesioning of the dorsal root ganglion is a procedure intended to decrease persistent impairing radicular pain. There is some evidence that continuous RF for lumbar radicular pain does not result in improved pain and functional outcomes ([Geurts J 2003](#GeurtsJ2003)). Follow up of patients who had a dorsal nerve root ganglia procedure for failed low back surgery reported 2 out of 13 patients had a 50% reduction in pain and were satisfied with the procedure at 2 years. Fifty per cent or more of the group also reported worse sensory and motor findings ([North R 1991).](#NorthR1991) There is some evidence from a small study that pulsed RF used in patients with chronic cervical radicular pain who demonstrated a 50% reduction in pain on a diagnostic block will provide at least a 50% pain relief for 3 months ([Van Zundert J 2007](#VanZundertJ2007)). Recurrence of pain is common after 3 months with no significant effect at 6 months ([Simopoulos T 2008).](#SimopoulosT2008) No significant improvement in general function was documented. Due to the combination of possible adverse side effects, time limited effectiveness, and mixed study results, this therapy is not recommended. American Society of Anesthesiologist practice guidelines do not recommend routine use ([ASA, 2010).](#ASA2010) This treatment is not recommended.
		2. Trigger Point Injections and Dry Needling Treatment:

i.Description ⎯ Trigger point injections are a generally accepted treatment. Trigger point treatment can consist of dry needling or injection of local anesthetic, with or without corticosteroid, into highly localized, extremely sensitive bands of skeletal muscle fibers that produce local and referred pain when activated. There is conflicting evidence regarding the benefit of trigger point injections [Division of Workers’ Compensation [DOWC], [Low Back Pain Medical Treatment Guidelines-(MTG)] 2007](#DOWCLowBack2007). A truly blinded study comparing dry needle treatment of trigger points is not feasible. There is no evidence that injection of medications improves the results of trigger point injections. Needling alone may account for some of the therapeutic response.

There is no indication for conscious sedation for patients receiving trigger point injections. The patient must be alert to help identify the site of the injection.

ii.Indications – Trigger point injections may be used to relieve myofascial pain and facilitate active therapy and stretching of the affected areas. They are to be used as an adjunctive treatment in combination with other active treatment modalities. Trigger point injections should be utilized primarily for the purpose of facilitating functional progress. Patients should continue in an aggressive aerobic and stretching therapeutic exercise program as tolerated throughout the time period they are undergoing intensive myofascial interventions. Myofascial pain is often associated with other underlying structural problems and any abnormalities need to be ruled out prior to injection.

For acute exacerbations trigger point injections are indicated in those patients where well-circumscribed trigger points have been consistently observed, demonstrating a local twitch response characteristic radiation of pain pattern and local autonomic reaction, such as persistent hyperemia following palpation. Generally, these injections are not necessary unless consistently observed trigger points are not responding to specific, noninvasive, myofascial interventions within approximately a 6-week time frame.

Complications – Potential but rare complications of trigger point injections include infection, pneumothorax, and anaphylaxis, penetration of viscera, neurapraxia and neuropathy. If corticosteroids are injected in addition to local anesthetic, there is a risk of local myopathy developing. Severe pain on injection suggests the possibility of an intraneural injection, and the needle should be immediately repositioned.

Patients should be reassessed after each injection session for an 80% improvement in pain (as measured by accepted pain scales) and evidence of functional improvement for 3 months. A positive result would include a return to base line function, return to increased work duties, and measurable improvement in physical activity goals including return to baseline after an exacerbation.

* Time to Produce Effect: Local anesthetic 30 minutes; 24 to 48 hours for no anesthesia.
* Frequency: No more than 4 injection sites per session per week for acute exacerbations only, to avoid significant post-injection soreness.
* Optimum Duration/Maximum: 4 sessions per year. Injections may only be repeated when the above functional and time goals are met.
	+ 1. Prolotherapy**:** also known as sclerotherapy consists of a series of injections of hypertonic dextrose, with or without glycerine and/or phenol, into the ligamentous structures of the low back and other joints (e.g. it has been used for “stabilization” of ankles, SI joints, etc. Its proponents claim that the inflammatory response to the injections will recruit cytokine growth factors involved in the proliferation of connective tissue, stabilizing the ligaments of the low back or treated joints when these structures have been damaged by mechanical insults.

		There are conflicting studies concerning the effectiveness of prolotherapy in the low back. Lasting functional improvement has not been shown. The injections are invasive, may be painful to the patient, and are not generally accepted or widely used. Therefore, the use of prolotherapy for low back or other chronic joint pain is not recommended.
		2. Epiduroscopy and Epidural Lysis of Adhesions**:** is an investigational treatment of low back pain. It involves the introduction of a fiberoptic endoscope into the epidural space via the sacral hiatus. With cephalad advancement of the endoscope under direct visualization, the epidural space is irrigated with saline. Adhesiolysis may be done mechanically with a fiberoptic endoscope. The saline irrigation is performed with or without epiduroscopy and is intended to distend the epidural space in order to obtain an adequate visual field. It is designed to produce lysis of adhesions, which are conjectured to produce symptoms due to traction on painful nerve roots. Saline irrigation is associated with risks of elevated pressures which may impede blood flow and venous return, possibly causing ischemia of the cauda equina and retinal hemorrhage.

		Other complications associated with instrumented lysis include catheter shearing, need for catheter surgical removal, infection (including meningitis), hematoma, and possible severe hemodynamic instability during application. Although epidural adhesions have been postulated to cause chronic low back pain, studies have failed to find a significant correlation between the level of fibrosis and pain or difficulty functioning. Studies of epidural lysis demonstrate no transient pain relief from the procedure. Given the low likelihood of a positive response, the additional costs and time requirement, and the possible complications from the procedure, epidural injection, or mechanical lysis, is not recommended.

		Epiduroscopy- directed steroid injections are also not recommended as there is no evidence to support an advantage for using an epiduroscope with steroid injections.
		3. Botulinum Toxin Injections**:**Description – Used to temporarily weaken or paralyze muscles. May reduce muscle pain in conditions associated with spasticity, dystonia, or other types of painful muscle spasm. Neutralizing antibodies develop in at least 4% of patients treated with botulinum toxin type A, rendering it ineffective. Several antigenic types of botulinum toxin have been described. Botulinum toxin type B, first approved by the Food and Drug Administration (FDA) in 2001, is similar pharmacologically to botulinum toxin type A. It appears to be effective in patients who have become resistant to the type A toxin. The immune responses to botulinum toxins type A and B are not cross-reactive, allowing type B toxin to be used when type A action is blocked by antibody. Experimental work with healthy human volunteers suggests that muscle paralysis from type B toxin is not as complete or as long lasting as that resulting from type A. The duration of treatment effect of botulinum toxin type B for cervical dystonia has been estimated to be 12 to 16 weeks. EMG needle guidance may permit more precise delivery of botulinum toxin to the target area.

		There is strong evidence that botulinum toxin A has objective and asymptomatic benefits over placebo for cervical dystonia ([Costa, [Cochrane], 2005](#Costa2005)).

		There is some evidence to support injections for electromyographically proven piriformis syndrome ([Fishman, 2002).](#Fishman2002) Prior to consideration of botulimum toxin injection for piriformis syndrome, patients should have had marked (80% or better) but temporary improvement with three separate trigger point injections. To be a candidate for botulinum toxin injection for piriformis syndrome, patients should have had symptoms return to baseline or near baseline despite an appropriate stretching program after trigger point injections. Botulinum toxin injections of piriformis should be performed by a physician experienced in this procedure and utilize either ultrasound, fluoroscopy, or EMG needle guidance. Botulinum toxin should be followed by limb strengthening and reactivation.

		Indications – For conditions which produce chronic spasticity, dystonia, or piriformis syndrome. There should be evidence of limited range-of-motion prior to the injection. Refer to Traumatic Brain Injury (TBI) Medical Treatment Guidelines for indications regarding headache.

		There is insufficient evidence to support its use other myofascial trigger points for longer-term pain relief and it is likely to cause muscle weakness or atrophy if used repeatedly ([Ferrante, 2005](#Ferrante2005); [Gobel, 2006;](#Gobel2006) [Porta, 2000](#Porta2000)). Examples of such consequences include subacromial impingement, as the stabilizers of the shoulder are weakened by repeated injections of trigger points in the upper trapezii. Therefore it is not recommended for use for other myofascial trigger points ([Abbott 2007](#Abbott2007)).

		Complications – There is good evidence that cervical botulinum toxin A injections cause transient dysphagia and neck weakness. Allergic reaction to medications, dry mouth and vocal hoarseness may also occur [Costa J [Cochrane] 2005](#Costa2005). Rare systemic effects include flu-like syndrome, and weakening of distant muscle. There is an increased risk of systemic effects in patients with motor neuropathy or disorders of the neuromuscular junction.
* Time to Produce Effect: 24 to 72 hours post injection with peak effect by 4 to 6 weeks.
* Frequency: No less than 3 months between re-administration. Patients should be reassessed after each injection session for an 80% improvement in pain (as measured by accepted pain scales) and evidence of functional improvement for 3 months. A positive result would include a return to base line function, return to increased work duties, and measurable improvement in physical activity goals including return to baseline after an exacerbation.
* Optimum Duration: 3 to 4 months.
* Maximum Duration: Currently unknown. Repeat injections should be based upon functional improvement and therefore used sparingly in order to avoid development of antibodies that might render future injections ineffective. In most cases, not more than four injections are appropriate due accompanying muscle atrophy.
	1. INTERDISCIPLINARY REHABILITATION PROGRAMSare the gold standard of treatment for individuals with chronic pain who have not responded to less intensive modes of treatment. In addition, there are current studies to support the use of pain programs.There is good evidence that interdisciplinary programs which include screening for psychological issues, identification of fear-avoidance beliefs and treatment barriers, and establishment of individual functional and work goals, will improve function and decrease disability ([Lambeek, L, 2010](#Lambeek2010); [Dobscha, 2009](#Dobscha2009)). These programs should assess the impact of pain and suffering on the patient’s medical, physical, psychological, social, and/or vocational functioning. In general, interdisciplinary programs evaluate and treat multiple and sometimes irreversible conditions, including but not limited to painful musculoskeletal, neurological, and other chronic painful disorders and psychological issues, drug dependence, abuse or addiction high levels of stress and anxiety, failed surgery; and pre-existing or latent psychopathology. The number of professions involved in the team in a chronic pain program may vary due to the complexity of the needs of the person served. The Division recommends consideration of referral to an interdisciplinary program within 6 months post-injury in patients with delayed recovery unless successful surgical interventions or other medical and/or psychological treatments complications intervene.

	Chronic pain patients need to be treated as outpatients within a continuum of treatment intensity. Outpatient chronic pain programs are available with services provided by a coordinated interdisciplinary team within the same facility (formal) or as coordinated among practices by the authorized treating physician (informal). Formal programs are able to provide coordinated, high intensity level of services and are recommended for most chronic pain patients who have received multiple therapies during acute management.Patients with addiction problems or high dose opioid or other drugs of abuse use may require inpatient and/or outpatient chemical dependency treatment programs before or in conjunction with other interdisciplinary rehabilitation. Guidelines from the American Society of Addiction Medicine are available and may be consulted relating to the intensity of services required for different classes of patients in order to achieve successful treatment.

	Informal interdisciplinary pain programs may be considered for patients who are currently employed, those who cannot attend all day programs, those with language barriers, or those living in areas not offering formal programs. Before treatment has been initiated, the patient, physician, and insurer should agree on treatment approach, methods, and goals. Generally the type of outpatient program needed will depend on the degree of impact the pain has had on the patient’s medical, physical, psychological, social and/or vocational functioning.

	When referring a patient for formal outpatient interdisciplinary pain rehabilitation, an occupational rehabilitation or an opioid treatment program, the Division recommends the program meets the criteria of the Commission on Accreditation of Rehabilitation Facilities (CARF).

	Inpatient pain rehabilitation programs are rarely needed but may be necessary for patients with any of the following conditions: (a) High risk for medical instability; (b) Moderate-to-severe impairment of physical/functional status; (c) Moderate-to-severe pain behaviors; (d) Moderate impairment of cognitive and/or emotional status; (e) Dependence on medications from which he or she needs to be withdrawn; and (f) the need for 24-hour supervised nursing.

	Whether formal or informal programs, they should be comprised of the following dimensions [(CARF 2010-11](#CARFMedRehab201011)):

a.Communication: To ensure positive functional outcomes, communication between the patient, insurer and all professionals involved must be coordinated and consistent. Any exchange of information must be provided to all professionals, including the patient. Care decisions should be communicated to all and should include the family or other support system.

b.Documentation: Through documentation by all professionals involved and/or discussions with the patient, it should be clear that functional goals are being actively pursued and measured on a regular basis to determine their achievement or need for modification.

c.Treatment Modalities: Use of modalities may be necessary early in the process to facilitate compliance with and tolerance to therapeutic exercise, physical conditioning, and increasing functional activities. Active treatments should be emphasized over passive treatments. Active treatments should encourage self-coping skills and management of pain, which can be continued independently at home or at work. Treatments that can foster a sense of dependency by the patient on the caregiver should be avoided. Treatment length should be decided based upon observed functional improvement. For a complete list of active and passive therapies, refer to Sections F. 13 and 14, Therapeutic Procedures, Non-Operative. All treatment timeframes may be extended based upon the patient’s positive functional improvement.

d.Therapeutic Exercise Programs: A therapeutic exercise program should be initiated at the start of any treatment rehabilitation. Such programs should emphasize education, independence, and the importance of an on-going exercise regime. There is good evidence that exercise alone or part of a multi-disciplinary program results in decreased disability for workers with non-acute low back pain ([Oesch P 2010](#OeschP2010)). There is no sufficient evidence to support the recommendation of any particular exercise regimen over any other exercise regimen.

e.Return-to-Work: The authorized treating physician should continually evaluate the patient for their potential to return to work. When return-to-work is an option, it may be appropriate to implement a Work Hardening Program (as described in Section F. 12, Therapeutic Procedures, Non-Operative). For patients currently employed, efforts should be aimed at keeping them employed. Formal rehabilitation programs should provide assistance in creating work profiles. For more specific information regarding return-to-work, refer to the Return-to-work section in this guideline.

f.Patient Education: Patients with pain need to re-establish a healthy balance in lifestyle. All providers should educate patients on how to overcome barriers to resuming daily activity, including pain management, decreased energy levels, financial constraints, decreased physical ability, and change in family dynamics.

g.Psychosocial Evaluation and Treatment: Psychosocial evaluation should be initiated, if not previously done. Providers of care should have a thorough understanding of the patient’s personality profile; especially if dependency issues are involved. Psychosocial treatment may enhance the patient’s ability to participate in pain treatment rehabilitation, manage stress, and increase their problem-solving and self-management skills.

h.Vocational Assistance: Vocational assistance can define future employment opportunities or assist patients in obtaining future employment. Refer to Return-to-work section for detailed information.

Interdisciplinary programs are characterized by a variety of disciplines that participate in the assessment, planning, and/or implementation of the treatment program. These programs are for patients with greater levels of perceived disability, dysfunction, de-conditioning and psychological involvement. Programs should have sufficient personnel to work with the individual in the following areas: behavior, functional, medical, cognitive, pain management, psychological, social and vocational.

The following programs are listed in alphabetical order.

a. Formal Interdisciplinary Rehabilitation Programs:

Interdisciplinary Pain Rehabilitation: An Interdisciplinary Pain Rehabilitation Program provides outcomes-focused, coordinated, goal-oriented interdisciplinary team services to measure and improve the functioning of persons with pain and encourage their appropriate use of health care system and services. The program can benefit persons who have limitations that interfere with their physical, psychological, social, and/or vocational functioning. The program shares information about the scope of the services and the outcomes achieved with patients, authorized providers, and insurers.

The interdisciplinary team maintains consistent integration and communication to ensure that all interdisciplinary team members are aware of the plan of care for the patient, are exchanging information, and implement the plan of care. The team members make interdisciplinary team decisions with the patient and then ensure that decisions are communicated to the entire care team.

The Medical Director of the pain program should ideally be board certified in pain management; or be board certified in his or her specialty area and have completed a one year fellowship in interdisciplinary pain medicine or palliative care recognized by a national board, or have two years experience in an interdisciplinary pain rehabilitation program. Individuals who assist in the accomplishment of functional, physical, psychological, social and vocational goal must include: a medical director, pain team physician(s), and pain team psychologist. Other disciplines on the team may include, but are not limited to: Biofeedback Therapist, Occupational Therapist, Physical Therapist, Registered Nurse, case manager, exercise physiologist, psychologist, psychiatrist, and/or nutritionist.

* Time to Produce Effect: 3 to 4 weeks
* Frequency: Full time programs - No less than 5 hours/day, 5 days/week; part-time programs- 4 hours/day for 2-3 days per week.
* Optimum Duration: 3 to 12 weeks at least 2-3 times a week. With follow up visits weekly or every other week during the first one to two months after the initial program is completed.
* Maximum duration: 4 months for full time programs and up to 6 months for part-time programs. Periodic review and monitoring thereafter for one year, additional follow up based upon the documented maintenance of functional gains.

ii.Occupational Rehabilitation: is an interdisciplinary program addressing a patient’s employability and return-to-work. It includes a progressive increase in the number of hours per day that a patient completes work simulation tasks until the patient can tolerate a full workday. A full workday is case specific and is defined by the previous employment of the patient. Safe work place practices and education of the employer and social support system regarding the person’s status should be included. This is accomplished by addressing the medical, psychological, behavioral, physical, functional, and vocational components of employability and return-to-work.

There is some evidence that an integrated care programs, consisting of workplace interventions and graded activity teaching that pain need not limit activity, is effective in returning patients with chronic low back pain to work, even with minimal reported reduction of pain [Lambeek L 2010](#Lambeek2010).

The interdisciplinary team should, at a minimum, be comprised of a qualified medical director who is board certified with documented training in occupational rehabilitation, team physicians having experience in occupational rehabilitation, occupational therapy and physical therapy.

As appropriate, the team may also include: chiropractor, RN, case manager, psychologist and vocational specialist or certified biofeedback therapist.

* Time to Produce Effect: 2 weeks.
* Frequency: 2 to 5 visits per week, up to 8 hours/day.
* Optimum Duration: 2 to 4 weeks.
* Maximum Duration: 6 weeks. Participation in a program beyond six weeks must be documented with respect to need and the ability to facilitate positive symptomatic and functional gains.

b. Informal Interdisciplinary Rehabilitation Program:

A coordinated interdisciplinary pain rehabilitation program is one in which the authorized treating physician coordinates all aspects of care. This type of program is similar to the formal programs in that it is goal oriented and provides interdisciplinary rehabilitation services to manage the needs of the patient in the following areas: (a) functional, (b) medical, (c) physical, (d) psychological, (e) social, and (f) vocational.

This program is different from a formal program in that it involves lower frequency and intensity of services/treatment. Informal rehabilitation is geared toward those patients who do not need the intensity of service offered in a formal program or who cannot attend an all-day program due to employment, daycare, language or other barriers.

Patients should be referred to professionals experienced in outpatient treatment of chronic pain. The Division recommends the authorized treating physician consult with physicians experienced in the treatment of chronic pain to develop the plan of care. Communication among care providers regarding clear objective goals and progress toward the goals is essential. Employers should be involved in return to work and work restrictions and the family/social support system should be included in the treatment plan. Other disciplines likely to be involved include biofeedback therapist, occupational therapist, physical therapist, registered nurse, psychologist, case manager, exercise physiologist, psychiatrist, and/or nutritionist.

* Time to Produce Effect: 3 to 4 weeks
* Frequency: Full time programs - no less than 5 hours/day, 5 days/week; Part time programs - 4 hours/day for 2-3 days per week.
* Optimum Duration: 3 to 12 weeks at least 2-3 times a week. With follow up visits weekly or every other week during the first one to two months after the initial program is completed.
* Maximum duration: 4 months for full time programs and up to 6 months for part-time programs. Periodic review and monitoring thereafter for one year, additional follow up based upon the documented maintenance of functional gains.

c. Opioid/Chemical Treatment Programs:

Chemical dependency, which for worker compensation issues will usually be related to opioids, anxiolytics, or hypnotics as prescribed for the original workers compensation injury, should be treated with specific programs providing medical and psychological assessment, treatment planning and individual as well group counseling and education.

They may be inpatient or outpatient programs, depending upon the level of intensity of services required. Formal treatment programs are appropriate for patients who have more intense (e.g. use extraordinarily excessive doses of prescription drugs to which they have developed tolerance) or multiple drug abuse issues (e.g. benzodiazepines and/or alcohol) and those with complex medical conditions or psychiatric issues drug misuse. A medical physician with appropriate training preferably board certified in addiction medicine, should provide the initial evaluation and oversee the program. Full primary assessment should include behavioral health assessment; medical history; physical examination, mental status; current level of functioning; employment history; legal history; history of abuse, violence, and risk taking behavior; education level; use of alcohol, tobacco and other drugs; and social support system ([CARF 2010-11](#CARFOpRehab201011)).

Addiction counselors, and other trained health care providers as needed, are involved in the program. Peer and group support is an integral part of the program and families are encouraged to attend. There should be good communication between the program and other external services, external health care providers, Alanon, AA and pain medicine providers. Drug screening is performed as appropriate for the individual, minimally initially and at least weekly during the initial detoxification and intensive initial treatment.

Clear withdrawal procedures are delineated for voluntary, against medical advice, and involuntary withdrawal. Withdrawal programs must have a clear treatment plan and include description of symptoms of medical and emotional distress, significant signs of opioid withdrawal, and actions taken. All programs should have clear direction on how to deal with violence in order to assure safety for all participants. Transition and discharge should be carefully planned with full communication to outside resources [CARF 2010-11](#CARFOpRehab201011). Duration of inpatient programs are usually 4 weeks while outpatient programs may take 12 weeks.

Drug detoxification may be performed on an outpatient or inpatient basis. Detoxification is unlikely to succeed in isolation when not followed by prolonged chemical dependency treatment. Isolated detoxification is usually doomed to failure with very high recidivism rates.

Neither ultra-rapid nor rapid-detoxification are recommended due to possible respiratory depression and death and the lack of evidence for long range treatment success.

Abstinence models are preferred by most chemical dependency treatment programs but are problematic for those chronic pain patients who may require the continued use of opioid analgesics. Methadone, buprenorphine, or buprenorphine/naloxone are usually the first line agents for treating such patients; however, continued use in an outpatient setting of methadone for opioid dependency requires dispensing by a licensed methadone clinic and buprenorphine, for the same purpose, by a physician possessing a special DEA license. As of the time of this guideline writing, some formulations of buprenorphine/naloxone have been FDA approved for the treatment of opioid dependence. It is strongly recommended that the use of either drug for the purpose of treating chronic pain be limited to physicians with additional training. In the case of methadone, there are increasing numbers of inadvertent deaths due to misuse, including prescribing errors. In the case of buprenorphine, its use as an analgesic is not currently FDA approved and conversion to this drug from other opioids is difficult. It should never be a first-line analgesic for chronic pain due to high cost and the presence of other opioids that may be more effective for moderate-to-severe chronic pain.

Tapering opioids on an outpatient basis requires a highly motivated patient and diligent treatment team and may be accomplished by decreasing the current dose 10% per day or per week. Tapering should be accompanied by addiction counseling. Failing a trial of tapering a patient should be sent to a formal addiction program. When the dose has reached 1/3 of the original dose, the taper should proceed at half or less of the initial rate. Doses should be held or possibly increased if severe withdrawal symptoms, pain, or reduced treatment failure otherwise occurs. This method is tedious, time consuming and more likely to fail than more rapid and formalized treatment programs.

* Time to Produce Effect: 3 to 4 weeks
* Frequency: Full time programs- no less than 5 hours/day, 5 days/week; part time programs- 4 hours/day for 2-3 days per week.
* Optimum Duration: 3 to 12 weeks at least 2-3 times a week. With follow up visits weekly or every other week during the first one to two months after the initial program is completed.
* Maximum duration: 4 months for full time programs and up to 6 months for part-time programs. Periodic review and monitoring thereafter for one year, additional follow up based upon the documented maintenance of functional gains
	1. MEDICATIONS and Medical ManagementThere is no single formula for pharmacological treatment of patients with chronic nonmalignant pain. A thorough medication history, including use of alternative and over the counter medications, should be performed at the time of the initial visit and updated periodically. The medication history may consist of evaluating patient refill records through pharmacies to determine if the patient is appropriately taking their prescribed regimen. Appropriate application of pharmacological agents depends on the patient’s age, past history (including history of substance abuse), drug allergies and the nature of all medical problems. It is incumbent upon the healthcare providerto thoroughly understand pharmacological principles when dealing with the different drug families, their respective side effects, drug interactions**,** bioavailability profiles, and primary reason for each medication’s usage. Patients should be aware that medications alone are unlikely to provide complete pain relief. In addition to pain relief, a primary goal of drug treatment is to improve the patient’s function as measured behaviorally. In addition to taking medications, continuing participation in exercise programs and using self-management techniques such as biofeedback, cognitive behavioral therapy and other individualized physical and psychological practices are essential elements for successful chronic pain management.

	Control of chronic non-malignant pain is expected to involve the use of medication. Strategies for pharmacological control of pain cannot be precisely specified in advance. Rather, drug treatment requires close monitoring of the patient’s response to therapy, flexibility on the part of the prescriber and a willingness to change treatment when circumstances change. Many of the drugs discussed in the medication section were licensed for indications other than analgesia, but are effective in the control of some types of chronic pain.

	It is generally wise tobegin management with lower cost medications whose efficacy equals higher cost medications and medications with a greater safety profile. Decisions to progress to more expensive, non-generic, and/or riskier products are made based on the drug profile, patient feedback, and improvement in function ([WHO [World Health Organization] (n.d.)](#WHO); [Ehrlich 2003](#Ehrlich2003); [Chou 2007](#Chou2007)). The provider must carefully balance the untoward side effects of the different drugs with therapeutic benefits,as well as monitoring forany drug interactions.

	Consensus regarding the use of opioids has generally been reached in the field of cancer pain, where nociceptive mechanisms are usually identifiable, expected survival may be short, and symptomatic relief is emphasized more than functional outcomes. In injured workers, by contrast, central and neuropathic mechanisms frequently overshadow nociceptive processes, expected survival is relatively long, and return to a high level of function is a major goal of treatment. Approaches to pain, which were developed in the context of malignant pain, therefore may not be transferable to chronic non-malignant pain.

	All medications should be given an appropriate trial in order to test for therapeutic effect. The length of an appropriate trial varies widely depending on the individual drug. Certain medications may take several months to determine the efficacy, while others require only a few doses. It is recommended that patients with chronic nonmalignant pain be maintained on drugs that have the least serious side effects. For example, patients need to be tried or continued on acetaminophen and/or low dose generic antidepressant medications whenever feasible, as part of their overall treatment for chronic pain. Patients with renal or hepatic disease may need increased dosing intervals with chronic acetaminophen use. Chronic use of NSAIDs is generally not recommended due to increased risk of cardiovascular events and GI bleeding. There is good evidence that naproxen has the least risk for cardiovascular events when compared to other NSAIDs [(Trelle S 2011](#TrelleS2011)). There is good evidence that glucosamine does not improve pain related disability in those with chronic low back pain and degenerative changes on radiologic studies; therefore, it is not recommended for chronic spinal or non-joint pain [(Wilkens P 2010](#WilkensP2010)). For chronic pain related to joint osteoarthritis see specific extremity guidelines.

	Opioid analgesics andother drugs of potential abuse such as sedative hypnotics or benzodiazepines may be used in properly selected cases ([Gourlay D 2009](#GourlayD2009)) for chronic pain patients, although total elimination of these medications is desirable whenever clinically feasible. It is strongly recommended that such pharmacological management be monitored or managed by an experienced pain medicine physician. Multimodal therapy is the preferred mode of treatment for chronic pain patients whether or not these drugs were used acutely or sub-acutely.

	Neuropathic pain can be treated with a variety of medications; however, all have specific side effects and other interactions that clinicians must be mindful of. It is suggested that patients with significant peripheral neuropathic pain be trialed with a tricyclic medication initially, as low dose medication in this category is frequently tolerated and performs sufficiently to decrease pain 30 to 50% ([Wiffen PJ, McQuay, Edwards, [Cochrane] 2005](#WiffenMcQuayEdwards2005)). When these fail, side effects are not tolerated, or a patient has medical issues precluding the use of this class of drugs, other appropriate medications can be tried. Second line drugs include the anti-convulsants, gabapentin and pregabalin. Comparison studies of amitriptyline (Elavil, Endep, Vanatrip) and gabapentin (Fanatrex, Gabarone, Gralise, Horizant, Neurontin) or carbamazepine (Carbatrol, Epitol, Equetro, Tegretol) have shown no appreciable difference between the drugs; thus, there is good evidence that there is little clinical outcome difference between the medications although gabapentin may be better tolerated ([Saarto T [Cochrane] 2007](#SaartoT2007); [Rowbotham, 2004](#RowbothamMC2004); [Rintala D 2007](#RintalaD2007)). Third line drugs are the SNRIs, which have demonstrated some effectiveness for treating neuropathic pain, and topical lidocaine ([Moulin DE 2007](#MoulinDE2007); [O’Connor A 2009](#OConnorA2009)). The SNRI duloxetine (Cymbalta, Ariclaim, Xeristar, Yentreve, Duzela) has not been shown to be superior to the tricyclic amitriptyline ([Kaur 2011](#Kaur2011)) and there is no reason to prefer duloxetine in patients who have not been treated with a tricyclic.Fourth line drugs are opioids, tramadol (Rybix, Ryzolt, Ultram), and tapentadol (Nucynta). Other medications have few clinical trials to support them but may be helpful in some patients.

	The preceding principles do not apply to chronic headache patients. These patients should be referred to a physician specializing in the diagnosis and treatment of headache and facial pain ([DOWC, [Traumatic Brain Injury MTG], 2006](#DOWCBrainInjury2006)).

	For the clinician to interpret the following material, it should be noted that: (1) drug profiles listed are not complete; (2) dosing of drugs will depend upon the specific drug, especially for off-label use; and (3) not all drugs within each class are listed, and other drugs within the class may be appropriate for individual cases. Clinicians should refer to informational texts or consult a pharmacist before prescribing unfamiliar medications or when there is a concern for drug interactions.

	The following drug classes are listed in alphabetical order, not in order of suggested use which is outlined above for neuropathic pain.
		1. Alpha-Acting Agents**:** Noradrenergic pain-modulating systems are present in the central nervous system and the alpha-2 adrenergic receptor may be involved in the functioning of these pathways. Alpha-2 agonists may act by stimulating receptors in the substantia gelatinosa of the dorsal horn of the spinal cord, inhibiting the transmission of nociceptive signals. Spasticity may be reduced by presynaptic inhibition of motor neurons. Given limited experience with their use, they cannot be considered first-line or second line analgesics for neurogenic pain, but a trial of their use may be warranted in some cases of refractory pain.
			1. Clonidine (Catapres, Kapvay, Nexiclon)
				1. Description – central alpha 2 agonist.
				2. Indications – sympathetically mediated pain, treatment of withdrawal from opioids. IV clonidine and lidocaine should be used for upper extremity surgery with IV regional anesthesia in patients with a history of CRPS as there is some evidence that it decreases the risk of recurrence (Reuben, 2004).

				As of the time of this guideline writing, formulations of clonidine have been FDA approved for hypertension.
				3. Major Contraindications – severe coronary insufficiency, renal impairment.
				4. Dosing and Time to Therapeutic Effect – increase dosage weekly to therapeutic effect.
				5. Major Side Effects – sedation, hypotension, sexual dysfunction, thrombocytopenia, weight gain, agitation, rebound hypertension with cessation.
				6. Drug Interactions – beta adrenergics, tricyclic antidepressants.
				7. Laboratory Monitoring – Renal function, blood pressure.
		2. Anticonvulsants**:** Although the mechanism of action of anticonvulsant drugs in neuropathic pain states remains to be fully defined, some appear to act as nonselective sodium channel blocking agents. A large variety of sodium channels are present in nervous tissue, and some of these are important mediators of nociception, as they are found primarily in unmyelinated fibers and their density increases following nerve injury. While the pharmacodynamic effects of the various anticonvulsant drugs are similar, the pharmacokinetic effects differ significantly. Gabapentin and pre-gabapentin, by contrast, is a relatively non-significant enzyme inducer, creating fewer drug interactions. Because anticonvulsant drugs may have more problematic side-effect profiles, their use should usually be deferred until tricyclic-related medications have failed to relieve pain. All patients on these medications should be monitored for suicidal ideation.

		Carbamazepine has important effects as an inducer of hepatic enzymes and may influence the metabolism of other drugs enough to present problems in patients taking interacting drugs. There is some evidence that oxcarbazepine (Trileptal) may be effective for neuropathic pain ([Dogra, 2005](#Dogra2005)) but dose escalation must be done carefully, since there is good evidence ([Dogra, 2005](#Dogra2005); [Beydoun, 2006](#Beydoun2006)) that rapid dose titration produces side-effects greater than the analgesic benefits. Carbamazepine is generally not recommended ([Moulin, 2007](#MoulinDE2007)).

		There is an association between older anticonvulsants including gabapentin and non-traumatic fractures for patients older than 50; this should be taken into account when prescribing these medications ([Jette N 2011](#JetteN2011)).
			1. Gabapentin (Fanatrex, Gabarone, Gralise, Horizant, Neurontin)
				1. Description – Structurally related to gamma-aminobutyric acid (GABA) but does not interact with GABA receptors.
				2. Indications – As of the time of this guideline writing formulations of gabapentin has been FDA approved for post-herpetic neuralgia and partial seizures.There is some evidence that gabapentin may benefit some patients with post-traumatic neuropathic pain ([Gordh T 2008](#Gordh2008)). There is good evidence that gabapentin is not superior to amitriptyline ([Rintala D 2007](#RintalaD2007); [Saarto T [Cochrane] 2007).](#SaartoT2007) There is some evidence that nortriptyline (Aventyl, Pamelor) and gabapentin are equally effective for pain relief of post herpetic neuralgia ([Chandra K 2006](#ChandraK2006)). There is some evidence that gabapentin given with morphine may result in lower side effects from morphine and produces greater analgesia at lower doses than those usually required for either medication alone ([Gilron I 2005)](#GilronI2005). There is strong evidence that gabapentin is more effective than placebo for neuropathic pain, even though it provides complete pain relief to a minority of patients ([Wiffen, Derry, 2005](#WiffenDerry2005); [Irving, 2009](#Irving2009)). There is some evidence that a combination of gabapentin and nortriptyline provides more effective pain relief than monotherapy with either drug ([Gilron 2009](#Gilron2009)). Given the cost of gabapentin it is recommended that patients who are medically appropriate receive a trial of tricyclics before use of gabapentin.
				3. Relative Contraindications – Renal insufficiency. Dosage may be adjusted to accommodate renal dysfunction.
				4. Dosing and Time to Therapeutic Effect – Dosage should be initiated at a low dose in order to avoid somnolence and may require 4 to 8 weeks for titration. Dosage shouldbe adjusted individually.
				5. Major Side Effects – Sedation, confusion, dizziness, peripheral edema. Patients should also be monitored for suicidal ideation and drug abuse.
				6. Drug Interactions – antacids.
				7. Laboratory Monitoring – Renal function.
			2. Pregabalin (Lyrica)
				1. Description – Structurally related to gamma-aminobutyric acid (GABA) but does not interact with GABA receptors.
				2. Indications –As of the time of this guideline writing formulations of pregabalin have been FDA approved for neuropathic pain associated with diabetic peripheral neuropathy, post-herpetic neuralgia, and fibromyalgia. It may also be an adjunctive therapy for partial-onset seizures.

				There is strong evidence that pregabalin has a substantive benefit for a minority, about 25%, of neuropathic pain patients, most of whom report between 30 and 50% relief of symptoms ([Van Seventer R 2010](#VanSeventerR2010); [Moore RA [Cochrane] 2009](#MooreRA2009)). Given the cost of pregabalin and its response for a minority of patients it is recommended that patients who are medically appropriate receive a trial of amitriptyline or another first-line agent before use of pregabalin.
				3. Contraindications – allergy to medication, prior history of angioedema. Renal insufficiency is a relative contraindication, requiring a modified dose.
				4. Dosing and Time to Therapeutic Effect – Dosage may be increased over several days and doses above 150 mg are usually required. The full benefit may not be achieved for 6 to 8 weeks.
				5. Major Side Effects – Dizziness, confusion, sedation, dry mouth, weight gain, and visual changes have been reported. Patients should also be monitored for suicidal ideation and drug abuse. Congestive heart failure may be exacerbated in some patients. Decreased platelets have been reported.
				6. Drug Interactions – Opioids, benzodiazepines, and alcohol.
				7. Laboratory Monitoring – Renal function, and platelets, and creatinine kinase as appropriate for individual cases.
			3. Topiramate (Topamax, Topiragen)
				1. Description – Sulfamate substitute monosacchride.
				2. Indications – FDA approved for partial seizures or prophylaxis for migraines. There is good evidence that topiramate demonstrates minimal effect on chronic lumbar radiculopathy or other neuropathic pain ([Thienel U 2004](#ThienelU2004); [Raskin P 2004](#RaskinP2004); [Khoromi S 2005)](#KhoromiS2005). . Therefore it is generally not recommended for chronic pain with the exception of chronic, functionally impairing headache. If it is utilized this would be done as a third or fourth line medication in appropriate patients.
			4. Lamotrigine (Lamictal) – This anti-convulsant drug is not FDA approved for use with neuropathic pain. Due to reported deaths from toxic epidermal necrolysis and Stevens Johnson syndrome, increased suicide risk, and incidents of aseptic meningitis, it is used with caution for patients with seizure or mood disorders. There is good evidence that lamotrigine is not effective for neuropathic pain and that the potential harms are likely to outweigh the benefits, therefore it is not recommended for most patients ([Wiffen, 2007 [Cochrane](#Wiffen2007)]; [Vinik A 2007](#VinikA2007)).
		3. Antidepressants**:** are classified into a number of categories based on their chemical structure and their effects on neurotransmitter systems. Their effects on depression are attributed to their actions on disposition of norepinephrine and serotonin at the level of the synapse; although these synaptic actions are immediate, the symptomatic response in depression is delayed by several weeks. When used for chronic pain, the effects may in part arise from treatment of underlying depression, but may also involve additional neuromodulatory effects on endogenous opioid systems, raising pain thresholds at the level of the spinal cord.

		Pain responses may occur at lower drug doses with shorter times to symptomatic response than are observed when the same compounds are used in the treatment of mood disorders. Neuropathic pain, diabetic neuropathy, post-herpetic neuralgia, and cancer-related pain may respond to antidepressant doses low enough to avoid adverse effects that often complicate the treatment of depression. First line drugs for neuropathic pain are the tricyclics with the newer formulations having better side effect profiles. SNRIs are considered second line drugs due to their costs and the number needed to treat for a response. SSRIs are used generally for depression rather than neuropathic pain and should not be combinedwith moderate to high-dose tricyclics ([Moulin DE 2007](#MoulinDE2007)).

		All patients being considered for anti-depressant therapy should be evaluated and continually monitored for suicidal ideation and mood swings.
			1. Tricyclics and older agents.

			(e.g., amitriptyline, nortriptyline, doxepin (Adapin, Silenor, Sinequan), desipramine (Norpramin, Pertofrane), imipramine (Tofranil), trazodone Desyrel, Oleptro)).
				1. Description – Serotonergics, typically tricyclic antidepressants (TCAs), are utilized for their serotonergic properties as increasing CNS serotonergic tone can help decrease pain perception in non-antidepressant dosages. Amitriptyline is known for its ability to repair Stage 4 sleep architecture, a frequent problem found in chronic pain patients and to treat depression, frequently associated with chronic pain. However, higher doses may produce more cholinergic side effects than newer tricyclics such as nortriptyline and desipramine. Doxepin and trimipramine also have sedative effects.
				2. Indications – Some formulations are FDA approved for depression and anxiety. For the purposes of this guideline, they are recommended for neuropathic pain and insomnia. They are not recommended as a drug treatment for depression. There is good evidence that gabapentin is not superior to amitriptyline ([Rintala D 2007](#RintalaD2007); [Saarto T [Cochrane] 2007](#SaartoT2007)). Given the cost of gabapentin it is recommended that patients who are medically appropriate to undergo a trial of lower cost tricyclic before use of gabapentin.
				3. Major Contraindications – Cardiac disease or dysrhythmia, glaucoma, prostatic hypertrophy, seizures, high suicide risk, uncontrolled hypertension and orthostatic hypotension. A screening cardiogram may be done for those 40 or older ([O’Connor A 2009](#OConnorA2009)), especially if higher doses are used.
				4. Dosing and Time to Therapeutic Effect – Varies by specific tricyclic. Low dosages, less than 100 mg are commonly used for chronic pain and/or insomnia. Lower doses decrease side effects and cardiovascular risks.
				5. Major Side Effects – Side effects vary according to the medication used; however, the side effect profile for all of these medications is generally higher in all areas except GI distress, which is more common among the SSRIs and SNRIs. Anticholinergic side effects include, but not limited to, dry mouth, sedation, orthostatic hypotension, cardiac arrhythmia, urinary retention, and weight gain. Patients should also be monitored for suicidal ideation and drug abuse.
				6. Drug Interactions – Tramadol (may cause seizures, both also increase serotonin/norepinephrine, so serotonin syndrome is a concern), clonidine, cimetidine (Tagemet), sympathomimetics, valproic acid (Depakene, Depakote, Epilim, Stavzor), warfarin (Coumadin, Jantoven, Marfarin), carbamazepine, bupropion (Aplezin, Budeprion, Buproban, Forfivo, Wellbutrin, Zyban), anticholinergics, quinolones.
				7. Recommended Laboratory Monitoring – Renal and hepatic function. EKG for those on high dosages, or with cardiac risk.
			2. Selective serotonin reuptake inhibitors (SSRIs) (e.g., citalopram (Celexa), fluoxetine (Prozac, Rapiflux, Sarafem, Selfemra), paroxetine (Paxil, Pexeva), sertraline (Zoloft)) are not recommended for neuropathic pain. They may be used for depression.
			3. Selective Serotonin Nor-epinephrine Reuptake Inhibitor (SSNRI)/Serotonin Nor-epinephrine Reuptake Inhibitors (SNRI).
				1. Description – Venlafaxine (Effexor), duloxetine, and milnacipran (Savella).
				2. Indications – At the time of this guideline writing, duloxetine has been FDA approved for treatment of diabetic neuropathic pain and chronic musculoskeletal pain. There is good evidence that it is superior to placebo for neuropathic pain at doses of 60mg or 120mg [(Lunn M [Cochrane] 2009](#LunnM2009); [Goldstein D 2005](#GoldsteinD2005)). There is some evidence that it is comparable to pregabalin and gabapentin ([Quilici, 2009](#Quilici2009)).

				As of the time of this guideline writing, formulations of venlafaxine hydrochloride has been FDA approved for generalized anxiety disorder. There is some evidence it is modestly effective in diabetic neuropathic pain at doses of 150 to 225 mg ([Rowbotham MC 2004](#RowbothamMC2004)). There is no evidence of superiority over tricyclics.

				As of the time of this guideline writing formulations of milnacipran have been FDA approved for treatment of fibromyalgia and has a success rate similar to imipramine. It is not recommended in patients as a first or second line treatment and is reserved for patients who fail other regimes due to side effects.
				3. Relative Contraindications – Seizures, eating disorders.
				4. Major Side Effects - Depends on the drug, but commonly includes dry mouth, nausea, fatigue, constipation, and abnormal bleeding. Serotonin syndrome is also a risk. GI distress, drowsiness, sexual dysfunction less than other classes. Hypertension and glaucoma (venlafaxine). Cardiac issues with venlafaxine and withdrawal symptoms unless tapered [(O’Connor A 2009](#OConnorA2009)). Studies show increased suicidal ideation and attempts in adolescents and young adults. Patients should also be monitored for suicidal ideation and drug abuse.
				5. Drug Interactions – Drug specific.
				6. Laboratory Monitoring – Drug specific. Hepatic and renal monitoring, venlafaxine may cause cholesterol or triglyceride increases.
			4. Atypical Antidepressants/Other Agents. May be used for depression; however, are not appropriate for neuropathic pain.
		4. Hypnotics and Sedatives**:** Sedative and hypnotic drugs decrease activity and induce drowsiness and may cause moderate agitation in some individuals. Many other medications, such as antihistamines and antidepressants also produce these side effects. Due to the addiction potential, withdrawal symptoms, and sedating side effects benzodiazepines and other similar drugs found in this class, are not generally recommended. They should be used with extreme caution when the patient is on chronic opioids management. When used, extensive patient education should be documented. Some of these medications have long half-lives and sleep apnea can occur or be aggravated on these medications. Many unintentional drug deaths are related to concomitant opioid and benzodiazepine drug use. Retrograde amnesia can occur and is implicated in “sleep driving,” “sleep eating” and other activities.

		Most insomnia in chronic pain patients should be managed primarily through behavioral interventions, with medications as secondary measures (refer to Section F.4, Disturbances of Sleep).
			1. Zaleplon (Sonata), Eszopiclone (Lunesta, Lunestar), Zolpidem (Ambien, Edluar, Intermezzo, Zolpimist).
				1. Description – A nonbenzodiazepine hypnotic.
				2. Indications – As of the time of this guideline writing, formulations of zaleplon, eszopiclonem and zolpidem have been FDA approved for insomnia.
				3. Dosing and Time to Therapeutic Effect – Time of onset is 30 to 60 minutes.
				4. Major Side Effects – Dizziness, dose-related amnesia.
				5. Drug Interactions – Increases sedative effect of other central nervous system (CNS) depressant drugs.
				6. Laboratory Monitoring **-** none required, based on individual patient history.
			2. Benzodiazepine-based hypnotics include temazepam (Restoril, Temazepam, Gelthix) and flurazepam (Dalmane). Neither is recommended because of habit-forming potential, withdrawal symptoms, and sedating side effects. Flurazepam has an active metabolite with a very long half-life, resulting in drug accumulation and next-day somnolence, and should be avoided.
		5. Marijuana:

		At the time of this guidelines writing, marijuana use is illegal under federal law and cannot be recommended for use in this guideline. The Colorado statute also states that insurers are not required to pay for marijuana.

		Marijuana produces many cannabinoids. Only a few of these substances have been explored in detail. Cannabis is currently procured in Colorado through a registry program. Products sold cannot be evaluated for pharmaceutically appropriate content or strength. THC content has increased from 2% in 1980 to 8.5% in 2007, thus making it difficult to correctly determine effects of a specific plant on an individual ([Hall W 2009](#HallW2009)). Because smoked marijuana reaches its effect quickly, it is thought that most smokers titrate their dosage when using higher potency agents ([Huestis M 1992](#Huestis1992)).

		There are only two oral pharmaceutical cannabinoid products on the market. These medications were developed initially for nausea due to oncological drug therapy but have been trialed in other settings and are described below. A buccal spray is accepted in Europe and Canada and may be approved by the FDA for use with neuropathic pain. Initial studies were done on neuropathic pain associated with multiple sclerosis.

		There are a number of studies evaluating the health effects of cannabinoids. Cannabis is associated with the subsequent development of psychosis in adolescents and can cause transient episodes of paranoia and psychotic symptoms in some individuals. It is not known whether or not the association with psychosis is causal. Cannabis increases heart rate in a dose related fashion and some studies suggest it may increase the risk for myocardial infarction in those with cardiovascular disease ([Hall W 2009](#HallW2009); [Kaufmann RM 2010](#KaufmannRM2010)). Because smoked marijuana contains many of the same carcinogens as smoked tobacco, it has been postulated that cancer risk may be increased in heavy marijuana smokers. However, the association has not been established epidemiologically ([Hall W 2009](#HallW2009); [Calabria B 2010](#Calabria2010)). There appears to be an increase in respiratory infections although there is no clear disposition for chronic obstructive lung disease in regular cannabis smokers. Cannabis dependence occurs in some users. In some individuals, withdrawal symptoms have been demonstrated after 20 days of high dose use and consist of decreased mood and appetite with irritability, insomnia, anxiety and depression ([Hall W 2009](#HallW2009)).

		Unlike alcohol and many other sedating drugs of abuse, marijuana does not appear to be lethal at any dose consumed by heavier users when used in isolation, unlike alcohol, probably because it is not a respiratory depressant. Some studies have shown a decrease in reaction time and some association with motor vehicle accidents. However, the risk appears to be less than ½ the risk of driving under alcohol intoxication [(Hall W 2009](#HallW2009); [Menetrey A 2005](#MenetreyA2005); [Calabria B 2010](#Calabria2010)). There is only one study that evaluated the use of marijuana in conjunction with chronic opioid management, thus no recommendations can be made to clinicians regarding this combination. Clinicians should keep in mind that there are an increasing number of deaths due to the toxic misuse of opioids with other medications and alcohol. Drug screening is a mandatory component of chronic opioid management. It is appropriate to screen for alcohol use and have a contractual policy regarding alcohol use during chronic opioid management as alcohol use in combination with opioids is more likely to contribute to death or accidents than marijuana.

		The contraindications and major side effects for cannabinoid are listed below. No laboratory monitoring is necessary.
* Relative Contraindications – history of psychosis or risk factors for psychosis, seizure history, cardiovascular risk history, history of addiction, hypersensitivity to cannabinoids.
* Major Side Effects – Dizziness or fatigue, rapid heart rate, dry mouth, euphoria, Less common effects- paranoia or hallucinations, seizures. A withdrawal reaction can occur when high doses are discontinued. It may include sweating and rhinorrhea with anorexia.
* Psychological reactions: intoxication from cannabis frequently results in impaired motor coordination, euphoria, anxiety, sensation of slowed time, impaired judgment, social withdrawal, and hallucinations. Psychotic and anxiety disorders can occur from the use of cannabis. Paranoid ideation ranging from suspiciousness to frank delusions, hallucinations and depersonalization or derealization have been reported. Some of these findings may be related to the higher level of THC (delta-9-tetrahydrocannabinol) found in the marijuana currently sold.
	+ - 1. Dronabinal (Marinol):
				1. Description – Dronabinol is a synthetic delta-9- tetrahydrocannabinol, which is also a naturally occurring component of Cannabis sativa L. (marijuana).
				2. Indications – As of the time of this guideline writing, formulations of dronabinol have been FDA approved for nausea and vomiting with cancer therapy and weight loss associated with AIDS.
				3. Dosing and Time to Therapeutic Effect – 2.5 mg twice a day titrated up to 20 mg total per day.
			2. Nabilone(Cesamet):
				1. Description – Nabilone is a synthetic cannabinoid which is also a naturally occurring component of Cannabis sativa L. (marijuana).
				2. Indications – As of the time of this guideline writing, formulations of nabilone have been FDA approved for nausea and vomiting with cancer therapy.
				3. Dosing and Time to Therapeutic Effect –1 to 2 mg twice a day titrated up to 6 mg per day.
			3. Nabiximols (Sativex):
				1. Description –tetrahydrocannabinol (THC) and cannabidiol (CBD) in a one to one ratio, plus other components of cannabis extracts such as terpenoids and flavonoids mixed in a tincture. In the UK, nabiximols has just been approved for spasticity due to multiple sclerosis. In Canada, nabiximols is approved under Health Canada’s Notice of Compliance with Conditions (NOC/c) policy for the relief of neuropathic pain and advanced cancer pain. It has not been approved in the US as of the time of this guideline writing. This drug is not intended to provide the euphoria produced with smoking marijuana.
				2. Indications – In other countries for neuropathic pain and spasticity of MS, cancer pain. There is some evidence that nabiximols can modestly decrease peripheral neuropathic pain with allodynia in some patients who were concomitantly treated with opioids or anticonvulsants, however, the drop out rate for those who continued the medication longer term was high ([Nurmikko T 2007](#NurmikkoT2007)).
				3. Dosing and Time to Therapeutic Effect – Spray administered under the tongue. Up to 8 sprays every 3 hours with a maximum of 48 per day.
		1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs):

		Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) are useful for pain and inflammation. In mild cases, they may be the only drugs required for analgesia.There are several classes of NSAIDs and the response of the individual injured worker to a specific medication is unpredictable. For this reason a range of NSAIDs may be tried in each case with the most effective preparation being continued.Patients should be closely monitored for adverse reactions. The US Food and Drug Administration advise all NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Administration of proton pump inhibitors, histamine 2 blockers, or misoprostol, a prostaglandin analog, along with these NSAIDs may reduce the risk of duodenal and gastric ulceration but do not impact possible cardiovascular complications. There is good evidence that naproxen has a more favorable cardiovascular risk profile than other NSAIDs when used over a long period for chronic pain ([Trelle, 2011](#TrelleS2011)). Due to the cross-reactivity between aspirin and NSAIDs, NSAIDs should not be used in aspirin-sensitive patients, and should be used with caution in all asthma patients. NSAIDs are associated with abnormal renal function, including renal failure, as well as, abnormal liver function. Certain NSAIDs may have interactions with various other medications. Individuals may have adverse events not listed above. Intervals for metabolic screening are dependent upon the patient’s age, general health status and should be within parameters listed for each specific medication. Complete blood count (CBC), liver and renal function should be monitored at least every six months in patients on chronic NSAIDs and initially when indicated.
			1. Non-selective Nonsteroidal Anti-Inflammatory Drugs.

			Includes NSAIDs and acetylsalicylic acid (aspirin). Serious GI toxicity, such as bleeding, perforation, and ulceration can occur at any time, with or without warning symptoms in patients treated with traditional NSAIDs. Physicians should inform patients about the signs and/or symptoms of serious gastrointestinal toxicity and what steps to take if they occur. Anaphylactoid reactions may occur in patients taking NSAIDs. NSAIDs may interfere with platelet function. Fluid retention and edema have been observed in some patients taking NSAIDs.
* Optimal Duration: 1 to 2 weeks.
* Maximum Duration: Chronic use is not generally recommended but may be appropriate in select cases if monitored regularly. Use of these substances long-term (3 days per week or greater) is associated with rebound pain upon cessation.
	+ - 1. Selective Cyclo**-**oxygenase-2 (COX-2) Inhibitors.

			COX-2 inhibitors are more recent NSAIDs and differ in adverse side effect profiles from the traditional NSAIDs. The major advantages of selective COX-2 inhibitors over traditional NSAIDs are that they have less gastrointestinal toxicity and no platelet effects. COX-2 inhibitors can worsen renal function in patients with renal insufficiency; thus, renal function may need monitoring.

			COX-2 inhibitors should not be first-line for low risk patients who will be using an NSAID short-term but are indicated in select patients for whom traditional NSAIDs are not tolerated. Serious upper GI adverse events can occur even in asymptomatic patients. Patients at high risk for GI bleed include those who use alcohol, smoke, are older than 65, take corticosteroids or anti-coagulants, or have a longer duration of therapy. Celecoxib is (Celebrex) contraindicated in sulfonamide allergic patients.
* Optimal Duration: 7 to 10 days.
* Maximum Duration: Chronic use is not generally recommended but may be appropriate in select cases if monitored regularly. Use of these substances long-term (3 days per week or greater) is associated with rebound pain upon cessation.
	+ 1. Opioids**:** are the most powerful analgesics. Their use in acute pain and moderate-to-severe cancer pain is well accepted. Their use in chronic nonmalignant pain, however, is fraught with controversy and lack of scientific research.

		General Information: Opioids include some of the oldest and most effective drugs used in the control of severe pain. The discovery of opioid receptors and their endogenous peptide ligands has led to an understanding of effects at the binding sites of these naturally occurring substances. Most of their analgesic effects have been attributed to their modification of activity in pain pathways within the central nervous system; however, it has become evident that they also are active in the peripheral nervous system. Activation of receptors on the peripheral terminals of primary afferent nerves can mediate anti-nociceptive effects, including inhibition of neuronal excitability and release of inflammatory peptides. Some of their undesirable effects on inhibiting gastrointestinal motility are peripherally mediated by receptors in the bowel wall.

		The central nervous system actions of these drugs account for much of their analgesic effect and for many of their other actions, such as respiratory depression, drowsiness, mental clouding, reward effects, and habit formation. With respect to the latter, it is crucial to distinguish between three distinct phenomena: tolerance, dependence, and addiction.
* Tolerance refers to a state of adaptation in which exposure to a drug over time causes higher doses of that drug to be required in order to produce the same physiologic effectand/or markedly diminished effect with continued use of the same amount that drug.
* Dependence refers to a set of disturbances in body homeostasis that leads to withdrawal symptoms, which can be produced with abrupt discontinuation, rapid reduction, decreasing blood levels, and/or by administration of an antagonist.
* Addiction is a primary, chronic, neurobiological disease, with genetic, psychological, and environmental factors influencing its development and manifestations. It is a behavioral pattern of drug craving and seeking which leads to a preoccupation with drug procurement and an aberrant pattern of use. The drug use is frequently associated with negative consequences.

Tolerance and dependence are physiological phenomena, are expected with the continued administration of opioids, and should not deter physicians from their appropriate use. Before increasing the opioid dose due to a presumption of physiologic tolerance, the physician should review other possible causes for the decline in analgesic effect. Consideration should be given to possible new psychological stressors or an increase in the activity of the nociceptive pathways. Other possibilities include new pathology, low testosterone level that impedes delivery of opioids to the central nervous system, drug diversion, or abusive use of the medication.

The use of opioids is well accepted in treating cancer pain, where nociceptive mechanisms are generally present due to ongoing tissue destruction, expected survival may be short, and symptomatic relief is emphasized more than functional outcomes. In chronic non-malignant pain, by contrast, tissue destruction has generally ceased, meaning that central and neuropathic mechanisms frequently overshadow nociceptive processes. Expected survival in chronic pain is relatively long and return to a high-level of function is a major goal of treatment. Therefore, approaches to pain developed in the context of malignant pain may not be transferable to chronic non-malignant pain. Opioids are generally not the best choice of medication for controlling neuropathic pain. Tricyclics, SNRIs, and anticonvulsants should be tried before considering opioids for neuropathic pain.

In most cases, analgesic treatment should begin with acetaminophen, aspirin, and NSAIDs. While maximum efficacy is modest, they may reduce pain sufficiently to permit adequate function. When these drugs do not satisfactorily reduce pain, medications specific to the diagnosis should be used, (e.g. neuropathic pain medications as outlined in Medications section).

Most studies show that only around 50% of patients tolerate opioid side effects and receive an acceptable level of pain relief. Depending on the diagnosis and other agents available for treatment the incremental benefit can be small ([Cepeda M 2007](#CepedaM2007); [Landau C 2007](#LandauC2007), [Naliboff B 2010).](#NaliboffB2010) Patients should have a thorough understanding of the need to pursue many other pain management techniques in addition to medication use in order to function with chronic pain. They should also be thoroughly aware of the side effects and how to manage them. Common side effects are drowsiness, constipation, nausea and possible testosterone decrease with longer term use.

Physicians should be aware that deaths from unintentional drug overdoses exceed the number of deaths from motor vehicle accidents in the US. Most of these deaths are due to the use of opioids, usually in combination with other respiratory depressants such as alcohol or benzodiazepines ([Okie, 2010](#Okie2010)). The prevalence of drug abuse in the population of patients undergoing pain management varies according to region and other issues. A recent study indicated that ¼ of patients being monitored for chronic opioid use have abused drugs occasionally, and ½ of those have frequent episodes of drug abuse ([Manchikanti L 2001](#ManchikantiL2001); [2007](#Manchikanti2007)). Eighty per-cent of patients admitted to a large addiction program reported that their first use of opioids was from prescribed medication ([Cicero 2008](#Cicero2008)).

Choice of Opioids:

There is no evidence that one long-acting opioid is more effective than another, nor more effective than other types of medications, in improving function or pain ([Chou R 2008](#ChouR2008)). There is some evidence that long-acting oxycodone (Dazidox, Endocodone, ETH-oxydose, Oxycontin, Oxyfast, OxyIR, Percolone, Roxicodone) and oxymorphone have equal analgesic effects and side effects, although the milligram dose of oxymorphone (Opana) is ½ that of oxycodone ([Hale M 2005](#HaleM2005)). There is no evidence that long-acting opioids are superior to short-acting opioids for improving function or pain or causing less addiction ([Chou R 2008](#ChouR2008)). Long-acting opioids are generally preferred for chronic opioid management as they are thought to result in a less pronounced euphoria state and are thus less likely to lead to addiction. They may result in better tolerance for the sedative and cognitive effects of opioids. However, due to the lack of evidence physicians may choose to use short-acting opioids in some patients. Long-acting opioids should not be used for the treatment of acute, sub-acute or post-operative pain, as this is likely to lead to drug dependence and difficulty tapering the medication. Additionally, there is a potential for respiratory depression to occur. When choosing longer acting opioids for chronic pain management it is reasonable to consider cost given the lack of superiority profiles for one medication over another. The Food and Drug Administration (FDA) requires that manufacturers develop Risk Evaluation and Mitigation Strategies (REMS ) for most opioids. Physicians should carefully review the plans or educational materials provided under this program.

Addiction and abuse potentials of commonly prescribed opioid drugs may be estimated in a variety of ways, and their relative ranking may depend on the measure which is used. Hydrocodone is the most commonly prescribed opioid in the general population, and is one of the most commonly abused opioids in the population; however, the abuse rate per 1000 prescriptions is lower than the corresponding rates for extended release oxycodone, hydromorphone (Dilaudid, Palladone), and methadone. Extended release oxycodone appears to be the most commonly abused opioid, both in the general population and in the abuse rate per 1000 prescriptions ([Cicero T 2007](#CiceroT2007)). Tramadol, by contrast, appears to have a lower abuse rate than for other opioids ([Cicero T 2005](#CiceroT2005)). Newer drug formulations such as oxymorphone, have been assumed to be relatively abuse-resistant, but their abuse potential is unknown and safety cannot be assumed in the absence of sound data ([Butler S 2006](#ButlerS2006)).

Tapentadol (Nucynta) is a new mu opioid agonist which also inhibits serotonin and norepinephrine reuptake activity. It is currently available in an intermediate release formulation and may be available as extended release if FDA approved. Due to its dual activity it can cause seizures or serotonin syndrome, particularly when taken with other SSRIs, SNRIs, tricyclics, or MAO inhibitors. It has not been tested in patients with severe renal or hepatic damage. It has similar opioid abuse issues as other opioid medication; however, it is promoted as having fewer GI side effects, such as constipation. Further studies may be needed to verify this finding ([Sloan P 2010](#SloanP2010)). There is good evidence that extended release tapentadol is more effective than placebo and comparable to oxycodone [(Buynak R 2010](#BuynakR2010)). In that study the percent of patients who achieved 50% or greater pain relief was placebo, 18.9%, tapentadol, 27.0%, and oxycodone, 23.3% There is some evidence that tapentadol can reduce pain to a moderate degree in diabetic neuropathy, average difference 1.4/10 pain scale, with tolerable adverse effects ([Schwartz S 2011](#SchwartzS2011)). Tapentadol is not recommended as a first line opioid for chronic, subacute or acute pain due to the cost, lack of superiority over other analgesics and need for further testing to assess GI effects in comparison to other medications. It may be appropriate for patients who cannot tolerate other opioids due to GI side effects.

Methadone requires special precautions. It may cause cardiac arrhythmias due to QT prolongation and has been linked with a greater number of deaths due to its prolonged half life ([Chou, Fanciullo, R 2009](#ChouFanciullo2009)). Propoxyphene (Darvon, Davon-N, PP-Cap) has been withdrawn from the market due to cardiac effects including arrhythmias.

Fentanyl (Actiq, Duragesic, Fentora, Sublimaze) is not generally recommended for use with musculoskeletal chronic pain patients. It has been associated with a number of deaths and has high addiction potential. Fentanyl should never be used transbuccally in this population.

Meperidine (Demerol) should not be used for chronic pain; it and its active metabolite, normeperidine, present a serious risk of seizure and hallucinations. It is not a preferred medication for acute pain as its analgesic effect is similar to codeine.

Buprenorphine (Suboxone, Subutex) may be used for opioid addiction or habituation treatment in patients with chronic pain, it is not recommended for most chronic pain patients due to methods of administration, reports of euphoria in some patients, and lack of proof for improved efficacy in comparison with other opioids. It may be appropriate for some patients at high risk for addiction and should be used in consultation with an addiction medicine specialist.

Doses of opioids in excess of 120 mg morphine equivalent have been observed to be associated with increased duration of disability, even when adjusted for injury severity in injured workers with acute low back pain and thus any use above 120 mg should be very closely monitored ([Webster B 2007](#WebsterB2007); [Franklin G 2008)](#FranklinG2008). Doses in excess of 200 mg should be avoided [(National Opioid Use Guideline Group [NOUGG] 2010)](#NOUGG2010). Higher doses are more likely to be associated with hypo-gonadism and the patient should be informed of this risk (NOUGG, 2010). Higher doses of opioids also appear to contribute to the euphoric effect.

Health care professionals and their patients must be particularly conscientious regarding the potential dangers of combining over-the-counter acetaminophen with prescription medications that also contain acetaminophen. Opioid and acetaminophen combination medication are limited due to the acetaminophen component. Total acetaminophen dose per day should not exceed 4 grams per 24-hour period due to possible liver damage.

Physiologic Responses to Opiates: Physiologic responses to opiates are influenced by variations in genes which code for opiate receptors, cytochrome P450 enzymes, and catecholamine metabolism. Interactions between these gene products significantly affect opiate absorption, distribution, and excretion. Hydromorphone, oxymorphone, and morphine are metabolized through the glucuronide system. Other opioids generally use the cytochrome P450 system [(Smith, 2009](#Smith2009)). Allelic variants in the mu opiate receptor may cause increased analgesic responsiveness to lower drug doses in some patients. The genetic type can predict either lower or higher needs for opioids. For example, at least 10% of Caucasians lack the CYP450 2D6 enzyme that converts codeine to morphine ([Kosarac, 2009](#Kosarac2009)). In some cases genetic testing for cytochrome P450 type may be helpful. When switching patients from codeine to other medications assume the patient has little or no tolerance to opioids. Many gene-drug associations are poorly understood and of uncertain clinical significance; the treating physician needs to be aware of the fact that the patient’s genetic makeup may influence both the therapeutic response to drugs and the occurrence of adverse effects.

Physicians can expect chronic opioid patients to experience more pain, and require higher doses of opioids, peri-operatively than pre-operatively [(Fishbain D 2009)](#FishbainD2009).

Risk Factors: Consultation or referral to a pain specialist should be considered when the pain persists but the underlying tissue pathology is minimal or absent and correlation between the original injury and the severity of impairment is not clear. Consider consultation if suffering and pain behaviors are present and the patient manifests risk behaviors described below, or when standard treatment measures have not been successful or are not indicated.

A psychological consultation including psychological testing (with validity measures) is indicated for all chronic pain patients as these patients are at high risk for unnecessary procedures and treatment and prolonged recovery.

Many behaviors have been found related to prescription-drug abuse patients. None of these are predictive alone, and some can be seen in patients whose pain is not under reasonable control; however, the behaviors should be considered warning signs for higher risk of abuse or addiction by physicians prescribing chronic opioids ([Webster, 2010](#Webster2010Op)).

The following behaviors frequently seen in prescription drug - abusing patients should be considered warning signs for addiction and patients that are at high-risk when placed on chronic opioids. Consultation with an addiction specialist may be useful when patients present with these symptoms:

* + Unusual knowledge of controlled substances;
	+ Request for specific controlled substances or claims of allergy or ineffectiveness to other medications;
	+ Demanding assessment or medication after usual clinic hours;
	+ Requesting more refills than scheduled, “losing” drugs;
	+ Signs of mood disorders or other psychiatric conditions;
	+ Physical signs of drug abuse;
	+ No interest in their diagnosis, fails to keep other treatment or consultation appointments;
	+ Feigns or exaggerates physical problems;
	+ Pressures physician by eliciting sympathy, guilt or direct threats ([Webster L 2010](#Webster2010Op)).
* Subjective complaints exceed objective findings.
* Attempts to transfers care after a doctor refuses to fill prescription(s) for habit forming medication.

In one study four specific behaviors appeared to identify patients at risk for current substance abuse: increasing doses on their own, feeling intoxicated, early refills, and oversedating oneself. A positive test for cocaine also appeared to be related ([Fleming, 2008).](#Fleming2008)

Recommendations for Opioid Use: When considering opioid use for moderate to moderately severe chronic pain, a trial of opioids must be accomplished as described below and the patient must have failed other chronic pain management regimes. Physicians should complete the education recommended by the FDA, risk evaluation and mitigation strategies (REMS) provided by drug manufacturing companies.

* + - 1. General Indications – There must be a clear understanding that opioids are to be used for a limited term as a trial (see trial indications below). The patient should have a thorough understanding of all of the expectations for opioid use. The level of pain relief is expected to be relatively small, 2 to 3 points on a VAS pain scale, although in some individual patients it may be higher. For patients with a high response to opioid use, care should be taken to assure that there is no abuse or diversion occurring. The physician and patient must agree upon defined functional goals as well as pain goals. If functional goals are not being met the opioid trial should be reassessed. The full spectrum of side effects should be reviewed. The contract signed by the patient must clarify under what term the opioids will be tapered. See section iii. D below.
			2. Therapeutic Trial Indications – A therapeutic trial of opioids should not be employed unless the patient has begun multi-disciplinary pain management.

			Chronic use of opioids should not be prescribed until the following have been met:
				1. The failure of pain management alternatives by a motivated patientincluding active therapies, cognitive behavioral therapy, pain self-management techniques, and other appropriate medical techniques.
				2. Physical and psychological and/orpsychiatric assessment including a full evaluation for alcohol or drug addiction, dependenceor abuse, performed by two specialists including the authorized treating physician and a specialist with expertise in chronic pain. The patient should be stratified as to low, medium or high risk for abuse based on behaviors and prior history of abuse. High risk patients are those with active substance abuse of any type or a history of prescription opioid abuse. These patients should generally not be placed on chronic opioids. If it is deemed appropriate to do so, physician addiction specialists should be monitoring the care. Patients with a past history of substance abuse or other psychosocial risk factors should be co-managed with a physician addiction specialist ([Webster, 2010](#Webster2010)).
				3. Urine drug screening for substances of abuse and substances currently prescribed. Clinicians should keep in mind that there are an increasing number of deaths due to the toxic misuse of opioids with other medications and alcohol. Drug screening is a mandatory component of chronic opioid management. It is appropriate to screen for alcohol use and have a contractual policy regarding alcohol use during chronic opioid management as alcohol use in combination with opioids is more likely to contribute to death or accidents than marijuana.
				4. Physician PrescriptionDrug Monitoring Program review
				5. Informed, written, witnessed consent by the patient including the aspects noted above.
				6. The trial, usually with a short-acting agent first, should document sustained improvement of pain control, at least a 30% reduction, and of functional status, including return-to-work and/or increase in activities of daily living [Farrar, J. T., 2003](#FarrarJT2003); [Farrar, J. T., 2000](#FarrarJT2000)). Frequent follow-up at least every 2 to 4 weeks may be necessary to titrate dosage and assess clinical efficacy.
			3. On-Going, Long-Term Management after a successful trial should include:
				1. Prescriptions from a single practitioner;
				2. Ongoing review and documentation of pain relief, functional status, appropriate medication use, and side effects;
				3. Ongoing effort to gain improvement of social and physical function as a result of pain relief;
				4. Contract detailing the following:
* Side effects anticipated from the medication;
* Requirement to continue active therapy;
* Need to achieve functional goals including return to work for most cases;
* Reasons for termination of opioid management, referral to addiction treatment ([Rolfs R 2010](#RolfsR2010)), or for tapering opioids (tapering is usually over 30 days). Examples to be included in the contract include, but are not limited to:
	+ Diversion of medication
	+ Lack of functional effect at higher doses
	+ Non-compliance with other drug use
	+ Drug screening showing use of drugs outside of the prescribed treatment or evidence of non-compliant use of prescribed medication
	+ Requests for prescriptions outside of the defined time frames
	+ Lack of adherence identified by pill count, excessive sedation, or lack of functional gains
	+ Excessive dose escalation with no decrease in use of short-term medications ([NOUGG, 2010](#NOUGG2010); [Chou, Fanciullo, 2009](#ChouFanciullo2009)).
	+ Apparent hyperalgesia

 Contracts should be written at a 6th grade reading level to accommodate the majority of patients ([Roskos S 2007](#RoskosS2007)).

* + - * 1. Use of drug screening initially, randomly at least once a year and as deemed appropriate by the prescribing physician, [(Rolfs R 2010](#RolfsR2010); [NOUGG, 2010](#NOUGG2010); [Chou R, Fanciullo, 2009](#ChouFanciullo2009)). Drug screening is suggested for any patients who have been receiving opioids for 90 days ([Washington State, Agency Medical Directors Group [AMDG], 2010)](#WashingtonAMDG2010). A discussion regarding how screens positive for marijuana or alcohol will be handled should be included in the opioid contract. The concept of opioid misuse encompasses a variety of problems distinct from the development of addiction, such as nonmedical use, diversion, consultation with multiple prescribers, and unintentional overdose.

				It appears that users of prescription opioids who also experienced depression or anxiety disorders were more likely to abuse opioids [(Edlund, M, Steffick, 2007).](#EdlundSteffick2007) Urine testing, when included as one part of a structured program for pain management, has been observed to reduce abuse behaviors in patients with a history of drug misuse [(Wiedemer NL 2007](#WiedemerNL2007); [Starrels J 2010).](#StarrelsJ2010) Clinicians should keep in mind that there are an increasing number of deaths due to the toxic misuse of opioids with other medications and alcohol. Drug screening is a mandatory component of chronic opioid management. It is appropriate to screen for alcohol use and have a contractual policy regarding alcohol use during chronic opioid management as alcohol use in combination with opioids is more likely to contribute to death or accidents than marijuana***.***

				Physicians should recognize that occasionally patients may use non-prescribed substances because they have not obtained sufficient relief on the prescribed regime.

				Although drug screens done for chronic pain management should not be routinely available to employers, as screens are part of the treatment record to which employers have limited access, patients should be aware that employers might obtain the records through attorneys or the insurer.
				2. Use limited to two oral opioids: a long-acting opioid for maintenance of pain relief and a short-acting opioid for limited rescue use when pain exceeds the routine level. If more than two opioids are being considered for long-term use, a second opinion from specialist who is Board Certified in Addiction, or Pain Medicine is strongly recommended. Short-acting “rescue” medications should be used with caution in patients with a potential for abuse ([Chou, R, Fanciullo, 2009](#ChouFanciullo2009)). Buccal-delivered medications should not be used in this population. Transdermal medication use is generally not recomended.
				3. Use of acetaminophen-containing medications in patients with liver disease should be limited, including over the counter medications. Acetaminophen dose should not exceed 4 grams per day for short-term use or 250 mg/day for long-term use in healthy patients ([Washington State AMDG, 2010](#WashingtonAMDG2010)). A safer chronic dose may be 1800mg/day.
				4. Continuing review of overall therapy plan with regard to non opioid means of pain control and functional status.
				5. Monitoring of behavior for signs of possible substance abuse indicating an increased risk for addiction and possible need for consultation with an addiction specialist
				6. Tapering of opioids may be necessary due to the development of hyperalgesia, decreased effects from an opioid, lack of compliance with the opioid contract, or intolerance of side effects. Some patients appear to experience allodynia or hyperalgesia on chronic opioids. This premise is supported by a study of normal volunteers who received opioid infusions and demonstrated an increase in secondary hyperalgesia [(NOUGG, 2010)](#NOUGG2010). This is thought to be relatively uncommon and more frequently associated with methadone. Options for treating this include withdrawing the patient from opioids and reassessing their condition. In some cases the patient will improve when off of the opioid. In other cases another opioid may be substituted ([Chou R, Fanciullo, 2009](#ChouFanciullo2009); [Fishbain D 2009](#FishbainD2009); [Quigley C [Cochrane] 2004).](#QuigleyC2004)
				7. Inpatient treatment may be required for addiction or opioid tapering in complex cases. Refer to Section F.6, Interdisciplinary Rehabilitation Programs for detailed information on inpatient criteria.
			1. Relative Contraindications – Extreme caution should be used in prescribing controlled substances for workers with one or more “relative contraindications”: Consultation with a pain or addiction specialist may be useful in these cases.
				1. History of alcohol or other substance abuse, or a history of chronic, benzodiazepine use
				2. Sleep apnea – if patient has symptoms of sleep apnea diagnostic tests should be pursued prior to chronic opioid use.
				3. Off work for more than six months with minimal improvement in function from other active therapy.
				4. Severe personality disorder or other known severe psychiatric disease**.**
			2. General Contraindications ([Ballantyne JC 2007](#BallantyneJC2007); [Edlund M, Steffick, 2007;](#EdlundSteffick2007) [Edlund M, Sullivan, 2007](#EdlundMJSullivan2007); [Webster L 2010](#Webster2010Op)): The following are high risk warning signs for possible drug abuse or addiction. Patients with these findings should have a consultation by a pain and or addiction specialist.
				1. Active alcohol or other substance abuse.
				2. Untreated mood or psychotic disorders (e.g., depression).
				3. Decreased physical or mental function with continued opioid use.
				4. Addictive behaviors. Warning signs include but are not limited to:

1) Preoccupation with drugs;

2) Refusal to participate in medication taper;

3) Reporting that nothing but a specific opioid works;

4) Strong preference for short-acting over long-acting opioids;

5) Use of multiple prescribers and pharmacies;

6) Use of street drugs or other patient’s drugs;

7) Not taking medications as prescribed;

8) Loss of medications more than once; and/or

9) Criminal behaviors to obtain drugs, i.e., forged prescriptions.

* + - 1. Dosing and Time to Therapeutic Effect – Oral route is the preferred route of analgesic administration because it is the most convenient and cost-effective method of administration. Transbuccal administration should be avoided. When patient’s dosage exceeds 120 mg of morphine per day and/or the patient is sedentary with minimal function, consideration should be given to lowering the dosage. Consultation may be necessary. When patients cannot take medications orally, rectal and transdermal routes should be considered because they are also relatively noninvasive. However, careful consideration should be given to the possible abuse potential of these forms of administration.
			2. Major Side Effects – There is great individual variation in susceptibility to opioid-induced side effects and clinicians should monitor for these potential side effects. Common initial side-effects include nausea, vomiting, drowsiness, unsteadiness, and confusion. Occasional side-effects include dry mouth, sweating, pruritus, hallucinations, and myoclonus. Rare side effects include respiratory depression and psychological dependence. Constipation and nausea/vomiting are common problems associated with long-term opioid administration and should be anticipated, treated prophylactically, and monitored constantly. Stool softeners, laxatives and increased dietary fluid may be prescribed. Chronic sustained release opioid use is associated with decreased testosterone in males and females and estradiol in pre-menopausal females. Patients should be asked about changes in libido, sexual function, and fatigue ([Rhodin A 2010](#RhodinA2010); [Chou R, Fanciullo, 2009](#ChouFanciullo2009)).
			3. Sedation - Driving and other tasks – Although some studies have shown that patients on chronic opioids do not function worse than patients not on medication, caution should be exerted and patients should be counseled never to mix opioids with the use of alcohol or other sedating medication. When medication is increased or trials are begun patients should not drive for at least 5 days ([Chou R, Fanciullo, 2009](#ChouFanciullo2009); [NOUGG, 2010;](#NOUGG2010) “[painedu.org”, 2010](#Paineduorg2010)). Chronic untreated pain and disordered sleep can also impair driving abilities.
			4. Drug Interactions – Patients receiving opioid agonists should not be given a mixed agonist-antagonist such as (pentazocine (Talacen, Talwin),butorphanol (Stadol) because doing so may precipitate a withdrawal syndrome and increase pain.

			All sedating medication, especially benzodiazepines should be avoided or limited to very low doses. Over the counter medications such as antihistamines, diphenhydramine, and prescription medications such as hydroxyzine (Anx, Atarax, Atazine, Hypam, Rezine, Vistaril) should be avoided. Alcohol should not be used.
			5. Recommended Laboratory Monitoring– Primary laboratory monitoring is recommended for acetaminophen/aspirin/NSAIDs combinations (renal and liver function, blood dyscrasias), although combination opioids are not recommended for long-term use. Morphine and other medication may require renal testing and other screening.
			6. Sleep Apnea Testing- Both obstructive and central sleep apnea is likely to be exaggerated by opioid use or may occur secondary to higher dose chronic opioid use and combination medication use, especially benzodiazepines and sedative hypnotics. Patients should be questioned about sleep disturbance and family members or sleeping partners questioned about loud snoring or gasping during sleep. If present, qualified sleep studies and sleep medicine consultation should be obtained. Portable sleep monitoring units are generally not acceptable for diagnosing primary central sleep apnea. Type 3 portable units with 2 airflow samples and a 02 saturation device may be useful for monitoring respirator depression secondary to opioids although there are no studies on this topic ([*Mason: Murray and Nadel’s,* 2010](#MasonMurrayNadel2010))
			7. Regular consultation of the Prescription Drug Monitoring Program (PDMP) – Physicians should review their patient on the system whenever drug screens are done. This information should be used in combination with the drug screening results, functional status of the patient and other laboratory findings to review the need for treatment and level of treatment appropriate for the patient. There is a separate billing code created by the DOWC to cover this service. Refer to Rule 18, Medical Fee Schedule.
			8. Addiction – If addiction occurs, patients may require treatment, Refer to treatment section. After detoxification they may need long-term treatment with naltrexone (Depade, ReVia), an antagonist which can be administered in a long-acting form or buprenorphine which requires specific education per the DEA.
			9. Potentiating Agents – There is some evidence that dextromethorphan does not potentiate the effect of morphine opioids and therefore is not recommended to be used with opioids ([Galer B 2005](#GalerB2005)).
		1. Skeletal Muscle Relaxants**:** are most useful for acute musculoskeletal injury or exacerbation of injury. Chronic use of benzodiazepines or any muscle relaxant is not recommended due to their habit-forming potential, seizure risk following abrupt withdrawal, and documented contribution to deaths of patients on chronic opioids due to respiratory depression.
			1. Baclofen (intrathecal).
				1. Description – May be effective due to stimulation of Gamma Aminobutyric Acid (GABA) receptors.
				2. Indications –Pain from muscle rigidity. As of the time of this guideline writing, formulations of baclofen injection have been FDA approved for the management of severe spasticity of a spinal cord or cerebral origin.
				3. Side Effects – exacerbation of psychotic disorders, may precipitate seizures in epileptics, dry mouth, and sexual dysfunction.
				4. Recommended Laboratory Monitoring – Renal and hepatic function.
			2. Cyclobenzaprine (Amrix, Fexmid, Flexeril).
				1. Description – Structurally related to tricyclics.
				2. Indications – Acute or exacerbated chronic pain associated with muscle spasm. As of the time of this guideline writing, formulations of this drug are FDA approved as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. It should only be used for short periods (2 to 3 weeks) because of lack of evidence for effectiveness with prolonged use.
				3. Major Contraindications – Cardiac dysrhythmias
				4. Dosing and Time to Therapeutic Effect – Variable, onset of action is 1 hour.
				5. Major Side Effects – Sedation, anticholinergic, blurred vision. Patients should also be monitored for suicidal ideation and drug abuse.
				6. Drug Interactions – Contraindicated for use with MAO inhibitors; interacts with tramadol, duloxetine, escitalopram, and fluoxetine. Likely interactions with other ssri’s and snri’s drug interactions are similar to those for tricyclics. Refer also to tricyclics.
				7. Recommended Laboratory Monitoring – Hepatic and renal function.
			3. Carisoprodol (Soma, Soprodal, Vanadom). This medication should not be used in chronic pain patients due to its addictive nature secondary to the active metabolite meprobamate ([NOUGG, 2010](#NOUGG2010)).
			4. Metaxalone (Skelaxin).
				1. Description – Central acting muscle relaxant.
				2. Indications – Muscle spasm. As of the time of this guideline writing, formulations of metaxalone have been FDA approved as an adjunct to rest, physical therapy and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions.
				3. Major Contraindications – significantly impaired renal or hepatic disease, pregnancy, and disposition to drug induced hemolytic anemia.
				4. Dosing and Time to Therapeutic Effect – Onset of action 1 hour.
				5. Major Side Effects – sedation, hematologic abnormalities
				6. Drug Interactions – other sedating drugs (e.g. opioids, benzodiazepines)
				7. Recommended Laboratory Monitoring – Hepatic Function, CBC
			5. Tizanidine (Zanaflex).
				1. Description – Alpha 2 adrenergic agonist.
				2. Indications – Spasticity, musculoskeletal disorders. As of the time of this guideline writing, formulations of tizanidine have been FDA approved for the management of spasticity.
				3. Major Contraindications – Concurrent use with ciprofloxacin (Cipro, Proquin) or fluvoxamine (Luvox); orhepatic disease.
				4. Dosing and Time to Therapeutic Effect – 4 mg/day orally and gradually increase in 2-4 mg increments on an individual basis over 2 to 4 weeks; maintenance, 8 mg orally every 6 to 8 hr (max dose 36 mg/day).
				5. Major Side Effects – Hypotension, sedation, hepatotoxicity, hallucinations and psychosis, dry mouth.
				6. Drug Interactions – Alcohol can increase sedation, concurrent use with ciprofloxacin or fluvoxamine contraindicated. Several other medications increase tizanidine plasma concentrations (e.g. oral contraceptives, verapamil, and cimetidine). Use with caution with other alpha agonists, and other antihypertensives as they may increase the risk of hypotension.
				7. Laboratory Monitoring – Hepatic function, blood pressure.
		2. Topical Drug Delivery:
			1. Description – Topical medications, such as lidocaine and capsaicin, may be an alternative treatment for neuropathic disorders and is an acceptable form of treatment in selected patients.
			2. Indications – Neuropathic pain for most agents. Episodic use of NSAIDs and salicylates for joint pain. Patient selection must be rigorous to select those patients with the highest probability of compliance. Many patients do not tolerate the side effects for some medication or the need for frequent application.
			3. Dosing and Time to Therapeutic Effect – All topical agents should be prescribed with strict instructions for application and maximum number of applications per day to obtain the desired benefit and avoid potential toxicity. There is no evidence that topical agents are more or less effective than oral medications. For most patients, the effects of long-term use are unknown and thus may be better used episodically.
			4. Side Effects – Localized skin reactions may occur, depending on the medication agent used.
			5. Topical Agents

a) Capsaicin –As of the time of this guideline writing, formulations of capsaicin have been FDA approved for management of pain associated with post-herpetic neuralgia.Capsaicin offers a safe and effective alternative to systemic NSAID therapy. Although it is quite safe, effective use of capsaicin is limited by the local stinging or burning sensation that typically dissipates with regular use, usually after the first 7 to 10 days of treatment. Patients should be advised to apply the cream on the affected area with a plastic glove or cotton applicator and to avoid inadvertent contact with eyes and mucous membranes.

There is good evidence that low dose capsaicin (0.075%) applied 4 times per day will decrease pain up to 50% [(Derry S [Cochrane] 2009)](#DerryS2009). There is also good evidence that a high dose (8%) capsaicin patch applied for 60 minutes can decrease post herpetic neuralgic pain for 3 months and thus may be useful in other chronic neuropathies ([Derry S [Cochrane] 2009](#DerryS2009); [Webster, 2010](#Webster2010Cap)). The high dose patch is preceded by the application of a lidocaine patch and many patients require a schedule II opioid immediately after the treatment ([Webster LR 2010](#Webster2010Cap)).

b) Ketamine and Tricyclics – Topical medications, such as the combination ofketamine and amitriptyline have been proposed as an alternative treatment for neuropathic disorders including CRPS. A study using a 10% concentration showed no signs of systemic absorption ([Finch P 2009](#FinchP2009)). This low-quality study demonstrated decreased allodynia at 30 minutes for some CRPS patients. However, as of the time of this guideline writing, neither tricyclic nor ketamine topicals are FDA approved for topical use in neuropathic pain. Furthermore, there is good evidence that neither 2% topical amitriptyline nor 1% topical ketamine reduces neuropathic pain syndromes ([Lynch M 2005).](#LynchM2005) Low dose topical ketamine and topical amitriptyline are not recommended tobe used in patients with neuropathic pain syndromes, including CRPS. Physiologically, it is possible that topical tricyclics and a higher dose of ketamine could have some effect on neuropathic pain. The use of topical tricyclics and/or ketamine should be limited to patients with neuritic and/or sympathetically mediated pain with documented supporting objective findings such as allodynia and/or hyperalgesia. Continued use of these agents beyond the initial prescription requires documentation of effectiveness, including functional improvement, and/or decreased use of other medications, particularly decreased use of opiates or other habituating medications.

c) Lidocaine – As of the time of this guideline writing formulations of lidocaine (patch form) have been FDA approved for pain associated with post-herpetic neuralgia.Evidence is mixed for long-term use of lidocaine topically. Physicians should always take into account the blood level that may be achieved with topical use as toxic levels have been reported ([Khaliq W 2007](#KhaliqW2007)). There is some evidence that a 5% lidocaine patch may be used as a secondary option for patients with focal neuropathic pain ([Meier T 2003](#MeierT2003)). A 30 to 50% pain reduction may be achieved in those who tolerate the patch ([Meier T 2003](#MeierT2003)). Up to three patches may be used simultaneously for twelve hours per day. It should be applied only to intact skin.Metered dose 8% pump sprays have also been used and usually require a three times per day reapplication. There is some evidence that the 8% sprays are effective for short-term, 2 week use ([Kanai A 2009](#KanaiA2009)). However, the effects of long-term use are unknown.

d) Topical Salicylates and Nonsalicylates –have been shown to be effective in relieving pain in acute musculoskeletal conditions and single joint osteoarthritis. Topical salicylate and nonsalicylates achieve tissue levels that are potentially therapeutic, at least with regard to COX inhibition. Other than local skin reactions, the side effects of therapy are minimal, although not non-existent and the usual contraindications to use of these compounds needs to be considered. Local skin reactions are rare and systemic effects were even less common. Their use in patients receiving warfarin therapy may result in alterations in bleeding time. Overall, the low level of systemic absorption can be advantageous; allowing the topical use of these medications when systemic administration is relatively contraindicated such as is the case in patients with hypertension, cardiac failure, or renal insufficiency [(DOWC [Cumulative Trauma MTG], 2010)](#DOWCCumulativeTrauma2010). There is good evidence that diclofenac gel (Voltaren, Solaraze) reduces pain and improves function in mild-to-moderate hand osteoarthritis ([Altman R 2009](#AltmanR2009)). Diclofenac gel has been FDA approved for acute pain due to minor strains, pains, and contusions; and for relief of pain due to osteoarthritis of the joints amenable to topical treatment, such as those of the knees and hands ([DOWC [Cumulative Trauma MTG], 2010).](#DOWCCumulativeTrauma2010)

d) Other Compounded Topical Agents: At the time this guideline was written, no studies identified evidence for the effectiveness of compounded topical agents other than those recommended above. Therefore, other compounded topical agents are not generally recommended. In rare cases they may be appropriate for patients who prefer a topical medication to chronic opioids or have allergies or side effects from other more commonly used oral agents.

f) Prior authorization is required for all agents that have not been recommended above. Continued use requires documentation of effectiveness including functional improvement and/or decrease in other medications.

* + 1. Tramadol (Ultram)
			1. Description – An opioid partial agonist that does not cause GI ulceration, or exacerbate hypertension or congestive heart failure. It also inhibits the reuptake of norepinephrine and serotonin which may contribute to its pain relief mechanism. Side effects similar to opioid opioid side effects and may limit its use. They include nausea, sedation and dry mouth.
			2. Indications – Mild to moderate pain relief. As of the time of this guideline writing, formulations of tramadol has been FDA approved for management of moderate to moderately severe pain in adults. This drug has been shown to provide pain relief equivalent to that of commonly prescribed NSAIDs ([Duehmke RM [Cochrane], 2006](#DuehmkeRM2006)). There is some evidence that it alleviates neuropathic pain following spinal cord injury ([Norrbrink C 2009).](#NorrbrinkC2009) However, given the effectiveness of other drug classes for neuropathic pain tramadol, should not be considered a first line medication. It may be useful for patients who cannot tolerate tricyclic antidepressants.
			3. Contraindications – Use cautiously in patients who have a history of seizures or who are taking medication that may lower the seizure threshold, such as MAO inhibitors, SSRIs, and TCAs. Not recommended in those with prior opioid addiction. Has been associated with deaths in those with an emotional disturbance or concurrent use of alcohol or other opioids. Significant renal and hepatic dysfunction requires dosage adjustment.
			4. Side Effects – May cause impaired alertness or nausea. This medication has physically addictive properties and withdrawal may follow abrupt discontinuation.
			5. Drug Interactions –Opioids, sedating medications, any drug that affects serotonin and/or norepinephrine (e.g. SNRI’S, SSRI’S, MAOI’S, and TCA’S).
			6. Laboratory Monitoring – Renal and hepatic function.
		2. Other Agents:
			1. Glucosamine:

			There is good evidence that glucosamine does not improve pain related disability in those with chronic low back pain and degenerative changes on radiologic studies, therefore it is not recommended for chronic lower spinal or non-joint pain ([Wilkens P 2010](#WilkensP2010)). For chronic pain related to joint osteoarthritis see specific extremity guidelines. Glucosamine should not be combined with chondroitin as it is ineffective.
	1. ORTHOTICS/PROSTHETICS/EQUIPMENTDevices and adaptive equipment may be necessary in order to reduce impairment and disability, to facilitate medical recovery, to avoid re-aggravation of the injury, and to maintain maximum medical improvement. Indications would be to provide relief of the industrial injury, prevent further injury and control neurological and orthopedic injuries for reduced stress during functional activities. In addition, they may be used to modify tasks through instruction in the use of a device or physical modification of a device. Equipment needs may need to be reassessed periodically. Refer to F.12, Return-to-work for more detailed information.

	Equipment may include high and low technology assistive devices, computer interface or seating, crutch or walker training, and self-care aids. It should improve safety and reduce risk of re-injury. Standard equipment to alleviate the effects of the injury on the performance of activities of daily living may vary from simple to complex adaptive devices to enhance independence and safety. Certain equipment related to cognitive impairments may also be required.

	Ergonomic modifications may be necessary to facilitate medical recovery, to avoid re-aggravation of the injury, and to maintain maximum medical improvement. Ergonomic evaluations with subsequent recommendations may assist with the patients’ return-to-work. (Refer to Section E.6, Jobsite Evaluation for further information.)

	For chronic pain disorders, equipment such as foot orthoses may be helpful. The injured worker should be educated as to the potential harm from using a lumbar support for a period of time greater than which is prescribed. Harmful effects include de-conditioning of the trunk musculature, skin irritation, and general discomfort. Use of cervical collars is not recommended for chronic cervical myofascial pain. Special cervical orthosis and/or equipment may have a role in the rehabilitation of a cervical injury such as those injuries to a cervical nerve root resulting in upper extremity weakness or a spinal cord injury with some degree of paraparesis or tetraparesis. Use of such devices would be in a structured rehabilitation setting as part of a comprehensive rehabilitation program.

	Fabrication/modification of orthotics, including splints, would be used when there is need to normalize weight-bearing, facilitate better motion response, stabilize a joint with insufficient muscle or proprioceptive/reflex competencies, to protect subacute conditions as needed during movement, and correct biomechanical problems. Orthotic/prosthetic training is the skilled instruction (preferably by qualified providers) in the proper use of orthotic devices and/or prosthetic limbs.

	For information regarding specific types of orthotics/prosthetics/equipment, refer to individual medical treatment guidelines.
	2. PATIENT EDUCATIONPatients should be educated on their specific injury, assessment findings, and plan of treatment and encouraged to take an active role in establishing functional outcome goals. No treatment plan is complete without addressing issues of individual and/or group patient education as a means of prolonging the beneficial effects of rehabilitation, as well as facilitating self-management of symptoms and prevention of secondary disability.

	In some cases, educational intervention combined with exercises may achieve results comparable to surgical intervention for patients who have undergone previous surgery. There is some evidence that, for patients who had undergone previous surgery for disc herniation and continued to experience low back pain for at least one year, educational lectures and materials provided to the patients in conjunction with exercise programs yield similar results as indicated by Oswestry Disability scores to patients who had undergone posterolateral low back fusion. It should be noted that the rehabilitation program included individual and group discussions targeted to assuring patients that participation in ordinary activities would not cause harm. Treatment period was 25 hours per week for three weeks ([Brox JI 2010](#BroxJI2010)).

	Patient education is an interactive process that provides an environment where the patient not only acquires knowledge but also gains an understanding of the application of that knowledge. Therefore, patients should be able to describe and/or will need to be educated on:

a. The treatment plan;

b.Indications for and potential side effects of medications;

c**.** Their home exercise program;

d.Expected results of treatment;

e.Tests to be performed, the reasons for them and their results;

f.Activity restrictions and return-to-work status;

g.Home management for exacerbations of pain;

h. Procedures for seeking care for exacerbations after office hours;

i. Home self-maintenance program;

j. Patient responsibility to communicate with all medical providers and the employer;

k. Patient responsibility to keep appointments;

l. The importance of taking medications exactly as prescribed; and

m. Basic physiology related to patient’s diagnosis.

Educational efforts should also target family and other support persons, the case manager, the insurer, and the employer as indicated to optimize the understanding of the patient and the outcome. Professional translators should be provided for non-English speaking patients to assure optimum communication. All education, teaching, and instruction given to the patient should be documented in the medical record.

Effects of education weaken over time; continuing patient education sessions will be required to maximize the patient’s function. The effectiveness of educational efforts can be enhanced through attention to the learning style and receptivity of the patient. Written educational materials may reinforce and prolong the impact of verbal educational efforts. Overall, patient education should emphasize health and wellness, return-to-work and return to a productive life.

* Time to Produce Effect: Varies with individual patient.
* Frequency: At each visit.
	1. PERSONALITY/PSYCHOLOGICAL/PSYCHOSOCIAL INTERVENTIONPsychosocial treatment is a well-established therapeutic and diagnostic intervention with selected use in acute pain problems, and more widespread use in sub-acute and chronic pain populations. Psychosocial treatment is recommended as an important component in the total management of a patient with chronic pain and should be implemented as soon as the problem is identified.

	If a diagnosis consistent with the standards of the American Psychiatric AssociationDiagnostic Statistical Manual of Mental Disorders has been determined, the patient should be evaluated for the potential need for psychiatric medications. Use of any medication to treat a diagnosed condition may be ordered by the authorized treating physician or by the consulting psychiatrist. Visits for management of psychiatric medications are medical in nature and are not a component of psychosocial treatment. Therefore, separate visits for medication management may be necessary, depending upon the patient and medications selected.

	Psychosocial interventions include psychotherapeutic treatments for mental health conditions, as well as behavioral medicine treatments for patients without psychiatric conditions, but who may need to make major life changes in order to cope with pain or adjust to disability. Examples of these treatments include cognitive behavioral therapy, relaxation training, mindfulness training, and sleep hygiene training.

	The screening or diagnostic workup should have clarified and distinguished between pre-existing, aggravated, and/or purely causative psychological conditions. Therapeutic and diagnostic modalities include, but are not limited to, individual counseling, and group therapy. Treatment can occur within an individualized model, a multi-disciplinary model, or within a structured pain management program.

	A psychologist with a PhD, PsyD, EdD credentials, or a Psychiatric MD/DO may perform psychosocial treatments. Other licensed mental health providers or licensed health care providers with training in cognitive behavior therapy (CBT), or certified as CBT therapists working in consultation with a PhD, PsyD, EdD, or Psychiatric MD/DO; and with experience in treating chronic pain disorders in injured workers may also perform treatment.

	Cognitive behavioral therapy (CBT) refers to a group of psychological therapies that are sometimes referred to by more specific names, such as Rational Emotive Behavior Therapy, Rational Behavior Therapy, Rational Living Therapy, Cognitive Therapy, and Dialectic Behavior Therapy. Variations of CBT methods can be used to treat a variety of conditions, including chronic pain, depression, anxiety, phobias and PTSD. For patients with multiple diagnoses, more than one type of CBT might be needed. The CBT used in research studies is often “manualized CBT”, meaning that the treatment follows a specific protocol in a manual ([Thorn 2004](#Thorn2004)). In clinical settings, CBT may involve the use of standardized materials, but is also commonly adapted by a psychologist or psychiatrist to the patient’s unique circumstances. If the CBT is being performed by a non-mental health professional, a manual approach would be strongly recommended. CBT must be distinguished from neuropsychological therapies used to teach compensatory strategies to brain injured patients, which are also called “cognitive therapy.”

	It should be remembered that most clinical trials on CBT exclude subjects who have significant psychiatric diagnoses. Consequently, the selection of patients for CBT should include the following considerations. CBT is instructive and structured, using an educational model with homework to teach inductive rational thinking. Because of this educational model, a certain level of literacy is assumed for most CBT protocols. Patients who lack the cognitive and educational abilities required by a CBT protocol are unlikely to be successful. Further, given the highly structured nature of CBT, it is more effective when a patient’s circumstances are relatively stable. For example, if a patient is about to be evicted, is actively suicidal, or coming to sessions intoxicated, these matters will generally preempt CBT treatment for pain, and require other types of psychotherapeutic response. Conversely, literate patients whose circumstances are relatively stable, but catastrophize or cope poorly with pain or disability are often good candidates for CBT for pain. Similarly, literate patients whose circumstances are relatively stable, but who exhibit unfounded medical phobias are often good candidates for CBT for anxiety.

	There is good evidence that psychological interventions, especially CBT, are superior to no psychological intervention for chronic low back pain, and that self-regulatory interventions such as biofeedback and relaxation training may be equally effective ([Hoffman BM 2007](#HoffmanBM2007)). There is good evidence that 6 sessions of 1.5 hour group therapy focused on CBT skills improved function and alleviated pain in uncomplicated subacute and chronic low back pain patients ([Lamb SE 2010](#LambSE2010)). There is some evidence that CBT provided in seven two-hour small group sessions can reduce the severity of insomnia in chronic pain patients ([Currie SR 2000](#CurrieSR2000)).A Cochrane meta-analysis grouped very heterogenous behavioral interventions and concluded that there is good evidence that CBT may reduce pain and disability but the effect size was uncertain [(Eccleston C [Cochrane] 2009).](#EcclestonC2009) In total, the evidence clearly supports cognitive behavioral therapy and it should be offered to all chronic pain patents without other serious issues, as discussed above.

	CBT is often combined with active therapy in an interdisciplinary program formal or informal. It must be coordinated with a psychologist or psychiatrist. Cognitive behavioral therapy can be done in a small group or individually and the usual number of treatments varies between 8 and16 sessions.

	Before CBT is done, the patient must have a full psychological evaluation. The CBT program must be done under the supervision of a PhD, PsyD, EdD, or Psychiatric MD/DO.

	Psychological DSM Axis I disorders are common in chronic pain. One study demonstrated that the majority of patients who had failed other therapy and participated in a functional restoration program also suffered from major depression. However, in a program which included CBT and other psychological counseling the success rate for return to work was similar for those with and without a DSM IV diagnosis. This study further strengthens the argument for having some psychological intervention included in all chronic pain treatment plans ([Gatchel RJ 1994).](#GatchelRJ1994)

	For all psychological/psychiatric interventions, an assessment and treatment plan with measurable behavioral goals, time frames, and specific interventions planned, **must** be provided to the treating physician prior to initiating treatment. A status report **must** be provided to the authorized treating physician every two weeks during initial more frequent treatment and monthly thereafter. The report should provide documentation of progress towards functional recovery and discussion of the psychosocial issues affecting the patient’s ability to participate in treatment. The report should also address pertinent issues such as pre-existing, aggravated, and/or causative, as well as project realistic functional prognosis.

i. Cognitive Behavioral Therapy (CBT) or similar treatment:

* Time to Produce Effect: 6 to 8 1-2 hour session, group or individual, 1 hour individual or two-hour group.
* Maximum Duration: 16 sessions.

NOTE: Before CBT is done, the patient must have a full psychological evaluation. The CBT program must be done under the supervision of a PhD, PsyD, EdD, or Psychiatric MD/DO.

ii. Other psychological/psychiatric interventions:

* Time to Produce Effect: 6 to 8 weeks.
* Frequency: 1 to 2 times weekly for the first 2 weeks (excluding hospitalization, if required), decreasing to 1 time per week for the second month. Thereafter, 2 to 4 times monthly with the exception of exacerbations which may require increased frequency of visits. Not to include visits for medication management

 Optimum Duration: 2 to 6 months.

 Maximum: 6 months. Not to include visits for medication management. For select patients, longer supervised psychological/psychiatric treatment may be required, especially if there are ongoing medical procedures or complications. If counseling beyond 6 months is indicated, the management of psychosocial risks or functional progress must be documented. Treatment plan/progress must show severity.

* 1. RESTRICTION OF ACTIVITIESContinuation of normal daily activities is the recommendation for chronic pain patients since immobility will negatively affect rehabilitation. Prolonged immobility results in a wide range of deleterious effects, such as a reduction in aerobic capacity and conditioning, loss of muscle strength and flexibility, increased segmental stiffness, promotion of bone demineralization, impaired disc nutrition, and the facilitation of the illness role.

	Immobility may range from bed rest to the continued use of orthoses, such as cervical collars and lumbar support braces. While these interventions may have been ordered in the acute phase, the provider should be aware of their impact on the patient’s ability to adequately comply with and successfully complete rehabilitation. There is strong evidence against the use of bed rest in acute low pain back cases without neurologic symptoms ([Malmivaara A 1995](#MalmivaaraA1995); [Hagen EM 2000](#HagenEM2000)).

	Patients should be educated to the detrimental effects of immobility versus the efficacious use of limited rest periods. Adequate rest allows the patient to comply with active treatment and benefit from the rehabilitation program. In addition, complete work cessation should be avoided, if possible, since it often further aggravates the pain presentation and promotes disability. Modified return-to-work is almost always more efficacious and rarely contraindicated in the vast majority of injured workers with chronic pain.
	2. RETURN-TO-WORK**,** and/or work-related activities whenever possibleis one of the major components in chronic pain management and rehabilitation. There is some evidence that an integrated care program including workplace interventions and graded activity teaching that pain need not limit activity, is effective in returning patients with chronic low back pain to work, even with minimal reduction of pain ([Lambeek LC 2010](#LambSE2010)). Return-to-work is a subject that should be addressed by each workers’ compensation provider at the first meeting with the injured employee, and be updated at each additional visit. A return-to-work format should be part of a company’s health plan, knowing that return-to-work can decrease anxiety, reduce the possibility of depression, and reconnect the worker with society.

	Because a prolonged period of time off work will decrease the likelihood of return to work, the first weeks of treatment are crucial in preventing and/or reversing chronicity and disability mindset. In complex cases, experienced nurse case managers may be required to assist in return-to-work. Other services, including psychological evaluation and/or treatment, jobsite analysis, and vocational assistance may be employed.

	The following should be considered when attempting to return an injured worker with chronic pain to work.
		1. Job History Interview**:** The authorized treating physician should perform a job history interview at the time of the initial evaluation and before any plan of treatment is established. Documentation should include the workers’ job demands, stressors, duties of current job, and duties of job at the time of the initial injury. In addition, cognitive and social issues should be identified and treatment of these issues should be incorporated into the plan of care.
		2. Coordination of Care**:** Management of the case is a significant part of return-to-work and may be the responsibility of the authorized treating physician, occupational health nurse, risk manager, or others. Case management is a method of communication between the primary provider, referral providers, insurer, employer, and employee. Because case management may be coordinated by a variety of professionals, the case manager should be identified in the medical record.
		3. Communication**:** is essential between the patient, authorized treating physician, employer, and insurer. Employers should be contacted to verify employment status, job duties and demands, and policies regarding injured workers. In addition, availability of temporary and permanent restrictions, for what duration, as well as other placement options should be discussed and documented. All communications in the absence of the patient are required to be documented and made available to the patient.
		4. Establishment of Return-To-Work Status**:** Return-to-work for persons with chronic pain should be thought of as therapeutic, assuming that work is not likely to aggravate the basic problem or increase the discomfort. In most cases of chronic pain, the worker may not be currently working or even employed. The goal of return-to-work would be to implement a plan of care to return the worker to any level of employment with the current employer or to return them to any type of new employment.
		5. Establishment of Activity Level Restrictions**:** A formal job description for the injured/ill employee who is employed is necessary to identify physical demands at work and assist in the creation of modified duty. A jobsite evaluation may be utilized to identify tasks such as pushing, pulling, lifting, reaching above shoulder level, grasping, pinching, sitting, standing, posture, ambulatory distance and terrain, and if applicable, environment for temperature, air flow, noise and the number of hours that may be worked per day. Due to the lack of predictability regarding exacerbation of symptoms affecting function, an extended, occupationally focused functional capacity evaluation may be necessary to determine the patient’s tolerance for job type tasks over a continuing period of time. Functional Capacity Evaluations should usually take place for 8 hours. Between one and three days after the evaluation, there should be a follow-up evaluation by the treating therapist and/or the authorized treating physician to assess the patient’s status. When prescribing the FCE, the physician must assess the probability of return to work against the potential for exacerbation of the work related condition. Work restrictions assigned by the authorized treating physician may be temporary or permanent. The case manager should continue to seek out modified work until restrictions become less cumbersome or as the worker’s condition improves or deteriorates.
		6. Rehabilitation and Return-To-Work**:** As part of rehabilitation, every attempt should be made to simulate work activities so that the authorized treating physician may promote adequate job performance. The use of ergonomic or adaptive equipment, therapeutic breaks, and interventional modalities at work may be necessary to maintain employment.
		7. Vocational Assistance**:** Formal vocational rehabilitation is a generally accepted intervention and can assist disabled persons to return to viable employment. Assisting patients to identify vocational goals will facilitate medical recovery and aid in the maintenance of MMI by 1) increasing motivation towards treatment and 2) alleviating the patient’s emotional distress. Chronic pain patients will benefit most if vocational assistance is provided during the interdisciplinary rehabilitation phase of treatment. To assess the patient’s vocational capacity, a vocational assessment utilizing the information from occupational and physical therapy assessments may be utilized to identify rehabilitation program goals, as well as optimize both patient motivation and utilization of rehabilitation resources. This may be extremely helpful in decreasing the patient’s fear regarding an inability to earn a living which can add to their anxiety and depression.

		Recommendations to employers and employees of small businesses: employees of small businesses who are diagnosed with chronic pain may not be able to perform any jobs for which openings exist. Temporary employees may fill those slots while the employee functionally improves. Some small businesses hire other workers and if the injured employee returns to the job, the supervisor/owner may have an extra employee. To avoid this, it is suggested that case managers be accessed through their payer or third party administrator. Case managers may assist with resolution of these problems, as well as assist in finding modified job tasks, or find jobs with reduced hours, etc., depending upon company philosophy and employee needs.

		Recommendations to Employers and Employees of mid-sized and Large Businesses – Employers are encouraged by the Division to identify modified work within the company that may be available to injured workers with chronic pain who are returning to work with temporary or permanent restrictions. To assist with temporary or permanent placement of the injured worker, it is suggested that a program be implemented that allows the case manager to access descriptions of all jobs within the organization.
	3. THERAPY—ACTIVEThe following active therapies are widely used and accepted methods of care for a variety of work-related injuries. Active therapy is based on the philosophy that therapeutic exercise and/or activity are beneficial for restoring flexibility, strength, endurance, function, range-of-motion, and can alleviate discomfort. All active therapy plans should be made directly with patients in the interest of achieving long-term individualized goals.

	Active therapy requires an internal effort by the individual to complete a specific exercise or task. This form of therapy requires supervision from a therapist or medical provider such as verbal, visual, and/or tactile instruction(s). Active therapy is intended to promote independence and self-reliance in managing the physical pain as well as to improve the functional status in regard to the specific diagnosis and general conditioning and well-being. At times, a provider may help stabilize the patient or guide the movement pattern but the energy required to complete the task is predominately executed by the patient. Therapy in this section should not be merely a repeat of previous therapy but should focus specifically on the individual goals and abilities of the patient with chronic pain.

	The goal of active therapy is to teach the patient exercises that they can perform regularly on their own. Patients should be instructed to continue active therapies at home as an extension of the treatment process in order to maintain improvement levels. Follow-up visits to reinforce and monitor progress and proper technique are recommended.Home exercise can include exercise with or without mechanical assistance or resistance and functional activities with assistive devices.

	The following active therapies are listed in alphabetical order:
		1. Activities of Daily Living (ADL)**:** instruction, active-assisted training, and/or adaptation of activities or equipment to improve a person's capacity in normal daily activities such as self-care, work re-integration training, homemaking, and driving.
* Time to Produce Effect: 4 to 5 treatments.
* Frequency: 3 to 5 times per week.
* Optimum Duration: 4 to 6 weeks.
* Maximum Duration: 6 weeks.
	+ 1. Aquatic Therapy**:** is a well-accepted treatment which consists of the therapeutic use of aquatic immersion for therapeutic exercise to promote strengthening, core stabilization, endurance, range-of-motion, flexibility, body mechanics, and pain management. Aquatic therapyis the implementation of active therapeutic procedures (individual or group) in a swimming or therapeutic pool heated to 88 to 92 degrees. The water provides a buoyancy force that lessens the amount of force of gravity applied to the body, and the pool should be large enough to allow full extremity range of motion and full erect posture. The decreased gravity effect allows the patient to have a mechanical advantage and more likely have a successful trial of therapeutic exercise. Indications are for individuals who may not tolerate active land-based or full weight-bearing therapeutic procedures or who require augmentation of other therapy. The therapy may be indicated for individuals who:
* Cannot tolerate active land-based or full-weight bearing therapeutic procedures;
* Require increased support in the presence of proprioceptive deficit;
* Are at risk of compression fracture due to decreased bone density;
* Have symptoms that are exacerbated in a dry environment;
* Have a higher probability of meeting active therapeutic goals than in a dry environment.

The pool should be large enough to allow full extremity range-of-motion and fully erect posture. Aquatic vests, belts and other devices can be used to provide stability, balance, buoyancy, and resistance.

* Time to Produce Effect: 4 to 5 treatments.
* Frequency: 3 to 5 times per week.
* Optimum Duration: 4 to 6 weeks.
* Maximum Duration: 6 weeks.

A self-directed program is recommended after the supervised aquatics program has been established, or, alternatively a transition to a self-directed dry environment exercise program.

* + 1. Functional Activities**:** are well-established interventions which involve the use of therapeutic activity to enhance mobility, body mechanics, employability, coordination, and sensory motor integration.
* Time to Produce Effect: 4 to 5 treatments.
* Frequency: 3 to 5 times per week.
* Optimum Duration: 4 to 6 weeks.
* Maximum Duration: 6 weeks.
	+ 1. Functional Electrical Stimulation**:** is an accepted treatment in which the application of electrical current to elicit involuntary or assisted contractions of atrophied and/or impaired muscles. Indications include muscle atrophy, weakness, and sluggish muscle contraction secondary to pain, injury, neuromuscular dysfunction, peripheral nerve lesion, or radicular symptoms. This modality may be prescribed for use at home when patients have demonstrated knowledge of how to self-administer and are in an independent exercise program.
* Time to Produce Effect: 2 to 6 treatments.
* Frequency: 3 times per week.
* Optimum Duration: 8 weeks.
* Maximum Duration: 8 weeks. If beneficial, provide with home unit.
	+ 1. Spinal Stabilization**:** is a generally well-accepted treatment. The goal of this therapeutic program is to strengthen the spine in its neural and anatomic position. The stabilization is dynamic which allows whole body movements while maintaining a stabilized spine. It is the ability to move and function normally through postures and activities without creating undue vertebral stress.
* Time to Produce Effect: 4 to 8 treatments.
* Frequency: 3 to 5 times per week.
* Optimum Duration: 4 to 8 weeks.
* Maximum Duration: 8 weeks.
	+ 1. Neuromuscular Re-education**:** is a generally accepted treatment. It is the skilled application of exercise with manual, mechanical, or electrical facilitation to enhance strength; movement patterns, neuromuscular response, proprioception, kinesthetic sense, coordination; education of movement, balance and posture. Indications include the need to promote neuromuscular responses through carefully timed proprioceptive stimuli, to elicit and improve motor activity in patterns similar to normal neurologically developed sequences, and improve neuromotor response with independent control.
* Time to Produce Effect: 2 to 6 treatments.
* Frequency: 3 times per week.
* Optimum Duration: 4 to 8 weeks.
* Maximum Duration: 8 weeks.
	+ 1. Therapeutic Exercise**:** with or without mechanical assistance or resistance, may include isoinertial, isotonic, isometric and isokinetic types of exercises. Indications include the need for cardiovascular fitness, reduced edema, improved muscle strength; improved connective tissue strength and integrity, increased bone density, promotion of circulation to enhance soft tissue healing, improvement of muscle recruitment, improved proprioception, and coordination, and increased range of motion are used to promote normal movement patterns. May also include alternative/complementary exercise movement therapy (with oversight of a physician or appropriate healthcare professional).

		There is some evidence that Iyengar yoga, which avoids back bending, results in improved function and decreased chronic mechanical low back pain for up to 6 months. One quarter of the participants dropped out. Instruction occurred 2 times per week for 24 weeks and was coupled with home exercise ([Williams K 2009](#WilliamsK2009)). Yoga may be an option for motivated patients. 48 sessions is the maximum expected duration and time to effect is 8.

		There is some evidence that intensive exercise coupled with cognitive behavioral therapy is as effect for chronic un-operated low back pain as posterolateral fusion ([Brox JI 2010).](#BroxJI2010)

		There is good evidence that exercise alone or part of a multi-disciplinary program results in decreased disability for workers with non-acute low back pain [(Oesch P 2010)](#OeschP2010).

		Therapeutic exercise programs should be tissue specific to the injury and address general functional deficits as identified in the diagnosis and clinical assessment. Patients should be instructed in and receive a home exercise program that is progressed as their functional status improves. Upon discharge, the patient would be independent in the performance of the home exercise program and would have been educated in the importance of continuing such a program. Educational goals would be to maintain or further improve function and to minimize the risk for aggravation of symptoms in the future.
* Time to Produce Effect: 2 to 6 treatments.
* Frequency: 3 to 5 times per week.
* Optimum Duration: 4 to 8 weeks and concurrent with an active daily home exercise program.
* Maximum Duration: 8 to 12 weeks of therapist oversight. Home exercise should continue indefinitely*.*
	+ 1. Work Conditioning**:** These programs are work-related, outcome-focused, individualized treatment programs. Objectives of the program include, but are not limited to, improvement of cardiopulmonary and neuromusculoskeletal functions (strength, endurance, movement, flexibility, stability, and motor control functions), patient education, and symptom relief. The goal is for patients to gain full- or optimal-function and return to work. The service may include the time-limited use of modalities, both active and passive, in conjunction with therapeutic exercise, functional activities, general conditioning body mechanics, and lifting techniques re-training.

		These programs are usually initiated once re-conditioning has been completed but may be offered at any time throughout the recovery phase. It should be initiated when imminent return of a patient to modified- or full-duty is not an option, but the prognosis for returning the patient to work at completion of the program is at least fair to good.
* Length of Visit: 1 to 2 hours per day.
* Frequency: 2 to 5 visits per week.
* Optimum Duration: 2 to 4 weeks.
* Maximum Duration: 6 weeks. Participation in a program beyond 6 weeks must be documented with respect to need and the ability to facilitate positive symptomatic and functional gains.
	+ 1. Work Simulation**:** is a program where an individual completes specific work-related tasks for a particular job and return to work. Use of this program is appropriate when modified duty can only be partially accommodated in the work place, when modified duty in the work place is unavailable, or when the patient requires more structured supervision. The need for work place simulation should be based upon the results of a functional capacity evaluation and/or jobsite analysis.
* Length of Visit: 2 to 6 hours per day.
* Frequency: 2 to 5 visits per week.
* Optimum Duration: 2 to 4 weeks.
* Maximum Duration: 6 weeks. Participation in a program beyond 6 weeks must be documented with respect to need and the ability to facilitate positive symptomatic and functional gains.
	1. THERAPY—PASSIVEMost of the following passive therapies and modalities are generally accepted methods of care for a variety of work-related injuries. Passive therapy includes those treatment modalities that do not require energy expenditure on the part of the patient. They are principally effective during the early phases of treatment and are directed at controlling symptoms such as pain, inflammation and swelling and to improve the rate of healing soft tissue injuries. They should be used adjunctively with active therapies such as postural stabilization and exercise programs to help control swelling, pain, and inflammation during the active rehabilitation process. Please refer to Section B. 4. General Guideline Principles, Active Interventions. Passive therapies may be used intermittently as a therapist deems appropriate or regularly if there are specific goals with objectively measured functional improvements during treatment;or if there are episodes of acute pain superimposed upon a chronic pain problem.

	On occasion, specific diagnoses and post-surgical conditions may warrant durations of treatment beyond those listed as "maximum.”Factors such as exacerbation of symptoms, re-injury, interrupted continuity of care and co-morbidities may extend durations of care. Having specific goals with objectively measured functional improvement during treatment can support extended durations of care. It is recommended that if after 6 to 8 visits no treatment effect is observed, alternative treatment interventions, further diagnostic studies or further consultations should be pursued.

	The following passive therapies are listed in alphabetical order:
		1. Electrical Stimulation (Unattended):

		TENS - Electrical stimulation, once applied, requires minimal on-site supervision by the physical or nonphysical provider. Indications include pain, inflammation, muscle spasm, atrophy, decreased circulation, and the need for osteogenic stimulation. A TENS home unit should be purchased if treatment is effective and frequent use is recommended.
* Time to Produce Effect: 2 to 4 treatments.
* Frequency: Varies, depending upon indication, between 2 to 3 times per day to 1 time week. A home unit should be purchased if treatment is effective and frequent use is recommended.
* Optimum and Maximum Duration: 4 treatments for clinic use.
	+ 1. Iontophoresis**:** is an accepted treatment which consists of the transfer of medication, including, but not limited to, steroidal anti-inflammatories and anesthetics, through the use of electrical stimulation. Indications include pain (lidocaine), inflammation (hydrocortisone, salicylate), edema (mecholyl, hyaluronidase, and salicylate), ischemia (magnesium, mecholyl, and iodine), muscle spasm (magnesium, calcium), calcific deposits (acetate), scars and keloids (chlorine, iodine, acetate).
* Time to Produce Effect: 1 to 4 treatments.
* Frequency: 3 times per week with at least 48 hours between treatments.
* Optimum Duration: 4 to 6 weeks.
* Maximum Duration: 6 weeks.

* + 1. Manipulation**:** Manipulative Treatment (not therapy) is defined as the therapeutic application of manually guided forces by an operator to improve physiologic function and/or support homeostasis that has been altered by the injury or occupational disease, and has associated clinical significance.

		There is good evidence that a combination of exercise and spinal manipulation is more effective than manipulation alone in relieving chronic neck pain, and that these advantages remain for more than one year after the end of treatment [(Bronfort 2001](#Bronfort2001), [Evans 2002](#Evans2002)).

		Conversely, there is some evidence that a combination of spinal manipulation and exercise is more effective than exercise alone in reducing pain and improving function of low back pain for one year ([Aure 2003](#Aure2003)).

		There is good evidence that spinal manipulation has a small superiority to other common interventions (standard medical care, physiotherapy, and exercise alone) for chronic low back pain, making it comparable to other commonly accepted interventions for this indication ([Rubinstein 2011](#Rubenstein2011)).

		The decision to refer a patient for spinal manipulation rather than for other treatments should be made on the basis of patient preference and relative safety, not on an expectation of a greater treatment effect. Manipulation may be indicated in patients who have not had an evaluation for manual medicine, or have not progressed adequately in an exercise program.

		Manipulative treatments may be applied by osteopathic physicians (D.O.), chiropractors (D.C.), properly trained physical therapists (P.T.), properly trained occupational therapists (O.T.), or properly trained medical doctors (M.D.). Some popular and useful techniques include, but are not limited to, high velocity, low amplitude (HVLA), muscle energy (ME), strain-counterstrain (SCS), a balanced ligamentous tension (BLT) and myofascial release (MFR). Under these different types of manipulation exist many subsets of different techniques that can be described as a) direct- a forceful engagement of a restrictive/pathologic barrier, b) indirect- a gentle/non-forceful disengagement of a restrictive/pathologic barrier, c) the patient actively assists in the treatment and d) the patient relaxing, allowing the practitioner to move and balance the body tissues. When the proper diagnosis is made and coupled with the appropriate technique, manipulation has no contraindications and can be applied to all tissues of the body, including muscles, tendons, ligaments, joints, fascia and viscera. Pre-treatment assessment should be performed as part of each manipulative treatment visit to ensure that the correct diagnosis and correct treatment is employed.

		Contraindications to HVLA manipulation include joint instability, fractures, severe osteoporosis, infection, metastatic cancer, active inflammatory arthritides, aortic aneurysm, and signs of progressive neurologic deficits.
* Time to Produce Effect: 4 to 6 treatments.
* Frequency: 1 to 2 times per week for the first 2 weeks as indicated by the severity of the condition. Treatment may continue at 1 treatment per week for the next 6 weeks.
* Optimum Duration: 8 weeks.
* Maximum Duration: 8 weeks. At week 8, patients should be re-evaluated. Care beyond 8 weeks may be indicated for certain chronic pain patients in whom manipulation is helpful in improving function, decreasing pain and improving quality of life. In these cases, treatment may be continued at one treatment every other week until the patient has reached MMI and maintenance treatments have been determined. Extended durations of care beyond what is considered “maximum” may be necessary in cases of re-injury, interrupted continuity of care, exacerbation of symptoms, and in those patients with comorbidities. Such care should be re-evaluated and documented on a monthly basis.
	+ 1. Manipulation under General Anesthesia (MUA)**:** refers to manual manipulation of the lumbar spine in combination with the use of a general anesthetic or conscious sedation. It is intended to improve the success of manipulation when pain, muscle spasm, guarding, and fibrosis appear to be limiting its application in patients otherwise suitable for their use. There have been no high quality studies to justify its benefits given the risks of general anesthetic and conscious sedation. It is not recommended.
		2. Manipulation Under Joint Anesthesia (MUJA)**:** refers to manipulation of the lumbar spine in combination with a fluoroscopically guided injection of anesthetic with or without corticosteroid agents into the facet joint at the level being manipulated. There are no controlled clinical trials to support its use. It is not recommended.
		3. Massage—Manual or Mechanical**:** Massage is manipulation of soft tissue with broad ranging relaxation and circulatory benefits. This may include stimulation of acupuncture points and acupuncture channels (acupressure), application of suction cups and techniques that include pressing, lifting, rubbing, pinching of soft tissues by or with the practitioners’ hands. Indications include edema (peripheral or hard and non-pliable edema), muscle spasm, adhesions, the need to improve peripheral circulation and range-of-motion, or to increase muscle relaxation and flexibility prior to exercise.

		There is good evidence that massage therapy in combination with exercise reduces pain and improves function short-term for patients with subacute low back pain ([Cherkin DC 2001](#CherkinDC2001); [Furlan AD 2008](#FurlanAD2008); [Preyde, 2010](#Preyde2010)).
* Time to Produce Effect: Immediate.
* Frequency: 1 to 2 times per week.
* Optimum Duration: 6 weeks.
* Maximum Duration: 2 months.
	+ 1. Mobilization (Joint)**:** Is a generally well-accepted treatment. Mobilization is passive movement involving oscillatory motions to the vertebral segment(s). The passive mobility is performed in a graded manner (I, II, III, IV, or V), which depicts the speed and depth of joint motion during the maneuver. It may include skilled manual joint tissue stretching. Indications include the need to improve joint play, segmental alignment, improve intracapsular arthrokinematics, or reduce pain associated with tissue impingement. For Level V mobilization contraindications include joint instability, fractures, severe osteoporosis, infection, metastatic cancer, active inflammatory arthritides, aortic aneurysm, and signs of progressive neurologic deficits.
* Time to Produce Effect: 6 to 9 treatments.
* Frequency: 3 times per week.
* Optimum Duration: 4 to 6 weeks.
* Maximum Duration: 6 weeks.
	+ 1. Mobilization (Soft Tissue)**:** Is a generally well-accepted treatment. Mobilization of soft tissue is the skilled application of muscle energy, strain/counter strain, myofascial release, manual trigger point release, and manual therapy techniques designed to improve or normalize movement patterns through the reduction of soft tissue pain and restrictions. These can be interactive with the patient participating or can be with the patient relaxing and letting the practitioner move the body tissues. Indications include muscle spasm around a joint, trigger points, adhesions, and neural compression. Mobilization should be accompanied by active therapy.
* Time to Produce Effect: 4 to 9 treatments.
* Frequency: Up to 3 times per week.
* Optimum Duration: 4 to 6 weeks.
* Maximum Duration: 6 weeks.
	+ 1. Percutaneous Electrical Nerve Stimulation (PENS)**:** Needles are used to deliver low-voltage electrical current under the skin. Theoretically this therapy prevents pain signals traveling through small nerve fibers from reaching the brain, similar to the theory of TENS. There is good evidence that PENS produces improvement of pain and function compared to placebo; however, there is no evidence that the effect is prolonged after the initial 3 week treatment episode (Ghoname, 1999, [Hamza 2000](#Hamza2000)). There are no well done studies that show PENS performs better than TENS for chronic pain patients. PENS is more invasive, requires a trained health care provider and has no clear long term effect; therefore it is not generally recommended.
* Time to Produce Effect: 1 to 4 treatments.
* Frequency: 2 to 3 times per week.
* Optimum 9 sessions.
* Maximum Duration: 12 sessions per year.
	+ 1. Superficial Heat and Cold Therapy (Including Infrared Therapy)**:** is a generally accepted treatment. Superficial heat and cold are thermal agents applied in various manners that lower or raise the body tissue temperature for the reduction of pain, inflammation, and/or effusion resulting from injury or induced by exercise. Includes application of heat just above the surface of the skin at acupuncture points. Indications include acute pain, edema and hemorrhage, need to increase pain threshold, reduce muscle spasm, and promote stretching/flexibility. Cold and heat packs can be used at home as an extension of therapy in the clinic setting.
* Time to Produce Effect: Immediate.
* Frequency: 2 to 5 times per week.
* Optimum Duration: 3 weeks as primary or intermittently as an adjunct to other therapeutic procedures up to 2 months.
* Maximum Duration: 2 months.
	+ 1. Traction—Manual**:** are an accepted treatment and an integral part of manual manipulation or joint mobilization. Indications include decreased joint space, muscle spasm around joints, and the need for increased synovial nutrition and response. Manual traction is contraindicated in patients with tumor, infection, fracture, or fracture dislocation.
* Time to Produce Effect: 1 to 3 sessions.
* Frequency: 2 to 3 times per week.
* Optimum/Maximum Duration: 1 month.
	+ 1. Traction—Mechanical**:** Mechanical traction is indicated for decreased joint space, muscle spasm around joints, and the need for increased synovial nutrition and response. Traction modalities are contraindicated in patients with tumor, infections, fracture, or fracture dislocation. Non-oscillating inversion traction methods are contraindicated in patients with glaucoma or hypertension. There is some evidence that mechanical traction, using specific, instrumented axial distraction technique, is not more effective than active graded therapy without mechanical traction. Therefore, mechanical traction is not recommended for chronic axial spine pain ([Schimmel J 2009](#SchimmelJ2009)).
* Time to Produce Effect: 1 to 3 sessions up to 30 minutes. If response is negative after 3 treatments, discontinue this modality.
* Frequency: 2 to 3 times per week.
* Optimum/Maximum Duration: 1 month.
	+ 1. Transcutaneous Electrical Nerve Stimulation (TENS)**:** should include least one instructional session for proper application and use. Indications include muscle spasm, atrophy, and decreased circulation and pain control. Minimal TENS unit parameters should include pulse rate, pulse width and amplitude modulation.
* Time to Produce Effect: Immediate.
* Frequency: Variable.
* Optimum Duration: 3 sessions. If beneficial, provide with home unit.
* Maximum Duration: 3 sessions. Purchase if effective.
	+ 1. Ultrasound (Including Phonophoresis)**:** is an accepted treatment which uses sonic generators to deliver acoustic energy for therapeutic thermal and/or non-thermal soft tissue effects. Indications include scar tissue, adhesions, collagen fiber and muscle spasm, and the need to extend muscle tissue or accelerate the soft tissue healing. Ultrasound with electrical stimulation is concurrent delivery of electrical energy that involves dispersive electrode placement. Indications include muscle spasm, scar tissue, pain modulation, and muscle facilitation.

		Phonophoresis is the transfer of medication to the target tissue to control inflammation and pain through the use of sonic generators. These topical medications include, but are not limited to, steroidal anti-inflammatory and anesthetics.
* Time to Produce Effect: 6 to 15 treatments.
* Frequency: 3 times per week.
* Optimum Duration: 4 to 8 weeks.
* Maximum Duration: 2 months.
	+ 1. Vertebral Axial Decompression (VAX-D)/DRX, 9000**:** Motorized traction devices which purport to produce non-surgical disc decompression by creating negative intradiscal pressure in the disc space include devices with the trade names of VAX-D and DRX 9000. There are no good studies to support their use. They are not recommended.
1. THERAPEUTIC PROCEDURES – OPERATIVE

When considering operative intervention in chronic pain management, the treating physician must carefully consider the inherent risk and benefit of the procedure. All operative intervention should be based on a positive correlation with clinical findings, the clinical course, and diagnostic tests. A comprehensive assessment of these factors should have led to a specific diagnosis with positive identification of the pathologic condition. Operative treatment is indicated when the natural history of surgically treated lesions is better than the natural history for non-operatively treated lesions.

Surgical procedures are seldom meant to be curative and would be employed in conjunction with other treatment modalities for maximum functional benefit. Functional benefit should be objectively measured and includes the following:

**a.** Return-to-work or maintaining work status.

**b.** Fewer restrictions at work or performing activities of daily living.

**c.** Decrease in usage of medications prescribed for the work-related injury.

**d.** Measurable functional gains, such as increased range of motion or a documented increase in strength.

Education of the patient should include the proposed goals of the surgery, expected gains, risks or complications, and alternative treatment.

Smoking may affect soft tissue healing through tissue hypoxia. Patients should be strongly encouraged to stop smoking and be provided with appropriate counseling by the physician. If a treating physician recommends a specific smoking cessation program peri-operatively, this should be covered by the insurer. Physicians may monitor smoking cessation with laboratory tests such as cotinine levels. The surgeon will make the final determination as to whether smoking cessation is required prior to surgery.

Prior to surgical intervention, the patient and treating physician should identify functional operative goals and the likelihood of achieving improved ability to perform activities of daily living or work activities and the patient should agree to comply with the pre- and post-operative treatment plan including home exercise. The provider should be especially careful to make sure the patient understands the amount of post-operative therapy required and the length of partial- and full-disability expected post-operatively.

* 1. NEUROSTIMULATION
		1. Description: Spinal cord stimulation (SCS) is the delivery of low-voltage electrical stimulation to the spinal cord or peripheral nerves to inhibit or block the sensation of pain. The system uses implanted electrical leads and a battery powered implanted pulse generator.

		There is some evidence that SCS is superior to reoperation in setting of persistent radicular pain after lumbosacral spine surgery ([North R 2005](#North2005)), and there is some evidence that SCS is superior to conventional medical management in the same setting ([Kumar K 2008](#KumarK2008)). Success was defined as achieving 50% or more pain relief ([North R 2005](#North2005); [Kumar K 2008](#KumarK2008)). Some functional gains have been demonstrated ([Kemler M 2000](#KemlerM2000); [Kumar K 2007](#KumarK2007); [Barolat G 1998](#BarolatG1998), [2001;](#BarolatG2001) [Frey M 2009](#FreyM2009)). These findings may persist at three years of follow-up in patients who had an excellent initial response and who are highly motivated.

		It is particularly important that patients meet all of the indications before a permanent neurostimulator is placed because several studies have shown that workers’ compensation patients are less likely to gain significant relief than other patients ([Hollingworth, 2011](#Hollingworth2011)). As of the time of this guideline writing, spinal cord stimulation devices have been FDA approved as an aid to in the management of chronic intractable pain of the trunk and/or limbs, including unilateral and bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain and leg pain.

		Some evidence shows that SCS is superior to re-operation and conventional medical management for severely disabled patients who have failed conventional treatment and have Complex Regional Pain Syndrome (CRPS I) or failed back surgery with persistent radicular neuropathic pain ([Kemler 2000;](#KemlerM2000) [North 2005](#North2005), [Kumar 2008](#KumarK2008)).

		While there is no evidence demonstrating effectiveness for use of SCS with CRPS II, it is generally accepted that SCS can be used for patients who have this condition. There is no evidence that supports its use for spinal axial pain. SCS may be most effective in patients with CRPS I or II who have not achieved relief with oral medications, rehabilitation therapy, or therapeutic nerve blocks, and in whom the pain has persisted for longer than 6 months ([Kemler M 2000;](#KemlerM2000) [North R 2005](#North2005); [Kumar K 2008](#KumarK2008); [Barolat G 1998](#BarolatG1998), [2001](#BarolatG2001)[; Frey M 2009](#FreyM2009)).

		Particular technical expertise is required to perform this procedure and is available in some neurosurgical, rehabilitation, and anesthesiology training programs and fellowships. Physicians performing this procedure must be trained in neurostimulation implantation and participate in ongoing training workshops on this subject, such as those sponsored by the International Spine Intervention Society (ISIS) or as sponsored by implant manufacturers. Surgical procedures should be performed by surgeons, usually with a neurosurgical or spinal background.
		2. Complications: Serious, less common complications include spinal cord compression, paraplegia, epidural hematoma, epidural hemorrhage, undesirable change in stimulation, seroma, CSF leakage, infection, erosion, and allergic response. Otherr complications consist of dural puncture, hardware malfunction or equipment migration, pain at implantation site, loss of pain relief, chest wall stimulation, and other surgical risks. In recent studies device complication rates have been reported to be 25% at 6 months ([Kemler M 2000](#KemlerM2000)), 32% at 12 months ([Kumar K 2007),](#KumarK2007) and 45% at 24 months ([Kumar K 2008](#KumarK2008)). The most frequent complications are reported to be electrode migration (14%) and loss of paresthesia (12%) ([Kemler 2000](#KemlerM2000); [North 2005](#North2005), [Kumar 2008](#KumarK2008)).
		3. Surgical Indications: Patients with established CRPS I or II or a failed spinal surgery with persistent functionally limiting radicular pain greater than axial pain who have failed conservative therapy including active and/or passive therapy, pre-stimulator trial psychiatric evaluation and treatment, medication management, and therapeutic injections. SCS is not recommended for patients with the major limiting factor of persistent axial spine pain. SCS may be indicated in a subset of patients who have a clear neuropathic radicular pain (radiculitis). The extremity pain should account for at least 50% or greater of the overall back and leg pain experienced by the patient. Prior authorization is required. Habituation to opioid analgesics in the absence of a history of addictive behavior does not preclude the use of SCS. Patients with severe psychiatric disorders, and issues of secondary gain are not candidates for the procedure ([Kemler M 2000)](#KemlerM2000). Approximately, one third to one half of patients who qualify for SCS can expect a substantial reduction in pain relief; however, it may not influence allodynia, and hypesthesia ([North R 2005](#North2005); [Kemler M 2008;](#KemlerM2008) [Barolat G 1998](#BarolatG1998), [2001;](#BarolatG2001) [Frey M 2009](#FreyM2009)). Patients’ expectations need to be realistic, and therefore, patients should understand that the SCS intervention is not a cure for their pain but rather a masking of their symptomatology which might regress over time. There appears to be a likely benefit of up to 3 years ([Kemler M 2008](#KemlerM2008)). Patients must meet the following criteria in order to be considered for neurostimulation:
			1. SCS may be indicated in a subset of patients who have a clear neuropathic radicular pain (radiculitis); are not candidates for surgical intervention on the spine; have burning pain in a distribution amenable to stimulation coverage and have pain at night not relieved by position. The extremity pain should account for at least 50% or greater of the overall leg and back pain experienced by the patient. In cases of complex regional pain syndrome, please refer to the CRPS Medical Treatment Guidelines.
			2. A comprehensive psychiatric or psychological evaluation *prior* to the stimulator trial has been performed. This evaluation should include a standardized detailed personality inventory with validity scales (such as MMPI-2, MMPI-2-RF, or PAI) pain inventory with validity measures (for example, BHI 2, MBMD); clinical interview and complete review of the medical records. Before proceeding to a spinal stimulator trial the evaluation should find the following:
* No indication of falsifying information, or of invalid response on testing; and
* No primary psychiatric risk factors or “red flags” (e.g. psychosis, active suicidality, severe depression, or addiction) ([Kemler M 2000](#KemlerM2000); [Bruns and Disorbio 2009).](#BrunsandDisorbio2009) (Note that tolerance and dependence to opioid analgesics are not addictive behaviors and do not preclude implantation); and
* A level of secondary risk actors or “yellow flags” (e.g. moderate depression, job dissatisfaction, dysfunctional pain conditions) judged to be below the threshold for compromising the patient’s ability to benefit from neurostimulation [(den Boer, et al, 2006;](#DenBoer2006) [Bruns and Disorbio, 2009;](#BrunsandDisorbio2009) [Rosenberger et al. 2006;](#Rosenberger2006) [Block, et al 2001).](#BlockA2001)
* The patient is cognitively capable of understanding and operating the neurostimulation control device; and
* The patient is cognitively capable of understanding and appreciating the risks and benefits of the procedure and
* The patient has demonstrated a history of motivation in and adherence to prescribed treatments.

The psychologist or psychiatrist performing these evaluations should not be an employee of the physician performing the implantation. This evaluation must be completed, with favorable findings, **before** the screening trial is scheduled. Significant personality disorders must be taken into account when considering a patient for spinal cord stimulation and other major procedures.

* + - 1. All reasonable surgical and non-surgical treatment has been exhausted; and
			2. The topography of pain and its underlying pathophysiology are amenable to stimulation coverage (the entire painful extremity area has been covered); and
			3. A successful neurostimulation screening test of at least 3 to 7 days (North R 2005; [Kemler M 2000,](#KemlerM2000) [2008](#KemlerM2008)).

			For a spinal cord neurostimulation screening test, a temporary lead is implanted at the level of pain and attached to an external source to validate therapy effectiveness. A screening test is considered successful if the patient meets both of the following criteria: (a) experiences a 50% decrease radicular or CRPS in pain, which may be confirmed by visual analogue scale (VAS) or Numerical Rating Scale (NRS) ([Kemler M 2000](#KemlerM2000); North R 2005; [Kumar K 2007](#KumarK2007)), and (b) demonstrates objective functional gains or decreased utilization of pain medications ([Kemler M 2000;](#KemlerM2000) North R 2005; [Kumar K 2007](#KumarK2007)). Objective, measurable, functional gains should be evaluated by an occupational therapist and/or physical therapist and the primary treating physician prior to and before discontinuation of the trial.
		1. Contraindications:
* Unsuccessful SCS test – inability to obtain objective, documented, functional improvement or reduction of pain.
* Those with cardiac pacemakers should be evaluated on an individual basis as some may qualify for surgery ([Ooi YC 2011](#OoiYC2011)).
* Patient who are unable to properly operate the system.
* Patients who are anti-coagulated and cannot be without anticoagulation for a few days (e.g. patients with artificial heart valves).
* Patients with frequent severe infections.
* Patients for whom a future MRI of a body part below the head is planned. MRI of the head is permissible with some manufacturers.
	+ 1. Operative Treatment: Implantation of stimulating leads connected by extensions to either an implanted neurostimulator or an implanted receiver powered by an external transmitter. The procedure may be performed either as an open or a percutaneous procedure, depending on the presence of epidural fibrosis and the anatomical placement required for optimal efficacy. During the final procedure the patient must be awakened to establish full coverage from the placement of the lead. One of the most common failures is misplaced leads. Functional improvement is anticipated for up to 3 years or longer when objective functional improvement has been observed during the time of neurostimulation screening exam ([Kemler M 2008).](#KemlerM2008)
		2. Post-operative Considerations: MRI is contraindicated after placement of neurostimulators except for cranial imaging with some models.
		3. Post-operative Therapy: Active and/or passive therapy should be employed to improve function. Implantable stimulators will require frequent monitoring such as adjustment of the unit and replacement of batteries. Estimated battery life of SCS implantable devices is usually 5 – 10 years depending on the manufacturer ([Kemler M 2008).](#KemlerM2008)
	1. PERIPHERAL NERVE STIMULATION

	There are no randomized controlled studies for this treatment. This modality should only be employed with a clear nerve injury or when the majority of pain is clearly in a nerve distribution in patients who have completed 6 months of other appropriate therapy including pre-trial psychosocial evaluation and treatment. A screening trial should take place over 3 to 7 days and is considered successful if the patient meets both of the following criteria: (a) experiences a 50% decrease in pain, which may be confirmed by Visual Analogue Scale (VAS) or Numerical Rating Scale (NRS) and (b) demonstrates objective functional gains or decreased utilization of pain medications. Objective, measurable, functional gains should be evaluated by an occupational therapist and/or physical therapist and the primary treating physician prior to and before discontinuation of the trial. It may be used for proven occipital, ulnar, median and other isolated nerve injuries ([Van Calenbergh F 2009;](#VanCalenberghF2009) [Mekhail N 2010;](#MekhailN2010) [Cruccu G 2007;](#CruccuG2007) [Frey M 2009](#FreyM2009)).
	2. INTRATHECAL DRUG DELIVERYNot generally recommended. Requires prior authorization. Due to conflicting studies in this population and complication rate for long-term use, it may be considered only in very rare occasions when dystonia and spasticity are dominant features or when pain is not able to be managed using any other non-operative treatment. Specific brands of infusion systems have been FDA approved for the following: chronic intraspinal (epidural and intrathecal) infusion of preservative-free morphine sulfate sterile solution in the treatment of chronic intractable pain, chronic infusion of preservative-free ziconotide sterile solution for the management of severe chronic pain, and chronic intrathecal infusion of baclofen for the management of severe spasticity.
		1. **Description:** This mode of therapy delivers small doses of medications directly into the cerebrospinal fluid.
		2. **Complications:** Intrathecal delivery is associated with significant complications, such as infection, catheter disconnects, CSF leak, arachnoiditis, pump failure, nerve injury, and paralysis.

		Typical adverse events reported with opioids (ie, respiratory depression, tolerance, and dependence), or spinal catheter-tip granulomas that might arise during intrathecal morphine or hydromorphone treatment have not currently been recorded for ziconotide. The most common presentation of an intraspinal mass is a sudden increase in dosage required for pain relief, with new neurologic defects secondary to a mass effect ([Miele 2006](#Miele2006)). Technical errors can lead to drug overdose which can be life-threatening ([Johnson 2011](#Johnson2011)).

		Surveys have shown technical problems requiring surgical correction in 18% to 40% of patients ([Gerber 2003](#Gerber2003), [Turner 2007](#Turner2007)). CSF leakage may occur with multiple dural punctures. Since the needle is larger than the spinal catheter, there may be incomplete tissue sealing around the catheter ([Gerber 2003](#Gerber2003)). The function of the pump depends on its electronic power source, which may be disrupted by the magnet of an MRI; therefore, after the patient has an MRI, the pump should be checked to ensure that it does not need to be restarted [(Staats 2008)](#Staats2008). The delivery rate can be affected by atmospheric pressure and body temperature ([Ghafoor, 2007](#Ghafoor2007)).
		3. **Indications:** Clinical studies are conflicting, regarding long-term, effective pain relief in patients with non-malignant pain. The Division does not generally recommend the use of intrathecal drug delivery systems in injured workers with chronic pain. Due to the complication rate for long-term use, it may be considered only in very rare occasions when dystonia and spasticity are dominant features or when pain is not able to be managed using any other non-operative treatment. This treatment must be prior authorized and have the recommendation of at least one physician experienced in chronic pain management in consultation with the primary treating physician. The procedure should be performed by physicians with documented experience. This small eligible sub-group of patients must meet all of the following indications:
			1. A diagnosis of a specific physical condition known to be chronically painful has been made on the basis of objective findings; and
			2. All reasonable surgical and non-surgical treatment has been exhausted including failure of conservative therapy including active and/or passive therapy, medication management, or therapeutic injections; and
			3. Pre-trial psychiatric or psychological evaluation has been performed (as for SCS) and has demonstrated motivation and long-term commitment without issues of secondary gain. Significant personality disorders must be taken into account when considering a patient for spinal cord stimulation and other major procedures; and
			4. There is no evidence of current addictive behavior. (Tolerance and dependence to opioid analgesics are not addictive behaviors and do not preclude implantation); and
			5. A successful trial of continuous infusion by a percutaneous spinal infusion pump for a minimum of 24 hours. A screening test is considered successful if the patient (a) experiences a 50% decrease in pain, which may be confirmed by VAS, and (b) demonstrates objective functional gains or decreased utilization of pain medications. Functional gains should be evaluated by an occupational therapist and/or physical therapist prior to and before discontinuation of the trial.
		4. **Contraindications:** Infection, body size insufficient to support the size and weight of the implanted device. Patients with other implanted programmable devices should be given these pumps with caution since interference between devices may cause unintended changes in infusion rates.
	3. NEUROABLATION WITH RHIZOTOMY AS THE EXCEPTIONNeuroablation or neuro-destructive procedures are not commonly used in the management of non-malignant pain. These techniques require specific expertise to perform, have erratic results, and high rates of complication. Therefore, the Division does not recommend the use of neuroablative procedures, except rhizotomy, for injured workers with chronic pain.
	4. DORSAL NERVE ROOT RESECTION This procedure is not recommended. There exists the possibility of complications including unintended extensive nerve damage causing significant motor or sensibility changes from larger than anticipated lesioning of the ganglia at the dorsal ganglia level (North R 1991)[.](#NorthR1991) For radio-frequency ablation refer to Section F. Therapeutic Procedures, Non-operative, Dorsal Root Ganglion Radiofrequency Ablation.
1. MAINTENANCE MANAGEMENT

Successful management of chronic pain conditions results in fewer relapses requiring intense medical care. Failure to address long-term management as part of the overall treatment program may lead to higher costs and greater dependence on the health care system. Management of CPD continues after the patient has met the definition of maximum medical improvement (MMI). MMI is declared when a patient’s condition has plateaued and the authorized treating physician believes no further medical intervention is likely to result in improved function. When the patient has reached MMI, a physician must describe in detail the maintenance treatment.

Maintenance care in CPD requires a close working relationship between the carrier, the providers, and the patient. Providers and patients have an obligation to design a cost-effective, medically appropriate program that is predictable and allows the carrier to set aside appropriate reserves. Carriers and adjusters have an obligation to assure that medical providers can design medically appropriate programs. A designated primary physician for maintenance team management is recommended.

Maintenance care will be based on principles of patient self-management. When developing a maintenance plan of care, the patient, physician and insurer should attempt to meet the following goals:

a. Maximal independence will be achieved through the use of home exercise programs or exercise programs requiring special facilities (e.g., pool, health club) and educational programs;

b. Modalities will emphasize self-management and self-applied treatment;

c. Management of pain or injury exacerbations will emphasize initiation of active therapy techniques and may occasionally require anesthetic injection blocks.

d. Dependence on treatment provided by practitioners other than the authorized treating physician will be minimized;

e. Periodic reassessment of the patient’s condition will occur as appropriate;

f. Patients will understand that failure to comply with the elements of the self-management program or therapeutic plan of care may affect consideration of other interventions.

The following are Specific Maintenance Interventions and Parameters:

* 1. HOME EXERCISE PROGRAMS AND EXERCISE EQUIPMENTMost patients have the ability to participate in a home exercise program after completion of a supervised exercise rehabilitation program. Programs should incorporate an exercise prescription including the continuation of an age-adjusted and diagnosis-specific program for aerobic conditioning, flexibility, stabilization, and strength. Some patients may benefit from the purchase or rental of equipment to maintain a home exercise program. Determination for the need of home equipment should be based on medical necessity to maintain MMI, compliance with an independent exercise program, and reasonable cost. Before the purchase or long-term rental of equipment, the patient should be able to demonstrate the proper use and effectiveness of the equipment. Effectiveness of equipment should be evaluated on its ability to improve or maintain functional areas related to activities of daily living or work activity. Home exercise programs are most effective when done 3 to 5 times a week. Prior to purchasing the equipment a therapist and/or exercise specialist who has treated the patient should visit a facility with the patient to assure proper use of the equipment. Occasionally, compliance evaluations may be made through a 4 week membership at a facility offering similar equipment.
	2. EXERCISE PROGRAMS REQUIRING SPECIAL FACILITIESSome patients may have higher compliance with an independent exercise program at a health club versus participation in a home program. All exercise programs completed through a health club facility should focus on the same parameters of an age-adjusted and diagnosis-specific program for aerobic conditioning, flexibility, stabilization, and strength. Prior to purchasing a membership, a therapist and/or exercise specialist who has treated the patient should visit a facility with the patient to assure proper use of the equipment. Selection of health club facilities should be limited to those able to track attendance and utilization, and provide records available for physician and insurer review.
* Frequency: 2 to 3 times per week
* Maximum Maintenance Duration: 3 months. Continuation beyond 3 months should be based on functional benefit and patient compliance. Health club membership should not extend beyond 3 months if attendance drops below 2 times per week on a regular basis.
	1. PATIENT EDUCATION MANAGEMENTEducational classes, sessions, or programs may be necessary to reinforce self-management techniques. This may be performed as formal or informal programs, either group or individual.
* Maintenance Duration: 2 to 6 educational visits during one 12 month period.
	1. PSYCHOLOGICAL MANAGEMENT An ideal maintenance program will emphasize management options implemented in the following order: (a) individual self-management (pain control, relaxation and stress management, etc.), (b) group counseling, (c) individual counseling by a psychologist or psychiatrist, and (d) inpatient treatment. Exacerbation of the injury may require psychological treatment to restore the patient to baseline. In those cases, use treatments and timeframe parameters listed in the Biofeedback and Psychological Evaluation or Intervention sections.
* Maintenance Duration: 6 to 10 visits during the first year and 4 to 6 visits per year thereafter. In cases of significant exacerbation, refer to the psychological treatment section in Therapeutic Procedures, Non-operative, Section F.
	1. NON OPIOID MEDICATION MANAGEMENTIn some cases, self-management of pain and injury exacerbations can be handled with medications, such as those listed in the Medication section. Physicians must follow patients who are on any chronic medication or prescription regimen for efficacy and side effects. Laboratory or other testing may be appropriate to monitor medication effects on organ function.
* Maintenance Duration: Usually, four medication reviews within a 12 month period. Frequency depends on the medications prescribed. Laboratory and other monitoring as appropriate.
	1. OPIOID MEDICATION MANAGEMENTAs compared with other painful conditions there may be a role for chronic augmentation of the maintenance program with opioid medications. In selected cases, scheduled medications may prove to be the most cost effective means of insuring the highest function and quality of life; however, inappropriate selection of these patients may result in a high degree of iatrogenic illness. A patient should have met the criteria in the opioids section of these guidelines before beginning maintenance opioids. Laboratory or other testing may be appropriate to monitor medication effects on organ function. The following management is suggested for maintenance opioids:

a. The medications should be clearly linked to improvement of function, not just pain control. All follow-up visits should document the patient’s ability to perform routine functions satisfactorily. Examples include the abilities to perform: work tasks, drive safely, pay bills or perform basic math operations, remain alert and upright for 10 hours per day, or participate in normal family and social activities. If the patient is not maintaining reasonable levels of activity the patient should usually be tapered from the opioid and tried on a different long-acting opioid.

b. A low dose opioid medication regimen should be defined, which may minimally increase or decrease over time. Dosages will need to be adjusted based on side effects of the medication and objective function of the patient. A patient may frequently be maintained on additional non-opioid medications to control side effects, treat mood disorders, or control neuropathic pain; however, only one long-acting opioid and one short-acting opioid for rescue use should be prescribed in most cases. Buccally absorbed opioids are not appropriate for these non-malignant pain patients. Transdermal medications are generally not recommended.

c. All patients on chronic opioid medication dosages need to sign an appropriate opioid contract with their physician for prescribing the opioids.

d. The patient must understand that continuation of the medication is contingent on their cooperation with the maintenance program. Use of non-prescribed drugs may result in tapering of the medication. The clinician should order random drug testing at least annually and when deemed appropriate to monitor medication compliance.

e. Patients on chronic opioid medication dosages must receive them through one prescribing physician.

* Maintenance Duration: Up to 12 visits within a 12 month period to review the opioid plan. Laboratory and other monitoring as appropriate.
	1. THERAPY MANAGEMENT Some treatment may be helpful on a continued basis during maintenance care if the therapy maintains objective function and decreases medication use. With good management, exacerbations should be uncommon; not exceeding two times per year and using minimal or no treatment modality beyond self-management. On occasion, exacerbated conditions may warrant durations of treatment beyond those listed below. Having specific goals with objectively measured functional improvement during treatment can support extended durations of care. It is recommended that if after 6 to 8 visits no treatment effect is observed, alternative treatment interventions should be pursued.
* Active Therapy, Acupuncture, or Manipulation Maintenance Duration: 10 visits [for each treatment] during the first year and then decreased to 5 visits per year thereafter.
	1. INJECTION THERAPY
		1. Trigger Point Injections - These injections may occasionally be necessary to maintain function in those with myofascial problems.
* Maintenance Duration: Not more than 4 injections per session not to exceed 4 sessions per 12 month period.
	+ 1. Epidural and Selective Nerve Root Injections - Patients who have experienced functional benefits from these injections in the past may require injection for exacerbations of the condition.
* Maintenance Duration: 2 to 4 injections per 12 month period. For chronic radiculopathy, injections may be repeated only when a functional documented response lasts for 3 months. Patients should be reassessed after each injection session for an 80% improvement in pain (as measured by accepted pain scales) and evidence of functional improvement. A positive result would include a return to baseline function, return to increased work duties, and measurable improvement in physical activity goals including return to baseline after an exacerbation. Injections may only be repeated when these functional and time goals are met. Repeated injections with steroids should be done with caution especially in patients who have received other steroid injections or oral steroid therapy as higher yearly total doses of steroids may be associated with an increase in osteoarthritis ([Felson D 1987](#FelsonD1987)).
	+ 1. Zygapophyseal (facet) injections -
* Maintenance Duration: 2 injections per year and limited to 3 joint levels either unilaterally or bilaterally. Injections may be repeated only when a functional documented response lasts for 3 months. Patients should be reassessed after each injection session for an 80% improvement in pain (as measured by accepted pain scales) and evidence of functional improvement. A positive result would include a return to base line function, return to increased work duties, and a measurable improvement in physical activity goals including return to baseline after an exacerbation. Injections may only be repeated when these functional and time goals are met. Repeated injections with steroids should be done with caution especially in patients who have received other steroid injections or oral steroid therapy as higher yearly total doses of steroids may be associated with an increase in osteoarthritis ([Felson D 1987](#FelsonD1987)).
	+ 1. Sacro-iliac Joint -
* Maintenance Duration: 2 per year injections may be repeated only if when a functional documented response lasts for 3 months. Patients should be reassessed after each injection session for an 80% improvement in pain (as measured by accepted pain scales) and evidence of functional improvement. A positive result would include a return to base line function, return to increased work duties, and a measurable improvement in physical activity goals including return to baseline after an exacerbation. Injections may only be repeated when these functional and time goals are met. Repeated injections with steroids should be done with caution especially in patients who have received other steroid injections or oral steroid therapy as higher yearly total doses of steroids may be associated with an increase in osteoarthritis ([Felson D 1987](#FelsonD1987)).
	+ 1. Radiofrequency Medical Branch Neurotomy/ Facet Rhizotomy
* Maintenance Duration: 1 time per year up to 12 total-not exceeding 3 levels. The patient must meet the criteria as described in Section F. 5 b. The initial indications including repeat blocks and limitations apply. The long-term effects of repeat rhizotomies, especially on younger patients are unknown. There is a possibility that repeated denervation could result in premature degenerative changes. In addition the patient should always reconsider all of the possible permanent complications before consenting to a repeat procedure. There are no studies addressing the total number of RF neurotomies that should be done for a patient. Patient should receive at least 6 to 18 months minimum improvement in order to qualify for repeat procedures.
* Optimum/Maximum duration twice in the first year after the initial rhizotomy and once a year after up to 12 total.
	1. PURCHASE OR RENTAL OF DURABLE MEDICAL EQUIPMENTIt is recognized that some patients may require ongoing use of self-directed modalities for the purpose of maintaining function and/or analgesic effect. Purchase or rental of modality based equipment should be done only if the assessment by the physician and/or therapist has determined the effectiveness, compliance, and improved or maintained function by its application. It is generally felt that large expense purchases such as spas, whirlpools, and special mattresses are not necessary to maintain function.
* Maintenance Duration: Not to exceed 3 months for rental equipment.

**CHRONIC PAIN DISORDER & COMPLEX REGIONAL PAIN SYNDROME/REFLEX SYMPATHETIC DYSTROPHY (CRPS/RSD)
MEDICAL TREATMENT GUIDELINES
BIBLIOGRAPHY**

**NOTE:** The bibliography for the Chronic Pain and Complex Regional Pain Syndrome Medical Treatment Guidelines reflects the articles, abstracts, and literature reviewed during the Chronic Pain and CRPS update process. Where applicable, literature was given a designation of one of the following: High quality, adequate, inadequate, or not applicable. It should be noted that some articles might have more than one designation, such as, ‘adequate’ on one concept and ‘high-quality’ on another concept.Literature with these designations is noted in the bibliography. Each designation was assigned in accordance with the related Assessment Criteria.

Literature that was used to support evidence statements (eg. some, good, strong) is listed in the bibliography. Over 550 articles and literature were examined for consideration during the course of this update. A limited number of those articles qualified for evidence statements. The designated strength of the evidence may not coincide with acceptability of treatment. When the evidence is conflicting or inconclusive, acceptability of treatment is determined by a combination of available medical literature and group consensus. Some of the elements that are considered in making consensus determinations are: level of functional benefit, acceptable risk/morbidity/mortality, and acceptable cost.

A review of the Chronic Pain and CRPS Medical Treatment Guidelines bibliography needs to coincide with a review of the General Guidelines Principles. In particular, please review Guidelines Principle #12: Guidelines Recommendations and the Strength of Medical Evidence and Consensus Recommendations. All recommendations in the guidelines are considered to represent reasonable care in appropriately selected cases, regardless of the level of evidence or consensus attached to it. Those procedures considered inappropriate, unreasonable, or unnecessary are designated in the guideline as 'not recommended.'

1. Abbott, Z., & Richardson, J.K. (2007). Subacromial Impingement Syndrome as a Consequence of Botulinum Therapy to the Upper Trapezii: A Case report. *Arch Physical Medicine Rehabil.* 88:947-949.
2. Abramowicz, M. (Ed.) (January 2010). Medical Marijuana. *The Medical Letter. 52*: 1330. 5-6.
3. Abrams, DI, Jay, CA, Shade, SB, Vizoso, H., Reda, H., Press, S.,...Petersen, KL. (2007). Cannabis in Painful HIV-Associated Sensory Neuropathy. A Randomized Placebo-Controlled Trial. *Neurology. 68*: 515-521.
4. Adami, S., Fossaluzza, V., Gatti, D., Fracassi, E., & Braga, V. (1997). Bisphosphonate Therapy of Reflex Sympathetic Dystrophy Syndrome. *Annals of Rheumatic Disease. 56*: 201-204. Assessment: Inadequate.
5. Albazaz, R., Wong, YT, & Homer-Vanniasinkam, S. (2008). Complex Regional Pain Syndrome: A Review. *Annals of Vascular Surgery. 22*: 297-306. DOI: 10.1016/j.avsg.2007.10.1006
6. Altan, L., Bingol, U., Aykac, M., & Yurtkuran, M. (2005). Investigation of the Effect of GaAs Laser Therapy on Cervical Myofascial Pain Syndrome. *Rheumatol Int. 25*: 23-27. DOI 10.1007/s00296-003-0396-y
7. Altman, R., Dreiser, R-L., Fisher, C., Chase, W., Dreher, D., & Zacher, J. (2009). Diclofenac Sodium Gel in Patients with Primary Hand Osteoarthritis: A Randomized, Double Blind, Placebo Controlled Trial. *The Journal of Rheumatology.* 36: 1991-1999. DOI 10.3899/jrheum.081316. *High Quality. \*Used in Evidence Statement****.***
8. American Society of Anesthesiologists Task Force on Chronic Pain Management: Rosenquist, R., Benson, H., Connis, R., De Leon-Casasola, O., Glass, D., Korevaar, W., Cynwyd, B.,...Simon, D. (2010). Practice Guidelines for Chronic Pain Management. *Anesthesiology. 112*: 810-33.
9. Anagnostis, C., Gatchel, RJ, & Mayer, TG. (2004). The Pain Disability Questionnaire. *Spine. 29*; 20, 2290-2302.
10. Andersen, T., Christensen, FB, & Bunger, C. (2006). Evaluation of a Dallas Pain Questionnaire Classification in Relation to Outcome in Lumbar Spinal Fusion. *Eur Spine Journal. 15*: 1671-1685. DOI 10.1007/s00586-005-0046-z
11. Andersson, G., Lucente, T., Davis, A., Kappler, R., Lipton, J., & Leurgans, S. (1999). A Comparison of Osteopathic Spinal Manipulation with Standard Care for Patients with Low Back Pain. *The New England Journal of Medicine. 341*: 1426-31*.*
12. Ansari, A. (2000). The Efficacy of Newer Antidepressants in the Treatment of Chronic Pain: A Review of Current Literature. *Harvard Rev Psychiatry. 7*: 257-277.
13. Antman, E., Lau, J., Kupelnick, B., Mosteller, F., & Chalmers, T. (1992). A Comparison of Results of Meta-Analyses of Randomized Control Trials and Recommendations of Clinical Experts. *JAMA. 268:* 2, 240-248.
14. Argoff, C., (2011). Review of Current Guidelines on the Care of Postherpetic Neuralgia. *Postgraduate Medicine.* 123: 5, 134-142.
15. Armer, JM, & Stewart, BR. (2005). A Comparison of Four Diagnostic Criteria for Lymphedema in a Post-Breast Cancer Population. *Lymphatic Research and Biology.*  *3*, 4: 208-218.
16. Assefi, N., Bogart, A., Goldbert, J., & Buchwald, D. (2008). Reiki for the Treatment of Fibromyalgia: A Randomized Controlled Trial. *J Alterm Complement Med. 14* (9); 1115-22. Abstract Only.
17. Attal, N., Cruccu, G., Baron, R., Haanpaa, M., Hansson, P., Jensen, TS, & Nurmikko, T. (2010). EFNS Guidelines on Pharmacological Treatment of Neuropathic Pain: 2010 Revision. *European Journal of Neurology. 17:* 1113-1123. doi:10.1111/j.1468-1331.2010.02999.x
18. Attal, N., Cruccu, G., Haanpaa, M., Hansson, P., Jensen, TS, Nurmikko, T., Sampaio, C., Sindrup, S., & Wiffen, P. (2006). EFNS Guidelines on Pharmacological Treatment of Neuropathic Pain. *European Journal of Neurology. 13*: 1153-1169. doi:10.1111/j.1468-1331.2006.01511.x
19. Aure, OF, Nilsen, JH, & Vasseljen, O. (2003). Manual Therapy and Exercise Therapy in Patients with Chronic Low Back Pain. A Randomized, Controlled Trial with 1-Year Follow-up. *Spine. 28*:6, 525-532. Assessment: Adequate. *\*Used in Evidence Statement.*
20. Avins, A. (2010). Glucosamine and the Ongoing Enigma of Chronic Low Back Pain. *JAMA. 304* (1): 93-94.
21. Ballantyne, JC, & LaForge, KS. (2007). Opioid Dependence and Addiction During Opioid Treatment of Chronic Pain. *Pain. 129*: 235-255.
22. Ballantyne, JC, & Mao, J. (2003). Opioid Therapy for Chronic Pain. *The New England Journal of Medicine. 349*; 1943-53.
23. Barnett, G. Licko, V., Thompson, T. (1985). Behavioral pharmacokinetics of marijuana. *Psychopharmacology. 85:*51. 51-56.
24. Barolat, G., Ketcik, B., & He, J. (1998). Long-term Outcome of Spinal Cord Stimulation for Chronic Pain Management. *Neuromodulation. 1*, 1; 19-29.
25. Barolat, G., Oakley, JC, Law, JD, North, RB, Ketcik, B., & Sharan, A. (2001). Epidural Spinal Cord Stimulation with a Multiple Electrode Paddle Lead Is Effective in Treating Intractable Low Back Pain. *Neuromodulation. 4*, 2; 59-66.
26. Baron, R. (2009). Neuropathic Pain: A Clinical Perspective. *Handbook of Experimental Pharmacology. 194*, DOI: 10.1007/978-3-540-79090-7\_1.
27. Barton, D. L., Wos, E. J., Rui, Q., Mattar, B.I., Green, N.B., Lanier….Loprinzi, C.L. (2011). A double-blind placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. *Support Care Cancer*. *19.* 833-841. DOI: 10.1007/s00520-010-0911-0.
28. Bates, MN, & Blakely, TA. (1999). Role of Cannabis in Motor Vehicle Crashes. *Epidemiologic Reviews. 21*; 2, 222-232.
29. Bentsen, BG, Natvig, B., & Winnem, M. (1999). Questions You Didn’t Ask? COOP/WONCA Charts in Clinical Work and Research. *Family Practice. 16*; 2, 190-195.
30. Beydoun, A., Shaibani, A., Hopwood, M., & Wan, Y. (2006). Oxcarbazepine in Painful Diabetic Neuropathy: Results of a Dose-Ranging Study. *Acta Neurol Scand. 113*: 385-404. DOI:10.1111/j.1600-0404.2006.00631.x. Assessment: Adequate. (also inadequate on another issue). *\*Used in Evidence Statement.*
31. Bianchi, C., Rossi, S., Turi, S., Brambilla, A., Felisari, G., & Mascheri, D. (2006). Long-Term Functional Outcome Measures in Corticosteroid-Treated Complex Regional Pain Syndrome. *Eur Med Phys. 42*: 105-11.
32. Birklein, F., Riedl, B., Claus, D., & Neundorfer, B. (1998). Pattern of Autonomic Dysfunction in Time Course of Complex Regional Pain Syndrome. *Clinical Autonomic Research. 8*; 79-85.
33. Block, AR, Ohnmeiss, DD, Guyer, RD, Rashbaum, RF, & Hochschuler, SH. (2001). The Use of Presurgical Psychological Screening to Predict the Outcome of Spine Surgery. *Spine J. 1* (4): 274-82. Assessment: Adequate. \**Used in Evidence Statement.*
34. Blonk, M., Koder, B., van den Bemt, P., & Huygen, F. (2010). Use of Oral Ketamine in Chronic Pain Management: A Review. *European Journal of Pain. 14*: 466-472.
35. Bohnert, A., Valenstein, M., Bair, M., Ganoczy, D., McCarthy, J., Ilgen, M., & Blow, F. (2011). Association between Opioid Prescribing Patterns and Opioid Overdose-Related Deaths. *JAMA. 305* (13): 1315-1321.
36. Borckardt, J., Smith, A., Reeves, S., Madan, A., Shelley, N., Branham, R.,...George, M. (2009). A Pilot Study Investigating the Effects of Fast Left Prefrontal rTMS on Chronic Neuropathic Pain. *Pain Med. 10* (5): 840-849. doi:10.1111/j.1526-4637.2009.00657.x.
37. Borman, P., Keskin, D., Ekici, N., & Bodur, H. (2008). The Efficacy of Intermittent Cervical Traction in Patients with Chronic Neck Pain. *Clinical Rheumatology. 27*: 1249-1253. DOI 10.1007/s10067-008-0895-z.
38. Braus, DF, Krauss, JK, & Strobel, J. (1994). The Shoulder-hand Syndrome after Stroke: A Prospective Clinical Trial. *Annals of Neurology. 36*: 728-733.
39. Brennan Braden, J., Russo, J., Fan, MY, Edlund, M., Martin, B., DeVries, A., & Sullivan, M. (2010). Emergency Department Visits among Recipients of Chronic Opioid Therapy. *Arch Intern Med. 170* (16): 1425-1432.
40. Bril, V., England, J., Franklin, G.M., et al. (2011). Evidence-based Guideline: Treatment of Painful Diabetic Neuropathy. *Neurology* Pre-published online. Doi:10.1212/WNL.0b013e3182166ebe
41. Brinkhaus, B., Witt, C., Jena, S., Linde, K., Streng, A., Wagenpfeil, S., Irnich, D., & Willich, S. (2006). Acupuncture in Patients with Chronic Low Back Pain. *American Medical Association. 166*: 450-457. Assessment: High-Quality. *\*Used in Evidence Statement.*
42. Bronfort, G., Evans, R., Nelson, B., Aker, P., Goldsmith, C., & Vernon, H. (2001). A Randomized Clinical Trial of Exercise and Spinal Manipulation for Patients with Chronic Neck Pain. *Spine. 27*: 7, 788-799. Assessment: Adequate. *\*\*Used in Evidence Statement.*
43. Brox, JI, Nygaard, OP, & Holm, I. (2010). Four-year Follow-up of Surgical versus Non-surgical Therapy for Chronic Low Back Pain. *Annals of the Rheumatic Diseases. 69*; 1643-1648. Assessment: Adequate. *\*Used in Evidence Statement.*
44. Brox, JI, Sorensen, R, Friis, A., Nygaard, O., Indahl, A., Keller, A.,...Reikeras, O. (2003). Randomized Clinical Trial of Lumbar Instrumented Fusion and Cognitive Intervention and Exercises in Patients with Chronic Low Back Pain and Disc Degeneration. *Spine. 28;* 17, 1913-1921. Assessment: Adequate. *\*Used in Evidence Statement.*
45. Bruehl, S. (2010). An Update on the Pathophysiology of Complex Regional Pain Syndrome. *Anesthesiology. 113*; 713-25.
46. Bruehl, S., Harden, R., Galer, B., Saltz, S., Bertram, M., Backonja, M.,...Stanton-Hicks, M. (1999). External Validation of IASP Diagnostic Criteria for Complex Regional Pain Syndrome and Proposed Research Diagnostic Criteria. *Pain. 81*: 147-154.
47. Brunner, F., Bachmann, LM, Weber, U., Kessels, AGH, Perez, RSGM, Marinus, J., & Kissling, R. (2008). Complex Regional Pain Syndrome I - The Swiss Cohort Study. *BMC Musculoskeletal Disorders. 9*:92. doi:10.1186/1471-2474-9-92
48. Bruns, D., & Disorbio, JM. (2009). Assessment of Biopsychosocial Risk Factors for Medical Treatment: A Collaborative Approach. *J Clinical Psychol Med Settings. 16*; 127-147. DOI 10.1007/s10880-009-9148-9
49. Bruns, D., & Disorbio, JM. (2010). The Psychological Assessment of Patients with Chronic Pain. *AAPM Textbook of Pain Medicine.*
50. Bultmann, U., Sherson, D., Olsen, J., Hansen, CL, Lund, T., & Kilsgaard, J. (2009). Coordinated and Tailored Work Rehabilitation: A Randomized Controlled Trial with Economic Evaluation Undertaken with Workers on Sick Leave Due to Musculoskeletal Disorders.  *Journal of Occupation Rehabilitation. 19*: 81-93. DOI 10.1007/s10926-009-9162-7
51. Burchman, SL, & Pagel, PS. (1995). Implementation of a Formal Treatment Agreement for Outpatient Management of Chronic Nonmalignant Pain with Opioid Analgesics. *Journal of Pain and Symptom Management. 10*; 7, 556-563.
52. Burns, J.W., Glenn, B., Bruehl, S., Harden, R.N., & Lofland, K. (2003). Cognitive Factors Influence Outcome Following Multidisciplinary Chronic Pain Treatment: A Replication and Extension of a Cross-lagged Panel Analysis. *Behaviour Research and Therapy 41*: 1163-1182. doi:10.1016/S0005-7967/(03)00029-9
53. Butler, SF, Benoit, C., Budman, SH, Fernandez, KC, McCormick, C., Venuti, SW, & Katz, N. (2006). Development and Validation of an Opioid Attractiveness Scale: A Novel Measure of the Attractiveness of Opioid Products to Potential Abusers. *Harm Reduction Journal. 3*: 5 doi:10.1186/1477-7517-3-5
54. Buynak, R., Shapiro, D., Okamoto, A., Van Hove, I., Rauschkolb, C., Steup, A.,...Etropolski, M. (2010). Efficacy and Safety of Tapentadol Extended Release for the Management of Chronic Low Back Pain: Results of a Prospective, Randomized, Double-Blind, Placebo-and Active-Controlled Phase III Study. *Expert Opinion Pharmacotherapy. 11*: 11, 787-1804. Assessment: High Quality. *\*Used in Evidence Statement.*
55. Buysse, DJ, Reynolds, CF, Monk, TH, Berman, SR, & Kupfer, DJ. (1989). Pittsburgh Sleep Quality Index. *Psychiatry Research. 28*; 193-213.
56. Cacchio, A. (2009). Mirror Therapy for Chronic Complex Regional Pain Syndrome Type 1 and Stroke. *The New England Journal of Medicine. 361*: 6, 634-635. Assessment: Adequate. *\*Used in Evidence Statement.*
57. Calabria, B., Degenhardt, L., Hall, W.,...Lynskey, M. (2010). Does Cannabis Use Increase the Risk of Death? Systematic Review of Epidemiological Evidence on Adverse Effects of Cannabis Use. *Drug and Alcohol Review. 29*, 318-330. DOI:10.1111/j.1465-3362.2009.00149.x
58. Campa, D., Gioia, A., Tomei, A., Poli, P., & Barale, R. (2008). Association of ABCB1/MDR1 and OPRM1 Gene Polymorphisms with Morphine Pain Relief. *Clinical Pharmacology & Therapeutics. 83*: 4.
59. Canadian Sleep Society Committee Members: Blackman, A., McGregor, C., Dales, R., Driver, H., Dumor, I., Fleming, J.,...Sullivan, G., Canadian Thoracic Society Committee Members: Fleetham, J., Ayas, N., Bradley, T., Fitzpatrick, M., Kimoff, J., Morrison, D., ...Tsai, W. (2010). Canadian Sleep Society/Canadian Thoracic Society Position Paper on the Use of Portable Monitoring for the Diagnosis of Obstructive Sleep Apnea/Hypopnea in Adults. *Canadian Respir Journal 17*(5): 229-232.
60. Canlas, B., Drake, T., & Gabriel, E. (2010). A Severe Case of Complex Regional Pain Syndrome I (Reflex Sympathetic Dystrophy) Managed with Spinal Cord Stimulation. *Pain Practice. 10*:1, 78-83.
61. Carragee, E., Alamin, T., Miller, J., & Carragee, J. (2005). Discographic, MRI and psychosocial determinants of low back pain disability and remission: a prospective study in subjects with benign persistent back pain. *The Spine Journal.* 5: 24-35.
62. Ceccherelli, F., Altafini, L., Lo Castro, G., Avila, A., Ambrosio, F., & Giron, GP. (1989). Diode Laser in Cervical Myofascial Pain: A Double-Blind Study versus Placebo. *The Clinical Journal of Pain. 5*: 301-304.
63. Cecchi, F., Molino-Love, R., Chilti, M., Pasquini, G., & Paperini, A. (2010). Spinal Manipulation Compared with Back School and with Individually Delivered Physiotherapy for the Treatment of Chronic Low Back Pain: A Randomized Trial with One-Year Follow-Up. *Clinical Rehabilitation. 24*: 26-36.
64. Cepeda, MS, Camargo, F., Zea, C., & Valencia, L. (2007). Tramadol for Osteoarthritis: A Systematic Review and Metaanalysis. *The Journal of Rheumatology. 34*:3, 543-555.
65. Cepeda, MS, Carr, DB, Lau, J., & Alvarez, H. Music for Pain Relief. *Cochrane Database of Systematic Reviews* 2006, Issue 2. Art. No.: CD004843. DOI:10.1002/14651858.CD004843.pub2.
66. Cepeda, MS, Carr, DB, & Lau, J. Local Anaesthetic Sympathetic Blockade for Complex Regional Pain Syndrome. *Cochrane Database of Systematic Reviews* 2005, Issue 4. Art. No.: CD004598. DOI:10.1002/14651858.CD004598.pub2.
67. Challapalli, V., Tremont-Lukats, IW, McNicol, ED, Lau, J., & Carr, DB. Systemic Administration of Local Anesthetic Agents to Relieve Neuropathic Pain. *Cochrane Database of Systematic Reviews* 2005, Issue 4. Art. No.: CD003345. DOI:10.1002/14651858.CD003345.pub2. Assessment: Adequate.
68. Chan, DKC, Johnson, M., Sun, KO, Doble, SJ, & Jenkins, S. (2009). Electrical Acustimulation of the Wrist for Chronic Neck Pain: A Randomized, Sham-Controlled Trial Using a Wrist-Ankle Acustimulation Device. *Clinical Journal of Pain. 25*: 320-326. Assessment: Adequate. \*\**Used in Evidence Statement*
69. Chandra, K., Shafiq, N., Pandhi, P., Gupta, S., & Malhotra, S. (2006). Gabapentin Versus Nortriptyline in Post-herpetic Neuralgia Patients: A Randomized, Double-Blind Clinical Trial - The GONIP Trial. *International Journal of Clinical Pharmacology and Therapeutics. 44*: 8, 358-363. Assessment: Adequate. *\*Used in Evidence Statement.*
70. Chao, S-C, Lee, H-T, Kao, T-H, Yang, M-Y, Tsuei, Y-S, Shen, C-C, & Tsou, H-K. (2008). Percutaneous Pulsed Radiofrequency in the Treatment of Cervical and Lumbar Radicular Pain. *Surgical Neurology. 70*: 59-65. doi:10.101+/j.surneu.2007.05.046
71. Chelimsky, TC, Low, PA, Naessens, JM, Wilson, PR, Amadio, PC, & O’Brien, PC. (1996). Reflex Sympathetic Dystrophy. *Mayo Clinic Proc. 71*; 524-525.
72. Chelimsky, TC, Low, PA, Naessens, JM, Wilson, PR, Amadio, PC, & O’Brien, PC. (1995). Value of Autonomic Testing in Reflex Sympathetic Dystrophy. *Mayo Clinic Proc. 70*; 1029-1040. Assessment: Inadequate.
73. Cherkin, DC, Eisenberg, D., Sherman, KJ, Barlow, W., Kaptchuk, TJ, Street, J., & Deyo, RA. (2001). Randomized Trial Comparing Traditional Chinese Medical Acupuncture, Therapeutic Massage, and Self-care Education for Chronic Low Back Pain. *Arch Intern Med. 161*: 1081-1088. Assessment: Adequate. \**Used in Evidence Statement.*
74. Chou, R., Fanciullo, G., Fine, P., Adler, J., Ballantyne, J., Davies, P.,...Miaskowski, C. (2009). Opioid Treatment Guidelines. Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain. *The Journal of Pain. 10*, 2: 113-130.
75. Chou, R. (2009). Low Back Pain (Chronic). *Clinical Evidence. 10*: 1116, 1-40.
76. Chou, R., & Carson, S. (2008). Drug Class Review on Long-Acting Opioid Analgesics. Final Report. *Oregon Health & Science University.*
77. Chou, R., Huffman, L.H. (2007). Guideline for the Evaluation and Management of Low Back Pain: Evidence Review. *American Pain Society.* <http://www.ampainsoc.org/library/pdf/LBPEvidRev.pdf>.
78. Chow, R., Johnson, M., Bjordal, J., & Lopes-Martins, R. (2010). Low-level Laser Therapy for Neck Pain - Authors’ Reply. *The Lancet. 375*; 9716, 722. doi: 10.1016/S0140-6736(10)60298-X
79. Chow, R., Johnson, M., Lopes-Martins, RAB, & Bjordal, JM. (2009). Efficacy of Low-level Laser Therapy in the Management of Neck Pain: A Systematic Review and Meta-Analysis of Randomised Placebo or Active-treatment Controlled Trials. *Lancet. 374*: 1897-908. Assessment: Adequate.
80. Chow, R., Heller, GZ, & Barnsley, L. (2006). The Effect of 300 mW, 830 nm Laser on Chronic Neck Pain: A Double-blind, Randomized, Placebo-controlled Study. *Pain. 124*: 201-210.
81. Chow, R., Barnsley, L., Heller, GZ, & Siddall, PJ. (2004). A Pilot Study of Low-Power Laser Therapy in the Management of Chronic Neck Pain. *Journal of Musculoskeletal Pain. 12* (2). DOI 10.1300/J094v12n02\_09
82. Christensen, K., Jensen, EM, & Noer, I. (1982). The Reflex Dystrophy Syndrome Response to Treatment with Systemic Corticosteroids. *Acta Chir Scand. 148*: 653-655. Assessment: Adequate.
83. Chrubasik, S., Eisenberg, E., Balan, E., Weinberger, T., Luzzati, R., & Conradt, C. (2000). Treatment of Low Back Pain Exacerbations with Willow Bark Extract: A Randomized Double-Blind Study. *American Journal of Medicine. 109*: 9-14. Assessment: Adequate.
84. Chu, LF, Clark, DJ, & Angst, MS. (2006). Opioid Tolerance and Hyperalgesia in Chronic Pain Patients after One Month of Oral Morphine Therapy: A Preliminary Prospective Study. *The Journal of Pain. 7*; 1, 43-48.
85. Cicero, TJ, Lynskey, M., Todorov, A., Inciardi, JA, & Surratt, HL. (2008). Co-morbid Pain and Psychopathology in Males and Females Admitted to Treatment for Opioid Analgesic Abuse. *Pain. 139*; 127-135.
86. Cicero, TJ, Dart, RC, Inciardi, JA, Woody, GE, Schnoll, S., & Munoz, A. (2007). The Development of a Comprehensive Risk-Management Program for Prescription Opioid Analgesics: Researched Abuse, Diversion and Addition-Related Surveillance (RADARS®). *Pain. 8*: 2.
87. Cicero, TJ, Inciardi, JA, Adams, EH, Geller, A., Senay, EC, Woody, GE, & Munoz, A. (2005). Rates of Abuse of Tramadol Remain Unchanged with the Introduction of New Branded and Generic Products: Results of an Abuse Monitoring System, 1994-2004. *Pharmacoepidemiology and Drug Safety. 14*: 851-859.
88. Cifuentes, M., Webster, B., Genevay, S., & Pransky, G. (2010). The Course of Opioid Prescribing for a New Episode of Disabling Low Back Pain: Opioid Features and Dose Escalation. *Pain. 151*: 22-29.
89. Coffey, R., Owens, M., Broste, S., Dubois, M., Ferrante, F., Schultz, D., Stearns, L., & Turner, M. (2010). Medical Practice Perspective: Identification and Mitigation of Risk Factors for Mortality Associated with Intrathecal Opioids for Non-Cancer Pain. *Pain Medicine.* 11: 1001-1009.
90. Cohen, S., Williams, K., Kurihara, C., Nguyen, C., Shields, C., Kim, P.,...Strassels, S. (2010). Multicenter, Randomized, Comparative Cost-Effectiveness Study Comparing, 0, 1, and 2 Diagnostic Medial Branch (Facet Joint Nerve) Block Treatment Paradigms before Lumbar Facet Radiofrequency Denervation. *Anesthesiology. 113*: 395-405.
91. Cohen, S., Hurley, R., Buckenmaier, III, C., Kurihara, C., Morlando, B., & Dragovich, A. (2008). Randomized Placebo-Controlled Study Evaluating Lateral Branch Radiofrequency Denervation for Sacroiliac Joint Pain. *Anesthesiology. 109* (2): 279-288.
92. Collins, S., Sigtermans, M., Dahan, A., Zuurmond, W., & Perez, R. (2010). NMDA Receptor Antagonists for the Treatment of Neuropathic Pain. *Pain. Medicine. 11*: 1726-1742.
93. Collins, S., Van Hilten, JJ, Marinus, J., Zuurmond, WW, De Lange, JJ, & Perez, RS. (2008). Development of a Symptoms Questionnaire for Complex Regional Pain Syndrome and Potentially Related Illness: The Trauma Related Neuronal Dysfunction Symptoms Inventory. *Arch Phys Med Rehabil. 89*: 1114-1120.
94. *Colorado Clinical Guidelines Collaborative.* (2006). Major Depression Disorder in Adults. Diagnosis & Treatment Guidelines. Overview.
95. Colorado Division of Workers’ Compensation. (2007). Cervical Spine Injury Medical Treatment Guidelines. Retrieved from [www.colorado.gov/cdle/dwc](http://www.colorado.gov/cdle/dwc).
96. Colorado Division of Workers’ Compensation. (2010). Cumulative Trauma Conditions Medical Treatment Guidelines. Retrieved from [www.colorado.gov/cdle/dwc](http://www.colorado.gov/cdle/dwc).
97. Colorado Division of Workers’ Compensation. (2007). Low Back Pain Medical Treatment Guidelines. Retrieved from [www.colorado.gov/cdle/dwc](http://www.colorado.gov/cdle/dwc). *\*Used in Evidence Statement.*
98. Colorado Division of Workers’ Compensation. (2006). Traumatic Brain Injury Medical Treatment Guidelines. Retrieved from [www.colorado.gov/cdle/dwc](http://www.colorado.gov/cdle/dwc).
99. *Commission on Accreditation of Rehabilitation Facilities (CARF)*. Opioid Treatment Program. Standards Manual 2010-2011.
100. *Commission on Accreditation of Rehabilitation Facilities (CARF)*. Medical Rehabilitation. Standards Manual 2010-2011.
101. Conwell, TD, Hobbins, WN, & Giordano, J. (2010). Sensitivity, Specificity and Predictive Value of Infrared Cold Water Autonomic Functional Stress Testing As Compared with Modified IASP Criteria for CRPS. *Thermology International.* *20/*2. Assessment: Inadequate.
102. Correll, GE, Maleki, J., Gracely, EJ, Muir, JJ, & Harbut, RE. (2004). Subanesthetic Ketamine Infusion Therapy: A Retrospective Analysis of a Novel Therapeutic Approach to Complex Regional Pain Syndrome. *Pain. 5*: 3, 263-275.
103. Costa, J., Espírito-Santo, CC, Borges, AA, Ferreira, J., Coelho, MM, Moore, P., & Sampaio, C. Botulinum Toxin Type A Therapy for Cervical Dystonia. *Cochrane Database of Systematic Reviews* 2005, Issue 1. Art. No.:CD003633.DOI: 10.1002/14651858.CD003633.pub2. Assessment: Adequate/High Quality. \**Used in Evidence Statement.*
104. Coutu, MF, Baril, R., Durand, MH, Cote, D., Rouleau, A., & Cadieux, G. (2010). Transforming the Meaning of Pain: An Important Step for the Return to Work. *Work. 35:* 209-219.
105. Cruccu, G., Sommer, C., Anand, P., Attal, N., Baron, R., Garcia-Larrea, L., ... Treede, R-D. (2010). EFNS Guidelines on Neuropathic Pain Assessment: Revised 2009. *European Journal of Neurology. 17*; 1010-1018. doi:10.1111/j.1468-1331.2010.02969.x
106. Cruccu, G., Aziz, TZ, Garcia-Larrea, L., Hansson, P., Jensen, TS, Lefaucheur, J-P, Simpson, BA, & Taylor, RS. (2007). EFNS Guidelines on Neurostimulation Therapy for Neuropathic Pain. *European Journal of Neurology. 14*: 952-970. doi:10.1111/j.1468-1331.2007.01916.x
107. Currie, SR, & Wilson, KG. (2000). Cognitive-Behavioral Treatment of Insomnia Secondary to Chronic Pain.  *Journal of Consulting and Clinical Psychology. 68*; 3, 407-416. Assessment: Adequate. *\*Used in Evidence Statement.*
108. Dasgupta, N., Kramer, ED, Zalman, MA, Carino, Jr., S., Smith, MY, Haddox, JD, & Wright, IV, C. (2006). Association between Non-Medical and Prescriptive Usage of Opioids. *Drug and Alcohol Dependence. 82*: 135-142.
109. Datta, S., Lee, M., Falco, F., Bryce, D., & Hayek, S. (2009). Systematic Assessment of Diagnostic Accuracy and Therapeutic Utility of Lumbar Facet Joint Interventions. *Pain Physician. 12:* 437-460.
110. Daubs, M., Patel, A., Willick, S., Kendall, R., Hansen, P., Petron, D., & Brodke, D. (2010). Clinical Impression Versus Standardized Questionnaire: The Spinal Surgeon’s Ability to Assess Psychological Distress. *JBJS. 92*; 2878-2883.
111. Davis, K., & Heaney, C. (2000). The Relationship between Psychosocial Work Characteristics and Low Back Pain: Underlying Methodological Issues. *Clinical Biomechanics. 15;* 389-406.
112. DeBerard, MS, Masters, KS, Colledge, AL, & Holmes, EB. (2003). Presurgical Biopsychosocial Variables Predict Medical and Compensation Costs of Lumbar Fusion in Utah Workers’ Compensation Patients. *The Spine Journal. 3*; 420-429.
113. Deer, T., Kim, C., Bowman, R., Tolentino, D., Stewart, C., & Tolentino, W. (2009). Intrathecal Ziconotide and Opioid Combination Therapy for Noncancer Pain: An Observational Study. *Pain Physician. 12;* E291-E296.
114. Deer, T., Krames, ES, Hassenbusch, SJ, Burton, A., Caraway, D., Dupen, S., ...Ver Donck, A. (2007). Polyanalgesic Consensus Conference 2007: Recommendations for the Management of Pain by Intrathecal (Intraspinal) Drug Delivery: Report of an Interdisciplinary Expert Panel. *Neuromodulation: Technology at the Neural Interface. 10*: 4.
115. Deltombe, T., Jamart, J., Recloux, S., Legrand, C., Vandenbroeck, N., Theys, S., & Hanson, P. (2007). Reliability and Limits of Agreement of Circumferential, Water Displacement, and Optoelectronic Volumetry in the Measurement of Upper Limb Lymphedema. *Lymphology. 40* (1): 26-34.
116. Den Boer, JJ, Oostendorp, RA, Beems, T., Munneke, M., Oerlemans, M., & Evers, AW. (2006). A Systematic Review of Bio-psychosocial Risk Factors for an Unfavourable outcome After Lumbar Disc Surgery. *Eur Spin Journal. 15*: 527-536 DOI 10.1007/s00586-005-0910-x
117. Denison, E., Asenlof, P., & Linberg, P. (2004). Self-Efficacy, Fear Avoidance and Pain Intensity of Predictors of Disability in Sub Acute and Chronic Musculoskeletal Pain Patients in Primary Care. *Pain. 111*: 245-52.
118. Derry, S., Lloyd, R., Moore, RA, & McQuay, HJ. Topical Capsaicin for Chronic Neuropathic Pain in Adults. *Cochrane Database of Systematic Reviews* 2009, Issue 4. Art. No.: CD007393. DOI:10.1002/14651858.CD007393.pub2. Assessment: Overall Adequate. *\*Used in Evidence Statement.*
119. Dersh, J., Gatchel, RJ, Polatin, P., & Mayer, T. (2002). Prevalence of Psychiatric Disorders in Patients with Chronic Work-Related Musculoskeletal Pain Disability. *JOEM. 44;* 5, 459-468.
120. Deshpande, A., Furlan, AD, Mailis-Gagnon, A., Atlas, S., & Turk, D. Opioids for Chronic Low-Back Pain. *Cochrane Database of Systematic Reviews* 2007, Issue 3. Art. No.: CD004959. DOI:10.1002/14651858.CD004959.pub3.
121. Dewey, WS, Hedman, TL, Chapman, TT, Wolf, SE, & Holcomb, JB. (2007). The Reliability and Concurrent Validity of the Figure-of- Eight Method of Measuring Hand Edema in Patients with Burns. *J Burn Care Res. 28*:157–162.
122. Deyo, R. (2010). Point of View. Efficacy and Safety of Duloxetine in Patients with Chronic Low Back Pain. *Spine. 35*:13, E586.
123. Dilke, TFW, Burry, HC, & Grahame, R. (1973). Extradural Corticosteroid Injection in Management of Lumbar Nerve Root Compression. *British Medical Journal. 2*; 635-637.
124. Dincer, F., & Linde, K. (2003). Sham Interventions in Randomized Clinical Trials of Acupuncture-A Review. *Therapeutics in Medicine. 11*; 235-242. doi: 10.1016/S0965-2299(03)00124-9.
125. Dobscha, SK, Corson, K., & Perrin, NA. (2009). Collaborative Care for Chronic Pain in Primary Care: A Cluster Randomized Trial. *JAMA. 301* (12): 1242-1252. doi:10.1001/jama.2009.377. Assessment: Adequate. *\*Used in Evidence Statement.*
126. Dogra, S., Beydoun, S., Mazzola, J., Hopwood, M., & Wan, Y. (2005). Oxcarbazepine in Painful Diabetic Neuropathy: A Randomized, Placebo-Controlled Study. *European Journal of Pain. 9*: 543-554. Assessment: Adequate. *\*Used in Evidence Statement.*
127. Donceel, P., Du Bois, M. (1999). Predictors for work incapacity continuing after disc surgery. *Scand J Work Environ Health.* 25(3): 264-271.
128. Duehmke, RM, Hollingshead, J., & Cornblath, DR. Tramadol for Neuropathic Pain. *Cochrane Database of Systematic Reviews* 2006, Issue 3. Art. No.: CD003726. DOI:10.1002/14651858.CD003726.pub3. Assessment: Adequate.
129. Dufour, N., Thamsborg, G., Oefeldt, A., Lundsgaard, C., & Stender, S. (2010). Treatment of Chronic Low Back Pain. *Spine. 35*; 5, 469-476.
130. Dundar, U., Evcik, D., Samli, F., Pusak, H., & Kavuncu, V. (2007). The Effect of Gallium Arsenide Aluminum Laser Therapy in the Management of Cervical Myofascial Pain Syndrome: A Double Blind, Placebo-Controlled Study. *Clinical Rheumatol. 26*: 930-934. DOI 10.1007/s10067-006-0438-4
131. Dunn, K., Saunders, K., Rutter, C., Banta-Green, C., Merrill, J., Sullivan, M., Weisner, C., Silverberg, M.,...Von Korff, M. (2010). Opioid Prescriptions for Chronic Pain and Overdose. *Ann Intern Med. 152*: 85-92.
132. Dworkin, R., O’Connor, A., Audette, J., Baron, R., Gourlay, G., Haanpaa, M.,...Wells, C. (2010). Recommendations for the Pharmacological Management of Neuropathic Pain: An Overview and Literature Update. *Mayo Clinic Proceedings. 85* (3) (Suppl.):S3-S14.
133. Ebell, M., & Kripke, C. (2006). Cochrane Briefs. Gabapentin for Pain: Balancing Benefit and Harm. *American Family Physicians. 73*; 3.
134. Eberle, T., Doganci, B., Kramer, H.H., (2009). Warm and cold complex regional pain syndromes: Differences beyond skin temperature? *Neurology. 72.* 505. DOI: 10.1212/01.wnl.0000341930.35494.66.
135. Eccleston, C., Williams, ACDC, & Morley, S. Psychological Therapies for the Management of Chronic Pain (Excluding Headache) in Adults. *Cochrane Database of Systematic Reviews* 2009, Issue 2. Art. No.: CD007407. DOI:10.1002/14651858.CD007407.pub2. Assessment: Adequate. *\*Used in Evidence Statement.*
136. Edlund, MJ, Steffick, D., Hudson, T., Harris, KM, & Sullivan, M. (2007). Risk Factors for Clinically Recognized Opioid Abuse and Dependence among Veterans Using Opioids for Chronic Non-cancer Pain. *Pain. 129*: 355-362.
137. Edlund, MJ, Sullivan, M., Steffick, D., Harris, K., & Wells, K. (2007). Do Users of Regularly Prescribed Opioids have Higher Rates of Substance Use Problems than Nonusers? *Pain Medicine. 8*: 8, 647-656.
138. Ehrlich, G.E. (2003). Low back pain. *Bulletin of the World Health Organization* 81(9): 671-676.
139. Eisenberg, E., Waisbrod, H., & Gerbershagen, HU. (2004). Long-Term Peripheral Nerve Stimulation for Painful Nerve Injuries. *Clinical Journal of Pain. 20*; 3: 143-146.
140. Ellis, R., Toperoff, W., Vaida, F., Van den Brande, G., Gonzales, J., Gouaux, B.,...Atkinson, J. (2009). Smoked Medicinal Cannabis for Neuropathic Pain in HIV: A Randomized, Crossover Clinical Trial.  *Neuropsychopharmacology. 34*; 672-680.
141. Epker, J., & Block, A. (2001). Presurgical Psychological Screening in Back Pain Patients: A Review. *The Clinical Journal of Pain. 17*; 200-205.
142. Epstein, J.B., Epstein, J.D., Epstein, M.S., Oien, H., Truelove, E.L. (2006). Oral doxepin rinse: The analgesic effect and duration of pain reduction in patients with oral mucositis due to cancer therapy. *Pain Medicine (103)* 2. DOI: 10.1213/01.ane.0000223661.60471.78.
143. Ernst, E., Soo Lee, M., & Choi, TY. (2011). Acupuncture: Does it Alleviate Pain and are There Serious Risks? A Review of Reviews. *Pain. 152*; 755-764. doi:10.1016/j.pain.2010.11.004 Assessment: Adequate. *\*Used in Evidence Statement.*
144. Esmer, G., Blum, J., Rulf, J., & Pier, J. (2011). Mindfulness-Based Stress Reduction for Failed Back Surgery Syndrome: A Randomized Controlled Trial. *J Am Osteopath Assoc. 111* (1): 3.
145. Espie, CA, Fleming, L., Cassidy, J., Samuel, L., Taylor, LM, White, CA, Douglas, NJ, Engleman, HM, Kelly, H-L, & Paul, J. (2008). Randomized Controlled Clinical Effectiveness Trial of Cognitive Behavior Therapy Compared with Treatment as Usual for Persistent Insomnia in Patients with Cancer. *Journal of Clinical Oncology. 26*; 28, 4651-4658.
146. Evans, R., Bronfort, G., Nelson, B., & Goldsmith, C. (2002). Two-Year Follow-Up of a Randomized Clinical Trial of Spinal Manipulation and Two Types of Exercise for Patients with Chronic Neck Pain. *Spine. 27*: 21, 2383-2389. DOI: 10.1097/01.BRS.0000030192.39326.FF. Adequate. *\*Used in Evidence Statement.*
147. *Executive Office of the President of the United States.* (2011). Epidemic: Responding to America’s Prescription Drug Abuse Crisis.
148. Ezendam, D., Bongers, R., & Jannink, M. (2009). Systematic Review of the Effectiveness of Mirror Therapy in Upper Extremity Function. *Disability and Rehabilitation. 31* (26): 2135-2149.
149. Fairbank, J., Frost, H., Wilson-MacDonald, J., Yu, LM, Barker, K., & Collins, R. (2005). Randomised Controlled Trial to Compare Surgical Stabilisation of the Lumbar Spine with an Intensive Rehabilitation Programme for Patients with Chronic Low Back Pain: The MRC Spine Stabilisation Trial. *BMJ.* doi:10.1136/bmj.38441.620417.BF
150. Farrar, J.T., Berlin, J.A., & Strom, B.L. (2003). Clinically Important Changes in Acute Pain Outcome Measures: A Validation Study. *Journal of Pain and Symptom Management 25*:5, 406-411. doi:10.1016/S0885-3924(03)00162-3
151. Farrar, J.T., Portenoy, R.K., Berlin, J.A., Kinman, J.L., & Strom, B.L. (2000). Defining the Clinically Important Difference in Pain Outcome Measures. *Pain 88*: 287-294.
152. Farrell, K., Johnson, A., Duncan, H., & Offenbacker, T. (2003). The Intertester and Intratester Reliability of Hand Volumetrics. *Journal of Hand Therapy. 16:* 292-299.
153. Fechir, M., Geber, C., & Birklein, F. (2008). Evolving Understandings about Complex Regional Pain Syndrome and its Treatment. *Current Pain and Headache Reports. 12*: 186-191.
154. Feeler, L., St. James, J., & Schapmire, D. (2010). Isometric Strength Assessment, Part I: Static Testing Does Not Accurately Predict Dynamic Lifting Capacity. *Work. 37.* 301-308. DOI 10.3233/WOR-2010-1082
155. Felson, DT, & Anderson, JJ. (1987). Across-Study Evaluation of Association between Steroid Dose and Bolus Steroids and Avascular Necrosis of Bone. *The Lancet.* 902-906.
156. Ferrante, F.M., Bearn, L., Rothrock, R., & King, L. (2005). Evidence against Trigger Point Injection Technique for the Treatment of Cervicothoracic Myofascial Pain with Botulinum Toxin Type A. *Aenesthesiology* 103(2): 377-383.
157. Ferreira, M., Ferreira, P., Latimer, J., Herbert, R., Hodges, P., Jennings, M., Maher, C., & Refshauge, K. (2007). Comparison of General Exercise, Motor Control Exercise and Spinal Manipulative Therapy for Chronic Low Back Pain: A Randomized Trial. *Pain. 131*: 31-37. doi:101016/j.pain.2006.12.0008.
158. Finch, P., Knudsen, L., & Drummond, P. (2009). Reduction of Allodynia in Patients with Complex Regional Pain Syndrome: A Double-Blind Placebo-Controlled Trial of Topical Ketamine. *Pain. 146*: 18-25.
159. Fiore, K. (2010). EASD: Fecal Transplant Flushes Insulin Resistance. Medpage Today.
160. Fishbain, D., Cole, B., Lewis, JE, Gao, J., & Rosomoff, RS. (2009). Do Opioids Induce Hyperalgesia in Humans? An Evidence-Based Structured Review. *Pain Med. 10* (5): 829-39.
161. Fishman, L.M., Anderson, C., & Rosner, B. (2002). BOTOX and Physical Therapy in the Treatment of Piriformis Syndrome. *American Journal of Physical Medicine & Rehabilitation.* 81(12): 936-942. Assessment: Adequate. *\*Used in Evidence Statement.*
162. Fleming, M.F., Davis, J., & Passik, S.D. (2008). Reported Lifetime Aberrant Drug-taking Behaviors are Predictive of Current Substance Use and Mental Health Problems in Primary Care Patients. *Pain Med 9*:8, 1098-1106. doi:10.111/j.1526-4637.2008.00491.x.
163. Fontaine, D., Hamani, C., & Lozano, A. (2009). Efficacy and Safety of Motor Cortex Stimulation for Chronic Neuropathic Pain: Critical Review of the Literature. *J. Neurosurg. 110*: 251-256.
164. Forouzanfar, T., Weber, WEJ, Kemler, M., & Van Kleef, M. (2003). What is Meaningful Pain Reduction in Patients with Complex Regional Pain Syndrome Type 1? *The Clinical Journal of Pain. 19*: 281-285.
165. Fosbol, E., Folke, F., Jacobsen, S., Rasmussen, J., Sorensen, R., Schramm, T.,...Gislason, G. (2010). Cause-Specific Cardiovascular Risk Associated with Nonsteroidal Antiinflammatory Drugs Among Healthy Individuals. *Circ Cardiovasc Qual Outcomes.* *3*: 395-405.
166. Fox, SA, & Stein, JA. (2011). The Effect of Physician-Patient Communication on Mammography Utilization by Different Ethnic Groups. *Medical Care. 29*, 11: 1065-1082.
167. Frank, B., Serpell, M., Hughes, J., Matthews, JNS, & Kapur, D. (2008). Comparison of Analgesic Effects and Patient Tolerability of Nabilone and Dihydrocodeine For Chronic Neuropathic Pain: Randomised, Crossover, Double Blind Study. *BMJ. 336*: 199-201. doi:10.1136/bmj.39429.619653.80. Assessment: Inadequate.
168. Franklin, GM, Mai, J., Wickizer, TM, Tuner, J., Fulton-Kehoe, D., & Grant, L. (2005). Opioid Dosing Trends and Mortality in Washington State Workers’ Compensation, 1996-2002. *American Journal of Industrial Medicine. 48*:2, 91-99.
169. Franklin, GM, Stover, BD, Turner, JA, Fulton-Kehoe, D., & Wickizer, TM. (2008). Early Opioid Prescription and Subsequent Disability among Workers with Back Injuries. *Spine. 33*: 2, 199-204.
170. Frey, ME, Manchikanti, L., Benyamin, RM, Schultz, DM, Smith, HS, & Cohen, SP. (2009). Spinal Cord Stimulation for Patients with Failed Back Surgery Syndrome: A Systematic Review. *Pain Physician. 12*: 379-397.
171. Fritz, J., Lindsay, W., Matheson, J., Brennan, G., Hunter, S., Moffit, S., Swalberg, A., & Rodriquez, B. (2007). Is There a Subgroup of Patients with Low Back Pain Likely to Benefit from Mechanical Traction? *Spine. 32*: 26, E793-E800.
172. Furlan, AD, Imamura, M., Dryden, T., & Irvin, E. Massage for Low-back Pain (Review). Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.: CD001929. DOI: 10.1002/14651858.CD001929.pub 2. Assessment: Adequate. \**Used in Evidence Statement.*
173. Galer, B., Bruehl, S., & Harden, R. (1998). IASP Diagnostic Criteria for Complex Regional Pain Syndrome: A Preliminary Empirical Validation Study. *The Clinical Journal of Pain. 14* (1): 48-54.
174. Galer, B., Lee, D., Ma, T., Nagle, B., & Schlagheck, T. (2005). MorphiDex® (Morphine Sulfate/Dextromethorphan Hydrobromide Combination) in the Treatment of Chronic Pain: Three Multicenter, Randomized, Double-Blind, Controlled Clinical Trials Fail to Demonstrate Enhanced Opioids Analgesia or Reduction in Tolerance. *Pain. 115*: 284-295. Assessment: Adequate. \**\*Used in Evidence Statement*.
175. Garcia-Larrea, L., & Peyron, R. (2007). Motor Cortex Stimulation for Neuropathic Pain: From Phenomenology to Mechanics. *NeuroImage. 37*: S71-S79.
176. Gatchel, RJ, Mayer, TG, & Theodore, BR. (2006). The Pain Disability Questionnaire: Relationship To One-Year Functional and Psychosocial Rehabilitation Outcomes. *Journal of Occupational Rehabilitation. 16*; 1. DOI: 10.1007/s10926-005-9005-0
177. Gatchel, RJ, Polatin, PB, & Kinney, R. (1995). Predicting Outcome of Chronic Back Pain Using Clinical Predictors of Psychopathology: A Prospective Analysis. *Health Psychology. 14*; 5, 415-420.
178. Gatchel, RJ, Polatin, PB, Mayer, TG, & Garcy, PD. (1994). Psychopathology and the Rehabilitation of Patients with Chronic Low Back Pain Disability. *Arch Phys Med Rehabil. 75.*
179. Gebruers, N., Truijen, S., Engelborghs, S., & De Deyn, PP. (2007). Volumetric Evaluation of Upper Extremities in 250 Healthy Persons. *Clin. Physiol Funct Imaging. 27*: 17-22. doi: 10.1111/j.1475-097X.2007.00708.x
180. Gerber, HR. (2003). Intrathecal Morphine for Chronic Benign Pain. *Best Practice & Research Clinical Anaesthesiology*. 17, 3; 429-442. DOI: 10.1016/S1521-6896(03)
000I4-4.
181. Geurts, J., van Wijk, R., Wynne, H., Hammink, E., Buskens, E., Lousberg, R.,...Groen, G. (2003). Radiofrequency Lesioning of Dorsal Ganglia for Chronic Lumbosacral Radicular Pain: A Randomised, Double-Blind, Controlled Trial. *The Lancet. 361*: 21-26. Assessment: Adequate. *\*Used in Evidence Statement.*
182. Ghafoor, VL, Epshteyn, M., Carlson, GH, Terhaar, DM, Charry, O., & Phelps, PK. (2007). Intrathecal Drug Therapy for Long-Term Pain Management. *American Journal Health-Syst Pharm. 64*; 2447-61.
183. Ghoname, E., Craig, W., White, P., Ahmed, H., Hamza, M., Henderson, B.,...Gatchel, R. (1999). Percutaneous Electrical Nerve Stimulation for Low Back Pain. *JAMA. 281*; 9, 818-823. \**Used in Evidence Statement*
184. Ghoname, E.A., White, P.F., Ahmed, H.E., Hamza, M.A., Craig, W.F., & Noe, C.E. (1999). Percutaneous Electrical Nerve Stimulation: An Alternative to TENS in the Management of Sciatica. *Pain 83*: 193-199.
185. Giles, LGF, & Muller, R. (2003). Chronic Spinal Pain. A Randomized Clinical Trial Comparing Medication, Acupuncture, and Spinal Manipulation. *Spine. 28:* 14, 1490-1503.
186. Gilron, I, Bailey, J., Tu, D., Holden, R., Jackson, A., & Houlden, R. (2009). Nortriptyline and Gabapentin, Alone and in Combination for Neuropathic Pain: a Double-Blind, Randomised Controlled Crossover Trial. *Lancet. 374*: 1252-61. Assessment: Adequate. \**Used in Evidence Statement*
187. Gilron, I., Bailey, J., Tu, D., Holden, R., Weaver, D., & Houlden, R. (2005). Morphine, Gabapentin, or Their Combination for Neuropathic Pain. *N Engl J Med. 352*:1324-34. Assessment: Adequate. *\*Used in Evidence Statement*.
188. Gobel, H., Heinze, A., Reichel, G., Hefter, H., & Benecke, R. (2006). Efficacy and safety of a single botulinum type A toxin complex treatment ( Dysport®) for the relief of upper back Myofascial pain syndrome: Results from a randomized double-blind placebo-controlled multicentre study. *Pain.* 125: 82-88.
189. Gobelet, C., Waldburger, M., & Meier, JL. (1992). The Effect of Adding Calcitonin to Physical Treatment on Reflex Sympathetic Dystrophy. *Pain. 48*.171-175. Assessment: Inadequate.
190. Godert, HW, Gamer, M., Rill, HG, & Vossel, G. (2005). Statement Validity Assessment: Inter-Rater Reliability of Criteria-Based Content Analysis in the Mock-Crime Paradigm. *Legal and Criminological Psychology. 10:* 225-245.
191. Goldstein, DJ, Detke, M., Lee, T., & Iyengar, S. (2005). Duloxetine vs. Placebo in Patients with Painful Diabetic Neuropathy\* *Pain. 116*: 109-118. Assessment: Adequate. *\*Used in Evidence Statement.*
192. Gomes, T., Mamdani, M., Dhalla, IA, Paterson, JM, & Juurlink, DN. (2011). Opioid Dose and Drug-Related Mortality in Patients with Nonmalignant Pain. *Arch Intern Med. 171* (7): 686-691.
193. Gordh, T., Stubhaug, A., Jensen, T., Arner, S., Biber, B., Boivie, J.,...Kalso, E. (2008). Gabapentin in Traumatic Nerve Injury Pain: A Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Multi-Center Study. *Pain. 138*: 255-266. Assessment: Adequate. *\*Used in Evidence Statement.*
194. Gourlay, DL, & Heit, HA. (2009). Universal Precautions Revisited: Managing the Inherited Pain Patient. *Pain Medicine. 10*: S2, S115-S123.
195. Graver, V., Haaland, A, Magnaes, B., & Loeb, M. (1999). Seven-year Clinical Follow-up after Lumbar Disc Surgery: Results and Predictors of Outcome. *British Journal of Neurosurgery. 13* (2): 178-184.
196. Graver, V., Ljunggren, AE, Malt, UF, Loeb, M., Haaland, AK, Magnes, B., & Lie, H. (1995). Can Psychological Traits Predict the Outcome of Lumbar Disc Surgery When Anamnestic and Physiological Risk Factors are Controlled For? Results of a Prospective Cohort, Study. *Journal of Psychosomatic Research. 39*; 4, 465-476.
197. Grosskopf, J., Mazzola, J., Wan, Y., & Hopwood, M. (2006). A Randomized, Placebo-Controlled Study of Oxcarbazepine in Painful Diabetic Neuropathy. *Act Neurol Scand. 114*: 177-180. Assessment: Inadequate.
198. Grotenhermen, F., Leson, G., Berghaus, G., Drummer, O.H., Kruger, H., Longo, M., Moskowitz, H., Perrine, B., Ramaekers, J., Smiley, A., & Tunbridge, R. (2005). Developing Science-Based Per Se Limits for Driving Under the Influence of Cannabis (DUIC): Findings and Recommendations by an Expert Panel. *DUIC Report*: 1-49.
199. Gulevich, S.J., Conwell, T.D., Lane, J., Lockwood, B., Schwettman, R.S., Rosenberg, N., Goldman, L., & Barton. Stress Infrared Telethermography Is Useful in the Diagnosis of Complex Regional Pain Syndrome, Type I (Formerly Reflex Sympathetic Dystrophy). *The Clinical Journal of Pain.* 13(1). 50-59.
200. Gur, A., Sarac, AJ, Cevik, R., Altindag, O., & Sarac, S. (2004). Efficacy of 904 nm Gallium Arsenide Low Level Laser Therapy in the Management of Chronic Myofascial Pain in the Neck: A Double-Blind and Randomize-Controlled Trial. *Lasers in Surgery and Medicine. 35*: 229-235.
201. Haake, M., Muller, HH, Schade-Brittinger, C., Basler, H., Schafer, H., Maier, C., Endres, H., Trampisch, HJ, & Molsberger, A. (2007). German Acupuncture Trials (GERAC) for Chronic Low Back Pain. *Archives of Internal Medicine. 167* (17): 1892-1898. Assessment: High Quality. *\*Used in Evidence Statement.*
202. Haanpaa, M., Attal, N., Backonja, M., Baron, R., Bennett, M., Bouhassira, D.,...Treede, RD. (2011). NeuPSIG Guidelines on Neuropathic Pain Assessment. *Pain. 152*: 14-27.
203. Hagen, EM, Eriksen, HR, & Ursin, H. (2000). Does Early Intervention with a Light Mobilization Program Reduce Long-Term Sick Leave for Low Back Pain? *Spine. 25,* 15: 1973-1976. Assessment: High Quality. *\*Used in Evidence Statement.*
204. Hakguder, A., Birtane, M., Gurcan, S., Kokino, S., & Turan, FN. (2003). Efficacy of Low Level Laser Therapy in Myofascial Pain Syndrome: An Algometric and Thermographic Evaluation. *Lasers in Surgery and Medicine. 33*: 339-343.
205. Hale, M., Dvergsten, C., & Gimbel, J. (2005). Efficacy and Safety of Oxymorphone Extended Release in Chronic Low Back Pain: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase III Study. *The Journal of Pain. 6*, 1: 21-28. Assessment: Adequate. *\*Used in Evidence Statement.*
206. Hall, H. (2011). Acupuncture Claims Punctured: Not Proven Effective for Pain, Not Harmless. *Pain. 152*; 711-712. DOI 10.1016/j.pain.2011.01.039
207. Hall, W. (2009). The Adverse Health Effects of Cannabis Use: What Are they, and What are Their Implications for Policy? *International Journal of Drug Policy. 20:* 458-466.
208. Hamza, MA, White, PF, Craig, WF, Ghoname, ESA, Proctor, TJ, Noe, CE, Vakharia, AS, & Gajraj, N. (2000). Percutaneous Electrical Nerve Stimulation. *Diabetes Care. 23;* 3: 365-370.
209. Han, A., Judd, M., Welch, V., Wu, T., Tugwell, P., & Wells, G. (2004). Tai Chi for Treating Rheumatoid Arthritis. *Cochrane Database of Systematic Reviews* 2004, Issue 3. Art. No.: CD004849. DOI: 10.1002/14651858.CD004849.
210. Hanna, M., O’Brien, C., & Wilson, M. (2008). Prolonged-Release Oxycodone Enhances the Effects of Existing Gabapentin Therapy in Painful Diabetic Neuropathy Patients. *European Journal of Pain. 12*: 804-813. Assessment: Adequate.
211. Harden, RN, & Bruehl, S. (2010). Clinical Guidelines. Complex Regional Pain Syndrome: Treatment Guidelines. *Reflex Sympathetic Dystrophy Syndrome Association.*
212. Harden, RN. (2010). Objectification of the Diagnostic Criteria for CRPS. *Pain Medicine. 11*: 1212-1215.
213. Harden, RN, Bruehl, S., Galer, B., Saltz, S., Bertram, M., Backonja, M.,...Stanton-Hicks, M. (1999). Complex Regional Pain Syndrome: Are the IASP Diagnostic Criteria Valid and Sufficiently Comprehensive? *Pain. 83*: 211-219.
214. Harden, RN, Bruehl, S., Perez, RSGM, Birklein, F., Marinus, J., Maihofner, C., Lubenow, T. ...Vatine, JJ. (2010). Development of a Severity Score for CRPS. *Pain. 151*: 870-876.
215. Harden, RN, Bruehl, S., Perez, RSGM, Birklein, F., Marinus, J., Maihofner, C., Lubenow, T. ...Vatine, JJ. (2010). Validation of Proposed Diagnostic Criteria (The “Budapest Criteria”) for Complex Regional Pain Syndrome. *Pain. 150*: 268-274.
216. Harden, RN, Weinland, SR, Remble, TA, Houle, TT, Colio, S., Steedman, S., & Kee, WG. (2005). Medication Quantification Scale Version III: Update in Medication Classes and Revised Detriment Weights by Survey of American Pain Society Physicians. *The Journal of Pain. 6*; 6, 364-371.
217. Haroutiunian, S., Drennan, D., & Lipman, A. (2010). Review Article. Topical NSAID Therapy for Musculoskeletal Pain. *Pain Medicine. 11*:535-549.
218. Hassenbusch, S., Portenoy, R., Cousins, M., Buchser, E., Deer, T., De Pen, S.,...Willis, D. (2004). Polyanalgesic Consensus Conference 2003: An Update on the Management of Pain by Intraspinal Drug Delivery-Report of an Expert Panel. *Journal of Pain and Symptom Management. 27*: 6, 540-563.
219. Hay, J., White, J., Bochner, F., Somogyi, A., Semple, T., & Rounsefell, B. (2009). Hyperalgesia in Opioid-Managed Chronic Pain and Opioid-Dependent Patients. *The Journal of Pain. 10*, 3: 316-322.
220. Hayden, JA, Dunn, KM, van der Windt, DA, & Shaw, WS. (2010). What is the Prognosis of Back Pain? *Best Practice & Research Clinical Rheumatology. 24:* 167-179.
221. Hayek, SM, Veizi, IE, Narouze, SN, & Mekhail, N. (2011). Age-dependent Intrathecal Opioid Escalation in Chronic Noncancer Pain Patients. *Pain Medicine.* 12:1179-1189.
222. Heckler, D., Gatchel, R., Lou, L., Whitworth, T., Bernstein, D., & Stowell, D. (2007). Presurgical Behavioral Medicine Evaluation (PBME) for Implantable Devices for Pain Management: A 1-Year Prospective Study. *Pain Practice. 7*: 2, 110-122.
223. Henderson, J., & Lad, S. (2006). Motor Cortex Stimulation and Neuropathic Facial Pain. *Neurosurg Focus. 21* (6): E6
224. Higgins, E. (1994). A Review of Unrecognized Mental Illness in Primary Care.  *Arch Family Med. 3*; 908-917.
225. Ho, K, Huh, B.K., White, W.D., Yeh, C., Miller, E.J. (2008). Topical amitriptyline versus lidocaine in the treatment of neuropathic pain. *Clin J Pain, (24)* 1. 51-55.
226. Hobby, JL, Lutchman, LN, Powell, JM, & Sharp, DJ. (2001). The Distress and Risk Assessment Method (DRAM) *J Bone Joint Surg. 83-B*, 19-21.
227. Hoffman, BM, Papas, RK, Chatkoff, DK, & Kerns, RD. (2007). Meta-Analysis of Psychological Interventions for Chronic Low Back Pain. *Health Psychology. 26*, 1: 1-9. Assessment: Adequate. *\*Used in Evidence Statement.*
228. Hollinghurst, S., Sharp, D., Ballard, K., Barnett, J., Beattie, A., Evans, M.,...Little, P. (2008). Randomised Controlled Trial of Alexander Technique Lessons, Exercise, and Massage (ATEAM) for Chronic and Recurrent Back Pain: Economic Evaluation. *BMJ. 337*; a2656.
229. Hollingworth, W., Turner, JA, Welton, NJ, Comstock, BA, & Deyo, RA. (2011). Costs and Cost-effectiveness of Spinal Cord Stimulation (SCS) for failed back surgery syndrome: An Observational Study in a Workers’ Compensation Population. *Spine*. 36(24): 2076-2083. DOI: 10.1097/BRS.0b013e31822a867c.
230. Hondras, MA, Long, CR, Cao, Y., Rowell, RM, & Meeker, WC. (2009). A Randomized Controlled Trial Comparing 2 Types of Spinal Manipulation and Minimal Conservative Medical Care for Adults 55 Years and Older with Subacute or Chronic Low Back Pain. *J. Manipulative Physiol Ther. 32*: 330-343.
231. Hord, AH, Rooks, MD, Stephens, BO, Rogers, HG, & Fleming, LL. (1992). Intravenous Regional Bretylium and Lidocaine for Treatment of Reflex Sympathetic Dystrophy: A Randomized, Double-Blind Study. *Anesth Analg. 74*: 818-21. Assessment: Inadequate.
232. Horlocker, TT, Wedel, DJ, Rowlingson, JC, Enneking, FK, Kopp, SL, Benzon, HT.,.. Yuan, CS. (2010). Regional Anesthesia in Patients Receiving Antithrombotic or Thrombolytic Therapy. *Regional Anesthesia and Pain Medicine. 35*; 1, 64-101.
233. Horwitz, RI. (1987). The Experimental Paradigm and Observational Studies of Cause-effect Relationships in Clinical Medicine. *Journal of Chronic Disorders. 40* (1); 91-9.
234. Hospitalizations for medication, illicit drug-related conditions on the rise fro those who are 45 and older (2010). *Managed Care Outlook, (23)* 23.
235. Hsu, E. (2009). Practical Management of Complex Regional Pain Syndrome. *American Journal of Therapeutics. 16*:147-154.
236. Huestis, MA, Henningfield, JE, & Cone, EJ. (1992). Blood Cannabinoids. I. Absorption of THC and Formation of 11-OH-THC and THCCOOH During and After Smoking Marijuana\* *Journal of Analytical Toxicology. 16*: 276-282.
237. Huestis, MA, Sampson, MS, Holicky, BJ, Henningfield, JE, & Cone, EJ. (1992). Characterization of the Absorption Phase of Marijuana Smoking. *Clin Pharmacol Ther 52*:1, 31-41.
238. Huge, V. Lauchart, M., Forderreuther, S., Kaughold, W., Valet, M., Azad, S.C., Beyer, A., Mageri, W. (2008) Interaction of Hyperalgesia and Sensory Loss in Complex Regional Pain Syndrome Type I (CRPS I). *Plos One 3*:7, e2742; 1-10.
239. Huge, V., Lauchart, M., Mageri, W., Beyer, A., Moehnle, P., Kaufhold, W., Schelling, G., & Azad, S.C. (2011). Complex Interaction of Sensory and Motor Signs and Symptoms in Chronic CRPS. *Plos One 6*: 4, e18775; 1-13.
240. Hulme, JM, Welch, V., de Bie, R., Judd, M., & Tugwell, P. (2002). Electromagnetic Fields for the Treatment of Osteoarthritis. *CochraneDatabase of Systematic Reviews* 2002, Issue 1. Art. No.: CD003523. DOI: 10.1002/14651858.CD003523.
241. *Institute for Clinical Systems Improvement (ICSI).* Health Care Guideline: Assessment and Management of Chronic Pain. Fourth Edition. November 2009.
242. International Research Foundation for RSD/CRPS*.* (2003). *Reflex Sympathetic Dystrophy/Complex Regional Pain Syndrome (RSD/CRPS).* Clinical Practice Guidelines- Third Edition. Retrieved from: www.rsdfoundation.org.
243. International Research Foundation for RSD/CRPS. (Producer). (2002). *Video presentation of sympathetic nerve blocks; Video of advances in neurostimulation systems; Sympathetic nerve blocks in children.* Retrieved from: http://www.rsdfoundation.org.
244. Irving, G., Jensen, M., Cramer, M., Wu, J., Chiang, Y., Tark, M., & Wallace, M. (2009). Efficacy and Tolerability of Gastric-Retentive Gabapentin for the Treatment of Postherpetic Neuralgia. Results of a Double-Blind, Randomized, Placebo-Controlled Clinical Trial. *Clin J. Pain. 25*: 3, 185-192. Assessment: Adequate. *\*Used in Evidence Statement.*
245. Iskedjian, M., Bereza, B., Gordon, A., Piwko, C., & Einarson, T. (2007). Meta-Analysis of Cannabis Based Treatments for Neuropathic and Multiple Sclerosis-Related Pain. *Current Medical Research and Opinions. 23*: 1, 17-24. Assessment: Inadequate.
246. Itoh, K., Itoh, S., Katsumi, Y., & Kitakoji, H. (2009). A Pilot Study on Using Acupuncture and Transcutaneous Electrical Nerve Stimulation to Treat Chronic Non-Specific Low Back Pain. *Complementary Therapies in Clinical Practice. 15*: 22-25.
247. Izzo, A., Borrelli, F., Capasso, R., Di Marzo, V., & Mechoulam, R. (2009). Non-Psychotropic Plant Cannabinoids: New Therapeutic Opportunities From an Ancient Herb. *Trends in Pharmacological Sciences. 30*:10, 515-527.
248. Jaradeh, SS, & Prieto, TE. (2003). Evaluation of the Autonomic Nervous System. *Physical Medicine and Rehabilitation Clinics of North America. 14*; 287-305.
249. Jasper, J., & Hayek, S. (2008). Implanted Occipital Nerve Stimulators. *Pain Physician. 11*: 187-200.
250. Jellad, A., Salah, ZB, Boudokhane, S., Migaou, H., & Rejeb, BN. (2009). The Value of Intermittent Cervical Traction in Recent Cervical Radiculopathy. *Annals of Physical and Rehabilitation Medicine. 52*: 635-652.
251. Jensen, MP. (2010). A Neurophyschological Model of Pain: Research and Clinical Implications. *The Journal of Pain. 11*; 1, 2-12.
252. Jensen, M., Barber, J., Romano, J., Hanley, M., Raichle, K., Molton, I., Engel, J., & Patterson, D. (2009). Effects of Self-Hypnosis Training and EMG Biofeedback Relaxation Training on Chronic Pain in Persons with Spinal-Cord Injury. *International Journal of Clinical and Experimental Hypnosis. 57*: 3, 239 — 268 DOI: 10.1080/00207140902881007
253. Jensen, LD, Maribo, T., Schiottz-Christensen, B., Madsen, FH, Gonge, B., Christensen, M. & Frost, P. (2011). Counselling Low-back Pain Patients in Secondary Healthcare: a Randomised Trial Addressing Experienced Workplace Barriers and Physical Activity. *Occup Environ Med.* Doi:10.1136/0em.2010.064055. Assessment: Inadequate.
254. Jensen, MP, Moore, MR, Bockow, TB, Ehde, DM, & Engel, JM. (2011). Psychosocial Factors and Adjustment to Chronic Pain in Persons with Physical Disabilities: A Systematic Review. *Arch Phys Med Rehabil 92*: 146-160.
255. Jette, N., Lix, L., Metge, C., Prior, H., McChesney, J., & Leslie, W. (2011). Association of Antiepileptic Drugs with Nontraumatic Fractures. *Arch. Neurol. 68* (1): 107-112.
256. Johnson, ML, Visser, EJ, & Goucke, CR. (2011). Massive Clonidine Overdose During Refill of an Implanted Drug Delivery Device for Intrathecal Analgesia: A Review of Indadvertent Soft-Tissue Injection During Implantable Drug Delivery Device Refills and Its Management. *Pain Medicine.* 12:1032-1040.
257. Jull, G., Trott, P., Potter, H., Zito, G., Niere, K., Shirley, D., Emberson, J., & Richardson, C. (2002). A Randomized Controlled Trial of Exercise and Manipulative Therapy For Cervicogenic Headache. *Spine. 27*:17, 1835-1843. DOI: 10.1097/01.BRS.0000025471.27251.BA
258. Kaapa, EH, Frantsi, K., Sarna, S., & Malmivaara, A. (2006). Multidisciplinary Group Rehabilitation v*ersus* Individual Physiotherapy for Chronic Nonspecific Low Back Pain. *Spine. 31*; 4, 371-376.
259. Kalita, J., Vijpayee, A., & Misra, UK. (2006). Comparison of Prednisolone with Piroxicam in Complex Regional Pain Syndrome Following Stroke: A Randomized Controlled Trial. *QJ Med. 99*: 89-95. doi:10.1093/qjmed/hc1004 Assessment: Adequate. \*\**Used in Evidence Statement*
260. Kanai, A., Kumaki, C., Niki, Y., Suzuki, A., Tazawa, T., & Okamoto, H. (2009). Efficacy of a Metered-Dose 8% Lidocaine Pump Spray for Patients with Post-Herpetic Neuralgia. *Pain Medicine. 10*: 5, 902-909. Assessment: Adequate. *\*\*\*Used in Evidence Statement*
261. Kapural, L. Current Dilemmas and Future Challenges in Intrathecal Therapies: Opioids versus Non-Opioids. *American Academy of Pain Medicine.* 25th Annual Meeting. January 28-31, 2009.
262. Kapural, L., Nageeb, F., Kapural, M., Cata, J., Narouze, S., & Mekhail, N. (2008). Cooled Radiofrequency System for the Treatment of Chronic Pain from Sacroiliitis: The First Case-Series. *Pain Practice. 8:* 5, 348-354.
263. Karges, JR, Mark, BE, Stikeleather, SJ, & Worrell, TW. (2003). Concurrent Validity of Upper-Extremity Volume Estimates: Comparison of Calculated Volume Derived from Girth Measurements and Water Displacement Volume. *Physical Therapy. 83*; 134-145.
264. Karjalainen, KA, Malmivaara, A., Van Tulder, MW, Roine, R., Jauhiainen, M., Hurri, H., & Koes, BW. Multidisciplinary Rehabilitation for Fibromyalgia and Musculoskeletal Pain in Working Age Adults. *Cochrane Database of Systematic Reviews* 1999, Issue 3. Art. No.: CD001984. DOI:10.1002/14651858.CD001984.
265. Katz, N. (2005). Methodological Issues in Clinical Trials of Opioids for Chronic Pain. *Neurology. 65:* Suppl. 4, S32-S49.
266. Kaufmann, RM, Kraft, B., Frey, R., Winkler, D., Weiszenbichler, S., Backer, C., ...Kress, HG. (2010). Acute Psychotropic Effects of Oral Cannabis Extract with a Defined Content of Δ9-Tetrahydroccannabinol (THC) in Healthy Volunteers. *Pharmacopsychiatry. 43*; 24-32.
267. Kaur, H., Hota, D., Bhansali, A., Dutta, P., Bansal, D., & Chakrabarti, A. (2011). A Comparative Evaluation of Amitriptyline and Duloxetine in Painful Diabetic Neuropathy: a Randomized, Double-blind, Cross-over Clinical Trial. *Diabetes Care 34;* 818-822.
268. Kay, J., Findling, JW, & Raff, H. (1994). Epidural Triamcinolone Suppresses the Pituitary-Adrenal Axis in Human Subjects. *Anesth Analg. 79*; 501-5.
269. Kemler, M., Barendse, G., Van Kleef, M., De Vet, H., Ruks, C., Furnee, C., & Van Den Wildenberg, F. (2000). Spinal Cord Stimulation in Patients with Chronic Reflex Sympathetic Dystrophy. *NEJM. 343*: 618-24. Assessment: Adequate. \**Used in Evidence Statement*
270. Kemler, M., De Vet, H., Barendse, G., Van den Wildenberg, F., & Van Kleef, M. (2008). Effect of Spinal Cord Stimulation for Chronic Complex Regional Pain Syndrome Type I: Five-Year Final Follow-up of Patients in a Randomized Controlled Trial. *J. Neurosurg. 108:* 292-298. Assessment: Adequate.
271. Kerns, RD, Turk, DC, & Rudy, TE. (1985). The West Haven-Yale Multidimensional Pain Inventory (WHYMPI). *Pain. 23*; 345-356.
272. Kerr, D., Walsh, D., & Baxter, D. (2003). Acupuncture in the Management of Chronic Low Back Pain: A Blinded Randomized Controlled Trial. *The Clinical Journal of Pain. 19*: 364-370.
273. Khaliq, W., Alam, S., & Puri, S. Topical Lidocaine For the Treatment of Postherpetic Neuralgia. *Cochrane Database of Systematic Reviews* 2007, Issue 2. Art. No.: CD004846. DOI:10.1002/14651858.CD004846.pub2. Assessment: Inadequate.
274. Khoromi, S., Patsalides, A., Parada, S., Salehi, V., Meegan, J., & Max, M. (2005). Topirmate in Chronic Lumbar Radicular Pain. *The Journal of Pain. 6*:12, 829-836. Assessment: Adequate. *\*Used in Evidence Statement.*
275. Kim, L, Lipton, S., & Deodhar, A. (2009). Pregabalin for Fibromyalgia: Some Relief But No Cure. *Cleveland Clinic Journal of Medicine. 76*: 4, 255-261.
276. King, TI. (1993). The Effect of Water Temperature on Hand Volume During Volumetric Measurement Using the Water Displacement Method. *J Hand Therapy. 6* (3): 202-4.
277. Kingery, WS, Guo, TZ, Agashe, GS, Davies, MF, Clark, JD, & Maze, M. (2001). Glucocorticoid Inhibition of Neuropathic Limb Edema and Cutaneous Neurogenic Extravasation. *Brain Research. 913*; 140-148.
278. Kingston, j., Chadwick, P., Meron, D., & Skinner, T.C. (2007). A Pilot Randomized Control Trial Investigating the Effect of Mindfulness Practice on Pain Tolerance, Psychological Well-being, and Physiological Activity. *Journal of Psychosomatic Research 62*; 297-300.
279. Kiralp, MZ, Yildiz, S., Vural, D., Keskin, I., Ay, H., & Dursun, H. (2004). Effectiveness of Hyperbaric Oxygen Therapy in the Treatment of Complex Regional Pain Syndrome. *The Journal of International Medical Research. 32*: 258-262. Assessment: Inadequate.
280. Kishima, H., Saitoh, Y., Osaki, Y., Nishimura, H., Kato, A., Hatazawa, J., & Yoshimine, T. (2007). Motor Cortex Stimulation in Patients with Deafferentation Pain: Activation of the Posterior Insula and Thalamus. *J. Neurosurg. 107* (1): 43-8. Abstract Only.
281. Klenerman, L., Slade, PD, Stanley, IM, Pennie, B., Reilly, JP, Atchison, LE, Troup, JD, & Rose, MJ. (1995). The Prediction of Chronicity in Patients with an Acute Attack of Low Back Pain in a General Practice Setting. *Spine. 20*: 478-484.
282. Knight, CL, & Burnell, JC. (1980). Systemic Side-effects of Extradural Steroids. *Anaesthesia. 35*; 593-594.
283. Konstantinovic, LM, Cutovic, MR, Milovanovic, AN, Jovic, SJ, Dragin, AS, Letic, MD, & Miler, VM. (2010). Low-Level Laser Therapy for Acute Neck Pain with Radiculopathy: A Double-Blind Placebo-Controlled Randomized Study. *Pain Medicine. 11*; 8, 1169-1178. doi: 10.1111/j.1526-4637.2010.00907.x
284. Kosarac, B., Fox, AA, & Collard, CD. (2009). Effect of Genetic Factors on Opioid Action. *Current Opinion in Anaesthesiology. 22*: 476-482.
285. Krause, N., Ragland, D, Fisher, J., & Syme, SL. (1998). 1998 Volvo Award Winner in Clinical Studies: Psychosocial Job Factors, Physical Workload, and Incidence of Work-Related Spinal Injury: A 5-Year Prospective Study of Urban Transit Operators. *Spine. 23* (23): 2507-2516.
286. Kress, H., Simpson, K., Marchettini, P., Ver Donck, A., & Varrassi, G. (2009). Intrathecal Therapy: What Has Changed with the Introduction of Ziconotide. *Pain Practice. 9*: 5, 338-347.
287. Krumova, EK, Frettloh, J., Klauenberg, S., Richter, H., Wasner, G., & Maier, C. (2008). Long-Term Skin Temperature Measurements - A Practical Diagnostic Tool in Complex Regional Pain Syndrome. *Pain. 140*: 8-22. Assessment: Adequate. *\*Used in Evidence Statement.*
288. Krusz, JC. (2003). Treatment of Chronic Pain with Zonisamide. *Pain Practice. 3* (4): 317-320. Assessment: Inadequate.
289. Kuchera, M.L. (2007). Applying Osteopathic Principles to Formulate Treatment for Patients with Chronic Pain. *Journal of American Osteopathic Assoc. 107(suppl 6):* ES28-ES38.
290. Kuczkowski, FM. (2003). Bretylium in the Treatment of Complex Regional Pain Syndrome: Uncommon Side-effect of a Common Drug. *Anaesthesia. 58*, 183-203.
291. Kuehn, B. (2010). Alarming Nonfatal Overdose Rates Found for Opioids, Sedatives, and Tranquilizers. *JAMA. 303* (20): 2020-2021.
292. Kuijpers, T., Van Middelkoop, M., Rubinstein, SM, Ostelo, R., Verhagen, A., Koes, B., & Van Tulder, M. (2010). A Systematic Review on the Effectiveness of Pharmacological Interventions for Chronic Non-specific Low-back Pain. *Eur Spine J.* DOI 10.1007/s00586-010-1541-4
293. Kumar, K., Taylor, R., Jacques, L., Eldabe, S., Meglio, M., Molet, J.,...Thomson, S. (2008). The Effects of Spinal Cord Stimulation in Neuropathic Pain are Sustained: A 24-month Follow-up of the Prospective Randomized Controlled Multicenter Trial of the Effectiveness of Spinal Cord Stimulation. *Neurosurgery. 63*: 762-770. \**Used in Evidence Statement.*
294. Kumar, K., Taylor, RS, Jacques, L, Eldabe, S., Meglio, M., Molet, J.,...North, R. (2007). Spinal Cord Stimulation versus Conventional Medical Management for Neuropathic Pain: A Multicentre Randomised Controlled Trial in Patients with Failed Back Surgery Syndrome. *Pain. 132*: 179-188. Assessment: Adequate.
295. Kumar, K., Hunter, G., & Demeria, D. (2006). Spinal Cord Stimulation in Treatment of Chronic Benign Pain: Challenges in Treatment Planning and Present Status, a 22-year Experience. *Neurosurgery. 58*: 481-496.
296. Kurzthaler, I., Bodner, T., Kemmler, G., Entner, T., Wissel, J., Berger, T., & Fleischhacker, WW. (2005). The Effect of Nabilone on Neuropsychological Functions Related to Driving Ability: An Extended Case Series. *Human Psycholpharmacology. 20*; 291-293.
297. Laaksonen, M., Kaaria, S-M, & Leino-Arjas, P. (2011). Different Domains of Health Functioning as Predictors of Sickness Absence - A Prospective Cohort Study. *Scand J Work Environ Health. 37* (3): 213-218. doi: 10.5271/sjweh.3131.
298. LaCaille, R., DeBerard, M., Masters, K., Colledge, A., & Bacon, W. (2005). Presurgical Biopsychosocial Factors Predict Multidimensional Patient: Outcomes of Interbody Cage Lumbar Fusion. *The Spine Journal. 5*; 71-78.
299. Lake B. (1985). Acute Back Pain. Treatment by the Application of Feldenkrais Principles. *Australian Family Physician. 14*: 11, 1175-1178.
300. Lamb, SE, Hansen, Z., Lall, R., Castelnuove, E., Withers, EJ, Nichols, V.,.. Underwood, MR. (2010). Group Cognitive Behavioural Treatment for Low-Back Pain in Primary Care: A Randomised Controlled Trial and Cost-Effectiveness Analysis. *Lancet. 375*; 916-23. Assessment: High Quality. *\*Used in Evidence Statement.*
301. Lambeek, L., van Mechelen, W., Knol, D., Loisel, P., & Anema, J. (2010). Randomised Controlled Trial of Integrated Care to Reduce Disability from Chronic Low Back Pain in Working and Private Life. *BMJ. 340*:c1035 doi:10.1136/bmj.c1035. Assessment: Adequate. *\*Used in Evidence Statement.*
302. Landau, CJ, Carr, WD, Razzetti, AJ, Sessler, NE, Murena, C., & Ripa, SR. (2007). Buprenorphine Transdermal Delivery System in Adults with Persistent Noncancer-Related Pain Syndromes Who Require Opioid Therapy: A Multicenter, 5-Week Run-in and Randomized, Double-Blind Maintenance-of-Analgesia Study. *Clin. Ther. 29* (10): 2179-93.
303. Landau, WM. (1996). Reflex Sympathetic Dystrophy. *Mayo Clin Proc. 71*; 5, 524-5.
304. Larkin, T., Dragovich, A., & Cohen, S. (2008). Acute Renal Failure During a Trial of Spinal Cord Stimulation: Theories as to a Possible Connection. *Pain Physician. 11*: 681-686.
305. Leard, JS, Breglio, L., Fraga, L., Ellrod, N., Nadler, L., Yasso, M., Fay, E., Ryan, K. & Pellecchia, GL. (2004). Reliability and Concurrent Validity of the Figure-of-Eight Method of Measuring Hand Size in Patients with Hand Pathology. *J. Orthop Sports Phys, Therapy. 34 (6)*: 335-40.
306. Lebel, A., Becerra, L., Wallin, D., Mounton, EA, Morris, S., Pendse, G., Jasciewicz, J.,...Borsook, D. (2008). fMRI Reveals Distinct CNS Processing During Symptomatic and Recovered Complex Regional Pain Syndrome in Children. *Brain.* doi:10.1093/brain/awnl23
307. Lee, J-H, Park, H-J, Lee, H., Shin, IM, & Song, MY. (2010). Acupuncture for Chronic Low Back Pain: Protocol for a Multicenter, Randomized, Sham-Controlled Trial. *BMC Musculoskeletal Disorders. 11*: 118.
308. Lefaucheur, JP, Drouot, X., Cunin, P., Bruckert, R., Lepetit, H., Creange, A.,...Nguyen, JP. (2009). Motor Cortex Stimulation for the Treatment of Refractory Peripheral Neuropathic Pain. *Brain. 132:* 1463-1471.
309. Levy, R., Deer, T., & Henderson, J. (2010). Intracranial Neurostimulation for Pain Control: A Review. *Pain Physician. 13*: 157-165.
310. Li, A., & Kaptchuk, TJ. (2011). The Case of Acupuncture for Chronic Low Back Pain. *Spine. 36*: 3, 181-182.
311. Licciardone, J., Stoll, S., Fulda, K., Russo, D., Siu, J., Winn, W., & Swift, Jr., J. (2003). Osteopathic Manipulative Treatment for Chronic Low Back Pain. *Spine. 28*: 13, 1355-1362.
312. Low, PA. (1993). Composite Autonomic Scoring Scale for Laboratory Quantification of Generalized Autonomic Failure. *Mayo Clinic Proc. 68* (8); 748-52.
313. Low, PA. (2004). Laboratory Evaluation of Autonomic Function. *Advances in Clinical Neurophysiology.* 358-368.
314. Low, V., Sandroni, P., Fealey, R., & Low, P. (2006). Detection of Small-Fiber Neuropathy by Sudomotor Testing. *Muscle & Nerve. 34*; 57-61.
315. Lowry, F. (November 2010). NSAIDS May Boost Stroke Risk. *Pain Medicine News. 11*
316. Lunn, MPT, Hughes, RAC, & Wiffen, PJ. Duloxetine for Treating Painful Neuropathy or Chronic Pain. *Cochrane Database of Systematic Reviews* 2009, Issue 4. Art. No.: CD007115. DOI:10.1002/14651858.CD007115.pub2. Assessment: High Quality. *\*Used in Evidence Statement.*
317. Lynch, M., Clark, A., Sawynok, J., & Sullivan, M. (2005). Topical 2% Amitriptyline and 1% Ketamine in Neuropathic Pain Syndromes. *Anesthesiology. 103*: 140-6. Assessment: High Quality. *\*Used in Evidence Statement.*
318. Maclure, M. (1991). The Case-Crossover Design: A Method for Studying Transient Effects on the Risk of Acute Events. *American Journal of Epidemiology. 133*: 2: 144-53.
319. Magnusson, M., Chow, D., Diamandopoulos, Z., & Pope, M. (2008). Motor Control Learning in Chronic Low Back Pain. *Spine. 33*: 16, E532-E538.
320. Maier, C., Baron, R., Tolle, T.R., Binder, A., Birbaumer, N., Birklein, F., Gierthmuhlen, J., et al. (2010). Quantitative Sensory Testing in the German Research Network on Neuropathic Pain (DFNS): Somatosensory abnormalities in 1236 Patients with Different Neuropathic Pain Syndromes. *Pain 150*: 439-450.
321. Mailis-Gagnon, A., & Furlan, AD. Sympathectomy for Neuropathic Pain. *Cochrane Database of Systematic Reviews* 2002, Issue 1. Art. No.: CD002918. DOI:10.1002/14651858.CD002918.
322. Mailis-Gagnon, A., Furlan, AD, Sandoval, JA, & Taylor, RS. Spinal Cord Stimulation for Chronic Pain. *Cochrane Database of Systematic Reviews* 2004, Issue 3. Art. No.: CD003783. DOI:10.1002/14651858.CD003783.pub2.
323. Malik, K., & Benzon, H. (2008). Radiofrequency Applications to Dorsal Root Ganglia. *Anesthesiology. 109*:3, 527-42.
324. Malmivaara, A., Hakkinen, U., Aro, T., Heinrichs, MJ, Koskenniemi, L., Kuosma, E.,...Hernberg, S. (1995). The Treatment of Acute Low Back Pain - Bed Rest, Exercises, or Ordinary Activity? *New England Journal of Medicine. 332*, 351-5. Assessment: High Quality. *\*Used in Evidence Statement.*
325. *Managed Care Outlook.* (December 2010). Hospitalizations for Medication, Illicit Drug-Related Conditions on the Rise for Those Who are 45 and Older. *23.*
326. Manchikanti, L., Cash, KA, Damron, KS, Manchukonda, R., Pampati, V., & McManus, CD. (2006). Controlled Substance Abuse and Illicit Drug use in Chronic Pain Patients: An Evaluation of Multiple Variables. *Pain Physician. 9*; 215-226.
327. Manchikanti, L., Giordano, J., Boswell, MV, Fellows, B., Manchukonda, R., & Pampati, V. (2007). Psychological Factors as Predictors of Opioid Abuse and Illicit Drug Use in Chronic Pain Patients.  *Journal of Opioid Management. 3*; 2.
328. Manchikanti, L., Pampati, V., Damron, KS, Fellows, B., Barnhill, RC, & Beyer, C. (2001). Prevalence of Opioid Abuse in Interventional Pain Medicine Practice Settings: A Randomized Clinical Evaluation. *Pain Physician. 4*: 4, 358-365.
329. Manicourt, D-H, Brasseur, J-P, Boutsen, Y., Depreseux, G., & Devogelaer, J-P. (2004). Role of Alendronate in Therapy for Posttraumatic Complex Regional Pain Syndrome Type I of the Lower Extremity. *Arthritis & Rheumatism. 50*: 11, 3690-3697. DOI.10.1002/art.20591 Assessment: Adequate. *\*Used in Evidence Statement.*
330. Marinus, J., Moseley, G.L., Birklein, F., Baron, R., Maihofner, C., Kingery, W.S., van Hilten, J.J. (2011). Clinical features and pathophysiology of complex regional pain syndrome. *Lancet Neurology, 8*. 637-648.
331. Martin-Sanchez, E., Furukawa, T., Taylor J., & Martin, JL. (2009). Systematic Review and Meta-Analysis of Cannabis Treatment for Chronic Pain. *Pain Medicine. 10*: 8, 1353-1368.
332. *Mason: Murray and Nadel’s Textbook of Respiratory Medicine. 5th Ed.* (2010). Diagnosis of Obstructive Sleep Apnea.
333. Masters-Steedman, S., Middaugh, SJ, Kee, WG, Carson, DS, Harden, RN, & Miller, MC. (1992). Chronic-Pain Medications: Equivalence Levels and Method of Quantifying Usage. *The Clinical Journal of Pain. 8*; 3, 204-214.
334. Mathur, V. (2000). Ziconotide: A New Pharmacological Class of Drug for the Management of Pain. *Seminars in Anesthesia, Perioperative Medicine and Pain. 19*, 2: 67-75.
335. Matthews, P., Derry, S., Moore, RA, & McQuay, HJ. Topical Rubefacients for Acute and Chronic Pain in Adults. *Cochrane Database of Systematic Reviews* 2009, Issue 3. Art. No.: CD007403. DOI:10.1002/14651858.CD007403.pub2.
336. Mayer, G., Wang-Weigand, S., Roth-Schechter, B., Lehmann, R., Staner, C., & Partinen, M. (2009). Efficacy and Safety of 6-month Nightly Ramelteon Administration in Adults with Chronic Primary Insomnia. *Sleep. 32*; 3, 351-360. Assessment: Adequate. *\*Used in Evidence Statement.*
337. Mazza, M., Mazza, O., Pazzaglia, C., Padua, L., & Mazza, S. (2010). Escitalopram 20 mg versus Duloxetine 60 mg for the Treatment of Chronic Low Back Pain. *Expert Opinion Pharmacotherapy. 11*: 1049-1052. Assessment: Inadequate.
338. McCleane, G. (2007). Topical analgesics. *Med Clin N Am. 91*: 125-139.
339. McCleane, G. (2000). Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. *British Journal of Clinical Pharmacology, (49)*. 574-579.
340. McLellan, AT. (2010). Chronic Noncancer Pain Management and Opioid Overdose: Time to Change Prescribing Practices. *Annals of Internal Medicine. 152*; 2, 123-124.
341. McMillan, M., Doud, T., & Nugent, W. (2003). Catheter-Associated Masses in Patients Receiving Intrathecal Analgesic Therapy. *Anesth Analg. 96*: 1, 186-90.
342. *Medical Letter on Drugs and Therapeutics.* (2010). Medical Marijuana. Issue 1330. Volume 52. 5.
343. *Medical Letter on Drugs and Therapeutics.* (2011). Duloxetine (Cymbalta) for Chronic Musculoskeletal Pain. Issue 1363, Volume 53.
344. *Medical Letter on Drugs and Therapeutics.* (2011). Transdermal Buprenorphine (Butrans) for Chronic Pain. Issue 1362, p.31
345. Meier, T., Wasner, G., Faust, M., Kuntzer, T., Oschner, F., Hueppe, M.,...Baron, R. (2003). Efficacy of Lidocaine Patch 5% in the Treatment of Focal Peripheral Neuropathic Pain Syndromes: A Randomized, Double-Blind, Placebo-Controlled Study. *Pain. 106*: 151-158. Assessment: Adequate. *\*Used in Evidence Statement.*
346. Mekhail, N., Cheng, J., Narouze, S., Kapural, L., Mekhail, M., & Deer, T. (2010). Clinical Applications of Neurostimulation: Forty Years Later. *Pain Practice. 10*: 2, 103-112.
347. Menetrey, A., Augsburger, M., Favrat, B., Pin, MA, Rothuizen, LE, Appenzeller, M., Buclin, T.,...Giroud, C. (2005). Assessment of Driving Capability Through the Use of Clinical and Pyschomotor Tests in Relation to Blood Cannabinoids Levels Following Oral Administration of 20 mg Dronabinol or of a Cannabis Decoction made with 20 or 60 mg Delta9-THC.  *J Anal Toxicol. 29* (5): 327-38. Abstract Only.
348. Meng, CF, Wang, D., Ngeow, J., Lao, L., Peterson, M., & Paget, S. (2003). Acupuncture for Chronic Low Back Pain in Older Patients: A Randomized, Controlled Trial. *Rheumatology. 42*: 12, 1508-1517.
349. Meyer, GJ, Finn, SE, Eyde, LD, Kay, GG, Moreland, KL, Dies, RD, ...Reed, GM. (2001). Psychological Testing and Psychological Assessment. *American Psychologist. 56*; 2, 128-165. DOI: 10.1037/0003-066X.56.2.128
350. Miele, VJ, Price, KO, Bloomfield, S., Hogg, J., & Bailes, JE. (2006). A Review of Intrathecal Morphine Therapy Related Granulomas. *European Journal of Pain.* 10; 251-261.
351. Mini, LJ, Wang-Weigand, S., & Zhang, J. (2007). Self-reported Efficacy and Tolerability of Ramelteon 8mg. in Older Adults Experiencing Severe Sleep-Onset Difficulty. *American Journal of Geriatric Pharmacotherapy. 5(3);* 177-184. DOI: 10.1016/j.amjopharm.2007.09.004.
352. Moore, RA, Straube, S., Wiffen, PJ, Derry, S., & McQuay, HJ. Pregabalin for Acute and Chronic Pain in Adults. *Cochrane Database of Systematic Reviews* 2009, Issue 3. Art. No.: CD007076. DOI:10.1002/14651858.CD007076.pub2. Assessment: High Quality. \**Used in Evidence Statement*
353. Moradi, B., Zahlten-Hinguranage, A., Barie, A., Caldeira, F., Schnatzer, P., Schiltenwolf, M., & Neubauer, E. (2010). The Impact of Pain Spread on the Outcome of Multidisciplinary Therapy in Patients with Chronic Musculoskeletal Pain- A Prospective Clinical Study in 389 Patients. *European Journal of Pain. 14*; 799-805.
354. Morin, CM, Bootzin, R., Buysse, D., Edinger, J., Espie, CA, & Lichstein, KL. (2006). Psychological and Behavioral Treatment of Insomnia: Update of the Recent Evidence (1998-2004). *Sleep. 29*: (11) 1398-1414.
355. Morin, CM, Vallieres, A., Guay, B., Ivers, H., Savard, J., Merette, C., Bastien, C., & Baillargeon, L. (2009). Cognitive Behavioral Therapy Singly and Combined With Medication, for Persistent Insomnia. A Randomized Controlled Trial. *JAMA. 301*: 19, 2005-2015. Assessment: Adequate. \*\**Used in Evidence Statement.*
356. Morley, S. (2011). Efficacy and Effectiveness of Cognitive Behaviour Therapy for Chronic Pain: Progress and some Challenges. *Pain 152:* S99-S106.
357. Moseley, GL. (2006). Graded Motor Imagery for Pathologic Pain: A Randomized Controlled Trial. *Neurology. 67*; 2129-2134.
358. Moseley, GL. (2004). Graded Motor Imagery is Effective for Long-Standing Complex Regional Pain Syndrome: A Randomized Controlled Trial. *Pain. 108;* 192-198.
359. Moulin, DE, Clark, AJ, Gilron, I., Ware, MA, Watson, CPN, Sessle, BJ,...Velly, A. (2007). Pharmacological Management of Chronic Neuropathic Pain - Consensus Statement and Guidelines from the Canadian Pain Society. *Pain Res Manage. 12*, 1: 13-21.
360. Muller, R., Lynton, GF, & Giles, DC. (2005). Long-Term Follow-Up of a Randomized Clinical Trial Assessing the Efficacy of Medication, Acupuncture, and Spinal Manipulation for Chronic Mechanical Spinal Pain Syndromes. *J. Manipulative Physiol Therapy. 28*: 3-11.
361. Munir, M., Enany, N., & Zhang, JM. (2007). Nonopioid Analgesics. *Med Clin N Am. 91*: 97-111.
362. Munts, AG, Van der Plas, AA, Ferrari, MD, Teepe-Twiss, IM, Marinus, J., & Van Hilten, JJ. (2010). Efficacy and Safety of a Single Intrathecal Methylprednosolone Bolus in Chronic Complex Regional Pain Syndrome. *European Journal of Pain. 14*; 523-528.
363. Naliboff, B., Wu, S., Schieffer, B., Bolus, R., Pham, Q., Baria, A.,...Skekelle, P. (2010). A Randomized Trial of 2 Prescription Strategies for Opioid Treatment of Chronic Nonmalignant Pain. *(In Press)*
364. Narang, S., Gibson, D., Wasan, A., Ross, E., Michna, E., Nedeljkovic, S., & Jamison, R. (2008). Efficacy of Dronabinol as an Adjuvant Treatment for Chronic Pain Patients on Opioid Therapy. *The Journal of Pain. 9*:3, 254-264. Assessment: Inadequate.
365. *National Collaborating Centre for Mental Health.* (2008). Drug Misuse: Opioid Detoxification.
366. *National Collaborating Centre for Mental Health.* (2008). Drug Misuse: Psychosocial Interventions.
367. *National Council on Compensation Insurance (NCCI).* (2011). Workers Compensation Prescription Drug Study: 2011 Update.
368. *National Institute for Health and Clinical Excellence (NICE).* (2011). Deep Brain Stimulation for Refractory Chronic Pain Syndromes (Excluding Headaches).
369. *National Institute for Health and Clinical Excellence (NICE).* (2010). Neuropathic Pain. The Pharmacological Management of Neuropathic Pain in Adults in Non-Specialist Settings.
370. *National Institute for Health and Clinical Excellence (NICE).* (2008). Spinal Cord Stimulation for Chronic Pain of Neuropathic or Ischaemic Origin.
371. *National Institute for Health and Clinical Excellence (NICE).* (2007). Drug Misuse: Psychosocial Interventions and Opioids Detoxification.
372. *National Institute on Drug Abuse (NIDA).* (2006). Epidemiologic Trends in Drug Abuse. Advance Report. Community Epidemiology Work Group.
373. *National Opioid Use Guideline Group (NOUGG) (2010).* Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain© Part B. Recommendations for Practice. *2010 National Opioid Use Guideline Group (NOUGG).*
374. *National Survey on Drug Use and Health (NSDUH).* (2007). Patterns and Trends in Nonmedical Prescription Pain Reliever Use: 2002 to 2005.
375. Ng, L., Chaudhary, N., & Sell, P. (2005). The Efficacy of Corticosteroids in Periradicular Infiltration for Chronic Radicular Pain. *Spine. 30*; 8, 857-862. Assessment: Adequate. *\*\*Used in Evidence Statement.* [Inadequate on another issue].
376. Niehof, SP, Beerthuizen, A., Huygen, FJPM, & Zijlstra, FJ. (2008). Using Skin Surface Temperature to Differentiate Between Complex Regional Pain Syndrome Type I Patients After a Fracture and Control Patients with Various Complaints After a Fracture. *Anesth. Alalg. 106*:270-7.
377. Niehof, SP, Huygen, FJ, Stronks, DL, Klein, J., & Zijlstra, FJ. (2007). Reliability of Observer Assessment of Thermographic Images in Complex Regional Pain Syndrome Type I. *Acta Orthop Belg. 73*(1): 31-7. Abstract Only.
378. Niehof, SP, Huygen, FJPM, Van der Weerd, RWP, Westra, M., & Zijlstra, FJ. (2006). Thermography Imaging During Static and Controlled Thermoregulation in Complex Regional Pain Syndrome Type I: Diagnostic Value and Involvement of the Central Sympathetic System. *BioMedical Engineering OnLine. 5*:30 doi:10.1186/1475-925X-5-30
379. Noble, M., Treadwell, JR, Tregear, SJ, Coates, VH, Wiffen, PJ, Akafomo, C., & Schoelles, KM. Long-Term Opioid Management for Chronic Noncancer Pain. *Cochrane Database of Systematic Reviews* 2010, Issue 1. Art. No.: CD006605. DOI:10.1002/14651858.CD006605.pub2.
380. Noble, M., Tregear, SJ, Treadwell, JR, & Schoelles, K. (2008). Long-Term Opioid Therapy for Chronic Noncancer Pain: A Systematic Review and Meta-Analysis of Efficacy and Safety.  *Journal of Pain and Symptom Management. 35*: 2, 214-228.
381. Noppers, I., Niesters, M., Aarts, L., Bauer, M., Drewes, A., Dahan, A., & Sarton, E. (2011). Drug-induced Liver Injury Following a Repeated Course of Ketamine Treatment for Chronic Pain in CRPS type 1 Patients: A Report of 3 Cases. *Pain.* 152: 2173-2178.
382. Norrbrink, C., & Lundeberg, T. (2009). Tramadol in Neuropathic Pain after Spinal Cord Injury a Randomized, Double-Blind, Placebo-Controlled Trial. *Clin J Pain. 25*: 3, 177-184. Assessment: Adequate. *\*Used in Evidence Statement.*
383. North, R., Kidd, D., Campbell, J., & Long, D. (1991). Dorsal Root Ganglionectomy for Failed Back Surgery Syndrome: A 5-year Follow-Up Study.  *Journal of Neurosurgery. 74*: 2. DOI:10.3171/jns.1991.74.2.0236
384. North, R., Kidd, D., Farrokhi, F., & Piantodosi, S. (2005). Spinal Cord Stimulation versus Repeated Lumbosacral Spine Surgery for Chronic Pain: A Randomized, Controlled Trial. *Neurosurgery. 56*: 1, 98-107. Assessment: Adequate. \**Used in Evidence Statement.*
385. North, R., Kidd, D., Olin, J., Sierachki, J., Farrokhi, F., Petrucci, L., & Cutchis, P. (2005). Spinal Cord Stimulation for Axial Low Back Pain. A Prospective, Controlled Trial Comparing Dual with Single Percutaneous Electrodes. *Spine. 30*: 12, 1412-1418.
386. Novak, C., Anastakis, D., Beaton, D., Mackinnon, S., & Katz, J. (2010). Relationships Among Pain Disability, Pain Intensity, Illness Intrusiveness, and Upper Extremity Disability in Patients with Traumatic Peripheral Nerve Injury. *J Hand Surg. 35A*: 1633-1639.
387. NUCYNTA ER – Prescribing Information. (2011).
388. Nurmikko, T., Serpell, M., Hoggart, B., Toomey, P., Morlion, B., & Haines, D. (2007). Sativex Successfully Treats Neuropathic Pain Characterized by Allodynia: A Randomised, Double-Blind, Placebo-Controlled Clinical Trial. *Pain. 133*: 210-220. Assessment: Adequate. *\*Used in Evidence Statement.*
389. Ochoa, JL. (1995). Reflex? Sympathetic? Dystrophy? Triple Questioned Again. *Mayo Clin Proc. 70*; 11; 1124-6.
390. O’Connell, NE, Wand, BM, & Goldacre, B. (2009). Interpretive Bias in Acupuncture Research? A Case Study. *Evaluation & the Health Professions. 32* (4); 393-409.
391. O’Connell, NE, Wand, BM, Marston, L, Spencer, S, & DeSouza, LH. Non-invasive Brain Stimulation Techniques for Chronic Pain. *Cochrane Database of Systematic Reviews* 2010, Issue 9. Art. No.: CD008208. DOI: 10.1002/14651858.CD008208.pub2.
392. O’Connor, A., & Dworkin, R. (2009). Treatment of Neuropathic Pain: An Overview of Recent Guidelines. *The American Journal of Medicine. 122:* S22-S32.
393. Oerlemans, HM, Goris, JA, & Oostendorp, RAB. (1998). Impairment Level SumScore in Reflex Sympathetic Dystrophy of One Upper Extremity. *Arch. Phys. Med. Rehabilitation. 79*: 979-990.
394. Oerlemans, HM, Oostendorp, RAB, De Boo, T., Perez, RSGM, & Goris, R JA. (1999). Signs and Symptoms in Complex Regional Pain Syndrome Type I / Reflex Sympathetic Dystrophy: Judgment of the Physician Versus Objective Measurement. *The Clinical Journal of Pain. 15* (3): 224-232.
395. Oesch, P., Kool, J., Hagen, KB, & Bachmann, S. (2010). Effectiveness of Exercise on Work Disability in Patients with Non-Acute Non-Specific Low Back Pain: Systematic Review and Meta-Analysis of Randomized Controlled Trials. *J. Rehabil Med. 42*: 193-205. Assessment: Adequate. *\*Used in Evidence Statement.*
396. Okie, S. (2010). A Flood of Opioids, A Rising Tide of Deaths. *New England Journal of Medicine. 363*:21.
397. Okoro, T., & Sell, P. (2009). The Prediction of Outcome in Somatised Patients Undergoing Elective Lumbar Surgery. *J Bone Joint Surg. 91-B*.
398. Ooi, YC, Falowski, S., Wang, D., Jallo, J., Ho, RT, & Sharan, A. (2011). Simultaneous Use of Neurostimulators in Patients with a Preexisting Cardiovascular Implantable Electronic Device. *Neuromodulation. 14*: 20-26. DOI: 10.1111/j.1525-1403.2010.00314.x
399. Oosterhof, J., Samwel, HJA, de Boo, TM, Wilder-Smith, OHG, Oostendorp, RAB, & Crul, BJP. (2008). Predicting Outcome of TENS in Chronic Pain: A Prospective Randomized, Placebo Controlled Trial. *Pain. 136*: 11-20.
400. Osborne, MD, Ghazi, SM, Palmer, SC, Boone, KM, Sletten, CD, & Nottmeier, EW. (2011). Spinal Cord Stimulator-Trial Lead Migration Study. *Pain Medicine. 12*; 204-208.
401. Otto, M., Bach, FW, Jensen, T., Brosen, K., & Sindrup, S. (2009). Escitalopram in Painful Polyneuropathy: A Randomized, Placebo-Controlled, Cross-Over Trial. *Pain. 139*: 275-283. Assessment: Adequate.
402. Ozdemir, F., Birtane, M., & Kokino, S. (2001). The Clinical Efficacy of Low-Power Laser Therapy on Pain and Function in Cervical Osteoarthritis. *Clinical Rheumatology. 20*: 181-184.
403. Ozturk, E., Mohur, H., Arslan, N., Entok, E., Tan, K., & Ozguven, MA. (2004). Quantitative Three-phase Bone Scintigraphy in the Evaluation of Intravenous Regional Blockade Treatment in Patients with Stage-I Reflex Sympathetic Dystrophy of Upper Extremity. *Annals of Nuclear Medicine. 18*; 8; 653-658.
404. *PainEdu.org* (2/2010). Chronic Opioid Therapy: Driving and Work Safety.
405. *PainMedicineNews.com* (11/2010). FDA Approves Injectable Drug to Treat Opioid Dependent Patients.
406. Parks, PD, Pransky, GS, & Kales, SN. (2010). Iatrogenic Disability and Narcotics Addition after Lumbar Fusion in a Worker’s Compensation Claimant. *Spine. 35*: 12, E549-E552.
407. Patterson, R., Li, Z., Smith, B., Smith, T., & Koman, L. (2011). Complex Regional Pain Syndrome of the Upper Extremity. *Journal of Hand Surgery.* 36A: 1553-1562.
408. Perez, RSGM, Burm, PET, Zuurmond, WWA, Bezeman, PD, Brink, HEJ, & De Lange, JJ. (2005). Physicians’ Assessments Versus Measured Symptoms of Complex Regional Pain Syndrome Type I. Presence and Severity. *Clinical Journal of Pain. 21*: 3, 272-276.
409. Perez, RSGM, Burm, PET, Zuurmond, WWA, Giezeman, MJMM, Van Dasselaar, NT, Vrankken, J., & De Lange, JJ. (2002). Interrater Reliability of Diagnosing Complex Regional Pain Syndrome Type I. *Acta Anaesthesiol Scand. 46*: 447-450.
410. Perez, RSGM, Collins, S., Marinus, J., Zuurmond, WWA, & De Lange, JJ. (2007). Diagnostic Criteria for CRPS I: Differences Between Patient Profiles Using Three Different Diagnostic Sets. *European Journal of Pain. 11*: 895-902.
411. Perez, RSGM, Keijzer, C., Bezemer, PD, Zuurmond, WWA, & De Lange, JJ. (2005). Predictive Value of Symptom Level Measurements for Complex Regional Pain Syndrome Type I. *European Journal of Pain. 9*: 49-56.
412. Perez, RSGM, Kwakkel, G., Zuurmond, WWA, & De Lange, J. (2001). Treatment of Reflex Sympathetic Dystrophy (CRPS Type I): A Research Synthesis of 21 Randomized Clinical Trials. *Journal of Pain and Symptom Management. 21*; 6, 511-526.
413. Perez, RSGM, Oerlemans, HM, Zuurmond, WWA, & De Lange, JJ. (2003). Impairment Level SumScore for Lower Extremity Complex Regional Pain Syndrome type I. *Disability and Rehabilitation. 25*(17); 984-991.
414. Perez, RSGM, Zollinger, PE, Dijkstra, PU, Thomassen-Hilgersom, IL, Zuurmond, WW, Rosenbrand, KCJ, & Geertzen, JH. (2010). Evidence Based Guidelines for Complex Regional Pain Syndrome Type 1. *BMC Neurology. 10*:20, 1471-2377.
415. Perez, RSGM, Zuurmond, WWA, Bezemer, PD, Kuik, DJ, Van Loenen, AC, De Lange, JJ, & Zuidhor, AJ. (2003). The Treatment of Complex Regional Pain Syndrome Type I with Free Radical Scavengers: A Randomized Controlled Study. *Pain. 102*; 297-307. Assessment: Inadequate.
416. Plouvier, S., Chastang, J-F, Lanoe, J-L, Niedhammer, I., & Leclerc, A. (2010). Personal and Occupational Factors Associated with Low-back Pain in a General Working Population in France.
417. Pool, JJM, Ostelo, RWJG, Know, DL, Vlaeyen, JWS, Bouter, LM, & De Vet, HCW. (2010). Is a Behavioral Graded Activity Program More Effective Then Manual Therapy in Patients with Subacute Neck Pain? *Spine. 35*: 10, 1017-1024**.**
418. Poole, H., Glenn, S., & Murphy, P. (2007). A Randomised Controlled Study of Reflexology for the Management of Chronic Low Back Pain. *European Journal of Pain. 11*; 878-887.
419. Porta, M. (2000). A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of Myofascial pain syndrome and pain from chronic muscle spasm. *Pain* 85:101-105.
420. Postma, T.J., Aaronson, J.J., Heimans, J.J., Muller, M.J., Hildebrand, J.G., Delattre, J.Y…..Lucey, R. (2005). The development of an EORTC [European Organization for Research and Treatment of Cancer] quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. *European Journal of Cancer (41).* 1135-1139.
421. Poyhia, R., Vainio, A. (2006). Topically administered ketamine reduces capsaicin-evoked mechanical hyperalgesia. *Clinical Journal of Pain, (22)*. 32-36.
422. *Prescrire International.* (2009). Complex Regional Pain Syndrome Type 1. *Rev Prescrire 29* (306): 284-289.
423. Preyde, M. (2010). Effectiveness of Massage Therapy for Subacute Low-Back Pain: A Randomized Controlled Trial. *CMAJ. 162* (13): 1815-20. Assessment: Adequate. *\*Used in Evidence Statement.*
424. Prochazka, AV. (2000). New Developments in Smoking Cessation\**Chest. 117:* 169S-175S. DOI 10.1378/chest.117.4\_suppl\_1.169S
425. Quigley, C. Hydromorphone for Acute and Chronic Pain. *Cochrane Database of Systematic Reviews* 2002, Issue 1. Art. No.: CD003447. DOI:10.1002/14651858.CD003447.
426. Quigley, C. Opioid Switching to Improve Pain Relief and Drug Tolerability. *Cochrane Database of Systematic Reviews* 2004, Issue 3. Art. No.: CD004847. DOI:10.1002/14651858.CD004847.
427. Quilici, S., Chancellor, J., Lothgren, M., Simon, D., Said, G., Kim Le, T., Garcia-Cebrian, A., & Monz, B. (2009). Meta-Analysis of Duloxetine vs. Pregabalin and Gabapentin in the Treatment of Diabetic Peripheral Neuropathic Pain. *BMC Neurology.* *9*:6. doi: 10.1186/1471-2377-9-6. Assessment: Adequate. *\*Used in Evidence Statement.*
428. Ramamurthy, S., Hoffman, J., & The Guanethidine Study Group\* (1995). Intravenous Regional Guanethidine in the Treatment of Reflex Sympathetic Dystrophy/Causalgia: A Randomized, Double-Blind Study. *Anesthesia Analg. 81*; 718-23. Assessment: Inadequate.
429. Ranoux, D., Attal, N., Morain, F., & Bouhassira, D. (2008). Botulinum Toxin Type A Induces Direct Analgesic Effects in Chronic Neuropathic Pain. *American Neurological Association. 64*; 274-284. Assessment: Adequate.
430. Rasche, D., Rinaldi, P., Young, R., & Tronnier, V. (2006). Deep Brain Stimulation for the Treatment of Various Chronic Pain Syndromes. *Neurosurgery Focus. 21* (6): E8
431. Raskin, P., Donofrio, PD, Rosenthal, NR, Hewitt, DJ, Jordan, DM, Xiang, J., & Vinik, A. (2004). Topiramate vs. Placebo in Painful Diabetic Neuropathy: Analgesic and Metabolic Effects. *American Academy of Neurology. 63*: 865-873. Assessment: Adequate. *\*Used in Evidence Statement.*
432. Rasmussen-Barr, E., Nilsson-Wlkmar, L., & Arvidsson, I. (2003). Stabilizing Training Compared with Manual Treatment in Sub-Acute and Chronic Low-Back Pain. *Manual Therapy. 8* (4): 233-241. doi:10.1016/S1356-689X(03)00053-5
433. Rathmell, J. (2008). The Promise of an Effective Treatment for Sacroiliac-Related Low Back Pain. *Anesthesiology. 109*: 167-8.
434. Rauck, R., Eisenach, J., Jackson, K., Young, L., & Southern, J. (1993). Epidural Clonidine Treatment for Refractory Reflex Sympathetic Dystrophy. *Anesthesiology. 79,* 6: 1163-1169. Assessment: Adequate. *\*Used in Evidence Statement.*
435. Rauck, R., Wallace, M., Burton, A., Kapural, L., & North, J. (2009). Intrathecal Ziconotide for Neuropathic Pain: A Review. *Pain Practice. 9*:5, 327-337.
436. Rauck, R., Wallace, M., Leong, M., MineHart, M., Webster, L., Charapata, G.,...The Ziconotide 301 Study Group. (2006). A Randomized, Double-Blind, Placebo-Controlled Study of Intrathecal Ziconotide in Adults with Severe Chronic Pain. *Journal of Pain and Symptom Management. 31*: 393-406.
437. Ravenek, MJ, Hughes, ID, Ivanovich, N., Tyrer, K., Desrochers, C., Klinger, L.,...Shaw, L. (2010). A Systematic Review of Multidisciplinary Outcomes in the Management of Chronic Low Back Pain. *Work. 35:* 349-367.
438. Reflex Sympathetic Dystrophy Syndrome Association. *RSDS.org.* (2010). Clinical Guidelines website.
439. Reid, KJ, Baron, KG, Lu, B., Naylor, E., Wolfe, L., & Zee, PC. (2010). Aerobic Exercise Improves Self-reported Sleep and Quality of Life in Older Adults with Insomnia. *Sleep Medicine. 11*; 934-940.
440. Reinders, M., Geertzen, J., & Dijkstra, P. (2002). Complex Regional Pain Syndrome Type I: Use of the International Association of the Study of Pain Diagnostic Criteria Defined in 1994. *Clinical Journal of Pain. 18* (4): 207-215.
441. Reuben, S., Rosenthal, E., Steinberg, R., Faruqi, S., & Kilaru, A. (2004). Surgery on the Affected Upper Extremity of Patients with a History of Complex Regional Pain Syndrome: The Use of Intravenous Regional Anesthesia with Clonidine. *Journal of Clinical Anesthesia. 16*:517-522. doi:10.1016/j.jcline.2004.02.001. Assessment: Adequate. *\*Used in Evidence Statement.*
442. Rhodin, A., Stridsberg, M., & Gordh, T. (2010). Opioid Endocrinopathy: A Clinical Problem in Patients with Chronic Pain and Long-Term Oral Opioid Treatment. *Clinical Journal of Pain. 26*: 5, 374-380.
443. Richeson, NE, Spross, JA, Lutz, K., & Peng, C. (2010). Effects of Reiki on Anxiety, Depression, Pain, and Physiological Factors in Community-Dwelling Older Adults. *Research in Gerontological Nursing. 3*; 3, 187-199.
444. Rintala, DH, Fiess, RN, Tan, G., Holmes, SA, & Bruel, BM. (2010). Effect of Dronabinol on Central Neuropathic Pain after Spinal Cord Injury. *Am J Phys Med. Rehabil. 89:* 10, 840-848.
445. Rintala, D., Holmes, S., Courtade, D., Fiess, R., Tastard, L., & Loubser, P. (2007). Comparison of the Effectiveness of Amitriptyline and Gabapentin on Chronic Neuropathic Pain in Persons with Spinal Cord Injuries. *Arch Phys Med Rehabil. 88*: 1547-60. Assessment: Adequate. *\*Used in Evidence Statement.*
446. Rivero-Arias, O., Campbell, H., Gray, A., Fairback, J., Frost, H., & Wilson-MacDonald, J. (2005). Surgical Stabilisation of the Management of Patients with Chronic Low Back Pain: Cost Utility Analysis Based on a Randomised Controlled Trial. *BMJ.* doi:10.1136/bmj.38441.429618.BF
447. Robinson, JN, Sandom, J., & Chapman, PT. (2004). Efficacy of Pamidronate in Complex Regional Pain Syndrome Type I. *Pain Medicine. 5*: 3, 176-280. Assessment: Inadequate.
448. Rog, D, Nurmikko, T., Friede, Tm, & Young, C. (2005). Randomized, Controlled Trial of Cannabis-based Medicine in Central Pain in Multiple Sclerosis. *Neurology. 65*; 812-819.
449. Rolfs, R., Johnson, E., Williams, N., & Sundwall, D. (2010). Utah Clinical Guidelines on Prescribing Opioids for Treatment of Pain. *Journal of Pain & Palliative Care Pharmacotherapy. 24*: 219-235.
450. Rose, M.J., Reilly, J.P., Pennie, B., Bowen-Jones, K., Stanley, I.M. (1997). Chronic Low Back Pain Rehabilitation Programs: A Study of the Optimum Duration of Treatment and a Comparison of Group and Individual Therapy. *Spine. 22*(19); 2246-2251.
451. Rosenberger, PH, Jokl, P., Ickovics, J. (2006). Psychosocial Factors and Surgical Outcomes: An Evidence-Based Literature Review. *J Am Acad Orthop. Surg. 14*: 397-405.
452. Rosenquist, R., Benzon, H., Connis, R., De Leon-Casasola, O., Glass, D., Mekhail, N.,...Simon, D. (2010). Practice Guidelines for Chronic Pain Management. *Anesthesiology. 112*: 810-33.
453. Roskos, SE, Keenum, AJ, Newman, LM, & Wallace, LS. (2007). Literacy Demands and Formatting Characteristics of Opioid Contracts in Chronic Nonmalignant Pain Management. *The Journal of Pain. 8*; 10, 753-758.
454. Rowbotham, MC, Veeraindar, G., Kunz, N., & Lei, D. (2004). Venlafaxine Extended Release in the Treatment of Painful Diabetic Neuropathy: A Double-Blind, Placebo-Controlled Study. *Pain. 110*: 697-706. Assessment: Adequate. *\*Used in Evidence Statement.*
455. Rubinstein, SM, Van Middelkoop, M., Assendelft, WJJ, de Boer, M, van Tulder, MW. (2011). Spinal manipulative therapy for chronic low-back pain: An update of a Cochrane Review. *Spine. 36:* 13, E825-E846. DOI: 10.1097/BRS.0b013e3182197fe1. Assessment: Adequate. \**Used in Evidence Statement*.
456. Rubinstein, SM, Van Middelkoop, M., Juijpers, T., Ostelo, R., Verhagen, A., De Boer, M., ...Van Tulder, M. (2010). A Systematic Review on the Effectiveness of Complementary and Alternative Medicine for Chronic Non-specific Low-back Pain. *Eur Spine J. 19*; 1213-1228. Abstract Only.
457. Rupert, M., Lee, M., Manchikanti, L., Datta, S., & Cohen, S. (2009). Evaluations of Sacroiliac Joint Interventions: A Systematic Appraisal of the Literature. *Pain Physician. 12*: 399-418.
458. Saarto, T., & Wiffen, PJ. Antidepressants for Neuropathic Pain. *Cochrane Database of Systematic Reviews* 2007, Issue 4. Art. No.: CD005454. DOI:10.1002/14651858.CD005454.pub2. Assessment: Adequate. *\*Used in Evidence Statement.*
459. Sahin, N., Ozcan, E., Sezen, K., Karatas, O., & Issever, H. (2010). Efficacy of Acupuncture in Patients with Chronic Neck Pain - A Randomised, Sham-Controlled Trial. *Acupuncture and Electro-Therapeutics Res. Int. J. 35*: 17-27.
460. Sahin, F., Yilmaz, F., Kotevoglu, N., & Kuran, B. (2006). Efficacy of Salmon Calcitonin in Complex Regional Pain Syndrome (Type 1) in Addition to Physical Therapy. *Clinical Rheumatology. 25*: 143-148. Assessment: Inadequate.
461. Sandroni, P., Low, P., Ferrer, T., Opfer-Gehrking, TL, Willner, CL, & Wilson, PR. (1998). Complex Regional Pain Syndrome I (CRPS I): Prospective Study and Laboratory Evaluation. *The Clinical Journal of Pain. 14*; 4, 282-289. Assessment: Inadequate.
462. Saper, J. Occipital Nerve Stimulation (ONS) For Treatment of Intractable Migraine Headache. *American Academy of Pain Medicine.* 25th Annual Meeting. January 28-31, 2009.
463. Sawynok, J. (2003). Topical and peripherally active analgesics. *Pharmacological Reviews.*
464. Sawynok, J. (2005). Topical analgesics in neuropathic pain. *Current Pharmaceutical Design.(11)*. 2995-3004.
465. Schapmire, D, St, James, JD, Feeler, L., & Kleinkort, J. (2010). Simultaneous Bilateral Hand Strength Testing in a Client Population, Part I: Diagnostic, Observational and Subjective Complaint Correlates to Consistency of Effort. *Work. 37*: 309-320. DOI 10.3233/WOR-2010-1083
466. Schapmire, D., St. James, JD, Townsend, R., & Feeler, L. (No date). Accuracy of Visual Estimation in Classifying Effort During a Lifting Task.
467. Schimmel, JJP, de Kleuver, M., Horsting, PP., Spruit, M., & Jacobs, WCH. (2009). No Effect of Traction in Patients with Low Back Pain: A Single Centre, Single Blind, Randomized Controlled Trial of Intervertebral Differential Dynamics Therapy® *Eur Spine Journal. 18*: 1843-1850. DOI 10.1007/s00586-009-1044-3
468. Schmidtko, A., Lotsch, J., Freynhagen, R., & Geisslinger, G. (2010). Ziconotide for Treatment of Severe Chronic Pain. *Lancet. 375*: 1569-77.
469. Schwartz, S., Etropolski, M., Shipiro, DY, Okamoto, A., Lange, R., Haeussler, J., & Rauschkolb, C. (2011). Safety and Efficacy of Tapentadol ER in Patients with Painful Diabetic Peripheral Neuropathy: Results of a Randomized-Withdrawal, Placebo-Controlled Trial. *Current Medical Research & Opinion. 27*; 1, 151-162. Assessment: Adequate. *\*Used in Evidence Statement.*
470. Schwartzman, R., Alexander, G., Grothusen, J., Paylor, T., Reichenberger, E., & Perreault, M. (2009). Outpatient Intravenous Ketamine for the Treatment of Complex Regional Pain Syndrome: A Double-Blind Placebo Controlled Study. *Pain. 147*: 107-115. Assessment: Inadequate.
471. Selvarajah, D., Gandhi, R., Emery, C., & Tesfaye, S. (2010). Randomized Placebo-Controlled Double-Blind Clinical Trial of Cannabis-Based Medicinal Product (Sativex) in Painful Diabetic Neuropathy. *Diabetes Care. 33*: 128-130. Assessment: Inadequate.
472. Shipley, J., & North, R. Review of the Evidence on the Cost-Effectiveness of SCS: What Types of Evidence are Credible and Do Peer-Reviewed Publications Ensure Quality? Improving Patient Outcomes by Agreeing on Study Methodology. *American Academy of Pain Medicine.* 25th Annual Meeting. January 28-31, 2009.
473. Siddall, P., Molloy, A., Walker, S., & Rutkowski, S. (2000). The Efficacy of Intrathecal Morphine and Clonidine in the Treatment of Pain after Spinal Cord Injury. *Anesth Analg. 91*: 1493-8.
474. Sigtermans, M., Van Hilten, J., Bauer, M., Arbous, M., Marinus, J., Sarton, E., & Dahan, A. (2009). Ketamine Produces Effective and Long-Term Pain Relief in Patients with Complex Regional Pain Syndrome Type 1. *Pain. 145*: 304-311. Assessment: Adequate. *\*Used in Evidence Statement.*
475. Silber, MH. (2005). Chronic Insomnia. *NEJM. 353*: 803-10.
476. Silverman, S. (2009). Opioid Induced Hyperalgesia: Clinical Implications for the Pain Practitioner. *Pain Physician. 12*: 679-684.
477. Simon, G., Goldberg, D., Tiemens, B., & Ustun, T. (1999). Outcomes of Recognized and Unrecognized Depression in an International Primary Care Study. *General Hospital Psychiatry. 21*; 97-105.
478. Simopoulos, T., Kraemer, J., Nagda, J., Aner, M., & Bajwa, Z. (2008). Response to Pulsed and Continuous Radiofrequency Lesioning of the Dorsal Root Ganglion and Segmental Nerves in Patients with Chronic Lumbar Radicular Pain. *Pain Physician. 11*: 137-144.
479. Simpson, EL, Duenas, A., Holmes, MW, Papaioannou, D., & Chilcott, J. (2009). Spinal Cord Stimulation for Chronic Pain of Neuropathic or Ischaemic Origin: Systematic Review and Economic Evaluation. *Health Technology Assessment. 13*:17, 1-154. Abstract Only.
480. Simpson, CA, (2006). Complementary Medicine in Chronic Pain Treatment. *Physical Medicine and Rehabilitation Clinics of North America. 17*; 451-472.
481. Sinikallio, S., Aalto, T., Airaksinen, O., Herno, A., Kroger, H., & Viinamaki, H. (2009). Depressive Burden in the Preoperative and Early Recovery Phase Predicts Poorer Surgery Outcome Among Lumbar Spinal Stenosis Patients. *Spine. 34*; 23, 2573-2578. Assessment: Adequate. *\*Used in Evidence Statement.*
482. Sinikallio, S., Aalto, T., Airaksinen, O., Lehto, SM, Kroger, H., & Viinamaki, H. (2007). Depression Is Associated with a Poorer Outcome of Lumbar Spinal Stenosis Surgery. *Eur Spine J. 16*: 905-912.
483. Sinikallio, S., Aalto, T., Airaksinen, O., Lehto, SM, Kroger, H., & Viinamaki, H. (2010). Depression Is Associated with a Poorer Outcome of Lumbar Spinal Stenosis Surgery. A Two-Year Prospective Follow-up Study. Spine. XX, XX, 000-000. Assessment: Adequate. *\*Used in Evidence Statement.*
484. Sinikallio, S., Aalto, T., Koivumaa-Honkanen, H., Airaksinen, O., Herno, A., Kroger, H., & Viinamaki, H. (2009). Life Dissatisfaction is Associated with a Poorer Surgery Outcome and Depression among Lumbar Spinal Stenosis Patients: A 2-year Prospective Study. *Eur Spine Journal. 18*; 1187-1193.
485. Sinikallio, S., Aalto, T., Lehto, S., Airaksinen, O., Herno, A., Kroger, H., & Viinamaki, H. (2010). Depressive Symptoms Predict Postoperative Disability among Patients with Lumbar Spinal Stenosis: A Two-year Prospective Study Comparing Two Age Groups. *Disability and Rehabilitation. 32* (6): 462-468.
486. Sinikallio, S., Airaksinen, O., Aalto, T., Lehto, SM, Kroger, H., & Viinamaki, H. (2010). Coexistence of Pain and Depression Predicts Poor 2-year Surgery Outcome among Lumbar Spinal Stenosis Patients. *Nord J. Psychiatry. 64*; 391-396.
487. Sinikallio, S., Koivumaa-Honkanen, H., Aalto, T., Airaksinen, O., Lehto, S., & Viinamaki, H. (2011). Life Dissatisfaction in the Pre-Operative and Early Recovery Phase Predicts Low Functional Ability and Coping among Post-Operative Patients with Lumbar Spinal Stenosis: A 2-year Prospective Study. *Disability and Rehabilitation. 33* (7): 599-604.
488. Sinikallio, S., Lehto, S., Aalto, T., Airaksinen, O., Kroger, H., & Viinamaki, H. (2010). Depressive Symptoms During Rehabilitation Period Predict Poor Outcome of Lumbar Spinal Stenosis Surgery: A Two-year Perspective. *BMC Musculoskeletal Disorders. 11*; 152.
489. Sitzman, T., & Prager, J. Complications of Intrathecal Therapies Including IT Granulomas. *American Academy of Pain Medicine.* 25th Annual Meeting. January 28-31, 2009.
490. Skljarevski, V., Desaiah, D., Lui-Seifert, H., Zhang, Q., Chappell, A., Detke, M.,...Backonja, M. (2010). Efficacy and Safety of Duloxetine in Patients with Chronic Low Back Pain. *Spine. 35*: 13, E578-E585. Assessment: Inadequate.
491. Slavin, KV, Colpan, ME, Munawar, N., Wess, C., & Nersesyan, H. (2006). Trigeminal and Occipital Peripheral Nerve Stimulation for Craniofacial Pain: A Single-institution Experience and Review of the Literature. *Neurosurg Focus. 21*, (6); E6.
492. Sletten, DM, Weigand, SD, & Low, PA. (2010). Relationship of Q-Sweat to Quantitative Sudomotor Axon Reflex Test (QSART) Volumes. *Muscle Nerve. 41* (2); 240-246. doi: 10.1002/mus.21464.
493. Sloan, P. (2010). Tapentadol for Acute and Chronic Pain. *Expert Opin. Pharmacother. 11*(11); 1783-1785.
494. Smith, H. (2009). Opioid Metabolism. *Mayo Clinic Proceedings.* 84(7); 613-624.
495. So, PS, Jiang, Y., & Qin, Y. Touch Therapies for Pain Relief in Adults. *Cochrane Database of Systematic Reviews* 2008, Issue 4. Art. No.: CD006535. DOI:10.1002/14651858.CD006535.pub2.
496. St. James, J., Schapmire, D., Feeler, L., & Kleinkort, J. (2010). Simultaneous Bilateral Hand Strength Testing in a Client Population, Part II: Relationship to a Distraction-based Lifting Evaluation. *Work. 37;* 395-403. DOI 10.3222/WOR-2010-1093
497. Staats, PS. (2008). Complications of Intrathecal Therapy. *Pain Medicine.* 9, S1; 102-107. DOI: 10.1111/j.1526-463.2008.00445x.
498. Stanton-Hicks, M.D., Burton, A.W., Bruehl, S.P., Carr, D.B., Harden, N., Hassenbusch, S.J., Lubenow, T.R., Oakley, J.C., Racz, G.B., Raj, P.P., Rauck, R.L., & Rezai, A.R. (2002). An Updated Interdisciplinary Clinical Pathway for CRPS: Report of an Expert Panel. *Pain Practice 2(1); 1-16.*
499. Starrels, J., Becker, W., Alford, D., Kapoor, A., Robinson Williams, A., & Turner, B. (2010). Systematic Review: Treatment Agreements and Urine Drug Testing to Reduce Opioid Misuse in Patients with Chronic Pain. *Annals Internal Medicine. 152*: 712-720.
500. Straube, S., Derry, S., Moore, RA, & McQuay, HJ. Vitamin D for the Treatment of Chronic Painful Conditions in Adults. *Cochrane Database of Systematic Reviews* 2010, Issue 1. Art. No.: CD007771. DOI:10.1002/14651858.CD007771.pub2.
501. Straube, S., Derry, S., Moore, RA, & McQuay, HJ. Cervico-Thoracic or Lumbar Sympathectomy for Neuropathic Pain and Complex Regional Pain Syndrome. *Cochrane Database of Systematic Reviews* 2010, Issue 7. Art. No.: CD002918. DOI:10.1002/14651858.CD002918.pub2. Assessment: Adequate.
502. Stucki, G., Daltry, L., Liang, MH, Lipson, SJ, Fossel, AH, & Katz, JN. (1996). Measurement Properties of a Self-Administered Outcome Measure in Lumbar Spinal Stenosis. *Spine. 7*; 796-803.
503. Sundberg, T., Petzold, M., Wandell, P., Ryden, A., & Falkenberg, T. (2009). Exploring Integrative Medicine for Back and Neck Pain - A Pragmatic Randomised Clinical Pilot Trial. *BMC Complementary and Alternative Medicine. 9*: 33 doi:10.1186/1472-6882-9-33
504. Svendsen, KB, Jensen, TS, & Bach, FW. (2004). Does the Cannabinoid Dronabinol Reduce Central Pain in Multiple Sclerosis? Randomised Double Blind Placebo Controlled Crossover Trial. *BMJ.* doi: 10.1136/bmj.38149.566979.AE (published 16 July 2004)
505. Swedlow, A., Ireland, J., & Johnson, G. (2011). Prescribing Patterns of Schedule II Opioids in California Workers’ Compensation. *California Workers’ Compensation Institute.*
506. Taskaynatan, MA, Ozgul, A., Tan, AK, Dincer, K, & Kalyon, TA. (2004). Bier Block with Methylprednisolone and Lidocaine in CRPS Type I: A Randomized, Double-Blinded, Placebo-Controlled Study. *Regional Anesthesia and Pain Medicine. 29*; 5, 408-412. Assessment: Inadequate.
507. Tavan, R., Coronel, B., Duperret, S., Meeus, P., & Blondet, R. (2002). Peroperative Opening of a Patent Foramen Ovale Caused by Pulmonary Artery Obstruction Due to Knotted Pulmonary Artery Catheter. *European Journal of Anesthesiology. 19*: 145-156.
508. Taylor, R. (2006). Spinal Cord Stimulation in Complex Regional Pain Syndrome and Refractory Neuropathic Back and Leg Pain / Failed Back Surgery Syndrome: Results of a Systematic Review and Meta-Analysis. *Journal of Pain and Symptom Management. 31*: S13-S19.
509. Taylor, R., Buyten, JP, & Buchser, E. (2006). Spinal Cord Stimulation for Complex Regional Pain Syndrome: A Systematic Review of the Clinical and Cost-Effectiveness Literature and Assessment of Prognostic Factors. *European Journal of Pain. 10*: 91-101.
510. Taylor, R., Ryan, J., O’Donnell, R., Eldabe, S., Kumar, K., & North, R. (2010). The Cost-Effectiveness of Spinal Cord Stimulation in the Treatment of Failed Back Surgery Syndrome. *Clin J Pain. 26*: 6, 463-469.
511. Tewari, N., Gill, PG, Bochner, MA, & Kollias, J. (2008). Comparison of Volume Displacement versus Circumferential Arm Measurements for Lymphoedema: Implications for the SNAC Trial. *ANZ J. Surg. 78*: 889-893.
512. Thienel, U., Neto, W., Schwabe, SK., & Vijapurkar, U. (2004). Topiramate in Painful Diabetic Polyneuropathy: Findings from Three Double-Blind Placebo-Controlled Trials. *Acta Neurol Scand. 110*: 221-231. Assessment: Adequate. *\*Used in Evidence Statement.*
513. Tilbrook, H.E., Cox, H. Hewitt, C.E., Kang’ombe, A.R., Chuang, L., Jayakody, S., ….Torgerson, D.J. (2011). Yoga for chronic low back pain. *Annals of Internal Medicine*: 155: 569-578.
514. Thomas, KJ, MacPherson, H., Thorpe, L., Brazier, J., Fitter, M., Campbell, MJ, & Nicholl, WJ. (2006). Randomised Controlled Trial of a Short Course of Traditional Acupuncture Compared with Usual Care for Persistent Non-Specific Low Back Pain. *BMJ.* doi:10.1136/bmj.38878.907361.7C
515. Thompson, D., Oldham, J., Urmston, M., & Woby, S. (2010). Cognitive Determinants of Pain and Disability in Patients with Chronic Whiplash-Associated Disorder: A Cross-Sectional Observational Study. *Physiotherapy. 96*: 151-159.
516. Thorn, B.E. (2004). Cognitive Therapy for Chronic Pain: A Step-by-Step Guide. *The Guilford Press.* ISBN: 1-57230-979-2.
517. Tillbrook, E.T., Cox, H., Hewitt, C.E., Kang’ombe, A.R., Chuang, L.C., Jayakody, S.,……Torgerson, D.J. (2011). Yoga for chronic low back pain. Annals of Internal Medicine. 155:569-578.
518. Todd, K.H., Deaton, C., D’Adamo, A.P., & Goe, L. (2000). Ethnicity and Analgesic Practice. *Annals of Emergency Medicine.* 35:1 11-16.
519. *Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)*. (2002). Torticollis Severity Scale.
520. Townsend, R., Schapmire, D., St. James, J., & Feeler, L. (2010). Isometric Strength Assessment, Part II: Static Testing Does Not Accurately Classify Validity of Effort. *Work. 37*; 387-394. DOI 10.3233/WOR-2010-1092
521. Trelle, S., Reichenbach, S., Wandel, S., Hildebrand, P., Tschannen, B., Villiger, P., Egger, M., & Juni, P. (2011). Cardiovascular Safety of Non-Steroidal Anti-Inflammatory Drugs: Network Meta-Analysis. *BMJ. 342*:c7086 doi: 10.1136/bmj.c7086 Assessment: High Quality. *\*Used in Evidence Statement.*
522. Tsuchiya, M., Sato, EF, Inoue, M., & Asada, A. (2007). Acupuncture Enhances Generation of Nitric Oxide and Increases Local Circulation. *Anesth Analg. 104*: 301-7.
523. Tsui, JKC, Eisen, A., Stoessl, AJ, Calne, S., & Calne, DB. (1986). Double-Blind Study of Botulinum Toxin in Spasmodic Torticollis. *The Lancet.*
524. Turner, J., Hollingworth, W., Corstock, B., & Deyo, R. (2010). Spinal Cord Stimulation for Failed Back Surgery Syndrome: Outcomes in a Workers’ Compensation Setting. *Pain. 148:* 14-25.
525. Turner, J., Holtzman, S., & Mancl, L. (2007). Mediators, Moderators, and Predictors of Therapeutic Change in Cognitive-behavioral Therapy for Chronic Pain. *Pain. 127*: 276-286.
526. Turner, J., Mancl, L., & Aaron, LA. (2006). Short- and Long-term Efficacy of Brief Cognitive-behavioral Therapy for Patients with Chronic Temporomandibular Disorder Pain: A Randomized, Controlled Trial. *Pain. 121*: 181-194.
527. Turner, J.A., Sears, J. M., Loeser, J.D. (2007). Programmable intrathecal opioid delivery systems for chronic non-cancer pain: A systematic review of effectiveness and complications. *Clin J Pain,(23)*. 2. 180-195.
528. Van Boxem, K., Cheng, J., Patijn, J., Van Kleef, M., Lataster, A., Mekahil, N.,...Van Zundert, J. (2010). 11. Lumbosacral Radicular Pain. *Pain Practice. 10:* 4, 339-358.
529. Van Boxem, K., Van Eerd, M., Brinkhuize, T., Patijn, J., Van Kleef, M.,...Van Zundert, J. (2008). Radiofrequency and Pulsed Radiofrequency Treatment of Chronic Pain Syndromes: The Available Evidence. *Pain Practice. 8:* 5, 385-393.
530. Van Calenbergh, F., Gybels, J., Van Laere, K., Dupont, P., Plaghki, L., Depreitere, B., & Kupers, R. (2009). Long Term Clinical Outcomes of Peripheral Nerve Stimulation in Patients with Chronic Peripheral Neuropathic Pain\* *Surgical Neurology. 72*: 330-335.
531. Van der Hulst, M., Vollenbroek-Hutten, M., & IJzerman, M. (2005). A Systematic Review of Sociodemographic, Physical, and Psychological Predictors of Multidisciplinary Rehabilitation - or, Back School Treatment Outcome in Patients with Chronic Low Back Pain. *Spine. 30*; 7, 813-825.
532. Van der Hulst, M., Vollenbroek-Hutten, MM, Schreurs, KM, Reitman, JS, & Hermens, HJ. (2010). Relationships between Coping Strategies and Lumbar Muscle Activity in Subjects with Chronic Low Back Pain. *European Journal of Pain. 14*; 640-647.
533. Van Der Plas, AA, Van Rijn, MA, & Van Hilten, JJ. (2010). Baclofen-Induced Chorea in Complex Regional Pain Syndrome-Related Dystonia. *Movement Disorders. 25*: 7.
534. Van Eijs, F., Stanton-Hicks, M., Van Zundert, J., Faber, CG, Lubenow, TR, Mekhail, N., Van Kleef, AM., & Huygen, F. (2010). Complex Regional Pain Syndrome. *Pain Practice.*
535. Van Hilten, B., Van De Beek, WJ, Hoff, J, Voormolen, J., & Delhaas, E. (2000). Intrathecal Baclofen for the Treatment of Dystonia in Patients with Reflex Sympathetic Dystrophy. *New England Journal of Medicine. 343*; 625-30.
536. Van Kleef, M., Liem, L., Lousberg, R., Barendse, G., Kennels, F., & Sluijter, M. (1996). Radiofrequency Lesion Adjacent to the Dorsal Root Ganglion for Cervicobrachial Pain: A Prospective Double Blind Randomized Study. *Neurosurgery. 38* (6): 1127-1132.
537. Van Middlekoop, M., Rubinstein, SM, Kuijpers, T., Verhagen, AP, Ostelo, R., Koes, BW, & Van Tulder, MW. (2011). A Systematic Review on the Effectiveness of Physical and Rehabilitation Interventions for Chronic Non-Specific Low Back Pain. *Eur Spine J.* DOI 10:1007/s00586-010-1518-3.
538. Van Seventer, R., Bach, FW, Toth, C., Serpell, M., Temple, J., Murphy, T.,...Nimour, M. (2010). Pregabalin in the Treatment of Post-Traumatic Peripheral Neuropathic Pain: A Randomized Double-Blind Trial. *European Journal of Neurology. 17*: 1082-1089. Assessment: Adequate. *\*Used in Evidence Statement.*
539. Van Wijk, RM, Geurts, JW, & Wynne, HJ. (2001). Long-Lasting Analgesic Effect of Radiofrequency Treatment of the Lumbosacral Dorsal Root Ganglion. *J Neurosurgery. 94* Suppl. 2, 227-31.
540. Van Zundert, J., Mekhail, N., Vanelderen, P., & Van Kleef, M. (2010). Diagnostic Medial Branch Blocks before Lumbar Radiofrequency Zygapophysial (Facet) Joint Denervation. Benefit or Burden? *Anesthesiology. 113*: 276-8.
541. Van Zundert, J., (2010). Diagnostic medial branch blocks before lumbar radiofrequency zygapophyseal (facet) joint denervation: Benefit or burden. *Anesthesiology.*
542. Van Zundert, J., Patijn, J., Kessels, A., Lame, I., Van Suijlekom, H., & Van Kleef, M. (2007). Pulsed Radiofrequency Adjacent to the Cervical Dorsal Root Ganglion in Chronic Cervical Radicular Pain: A Double Blind Sham Controlled Randomized Clinical Trial. *Pain. 127:* 173-182. Assessment: Adequate. *\*\*Used in Evidence Statement.*
543. Varenna, M., Zucchi, F., Ghiringhelli, D., Binelli, L., Bevilacqua, M., Bettica, P., & Sinigaglia, L. (2000). Intravenous Clodronate in the Treatment of Reflex Sympathetic Dystrophy Syndrome. A Randomized, Double Blind, Placebo Controlled Study. *Journal of Rheumatology. 27*: (6) 1477-83. Assessment: Adequate. *\*Used in Evidence Statement.*
544. Vas, J., Perea-Milla, E., Mendez, C., Sanchez Navarro, C., Leon Rubio, JM, Brioso, M., & Garcia Obrero, I. (2006). Efficacy and Safety of Acupuncture for Chronic Uncomplicated Neck Pain: A Randomised Controlled Study. *Pain. 126*: 245-255.
545. Vedula, SS, Bero, L., Scherer, RW, & Dickersin, K. (2009). Outcome Reporting in Industry-Sponsored Trials of Gabapentin for Off-Label Use [with appendix]. *The New England Journal of Medicine. 361*; 1963-71.
546. Veldman, PHJM, Reynen, HM, Arntz, IE, & Goris, RJA. (1993). Signs and Symptoms of Reflex Sympathetic Dystrophy: Prospective Study of 829 Patients. *The Lancet. 342*: 1012-16.
547. Verdugo, RJ, & Ochoa, JL. (1994). ‘Sympathetically Maintained Pain.’ *Neurology. 44*: 1003-1010.
548. Veterans Health Administration. (2006). Ziconotide for Intrathecal Infusion (Prialt). *National PBM Drug Monograph.* [www.pbm.va.gov/DrugMonograph.aspx](http://www.pbm.va.gov/DrugMonograph.aspx).
549. Villavicencio, A., & Burneikiene, S. (2006). Elements of the Pre-Operative Workup, Case Examples. *Pain Medicine. 7*: 51, S35-S46.
550. Vinik, A., Tuchman, M., Safirstein, B., Corder, C., Kirby, L., Wilks, K.,...Silver, M. (2007). Lamotrigine for Treatment of Pain Associated with Diabetic Neuropathy: Results of Two Randomized, Double-Blind, Placebo-Controlled Studies. *Pain. 128*: 169-179. Assessment: Adequate. *\*Used in Evidence Statement.*
551. Volkow, ND, & McLennan, TA. (2011). Curtailing Diversion and Abuse of Opioid Analgesics Without Jeopardizing Pain Treatment. *JAMA. 305*; 13.
552. Volkow, ND, McLennan, TA, & Cotto, JH. (2011). Characteristics of Opioid Prescriptions in 2009. *JAMA. 305*; 13.
553. Von Gunten, C., Eappen, S., Cleary, JF, Taylor, IV, S., Moots, P., Regevik, N.,...Cella, D. (2007). Flecainide for the Treatment of Chronic Neuropathic Pain: A Phase II Trial. Eastern Co-Operative Oncology Group Study E1Z95. *Palliative Medicine. 21*: 667-672.
554. Wade, AG, Ford, I., Crawford, G., McConnachie, A., Nir, T., Laudon, M., & Zisapel, N. (2010). Nightly Treatment of Primary Insomnia with Prolonged Release Melatonin for 6 Months: A Randomized Placebo Controlled Trial on Age and Endogenous Melatonin as Predictors of Efficacy and Safety. *BMC Medicine. 8*; 51.
555. Wallace, MS, Kosek, PS, Staats, P., Fisher, R., Schultz, DM, & Leong, M. (2008). Phase II, Open-Label, Multicenter Study of Combined Intrathecal Morphine and Ziconotide: Addition of Ziconotide in Patients Receiving Intrathecal Morphine for Severe Chronic Pain. *Pain Medicine. 9*; 3, 271-281.
556. Wallace, MS, Rauck, R., & Deer, T. (2010). Ziconotide Combination Intrathecal Therapy: Rationale and Evidence. *Clinical J. Pain. 26*, 7: 635-644.
557. Wallace, MS, Ridgeway, B., Leung, A., Gerayli, A., & Yaksh, T. (2000). Concentration-effect Relationship of Intravenous Lidocaine on the Allodynia of Complex Regional Pain Syndrome Types I and II. *Anesthesiology. 92*; 75-83.
558. Wang, C. (2008). Tai Chi Improves Pain and Functional Status in Adults with Rheumatoid Arthritis: Results of a Pilot Single-Blinded Randomized Controlled Trial. *Medicine and Sport Science. 52*; 218-229. – Abstract Only.
559. Ware, M., Wang, T., Shapiro, S., Robinson, A., Ducruet, T., Huynh, T.,...Collet, JP. (2010). Smoked Cannabis for Chronic Neuropathic Pain: A Randomized Controlled Trial. *CMAJ. 182* (14).
560. Warncke, T., Stubhaug, A., Jorum, E. (1997)
561. Warner, M., Chen, LH, & Makuc, DM. Increase in Fatal Poisoning Involving Opioid Analgesics in the United States, 1999-2006. NCHS Data Brief, no 22. Hyattsville, MD: *National Center for Health Statistics.* 2009.
562. Wasan, A. (2010). Commentary. Spinal Cord Stimulation in Workers’ Compensation Population: How Difficult it Can Be to Interpret a Clinical Trial. *Pain. 148*: 3-4.
563. *Washington State, Agency Medical Directors Group (AMDG).* (2010). Interagency Guideline on Opioid Dosing for Chronic Non-cancer Pain: An Educational Aid to Improve Care and Safety with Opioid Therapy.
564. Wasner, G. (2010). Vasomotor Disturbances in Complex Regional Pain Syndrome-A Review. *Pain Medicine. 11*: 1267-1273.
565. Wasner, G., Schattschneider, J., Heckmann, K., Maier, C., & Baron, R. (2001). Vascular Abnormalities in Reflex Sympathetic Dystrophy (CRPS I): Mechanisms and Diagnostic Value. *Brain. 124*: 587-599. Assessment: Adequate. *\*Used in Evidence Statement.* [also assessed as inadequate on another issue].
566. Webster, LR, Malan, P., Tuchman, M., Mollen, M., Tobias, J., & Vanhove, G. (2010). A Multicenter, Randomized, Double-Blind, Controlled Dose Finding Study of NGX-4010, a High-Concentration Capsaicin Patch, for the Treatment of Postherpetic Neuralgia. *The Journal of Pain.* 1-11. Assessment: Adequate. \**Used in Evidence Statement*
567. Webster, BS, Verma, SK, & Gatchel, RJ. (2007). Relationship Between Early Opioid Prescribing for Acute Occupational Low Back Pain and Disability Duration, Medical Costs, Subsequent Surgery and Late Opioid Use. *Spine. 32*:19, 2127-2132.
568. Webster, LR, Fakata, KL, Charapata, S., Fisher, R., & MineHart, M. (2008). Open-Label, Multicenter Study of Combined Intrathecal Morphine and Ziconotide: Addition of Morphine in Patients Receiving Ziconotide for Severe Chronic Pain. *Pain Medicine. 9*; 3, 282-290.
569. Webster, LR, & Fine, PG. (2010). Approaches to Improve Pain Relief While Minimizing Opioid Abuse Liability. *The Journal of Pain. 11*; 7, 602-611.
570. Weimer, L. (2010). Autonomic Testing.  *The Neurologist. 16*; 4, 215-222.
571. Weiner, DK, Perera, S., Rudy, T, Glick, R., Shenoy, S., & Delitto, A. (2008). Efficacy of Percutaneous Electrical Nerve Stimulation and Therapeutic Exercise for Older Adults with Chronic Low Back Pain: A Randomized Controlled Trial. *Pain. 30*; 140, 344-357. doi: 10.1016/j.pain.2008.09.005. [including appendices]. Assessment: Inadequate.
572. White, P., Lewith, G., Prescott, P., & Conway, J. (2004). Acupuncture versus Placebo for the Treatment of Chronic Mechanical Neck Pain: A randomized controlled trial. *Annals of Internal Medicine. 141*: 911-919.
573. Wickizer, TM, Franklin, G., Fulton-Kehoe, D., Gluck, J., Mootz, R., Smith-Weller, T., & Plaeger-Brockway, R. (2011). Improving Quality, Preventing Disability and Reducing Costs in Workers’ Compensation Healthcare: A Population-based Intervention Study. *Medical Care.* 00(00).
574. Wiedemer, NL, Harden, PS, Arndt, IO, & Gallagher, RM. (2007). The Opioid Renewal Clinic: A Primary Care, Managed Approach to Opioid Therapy in Chronic Pain Patients at Risk for Substance Abuse. *Pain Medicine. 8*: 7.
575. Wiffen, PJ, Collins, S., McQuay, HJ, Carroll, D., Jadad, A., & Moore, RA. Anticonvulsant Drugs for Acute and Chronic Pain. *Cochrane Database of Systematic Reviews* 2010, Issue 1. Art. No.: CD001133. DOI:10.1002/14651858.CD001133.pub3. Article Withdrawn 9/2009.
576. Wiffen, PJ, Derry, S., Moore, RA, McQuay, HJ. Carbamazepine for Acute and Chronic Pain in Adults. *Cochrane Database of Systematic Reviews* 2005, Issue 3. Art. No.: CD005451. DOI:10.1002/14651858.CD005451. Assessment: High Quality. *\*\*\*Used in Evidence Statement.*
577. Wiffen, PJ, McQuay, HJ, Edwards, J., & Moore, R. Gabapentin for Acute and Chronic Pain. *Cochrane Database of Systematic Reviews* 2005, Issue 3. Art. No.: CD005452. DOI: 10.1002/14651858.CD005452. Assessment: High Quality. *\*\*Used in Evidence Statement.*
578. Wiffen, PJ, & Rees, J. Lamotrigine for Acute and Chronic Pain. *Cochrane Database of Systematic Reviews* 2007, Issue 2. Art. No.: CD006044. DOI:10.1002/14651858.CD006044.pub2. Assessment: Adequate. *\*Used in Evidence Statement.*
579. Wilkens, P., Scheel, I., Grundnes, O., Hellum, C., & Kjersti, S. (2010). Effect of Glucosamine on Pain-Related Disability in Patients with Chronic Low Back Pain and Degenerative Lumbar Osteoarthritis. *JAMA. 304* (1): 45-52. Assessment: High Quality. *\*\*Used in Evidence Statement.*
580. Wilkey, A., Gregory, M., Byfield, D., & McCarthy, PW. (2008). A Comparison between Chiropractic Management and Pain Clinic Management for Chronic Low-Back Pain in a National Health Service Outpatient Clinic. *The Journal of Alternative and Complementary Medicine. 14*; 465-473. DOI: 10.1089/acm.2007.0796
581. Williams, J., Day, M., & Heavner, JE. (2008). Ziconotide: An Update and Review. *Expert Opin. Pharmacother. 9*; 9, 1575-1583.
582. Williams, K., Abildso, C., Steinberg, L. Doyle, E., Epstein, B., Smith, D.,...Cooper, L. (2009). Evaluation of the Effectiveness and Efficacy of Iyengar Yoga Therapy on Chronic Low Back Pain. *Spine. 34*; 19, 2066-2076. Assessment: Adequate.
583. Williams, NH, Wilkinson, C., Russell, I., Edwards, RT, Hibbs, R., Linck, P., & Muntz, R. (2003). Randomized Osteopathic Manipulation Study (ROMANS): Pragmatic Trial for Spinal Pain in Primary Care. *Family Practice. 20*: 662-669.
584. Witt, CM, Jena, S., Brinkhaus, B., Liecker, B., Wegscheider, K., & Willich, SN. (2006). Acupuncture for Patients with Chronic Neck Pain. *Pain. 125*: 98-106.
585. Woby, S., Roach, NK, Urmston, M., & Watson, PJ. (2007). The Relation Between Cognitive Factors and Levels of Pain and Disability in Chronic Low Back Pain Patients Presenting for Physiotherapy. *Eur J Pain. 11*: 869-877.
586. Wolf, S.L, Barton, D.L., Qin, R., Wos, E.J., Sloan, J.A., Liu, H. (2010). The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. *Support Care Cancer.* DOI 10.1007/s00520-011-1141-9.
587. Woolf, CJ, & Salter, MW. (2006). Plasticity and Pain: Role of the Dorsal Horn. *Wall and Melzack’s Textbook of Pain.* Fifth Edition.
588. World Health Organization. *WHO’s pain ladder.* http://www.who.int/cancer/palliative/painladder/en/.
589. Wylde, V., Palmer, S., Learmonth, I.D., & Dieppe, P. (2011). Test—Retest Reliability of Quantitative Sensory Testing in Knee Osteoarthritis and Healthy Participants.  *Osteoarthritis and Cartilage 19*: 655-658.
590. Yaksh, T., Hassenbusch, S., Burchiel, K., Hildebrand, K., Page, L., & Coffey, R. (2002). Inflammatory Masses Associated with Intrathecal Drug Infusion: A Review of Preclinical Evidence and Human Data. *Pain Medicine. 3*: 4, 300-312.
591. Yates, SL., Morley, S., Eccleston, C., & Williams, AC. (2005). A Scale for Rating the Quality of Psychological Trials for Pain. *Pain.* 314-325.
592. Young, IA, Michener, LA, Cleland, JA, Aguilera, AJ, & Synder, AR. (2009). Manual Therapy, Exercise, and Traction for Patients with Cervical Radiculopathy: A Randomized Clinical Trial. *Physical Therapy. 89*: 632-642.
593. Yuan, RY, Sheu, JJ, Yu, JM, Chen, WT, Tseng, IJ, Chang, HH, & HU, CJ. (2009). Botulinum Toxin for Diabetic Neuropathic Pain. *Neurology. 72*: 1473-1478. Assessment: Inadequate.
594. Zacharoff, K., McCarberg, B., Reisner, L., & Venuti, S. (2010). Managing Chronic Pain with Opioids in Primary Care. *Inflexxion Health Series.*
595. Zacny, JP, & Lichtor, SA. (2008). Within-subject Comparison of the Psychopharmacological Profiles of Oral Oxycodone and Oral Morphine in Non-Drug-Abusing Volunteers. (2008). *Psychopharmacology. 196*: 105-116. DOI 10.1007/s00213-007-0937-2
596. Zaghi, S., Heine, N., & Fregni, F. (2009). Brain Stimulation for the Treatment of Pain: A Review of Costs, Clinical Effects, and Mechanisms of Treatment for Three Different Central Neuromodulatory Approaches.  *J Pain Management. 2* (3): 339-352.
597. Zaringhalam, J., Manajehi, H., Rastqar, A., & Zaringhalam, M. (2010). Reduction of Chronic Non-Specific Low Back Pain: A Randomised Controlled Clinical Trial on Acupuncture and Baclofen. *Chinese Medicine. 5;* 15. doi:10.1186/1749-8546-5-15
598. Zhang, W., Robertson, J., Jones, AC, Dieppe, PA, & Doherty, M., (2008). The Placebo Effect and its Determinants in Osteoarthritis: Meta-analysis of Randomised Controlled Trials. *Ann Rheum Dis. 67*: 1716-1723.
599. Zhou, Yi Li. (2008). Bradley: Neurology in Clinical Practice, 5th ed. Chapter 48 - Principles of Pain Management. *MD Consult.*
600. Zin, CS, Nissen, LM, Smith, MT, O’Callaghan, JP, & Moore, BJ. (2008). An Update on the Pharmacological Management of Post-Herpetic Neuralgia and Painful Diabetic Neuropathy. *CNS Drugs. 22* (5): 417-442.
601. Zollinger, PE, Tuinebreijer, WE, Breederveld, RS, & Kreis, RW. (2007). Can Vitamin C Prevent Complex Regional Pain Syndrome in Patients with Wrist Fractures? *JBJS Am. 89*; 1424-31. Assessment: Adequate. *\*Used in Evidence Statement.*
602. Zuurmond, WWA, Langendijk, JNJ, Bezemer, PD, Brink, HEJ, De Lange, JJ, & Van Loenen, AC. (1996). Treatment of Acute Reflex Sympathetic Dystrophy with DMSO 50% in a Fatty Cream. *Acta Anaesthesiologica Scand. 40*: 364-367. Assessment: Inadequate.
603. Zyluk, A., & Puchalski, P. (2008). Treatment of Early Complex Regional Pain Syndrome Type I by a Combination of Mannitol and Dexamethasone. *Journal of Hand Surgery (European Volume). 33E*: 2, 130-136.